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Abstract
Rapid antigen detection and molecular tests for group A
streptococcal infections for acute sore throat: systematic
reviews and economic evaluation
Hannah Fraser , Daniel Gallacher , Felix Achana , Rachel Court ,
Sian Taylor-Phillips , Chidozie Nduka , Chris Stinton ,
Rebecca Willans , Paramjit Gill and Hema Mistry *
Warwick Medical School, University of Warwick, Coventry, UK
*Corresponding author Hema.Mistry@warwick.ac.uk
Background: Sore throat is a common condition caused by an infection of the airway. Most cases are
of a viral nature; however, a number of these infections may be caused by the group A Streptococcus
bacterium. Most viral and bacterial sore throat infections resolve spontaneously within a few weeks.
Point-of-care testing in primary care has been recognised as an emerging technology for aiding
targeted antibiotic prescribing for sore throat in cases that do not spontaneously resolve.
Objective: Systematically review the evidence for 21 point-of-care tests for detecting group A
Streptococcus bacteria and develop a de novo economic model to compare the cost-effectiveness of
point-of-care tests alongside clinical scoring tools with the cost-effectiveness of clinical scoring tools
alone for patients managed in primary care and hospital settings.
Data sources: Multiple electronic databases were searched from inception to March 2019. The
following databases were searched in November and December 2018 and searches were updated in
March 2019: MEDLINE [via OvidSP (Health First, Rockledge, FL, USA)], MEDLINE In-Process & Other
Non-Indexed Citations (via OvidSP), MEDLINE Epub Ahead of Print (via OvidSP), MEDLINE Daily
Update (via OvidSP), EMBASE (via OvidSP), Cochrane Database of Systematic Reviews [via Wiley
Online Library (John Wiley & Sons, Inc., Hoboken, NJ, USA)], Cochrane Central Register of Controlled
Trials (CENTRAL) (via Wiley Online Library), Database of Abstracts of Reviews of Effects (DARE)
(via Centre for Reviews and Dissemination), Health Technology Assessment database (via the Centre
for Reviews and Dissemination), Science Citation Index and Conference Proceedings [via the Web of
Science™ (Clarivate Analytics, Philadelphia, PA, USA)] and the PROSPERO International Prospective
Register of Systematic Reviews (via the Centre for Reviews and Dissemination).
Review methods: Eligible studies included those of people aged ≥ 5 years presenting with sore
throat symptoms, studies comparing point-of-care testing with antibiotic-prescribing decisions,
studies of test accuracy and studies of cost-effectiveness. Quality assessment of eligible studies was
undertaken. Meta-analysis of sensitivity and specificity was carried out for tests with sufficient data.
A decision tree model estimated costs and quality-adjusted life-years from an NHS and Personal Social
Services perspective.
Results: The searches identified 38 studies of clinical effectiveness and three studies of cost-effectiveness.
Twenty-six full-text articles and abstracts reported on the test accuracy of point-of-care tests and/or clinical
scores with biological culture as a reference standard. In the population of interest (patients with Centor/
McIsaac scores of ≥ 3 points or FeverPAIN scores of ≥ 4 points), point estimates were 0.829 to 0.946 for
sensitivity and 0.849 to 0.991 for specificity. There was considerable heterogeneity, even for studies using
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the same point-of-care test, suggesting that is unlikely that any single study will have accurately captured a
test’s true performance. There is some randomised controlled trial evidence to suggest that the use of rapid
antigen detection tests may help to reduce antibiotic-prescribing rates. Sensitivity and specificity estimates
for each test in each age group and care setting combination were obtained using meta-analyses where
appropriate. Any apparent differences in test accuracy may not be attributable to the tests, and may have
been caused by known differences in the studies, latent characteristics or chance. Fourteen of the 21 tests
reviewed were included in the economic modelling, and these tests were not cost-effective within the
current National Institute for Health and Care Excellence’s cost-effectiveness thresholds. Uncertainties in
the cost-effectiveness estimates included model parameter inputs and assumptions that increase the cost of
testing, and the penalty for antibiotic overprescriptions.
Limitations: No information was identified for the elderly population or pharmacy setting. It was not
possible to identify which test is the most accurate owing to the paucity of evidence.
Conclusions: The systematic review and the cost-effectiveness models identified uncertainties around the
adoption of point-of-care tests in primary and secondary care settings. Although sensitivity and specificity
estimates are promising, we have little information to establish the most accurate point-of-care test.
Further research is needed to understand the test accuracy of point-of-care tests in the proposed NHS
pathway and in comparable settings and patient groups.
Study registration: The protocol of the review is registered as PROSPERO CRD42018118653.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 31. See the NIHR Journals Library website for further project information.
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Plain English summary
Sore throat is a common condition caused by an infection of the airway. Most cases are viral;however, a small number may be caused by the group A Streptococcus bacterium. Most viral and
bacterial sore throat infections resolve spontaneously within a few weeks; however, some may be
more serious and require antibiotics. Currently, National Institute for Health and Care Excellence
guidance recommends the use of clinical scoring tools to identify patients for whom antibiotic
treatment is appropriate.
Ideally, a throat swab culture should be obtained to identify the organism causing the infection in cases
in which diagnosis is uncertain. However, this takes time, causing potential delays in administering the
correct treatment. Point-of-care tests can be administered at or near the site of the patient; therefore,
they are much faster.
Our review considered evidence for the test accuracy and cost-effectiveness of 21 point-of-care tests for
detecting group A Streptococcus bacteria. We built an economic model, predicting costs and benefits for
adults and children in a primary care or hospital setting. The findings will support the National Institute
for Health and Care Excellence to make recommendations about the use of these point-of-care tests for
detecting group A Streptococcus bacteria in the NHS in England and Wales.
The clinical effectiveness review found 38 relevant studies; of these, 26 reported on the accuracy of
point-of-care tests. These studies found wide variation in the accuracy of the tests. The quality of the
evidence was weak and there was little information on some of the 21 tests. As the studies were all so
different, it was not possible to identify which test is the most accurate.
The economic model found considerable uncertainty about how costs and benefits would change if
point-of-care tests were introduced in different care settings. Further research is needed to see
whether or not point-of-care testing provides value for money.
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Scientific summary
Background
Sore throat is a common condition caused by an infection of the airway. Clinical descriptions of acute
sore throat include acute pharyngitis and tonsillitis, which are both infections of the upper respiratory
airway affecting the mucosa. Most cases are viral; however, a small number of these infections may be
caused by the group A Streptococcus bacterium. Most sore throats resolve spontaneously within a few
weeks. An analysis of UK primary care use data identified a reduction in antibiotic prescribing in the
UK between 1993 and 2001 for diagnosed episodes of sore throat. Despite this reduction, sore throat
and other respiratory tract infections remain a common reason for primary care use.
Point-of-care testing (rapid antigen detection and molecular tests) in primary care has been recognised as
an emerging technology for aiding targeted antibiotic prescribing in cases of sore throat. These tests are
intended to be used in addition to clinical scoring systems, such as FeverPAIN and Centor. The purpose of
these tests is to increase diagnostic confidence of a suspected group A streptococcal infection, to guide
antimicrobial prescribing decisions in people presenting with an acute sore throat and to contribute to
improving antimicrobial stewardship. The tests may be suitable for use in all settings where patients may
present with an acute sore throat (Centor scores of ≥ 3 points, FeverPAIN scores of ≥ 4 points); these
include primary and secondary care, and community pharmacies.
Decision question
The decision problem for this assessment is what is the clinical effectiveness and cost-effectiveness
of rapid antigen detection and molecular tests in patients with high clinical scores (Centor scores of
≥ 3 points, FeverPAIN scores of ≥ 4 points), compared with the use of clinical scoring tools alone,
for increasing the diagnostic confidence of suspected group A streptococcal infection in people who
present with an acute sore throat in primary and secondary care?
Objectives
To systematically review the evidence for the clinical effectiveness of rapid antigen detection and
molecular tests; systematically review existing economic evaluations; and develop a de novo economic
model to assess the cost-effectiveness of rapid antigen detection and molecular tests in conjunction
with clinical scoring tools compared with clinical scoring tools alone in England and Wales.
Methods
Clinical effectiveness and cost-effectiveness systematic reviews
Multiple electronic databases were searched from inception to March 2019 for both the clinical
effectiveness reviews and the cost-effectiveness reviews.
The following databases were searched in November and December 2018 and searches were updated
in March 2019: MEDLINE [via OvidSP (Health First, Rockledge, FL, USA)], MEDLINE In-Process &
Other Non-Indexed Citations (via OvidSP), MEDLINE Epub Ahead of Print (via OvidSP), MEDLINE
Daily Update (via OvidSP), EMBASE (via OvidSP), Cochrane Database of Systematic Reviews [via Wiley
Online Library (John Wiley & Sons, Inc., Hoboken, NJ, USA)], Cochrane Central Register of Controlled
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Trials (CENTRAL) (via Wiley Online Library), Database of Abstracts of Reviews of Effects (DARE) (via
the Centre for Reviews and Dissemination), Health Technology Assessment database (via the Centre
for Reviews and Dissemination), Science Citation Index and Conference Proceedings [via the Web of
Science™ (Clarivate Analytics, Philadelphia, PA, USA)] and the PROSPERO International Prospective
Register of Systematic Reviews (via the Centre for Reviews and Dissemination).
Supplementary searches were used to identify additional published and unpublished studies. Reference
lists of the included studies and information provided by the manufacturers of the intervention tests
were checked for additional eligible studies.
Two reviewers independently screened and assessed titles and abstracts of all records. Studies were
included according to the following criteria:
l Population – people aged ≥ 5 years presenting with symptoms of an acute sore throat.
l Intervention – point-of-care tests for group A Streptococcus (including rapid antigen detection tests
and molecular tests), preferably in those identified as being at high risk.
l Comparator – antibiotic-prescribing decisions using clinical scoring tools for group A Streptococcus,
such as FeverPAIN or Centor/modified Centor (McIsaac) alone.
l Reference standard – microbiological culture.
l Outcomes – any patient-related outcome, test accuracy (the ability of a test to correctly
differentiate between people who do and people who do not have a disease) or performance,
prescribing behaviour and cost-effectiveness estimates.
l Study design – clinical test accuracy studies that compare the index tests and/or FeverPAIN/Centor/
McIsaac scores with throat swab culture. Studies of head-to-head comparisons of rapid tests were
eligible for inclusion if test accuracy statistics were reported for each test. For prescribing behaviour,
any study design that compared the index test and/or clinical scores (i.e. FeverPAIN/Centor/McIsaac)
with culture was eligible. For cost-effectiveness, any full economic evaluations (or economic models)
reporting both cost and outcome estimates were eligible.
l Health-care setting – primary care (general practice clinics, community pharmacies and walk-in
centres) and secondary care (urgent care/walk-in centres and emergency departments) settings.
Data were extracted by one reviewer and checked by a second reviewer. Discrepancies were resolved
via discussion or by a third reviewer. Evidence was synthesised using narrative review and statistical
methods where appropriate. Meta-analyses were undertaken in Stata® version 15 (StataCorp LP,
College Station, TX, USA).
Study quality assessment of eligible studies was undertaken using recognised checklists [tailored Quality
Assessment of Diagnostic Accuracy Studies – 2 (QUADAS-2), Cochrane Risk of Bias, Joanna Briggs
Institute Critical Appraisal Checklist for analytical cross-sectional studies and Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)].
Cost-effectiveness model
A de novo decision tree model was built in Microsoft Excel® (Microsoft Corporation, Redmond,WA, USA)
to assess the cost-effectiveness of rapid antigen detection and molecular tests in conjunction with clinical
scoring tools, compared with the use of clinical scoring tools alone. The base-case economic model included
adult patients who were seen in primary care with suspected group A streptococcal infection. The base-case
model was adapted to look at the following subgroups with suspected group A streptococcal infection: adult
patients seen in the hospital, children seen in primary care and children seen in the hospital. The data for the
model included prevalence information from the systematic clinical effectiveness review, published literature
and expert opinion. The model estimated the mean total costs and mean total quality-adjusted life-years for
each rapid antigen detection test and molecular test over a 1-year time horizon, and adopted an NHS and
Personal Social Services perspective. Costs were in 2017/18 prices. No discounting of costs and outcomes
was undertaken. Outcomes are reported as incremental cost-effectiveness ratios expressed in terms of
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cost per quality-adjusted life-year gained. A number of sensitivity analyses were undertaken. Probability
sensitivity analyses were also undertaken (1000 model runs).
Results
The searches identified 5919 records of clinical effectiveness and 6980 records of cost-effectiveness,
of which we included 38 and three studies, respectively.
The systematic review of clinical effectiveness studies identified 38 studies that used the point-of-care
tests identified in the National Institute for Health and Care Excellence scope and/or clinical scores
with biological cultures as a reference standard. These comprised 26 full-text articles, three abstracts,
five manufacturer’s submissions (submitted directly to the National Institute for Health and Care
Excellence in response to a request for information) and four US Food and Drug Administration
documents. There were 26 studies (23 full-text articles and three abstracts) that reported test accuracy
data. The methodological quality of the included studies was poor. In particular, in 65.4% (17/26) of
studies it was unclear whether the sample was consecutive or convenience. Convenience samples may
not provide a true representation of the prevalence of group A streptococci. There was judged to be a
high level of bias concerning methods of patient selection. Overall, the findings reveal variations in the
sensitivity (0.679 to 1.00) and specificity (0.733 to 1.00) estimates of point-of-care tests. These point
estimates were 0.829 to 0.946 for sensitivity and 0.849 to 0.991 for specificity in high-risk populations,
including patients with Centor/McIsaac scores of > 2 points, representing the population of interest.
These estimates do not account for any of the unpublished manufacturer submissions.
Direct comparison with sore throat clinical scoring tools revealed that point-of-care tests were
generally more specific. However, one methodological limitation concerns the varying way that clinical
scoring tools have been implemented across the included studies. For instance, different studies apply
different clinical score cut-off points when recruiting patients. None of these studies matched the
proposed pathway of care and treatment for patients with acute streptococcal pharyngitis, which
would entail evaluating the test accuracy of a combined strategy of sore throat clinical scores at the
recommended National Institute for Health and Care Excellence thresholds (Centor/McIsaac score of
≥ 3 points or FeverPAIN score of ≥ 4 points) and point-of-care tests. This limitation potentially holds
important economic implications, as attempts to model this proposed pathway may not be informed by
the availability of empirical data. In addition, the over-representation of the Alere™ TestPack +Plus
(Abbott Laboratories, Abbott Park, IL, USA) group A streptococcal test relative to other point-of-care
tests, as well as the overlap of patients across different age groups, potentially raises applicability
concerns in the economic model.
Data for test accuracy were sparse for each combination of test, population and setting. There were
very few head-to-head (direct) comparison studies between index tests. It was not possible to identify
which test is the most accurate owing to the lack of available evidence. There was a large degree of
heterogeneity among results for studies using the same rapid test. Where a test is reported in several
studies, its accuracy may appear lower than that of tests reported in only a single study, particularly
those at high risk of bias or with unpublished methods, so we report on number and quality of data
available as well as accuracy estimates. The heterogeneity introduced by the differing characteristics
of the studies further confounded attempts to produce meaningful estimates of test performance,
such as care setting, age group, throat score restriction and disease prevalence. Owing to the potential
heterogeneity, estimates for the sensitivity and specificity of each test were stratified by age group,
throat score and care setting, although a lack of evidence meant that generalisations had to be made
for the majority of estimates.
Of the scoped secondary outcomes, our search identified only studies discussing antibiotic-prescribing
rates and appropriateness (n = 12). There is some randomised controlled trial evidence to suggest
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that the use of rapid antigen detection tests may help to reduce antibiotic-prescribing rates, but there
was no evidence on the effect of using molecular technologies. If a test was proven to be extremely
accurate, then it is plausible that clinical staff would trust the outcomes. No information was found
on the number of appointments required per episode, morbidity, mortality, onward transmission of
infection, health-related quality of life, patient satisfaction with the test or health-care professional
satisfaction with the test.
Cost-effectiveness
The systematic review of cost-effectiveness studies identified three studies that used the rapid antigen
detection tests, as identified in the National Institute for Health and Care Excellence scope, and were
classed as economic evaluations. Two studies had some notable limitations and data could not be fully
extracted. The one study that allowed a full data extraction was classed as a high-quality economic
evaluation when checked against the CHEERS reporting tool.
Fourteen of the 21 tests listed in the National Institute for Health and Care Excellence’s scope had data
on test accuracy and costs that were relevant to be included in the final economic modelling. In the base-
case analysis, which included adult patients seen in primary care with suspected group A streptococcal
infection, the economic model found considerable uncertainty about the cost-effectiveness of the
different point-of-care tests for suspected group A streptococcal infection. This finding was also seen
in the other economic models that were adapted (adult patients seen in the hospital, children seen in
primary care and children seen in the hospital). Important uncertainties in the model include parameter
inputs and assumptions that increase the (1) cost of testing (acquisition cost of test, additional clinician
time for administering and processing test results, and cost of confirmatory throat culture for those
testing negative) and (2) penalty for antibiotic overprescription/unnecessary antibiotic use (acquisition
cost of antibiotic and probabilities for penicillin-induced anaphylaxis and rash).
Discussion and conclusions
Main findings
The systematic review and cost-effectiveness model identify uncertainties around the adoption of
point-of-care tests in the NHS. The available evidence is heterogeneous in populations studied, design,
methods and analysis. Although sensitivity and specificity estimates are promising, we have little
information on the best point-of-care test to use. Although there is potential for the point-of-care
tests to be cost-effectiveness in both primary and secondary care settings, key parameter inputs and
modelling assumptions need to be confirmed and model findings remain uncertain.
Strengths and limitations
Strengths of the work include a robust and comprehensive systematic review strategy (literature
search, data extraction and analysis) and the building of a de novo decision tree model to assess
cost-effectiveness.
No studies on point-of-care use in a pharmacy setting or in the elderly population were retrieved.
In addition, no study matched the proposed pathway of care and treatment for patients with acute
streptococcal pharyngitis, which would entail evaluating the test accuracy of a combined strategy of
sore throat clinical scores at the recommended National Institute for Health and Care Excellence
thresholds (i.e. Centor/McIsaac score of ≥ 3 points or FeverPAIN score of ≥ 4 points) and point-of-care
tests in the age groups defined in the scope.
Although the economic model represented the clinical care pathway in the NHS, practice and
management will vary from site to site (within and across both primary care settings and secondary
care settings). The modelling may have underestimated the costs as we did not take into account the
different strains of group A Streptococcus, which may have influenced test performance and altered the
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profile of complications, seasonality of group A streptococcal infection and the onward transmission of
the infection.
Implications for health care
Our findings indicate that point-of-care testing was not cost-effective within the current thresholds
and should be viewed cautiously by clinicians and policy-makers, in view of the poor quality of the
evidence that was available to us. Health-care professionals should be mindful of the potential
variation in performance of the different testing methods and strategies in their day-to-day practice.
Research priorities
Further research is needed to understand the test accuracy of point-of-care tests within the proposed NHS
pathway and within comparable settings and patient groups. Future work that considers head-to-head test
accuracy studies or randomised controlled trials using multiple point-of-care tests in relevant populations
would provide relevant comparator information and determine the value of point-of-care testing.
Study registration
The protocol of the review is registered as PROSPERO CRD42018118653.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 31.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Description of the health problem
Sore throat is a common condition;1,2 clinical descriptions of acute sore throat include acute pharyngitis
and tonsillitis, which are both infections of the upper respiratory airway affecting the mucosa.3,4 In a
Scottish survey, 31% of respondents reported having experienced a severe sore throat in the previous
12 months.1 Symptoms of sore throat include pain in the throat and may also include fever or headache;
however, not all patients will require or seek medical advice and/or treatment for these symptoms. An
analysis of UK primary care use data identified a reduction of diagnosed episodes of sore throat in the
UK between 1993 and 2001.2 This finding may suggest changes in patient behaviour regarding self-care,
changes in general practitioner (GP) diagnosis and recording of sore throat or an actual change in the
prevalence of sore throat, although there is no evidence to support these theories. Despite this reduction,
sore throat and other respiratory tract infections (RTIs) remain a common reason for primary care use;
one-quarter of the population will visit their GP because of a RTI each year.5
In the UK, diagnosis of sore throat is currently based mainly on clinical assessment and it is
recommended by the National Institute for Health and Care Excellence (NICE) that the FeverPAIN6
or Centor7 criteria are also used. The FeverPAIN and Centor tools were designed to predict group A
Streptococcus (strep A) (Centor, FeverPAIN), group C Streptococcus (strep C) (FeverPAIN) and group G
Streptococcus (strep G) (FeverPAIN),6,7 and have been proposed as methods by which clinicians can
identify which patients are most likely to benefit from antibiotic use for sore throat.8 This is because
sore throat is often a self-limiting illness; most cases have a viral aetiology and, therefore, antibiotics
would not be an effective treatment in these instances. In addition, as antibiotics reduce the duration
of symptoms by only a very short period, this must be traded off against the side effects. Around
5–17% of sore throats are due to a bacterial infection, typically group A beta-haemolytic Streptococcus,
also known as ‘Streptococcus pyogenes’, ‘group A Streptococcus’, ‘GAS’ or ‘strep A’.5,8 Expert advice suggests
that bacterial sore throat can also be caused by group C and group G streptococci; however, strep A
is thought to account for around 80% of bacterial throat infections, and groups C and G streptococci
are thought to account for around 20%. Most cases of strep A infection resolve without complications
and, in fact, many people carry the bacterium without experiencing illness. Despite these factors, most
patients presenting with sore throat in the UK will be given antibiotics in primary care.9,10 Although
rates of antibiotic prescribing for sore throat declined between 1993 and 2001, more recent prescribing
data, for 2011, remain close to the 2001 figure, with median practice-prescribed antibiotics for sore
throat at 60%.8 RTIs, which include sore throats, account for a large proportion of antibiotic use in
general practice in the UK (approximately 60%).8
There are clinical and epidemiological reasons why clinicians may prescribe antibiotics for sore throat
in the absence of microbiological confirmation. The first is practical. The current reference standard,
culture of the bacteria grown from a throat swab, takes > 18 hours for a result to be obtained.11
Where clinicians suspect strep A infection based on clinical judgement and use of the FeverPAIN or
Centor criteria, there is an opportunity to reduce the risk or harm caused by complications such as
tonsillitis, pharyngitis, scarlet fever, impetigo, erysipelas (an infection in the upper layer of the skin),
glomerular nephritis, rheumatic fever, cellulitis and pneumonia. Some vulnerable patient groups, such
as those who are immunocompromised, are at a higher risk of developing invasive strep A infection.
To prevent onward transmission, current Public Health England (PHE) guidance on invasive strep A
infection management12 indicates use of antibiotics in close contacts of people who have invasive
strep A infection if they have symptoms of strep A infection, such as sore throat, themselves or are in
a particular risk group or setting.11 Although these factors must be considered in understanding the
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reasons for use of antibiotics to treat sore throat in the absence of more accurate diagnosis, another
factor that has an impact on use is patient demand. Although patient attendances for minor ailments
at GP surgeries have reduced, when patients do visit their GP there is an expectation of intervention,
and this is increasingly the case.11 Furthermore, RTIs account for a high proportion of working days lost
in the UK – in 2016, almost one-quarter (24.8%, 34 million days) – so ensuring that patients receive
appropriate and timely treatment also has an economic impact on the UK economy and on patients.13
However, this rationale and the demands need to be balanced with the aforementioned statistics
regarding the low prevalence of bacterial infection in sore throat and the risk of antimicrobial
resistance (AMR).
Overuse or inappropriate use of antibiotics can lead to bacteria developing resistance, leading to an
emergence of multidrug-resistant pathogens, which are increasingly difficult to treat. AMR could contribute
to an estimated 10 million deaths every year globally by 2050 and a global productivity cost of £66T.11
In response to this threat, ‘antimicrobial stewardship’ has been a central strategy adopted by the Chief
Medical Officer and NICE.11,14 Point-of-care testing in primary care has been recognised as an emerging
technology for aiding targeted antibiotic prescribing in cases of sore throat, by supporting clinicians with
diagnosis and communicating appropriate use of antibiotics to patients.15 Several technologies have been
developed for point-of-care testing in primary care for appropriate administration of antibiotics to those
who would benefit and to prevent delay and associated complications.
The NICE Diagnostics Advisory Committee is tasked with providing guidance to the NHS about the use
of point-of-care tests for the detection of strep A in sore throat infections. To inform the Diagnostics
Advisory Committee, the External Assessment Group (EAG) has provided this assessment of the clinical
accuracy and cost-effectiveness of point-of-care tests for the detection of strep A as a replacement or
adjunct for standard assessment procedures. The potential value of the point-of-care tests is in rapidly
determining the presence and nature of a bacterial infection.
Aetiology and pathology
Most sore throats are caused by an infection, mainly viral, and so are typically spread from person to
person via respiratory droplets; non-infectious causes are uncommon.3 In the case of infectious causes,
viruses, bacteria or fungi invade the upper respiratory mucosa, causing a local inflammatory response.4
Complications associated with sore throat caused by infection are rare; however, strep A infection has
a small risk of the following complications:3
l otitis media
l acute sinusitis
l peritonsillar abscess
l rheumatic fever and post-streptococcal glomerulonephritis are also complications associated with
strep A throat infection; however, these are extremely rare in developed countries
l invasive strep A, if the bacteria move from the throat into a sterile body site (which can lead to
severe infections, sepsis and streptococcal toxic shock syndrome).
Children are most likely to carry or be infected by strep A; however, people aged > 65 years or those
whose immune system is compromised (e.g. people living with a human immunodeficiency virus infection,
diabetes mellitus, heart disease or cancer and people using high-dose steroids or intravenous drugs) are
at higher risk of developing an invasive strep A infection.16
A Fusobacterium necrophorum infection affecting the pharynx or tonsils can (very rarely) lead to
Lemierre’s syndrome (sepsis and jugular vein thrombosis).3
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Diagnosis and care pathway
Figure 1 depicts the care pathway for assessing and treating a sore throat as outlined in the NICE
antimicrobial prescribing guidance on sore throat [NICE Guidance (NG) number 84 (NG84)].8 Most
uncomplicated sore throats are managed without seeking medical advice and tend to resolve within
1 week.10 Suggested conservative measures include simple analgesia, maintaining hydration, salt gargling
and throat lozenges. In selected cases in which a GP, or a pharmacist or a health-care practitioner
in the secondary care setting, such as in accident and emergency, feels that the patient may benefit
from antibiotics, the prescriber should apply either the FeverPAIN or the Centor scores to guide their
decision-making. The NICE antimicrobial prescribing guideline on acute sore throat does not make any
recommendations about using point-of-care tests or throat cultures to confirm strep A infection.8
Significance to the NHS and current service cost
The significance of sore throat and inappropriate use of antibiotics to the NHS broadly falls into two
categories: the first is associated with health-care use directly owing to sore throat and the second is
the impact of inappropriate use of antibiotics contributing to AMR.
Respiratory tract infections, including sore throat, account for a large proportion of primary care use
and antibiotic prescribing.10 However, there is already evidence that the majority of patients prefer to
self-medicate minor ailments, such as sore throat, where they feel able to do so.1,2,14 For example, a
visit to the general practice for a diagnosis and treatment for sore throat incurs the cost of the visit to
a general practice and any treatment prescribed. In addition, in the current system, in which GPs can
use the FeverPAIN or Centor criteria to inform antibiotic prescribing, there is the potential cost of
additional health-care use for patients whose condition does not improve or who develop complications
owing to ineffective or no treatment being prescribed. The risk of complications, however, is low and
current prescribing activity suggests overuse rather than underuse of antibiotics for sore throat. Another
cost associated with the current system is laboratory costs where the reference standard for diagnosis is
used, namely throat swabs sent for culture.
Although these costs and the impact of minor ailment use on the NHS is a key consideration, the primary
aim of the intervention being considered is to reduce inappropriate antibiotic prescribing. Doing so could
support a reduction in promoters of AMR. The main antibiotic prescribed by general practice is penicillin,
and this is the first-line treatment currently recommended by NICE for suspected strep A throat infection.8,15
Across Europe, an estimated 25,000 people die each year as a result of hospital infections caused by the five
Acute sore throat
Risk assessment using the FeverPAIN or Centor clinical score tools
FeverPAIN score of 0 and 1 points
or Centor score of 0–2 points 
FeverPAIN score
of 2 and 3 points
FeverPAIN score of 4 and 5 points
or Centor score of 3 and 4 points 
Advice on self-care
and when to seek
further medical
advice
Advice on
self-care
and when to
seek further
medical advice
Advice on self-care with
back-up antibiotic
prescription to be used if
symptoms do not improve
within 3–5 days 
Immediate or
back-up antibiotic
prescription
FIGURE 1 Diagnostic and care pathway for managing acute sore throat in patients who are not at high risk of complications.
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most common resistant bacteria, and a parliamentary report estimated the annual cost to the NHS to be
£180M per year.17 Although it is often possible at present to use alternative treatments to treat resistant
infection, costs of treatment and risk of mortality for a resistant infection are likely to be approximately
double the cost of a non-resistant infection.17 One study investigating the cost of a 10-month outbreak of
a type of antibiotic-resistant bacteria (carbapenemase-producing enterobacteria) found the total cost to be
close to £1M. The main cost was missed revenue from cancellation of planned surgical procedures owing to
ward closures and lack of bed space. Other costs were associated with additional staff time, increased length
of patient stay in hospital, screening, bed and ward closure, contact precautions, anti-infective costs, human
papillomavirus decontamination and ward-based monitors.17 In addition to health-care costs and risk of
litigation associated with AMR-related harm, there is a wider societal cost of lost productivity and reduced
quality of life for patients suffering the effects of AMR infections.
Clear definition of interventions
There are rapid tests for the strep A bacterium, which are intended to be used in addition to clinical
scoring systems, such as FeverPAIN and Centor. The purpose is to increase diagnostic confidence in a
suspected strep A infection, to guide antimicrobial prescribing decisions in people presenting with an
acute sore throat and to contribute to improving antimicrobial stewardship. The tests may be suitable
for use in all settings where patients may present with an acute sore throat; these include both
primary and secondary care, and community pharmacies.11
Twenty-one rapid tests for strep A detection are available. The tests use either immunoassay detection
methods [rapid antigen detection tests (RADTs)] or molecular methods [polymerase chain reaction
(PCR) or isothermal nucleic acid amplification]. The tests listed in the following section were identified
from the NICE scope on point-of-care testing in primary care for strep A infection in sore throat.
Comparative technical overview of the point-of-care tests for
group A Streptococcus
Seventeen RADTs were identified, and their product properties are summarised in Table 1. The type of
information provided by each of the manufacturers is summarised in Appendix 14. For each test, the
limit of detection has been defined as the lowest concentration of strep A in a sample that can be
distinguished from negative samples. Of these, 16 tests use lateral flow techniques (also known as
immunochromatographic or immunofluorescent assays) and one test is a turbidimetric immunoassay.
Four molecular tests were identified which use nucleic acid amplification techniques, either PCR or
isothermal nucleic acid amplification, to amplify and detect a specific fragment of the GAS genome
(Table 2). In each test, any strep A deoxyribonucleic acid present in the sample is labelled during the
reaction, producing fluorescent light, which is monitored by a reader. If fluorescence reaches a specific
threshold, the test is considered positive. If the threshold is not reached during the set time (usually up
to 15 minutes), the test is negative.
The lateral flow (immunochromatographic and immunofluorescence) tests require a throat swab, which
is typically placed into a specimen extraction tube and mixed with reagents to extract the sample from
the swab. The swab is discarded and then either a test strip is immersed in the extracted solution or
drops of the extracted solution are added to the sample well of a test cassette. The sample then migrates
along the test strip or cassette, with any strep A antigens present in the sample binding to immobilised
strep A antibodies in the test strip or cassette. When strep A is present at levels above the detection
limit of the test, a line appears in the test line region of the strip or cassette. A control line shows
technical success of the test. Results should be discarded when the control line indicates that the test
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TABLE 1 Rapid antigen detection tests: product descriptions and properties from manufacturers’ data
Product Test format and supply Method Limit of detection Description of results
Time to result
(minutes)a
Clearview® Exact Strep A
cassetteb (Abbott Laboratories,
Lake Bluff, IL, USA)
25 individually pouched
test cassettes
Lateral flow
(immunochromatography)
5 × 104 organisms/test Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
Clearview Exact Strep A dipstick –
testb strip (Abbott Laboratories,
Lake Bluff, IL, USA)
25 test kits
Dipstick
Lateral flow
(immunochromatography)
5 × 104 organisms/test Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
BD Veritor Plus system group A
strep assay – cassette (Becton
Dickinson and Company, Sparks,
MD, USA)
30 test kits
Test cassette
Lateral flow
(immunochromatography)
Strain 12384: 1 × 105 CFU/ml
Strain 19615: 5 × 104 CFU/ml
Strain 25663: 2 × 105 CFU/ml
Analysed by a BD Veritor system
analyser module. Results are
displayed visually
5
Strep A Rapid Test – cassette
(Biopanda Reagents, Belfast, UK)
20 test cassettes Lateral flow
(immunochromatography)
1 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
Strep A Rapid Test – test strip
(Biopanda Reagents, Belfast, UK)
No information provided Lateral flow
(immunochromatography)
1 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
NADAL® Strep A – test strip
(nal von minden GmbH,
Regensburg, Germany)
40 test strips including
controls, 50 test strips
(tube) including controls,
as well as positive and
negative control vials
Lateral flow
(immunochromatography)
1.5 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
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TABLE 1 Rapid antigen detection tests: product descriptions and properties from manufacturers’ data (continued )
Product Test format and supply Method Limit of detection Description of results
Time to result
(minutes)a
NADAL Strep A – cassette
(nal von minden GmbH,
Regensburg, Germany)
20 test cassettes
including controls as
well as positive and
negative control vials
Lateral flow
(immunochromatography)
1.5 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
NADAL Strep A plus – cassette
(nal von minden GmbH,
Regensburg, Germany)
20-pack cassettes
including controls and
five-pack cassettes
including controls
Lateral flow
(immunochromatography)
1.5 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
NADAL Strep A plus – test strip
(nal von minden GmbH,
Regensburg, Germany)
40 test strips Lateral flow
(immunochromatography)
1.5 × 105 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
NADAL Strep A scan test –
cassette (nal von minden GmbH,
Regensburg, Germany)
20-pack cassettes
including controls
Lateral flow
(immunochromatography)
1.5 × 105 organisms/swab Extracted solution is placed into
the test cassette, with the Colibri
placed on top. Analysed using a
Colibri reader and Colibri USB and
software (nal von minden GmbH,
Regensburg, Germany)
5
OSOM Strep A test – test strip
(Sekisui Diagnostics, Burlington,
MA, USA)
50-test pack Lateral flow
(immunochromatography)
Not known Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
QuikRead Go Strep A test kit
(Orion Diagnostica, Espoo,
Finland)
50 tests including
controls
Turbidimetric
immunoassay
7 × 104 CFU/swab Analysed using the QuikRead Go
instrument
< 7a
Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories,
Lake Bluff, IL, USA)
20 or 40 tests Lateral flow
(immunochromatography)
Not known Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
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Product Test format and supply Method Limit of detection Description of results
Time to result
(minutes)a
bioNexia® Strep A plus – cassette
(bioMérieux, Marcy-l’Étoile,
France)
25 test cassettes Lateral flow
(immunochromatography)
1 × 104 organisms/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
bioNexia Strep A dipstick – test
strip (bioMérieux, Marcy-l’Étoile,
France)
25 test strips Lateral flow
(immunochromatography)
Not known Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
Biosynex Strep A – cassette
(Biosynex, Illkirch-Graffenstaden,
France)
Not reported Lateral flow
(immunochromatography)
1 × 105 bacteria/swab Positive results are indicated by
two lines: one in the control region
and the other in the test region.
Read by visual inspection
5
Sofia Strep A FIA (Quidel,
San Diego, CA, USA)
25 cassettes, including
positive and negative
control vials
Lateral flow
(immunofluorescence)
Strain Bruno [CIP 104226]:
1.86 × 104 CFU/test
Strain CDC-SS-1402:
9.24 × 103 CFU/test
Strain CDC-SS-1460:
2.34 × 104 CFU/test
Analysed using the Sofia
analyser, which interprets the
immunofluorescent signal using
on-board method-specific algorithms.
Results are displayed on screen as
positive, negative or invalid
5–6
CFU, colony-forming unit; CIP, ciprofloxacin; DNA, deoxyribonucleic acid; FIA, fluorescent immunoassay; USB, Universal Serial Bus.
a This information was obtained from NICE’s MedTech Innovation Briefing 145.16
b Clearview Exact Strep A cassette and Clearview Exact Strep A dipstick – test strip (both from Abbott Laboratories) have been updated and replaced with the Clearview Exact 2.
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TABLE 2 Molecular tests: product descriptions and properties
Product Test supply and format Method Analyser Limit of detection Description of results
Time to result
(minutes)a
Alere i Strep A (Abbott
Laboratories, Lake Bluff,
IL, USA)
24 test kits Isothermal nucleic
acid amplification
Alere i instrument Strain:
l ATCC 12344:
4.2 CFU/ml
l ATCC 19615:
41.8 CFU/ml
Alere i instrument heats,
mixes and detects, then
presents results
automatically on the
digital display
< 8
Alere i Strep A 2
(ID NOW™ Strep A 2)b
(Abbott Laboratories,
Lake Bluff, IL, USA)
Information not available Isothermal nucleic
acid amplification
Alere i instrument Not provided by
manufacturer
Alere i instrument heats,
mixes and detects, then
presents results
automatically on the
digital display
< 6
cobas® Strep A Assay
(Roche Diagnostics,
Basel, Switzerland)
Strep A assay box of 20 PCR cobas Liat®
analyser (Roche
Diagnostics, Basel,
Switzerland)
Strain:
l ATCC BAA-946: 5 CFU/ml
l ATCC BAA-1066:
10 CFU/ml
l ATCC 12370: 10 CFU/ml
l ATCC 700294: 20 CFU/ml
Results displayed digitally < 15
Xpert® Xpress Strep A
(Cepheid, Sunnyvale,
CA, USA)
Each kit contains
sufficient reagents to
process 10 specimens or
quality control samples
PCR GeneXpert®
system (Cepheid,
Sunnyvale, CA,
USA)
Strain:
l ATCC BAA-946
l ATCC 19615
l 9–18 CFU/ml in a
transport medium or
3–6 CFU/test
Results displayed digitally ≥ 18
CFU, colony-forming unit; DNA, deoxyribonucleic acid.
a This information was obtained from NICE’s MedTech Innovation Briefing 145.16
b The Alere i and Alere i Strep A 2 have now been replaced with the ID NOW Strep A 2.
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8
has failed (i.e. no line appears in the control line region). Depending on the technology, the results are
read either by visual inspection or by using an automated test reader device.
The turbidimetric immunoassay has similar sample collection and extraction steps to the lateral flow
tests, but the extracted solution is placed into a cuvette that is prefilled with reagents. This contains
rabbit anti-strep A antibodies, which bind to strep A antigens present in the sample. The QuikRead Go
(Orion Diagnostica, Espoo, Finland) instrument measures the absorbance of each cuvette and converts
the absorbance value into a positive or negative result.
Several of the companies recommend that negative RADT results are confirmed by microbiological
culture of a throat swab.
Target population
The population of interest is people aged ≥ 5 years presenting to health-care providers in a primary
care (GP surgeries and walk-in centres), secondary care (urgent care/walk-in centres and emergency
departments) or community pharmacy setting with symptoms of an acute sore throat. These patients
are identified as being more likely (FeverPAIN score of 2 or 3 points) or most likely (FeverPAIN score of
4 or 5 points, or a Centor score of 3 or 4 points) to benefit from an antibiotic by a clinical scoring tool.
Relevant subgroups to be evaluated may include children (aged 5–14 years), adults (aged 15–75 years)
and the elderly (adults aged > 75 years). In elderly patients, the infection is more likely to be invasive
and have a higher associated mortality rate.
Comparator
The comparator is antibiotic prescribing based on clinical judgement and clinical scoring tools alone for
strep A. However, the literature search for the comparator arm may also result in evidence referring
to clinical scoring for group C and group G streptococci. The clinical scoring tools that may be used in
NHS practice are FeverPAIN and Centor/modified Centor (McIsaac). These criteria are based on research
evidence that assessed the individual and combination of sore throat symptoms most likely to be present
in patients with clinically confirmed streptococcal infection (whether strep A or non-strep A).
FeverPAIN
The FeverPAIN clinical scoring tool includes the following variables:
l clinical history
¢ sore throat (none, mild, moderate or severe)
¢ cough or cold symptoms (none, mild, moderate or severe)
¢ muscle aches (none, mild, moderate or severe)
¢ fever in last 24 hours (yes or no)
¢ onset of illness (0–3, 4–7 or > 7 days)
l clinical examination
¢ cervical glands (none, 1–2 or > 2 cm)
¢ inflamed tonsils (none, mild, moderate or severe)
¢ pus on tonsils (yes or no).
The result of FeverPAIN is presented as a score ranging from 0 to 5 points, with 1 point assigned for
each symptom present.
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Centor
The Centor clinical scoring tool includes the following variables:
l cough (yes or no)
l exudate or swelling on tonsils (yes or no)
l tender/swollen anterior cervical lymph nodes (yes or no)
l temperature > 38 °C (yes or no).
Expert advice suggests that the McIsaac (modified Centor) clinical scoring tool may also be used.
The McIsaac score adjusts the Centor score to account for the higher incidence of strep A in children
and the reduced incidence of strep A in older adults. This adds age criteria (3–14 years, 15–44 years
and ≥ 45 years) and adds 1 point for those aged < 15 years and subtracts 1 point for those aged
> 45 years. The Centor result is presented as a score ranging from 0 to 4 points (0–5 points for the
modified Centor), with 1 point assigned for each symptom present.18
Reference standard
The reference standard for assessing the test accuracy of point-of-care tests for strep A infections is
microbiological culture of throat swabs using standard blood agar or streptococcal selective agar as
the culture medium. In the latter, antibiotics can be added to the standard blood agar to suppress the
normal pharyngeal microflora, thus improving the yield of the strep A bacteria. However, there is no
consensus on the preferred medium.19
Throat swab culture remains the best reference standard for diagnosing streptococcal pharyngitis.
However, several studies have identified discordance between throat swab culture with PCR or
other measures.20–22
In recent studies, PCR techniques were used as arbitrators of discordant results between throat
culture and point-of-care tests.20,23,24 In point-of-care tests, a threshold quantity of viable organisms
must be exceeded for culture to be positive, whereas PCR-based tests are able to detect the genome
of organisms irrespective of their viability. However, PCR cannot distinguish between acute strep A
pharyngitis and asymptomatic pharyngeal carriage and, therefore, may detect carriage in the absence
of a streptococcal infection. Therefore, our reference standard does not include PCR. Furthermore,
some of the index tests are PCR based, and so a PCR-based reference standard would be biased in
favour of these index tests. Where such arbitration using PCR is reported, we have included these
data in this report, but the main analysis uses culture as the reference standard.
INTRODUCTION
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Chapter 2 Definition of the decision problem
Decision question
This report undertaken for the NICE Diagnostics Assessment Programme examines the clinical
effectiveness and cost-effectiveness of point-of-care tests for diagnosing group A streptococcal
infections in people who present with an acute sore throat in primary care, secondary care or
community pharmacy settings. The report will help NICE to make recommendations about how well
the tests work and whether or not the benefits are worth the cost of the tests, when used in the NHS
in England and Wales. The assessment also considers other outcomes, including antibiotic prescription
behaviour, clinical improvement in patients’ symptoms and costs associated with treatment, based on
evidence identified through systematic literature searches.
The decision question for this project is what is the clinical effectiveness and cost-effectiveness of rapid
antigen detection and molecular tests in patients with high clinical scores (i.e. Centor scores of ≥ 3 points,
FeverPAIN scores of ≥ 4 points), compared with the use of clinical scoring tools alone, for increasing the
diagnostic confidence of suspected group A streptococcal infection in people who present with an acute
sore throat in primary, secondary or pharmacy care?
Overall aim of the assessment
The overall aim of this report was to present evidence on the clinical effectiveness and cost-effectiveness
of rapid antigen detection and molecular tests in those with high clinical scores (i.e. Centor scores of
≥ 3 points, FeverPAIN scores of ≥ 4 points), compared with the use of clinical scoring tools alone,
for increasing the diagnostic confidence of suspected group A streptococcal infection in people aged
≥ 5 years who present with an acute sore throat in primary, secondary or pharmacy care.
Objectives
l To systematically review the evidence for the clinical effectiveness of selected rapid tests for group
A streptococcal infections in people aged ≥ 5 years with a sore throat presenting in a primary,
secondary or pharmacy setting.
l To systematically review existing economic evaluations and develop a de novo economic model to
assess the cost-effectiveness of rapid tests in conjunction with clinical scoring tools for group A
streptococcal infections compared with clinical scoring tools alone.
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Chapter 3 Clinical effectiveness review
Methods
Search strategies for clinical effectiveness
The search strategy for the clinical effectiveness review is detailed in Appendix 1. An iterative procedure was
used to develop the database search strategies, building on the scoping searches undertaken by NICE for this
assessment and the searches underpinning the related MedTech innovation briefing published by NICE in
2018.16 Database searches were run in November and December 2018 and were updated in March 2019. No
date or language limits were applied. Grey literature searches were undertaken in February and March 2019.
Briefly, the search strategy included:
l databases – MEDLINE [via OvidSP (Health First, Rockledge, FL, USA)], MEDLINE In-Process &
Other Non-Indexed Citations (via OvidSP), MEDLINE Epub Ahead of Print (via OvidSP), MEDLINE
Daily Update (via OvidSP), EMBASE (via OvidSP), Cochrane Database of Systematic Reviews [via
Wiley Online Library (John Wiley & Sons, Inc., Hoboken, NJ, USA)], Cochrane Central Register of
Controlled Trials (CENTRAL) (via Wiley Online Library), Database of Abstracts of Reviews of Effects
(DARE) [via the Centre for Reviews and Dissemination (CRD)], Health Technology Assessment
(HTA) database (via CRD), Science Citation Index and Conference Proceedings [via the Web of
Science™ (Clarivate Analytics, Philadelphia, PA, USA)] and the PROSPERO International Prospective
Register of Systematic Reviews (via CRD)
l trial database – ClinicalTrials.gov
l reference lists of relevant reviews and included studies
l online resources of health services research organisations and regulatory bodies – International
Network of Agencies for Health Technology Assessment (INAHTA), the US Food and Drug
Administration (FDA) medical devices, FDA Clinical Laboratory Improvement Amendments (CLIA)
database and European Commission medical devices
l online resources of selected professional societies and conferences – British Society for Antimicrobial
Chemotherapy, British Infection Association, PHE, British Society for Antimicrobial Chemotherapy,
Royal College of Pathologists, streptococcal biology conference, Lancefield International Symposium on
Streptococci and Streptococcal Diseases, Federation of Infection Societies Conference, The European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Microbiology Society Conference,
American Society of Microbiology, and Association of Clinical Biochemistry and Laboratory Medicine
l online resources of manufacturers of the included rapid tests.
Inclusion and exclusion of relevant studies (Boxes 1 and 2)
BOX 1 Inclusion criteria
Population
l People aged ≥ 5 years presenting with symptoms of an acute sore throat. Where possible, relevant
subgroups evaluated included children (aged 5–14 years), adults (aged 15–75 years) and the elderly
(adults aged > 75 years); however, mixed populations were acceptable. Studies of children aged
< 5 years could be included providing ≥ 90% were above this age.
Intervention
l Point-of-care tests for strep A (including RADTs and molecular tests as described in Tables 1 and 2).
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Comparator
l Clinical scoring tools (such as FeverPAIN, Centor or McIsaac).
Reference standard
l Microbiological culture of throat swabs.
Outcome
l Outcomes of test performance:
¢ test accuracy – sensitivity, specificity, PPV and NPV. Where possible, evaluated by relevant clinical
scores (Centor/McIsaac ≥ 3 points and FeverPAIN ≥ 4 points)
¢ discordant results with throat culture
¢ test failure rates
¢ time to antimicrobial prescribing decision
¢ changes to antimicrobial prescribing decision
¢ number of appointments required per episode
¢ number of delayed or immediate antibiotic prescriptions issued.
l Clinical outcomes:
¢ morbidity, including post-strep A infection complications, such as rheumatic fever and side effects
from antibiotic therapy
¢ mortality
¢ contribution to antimicrobial stewardship and onward transmission of infection.
l Patient-reported outcomes:
¢ health-related quality of life
¢ patient satisfaction with test and antimicrobial prescribing decision
¢ health-care professional satisfaction with test and antimicrobial prescribing decision.
l Costs.
Study design
For test accuracy data:
l clinical test accuracy studies that compare the index tests (point-of-care tests for strep A) with throat
swab culture
l studies of head-to-head comparisons of rapid tests were eligible for inclusion if test accuracy statistics
were reported for each test.
For data on other clinical outcomes:
l any study design comparing the index tests (point-of-care tests for strep A) and/or clinical scoring tools
(Centor, McIsaac or FeverPAIN) with biological culture as a reference standard.
Health-care setting
l Primary care (GP clinics and walk-in centres), secondary care (urgent care/walk-in centres and
emergency departments) or community pharmacy settings.
NPV, negative predictive value; PPV, positive predictive value.
BOX 1 Inclusion criteria (continued)
CLINICAL EFFECTIVENESS REVIEW
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Study selection strategy
All publications that were identified in searches from all sources were collated in EndNote (Clarivate
Analytics) and deduplicated. Two reviewers independently screened the titles and abstracts of all
records identified by the searches (Cohen’s kappa = 0.997) and discrepancies were resolved through
discussion. Full copies of all studies deemed potentially relevant were obtained and two reviewers
independently assessed these for inclusion; any disagreements were resolved by consensus or discussion
with a third reviewer. Records excluded at full-text stage and reasons for exclusion were documented.
Data extraction strategy
All data were extracted by one reviewer, using a piloted data extraction form. A second reviewer
checked the extracted data on test accuracy [2 × 2 table, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV)], and a third reviewer checked other extracted data.
Any disagreements were resolved by consensus. A sample data extraction form used in this review is
available in Appendix 2. Test accuracy statistics for rapid/index tests were derived from data extracted
onto 2 × 2 contingency tables in the format shown in Table 3. As shown, A represents the number of
patients positive for strep A by rapid test and throat culture (true positives); B represents the number
of patients positive for strep A by rapid test but not throat culture (false positives); C represents the
number of patients negative for strep A by rapid test but positive by throat culture (false negatives);
and D represents the number of patients negative for strep A by rapid test and throat culture (true
negatives). Sensitivity was calculated as A/(A + C), specificity as D/(B +D), PPV as A/(A + B) and NPV
as D/(C +D). Similarly, using data extracted in the formats shown in Tables 4 and 5, we calculated
BOX 2 Exclusion criteria
Population
l Patients without acute sore throat.
l Patients with existing comorbidities.
l Patients with known invasive strep A infection.
Intervention
l Other point-of-care tests that are not listed in the NICE scope.
Comparator
l For test accuracy data: no comparison of index test vs. throat culture reported.
l For other outcomes: no comparison of index test vs. throat culture or clinical scoring tools (Centor,
McIsaac or FeverPAIN).
Study design
l Reviews, biological studies, case reports, editorials and opinions, poster presentations without
supporting abstracts, non-English-language reports, meeting abstracts without sufficient information to
produce 2 × 2 contingency tables for test performance.
Date
l Studies published before 1998 (keeping in line with the 1998 directive of the European parliament
requiring all in vitro diagnostic devices to have a CE marking).25
Setting
l Hospital inpatient.
CE, Conformité Européenne.
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accuracy statistics for the current pathway (Centor/McIssac/FeverPAIN scores) based on NICE thresholds.
Where PCR techniques were employed to arbitrate discordant results between microbiological culture
and rapid tests, we report the PCR results for the discordant cases. We also extracted test accuracy data
for each index test with culture as the reference standard in studies of head-to-head (direct) comparisons
of index tests. Data on other outcomes of test performance, morbidity, antibiotic-prescribing behaviour,
population characteristics and settings were also extracted using the extraction form.
Quality assessment strategy for test accuracy studies
Quality assessment of eligible test accuracy studies was undertaken with a tailored Quality Assessment
of Diagnostic Accuracy Studies – 2 (QUADAS-2) tool.26 Methodological quality was assessed by a single
reviewer and findings were checked by a second reviewer. Disagreements were resolved by consensus
or use of a third reviewer.
Quality assessment aimed to assess the risk of bias and applicability concerns of included studies
where one (or more) of our 21 scoped tests was the index test(s), and with biological throat culture as
the reference standard. Additional tests outside the scope were not quality appraised.
Modifications to tailor the QUADAS-2 form to the research question in terms of the risk-of-bias
assessment were as follows (see Appendix 4 for the tailored QUADAS-2 form and guidance notes).
TABLE 3 A 2 × 2 contingency table for rapid test vs. throat culture
Culture + Culture – Total
Index test + A B A+ B
Index test – C D C+D
Total A+C B+D A + B+C+D
TABLE 5 A 2 × 2 contingency table for FeverPAIN vs. throat culture
Culture + Culture – Total
FeverPAIN score of ≥ 4 points A B A+ B
FeverPAIN score of < 4 points C D C+D
Total A+C B+D A + B+C+D
TABLE 4 A 2 × 2 contingency table for Centor/Modified Centor vs. throat culture
Culture + Culture – Total
Centor/McIsaac score of ≥ 3 points A B A+ B
Centor/McIsaac score of < 3 points C D C+D
Total A+C B+D A + B+C+D
CLINICAL EFFECTIVENESS REVIEW
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Patient selection domain
Two further signalling questions were added to this domain. The first was ‘were selection criteria
clearly described?’. It is important that the correct patient groups were included in the studies. Patients
aged < 5 years follow a different NICE clinical pathway27 because they are more likely to present with
a sore throat and less likely to be able to articulate their symptoms, and it is less likely that a throat
swab can be obtained. Likewise, a clinical score (such as Centor or FeverPAIN) should be reported,
with patients included only if they have a score of > 3 points on Centor or > 4 points on FeverPAIN.
Those with lower scores may be systematically different and, therefore, test accuracy may also
differ, introducing bias. Including patients aged < 5 years and with a low clinical score also raises
applicability concerns.
The second signalling question that was added was ‘were patients seen in an ambulatory care setting?’.
Patients seen as inpatients may vary in severity and have comorbidities affecting their diagnosis.
Index test domain
Two questions were added within this domain. The first was ‘was a separate swab undertaken for the
index test?’. This question was added as manufacturers’ specifications require separate swabs to be
taken for index and reference standard tests. Using one swab for multiple purposes may reduce the
quantity of the sample for testing and, thus, affect the accuracy of the test. The second question was
‘is the test reading objective?’. Some of the tests require a subjective reading of whether or not a line,
indicating a positive result, has appeared. Owing to this, there is always a high level of bias in any
rapid test that requires a determination of the result by the human reader. Tests with automated
readings have been shown to have improved specificity and reduce operator errors, especially in
unclear results.28
Comparator domain
One additional signalling question was added in this domain: ‘was a separate swab taken for throat
culture testing?’. Using one swab for multiple purposes may reduce the quantity of the sample for testing
and, thus, affect the accuracy of the test. Under this domain, the directions for taking a throat culture
specimen were clarified based on the PHE guidelines on UK Standards for Microbiology Investigations.29
Flow and timing
Two further signalling questions were added to the flow and timing domain. The first was ‘were both
index test(s) and reference standard (and comparator where included) all carried out at the same
appointment?’. The swabs for a rapid test and culture should be obtained at the same appointment.
The levels of strep A are likely to vary by day, so taking a later sample could introduce systematic bias.
The additional signalling question was ‘were both index test(s) and reference standard (and comparator
where included) all carried out prior to commencement of antibiotics?’. Patients should not have
been treated with antibiotics prior to testing, as antibiotics are likely to have reduced the amount of
strep A present.
Quality appraisal strategy for studies of prescribing behaviour and clinical outcomes
Quality appraisal for studies of prescribing behaviour and clinical outcomes used two different tools:
the Cochrane risk-of-bias tool for randomised controlled trials (RCTs)30 and the Joanna Briggs Institute
(JBI) Critical Appraisal Checklist for analytical cross-sectional studies.31 Methodological quality was
assessed by a single reviewer and findings were checked by a second reviewer. Disagreements were
resolved by consensus or use of a third reviewer.
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Assessment of test accuracy
To assess the accuracy of the point-of-care tests, we planned to conduct a series of meta-analyses on
the available data. Data from studies that either presented 2 × 2 tables for one of the index tests
compared with culture or provided information that allowed calculation of the 2 × 2 table were
included in the meta-analyses.
The median age of participants was used to categorise each study into one of the three age groups of
interest, with two reviewers discussing when the categorisation was not straightforward. Setting was also
considered to inform the age categorisation where necessary (e.g. if the study was conducted within a
paediatric department). The setting of each study was treated as a categorical variable, indicating primary
care (health-care centre, GP clinic or primary care clinic), secondary care (emergency department, private
paediatric clinic, outpatient clinic, urgent care clinic or walk-in centre) and pharmacy setting or mixed.
For the purpose of the meta-analysis, the throat score of the population was dichotomised to 0, if
the study population included patients who had scores below the threshold set in the scope, and 1,
if the study population matched the scope (Centor/McIsaac score of ≥ 3 points or FeverPAIN score
of ≥ 4 points). Alternative throat score classification of study populations was also considered, using
the categories of a population matching the scope (see Chapter 1, Target population), a population
restricted by throat score but still including patients not in the scope (e.g. Centor score of 2 points)
and a population without any restriction by throat score.
Methods of analysis/synthesis
We planned to use bivariate models to conduct each meta-analysis, as they allow simultaneous estimation
of both sensitivity and specificity, accounting for correlation between the two measures. Where at least
two studies existed for a test, we used a random-effects model to allow for deviation in test performance
across each study. If bivariate or random-effects models failed to converge or produced results with
unexpectedly wide confidence intervals (CIs) around key parameters, then simpler models (e.g. fixed-effect
or univariate models) were used instead.32,33 Where bivariate models were used, a comparison with
the equivalent univariate models was made, and any difference noted. It was not anticipated that any
meaningful difference between the two model types would be observed given the small number of
data available.
For index tests that had just one study, a meta-analysis was not conducted. The impacts of age, setting
and prevalence on test performance were all assessed through the meta-analysis of relevant subgroups.
NICE advised the EAG against meta-analysis across rapid tests from different manufacturers.
Clinical effectiveness results
Search results
Figure 2 is a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram that illustrates the study selection process for the clinical effectiveness review. The search
identified 5919 records through database and other searches. Following duplicate removal, we screened
3309 records, of which 3072 were excluded by their titles and abstracts, leaving 237 assessed for their
eligibility to be included in the review. A total of 199 studies were subsequently excluded with reasons,
leaving 38 studies [26 full texts,6,20,23,24,34–55 three abstracts,56–58 five manufacturers’ studies (submitted
directly to NICE in response to a request for information) and four FDA documents59–62]. The most
common reason for exclusion at this stage was not reporting any of the rapid tests listed in the scope.
The full list of excluded studies with reasons for exclusion can be found in Appendix 3.
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Study characteristics
Characteristics of the 38 studies included in the clinical effectiveness review are described in Figures 3
and 4 and Table 6. Of the 29 studies (full texts and abstracts)6,20,23,24,34–58 identified by the search,
26 of the studies reported test accuracy data.20,23,24,34–52,54,57,58,63 Three of the identified studies6,53,55
reported only other outcomes (such as antibiotic-prescribing rates) and did not report test accuracy.
In addition, five studies were sent by manufacturers in response to a request for information by NICE
and four FDA documents were retrieved.59–62
The tests, their settings, the populations they cover and the head-to-head studies are illustrated in
Figures 3 and 4.
Population
The 38 included studies comprised ≈ 14,000 symptomatic participants. Prevalence of strep A ranged
from 15% to 49%, with no clear demographic or clinical patterns accounting for this variation.39,56
Similarly, prevalence estimates of strep A were no more or less likely to be higher in secondary
or primary care settings. The study population comprised adults and children; however, the exact
proportions are unknown as they were not reported in about half of the included studies. In most of
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FIGURE 2 The PRISMA flow diagram showing study selection for the clinical effectiveness review.
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FIGURE 3 Diagram of studies by test type, setting and population for included test accuracy studies with extractable
2 × 2 data. Note that lines between tests indicate head-to-head (direct) comparisons. M, molecular test; NR, not reported;
R, rapid test.
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FIGURE 4 Diagram of studies by test type, setting and population for included test accuracy studies with extractable
2 × 2 data. M, molecular test; NR, not reported; R, rapid test.
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TABLE 6 Characteristics of the included studies
Study (first author and
year of publication) Data source Setting
Study population
Index test
Comparison with
Centor/McIsaac/
FeverPAIN scores?
Throat swab
culture medium Outcomes
Test accuracy in high-risk
subpopulations with
Centor/McIsaac scores of
≥ 3 points or FeverPAIN
score of ≥ 4 pointsn
Age group as
reported
Sore throat clinical
score criteria
Strep A
prevalence (%)
Published articles and abstracts
Anderson 200356 Abstract Secondary 353 Children
(0–14 years)
No criteria reported
Used clinical
symptoms
15 Clearview Strep A No NR Test accuracy NR
Azrad 201934 Published article Secondary 100 NR No criteria reported
Used clinical
symptoms
25 BD Veritor system No Streptococcal
selective agar
Test accuracy NR
QuikRead Go Strep A
test kit (Orion
Diagnostica)
Berry 201820 Published article Secondary 215 Children
(age range not
reported)
NR 19.5 Alere i Strep A test No Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
NR
BD Veritor system NR
Bird 201835 Published article Secondary 395 Children McIsaac ≥ 3 points NR or not
calculable
bioNexia Strep A Yes/Centor NA Test accuracy
Antibiotic-
prescribing
behaviour
NR
Bura 201736 Published article Primary 101 Adults
(18–44 years)
Centor ≥ 2 points 22.7 OSOM Strep A test
(Sekisui Diagnostics)
Yes/Centor Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
No
Cohen 201537 Published article Secondary 481 Children (median
age 11 years)
McIsaac all scores 30.3 Alere i Strep A test Yes/McIsaac Blood agar Test accuracy No
Dimatteo 200138 Published article Secondary 383 Adults
(18–86 years)
Centor ≥ 1 point NR or not
calculable
Alere™ TestPack +Plus
Strep A (Abbott
Laboratories)
Yes/McIsaac Streptococcal
selective agar
Test accuracy NR
Humair 200639 Published article Primary 224 Adults
(15–65 years)
Centor= 2 points
Centor > 2 points
46.9 Alere TestPack +Plus
Strep A (Abbott
Laboratories)
Yes/Centor Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
Yes
Johansson 200340 Published article Primary 144 Mixed (children
and adults)
NR 31.4 Alere TestPack +Plus
Strep A (Abbott
Laboratories)
No NR Test accuracy
Antibiotic-
prescribing
behaviour
NR
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Study (first author and
year of publication) Data source Setting
Study population
Index test
Comparison with
Centor/McIsaac/
FeverPAIN scores?
Throat swab
culture medium Outcomes
Test accuracy in high-risk
subpopulations with
Centor/McIsaac scores of
≥ 3 points or FeverPAIN
score of ≥ 4 pointsn
Age group as
reported
Sore throat clinical
score criteria
Strep A
prevalence (%)
Johnson 200141 Published article Primary 522 Adults (median
age 26 years)
No criteria reported
Used clinical
symptoms
NR or not
calculable
Alere TestPack +Plus
Strep A (Abbott
Laboratories)
No Blood agar Test accuracy NR
Kurtz 200042 Published article Secondary 257 Children
(4–15 years)
No criteria reported
Used clinical
symptoms
31.1 Alere TestPack +Plus
Strep A (Abbott
Laboratories)
No Blood agar Test accuracy NR
Lacroix 201823 Published article Secondary 1002 Children McIsaac ≥ 2 points 38 Sofia Strep A FIA
(Quidel)
No Blood agar Test accuracy No
Alere TestPack +Plus
Strep A test (Abbott
Laboratories)
Lindbæk 200443 Published article Primary 306 Adults (median
age 23.9 years)
NR 35.9 Alere TestPack +Plus
Strep A (Abbott
Laboratories)
No Streptococcal
selective agar
Test accuracy NR
Little 20136 Published article Primary 1760 Mixed
(aged ≥ 3 years)
FeverPAIN
≥ 1 point
NR or not
calculable
Alere TestPack +Plus
Strep A (Abbott
Laboratories)
Yes None Antibiotic-
prescribing
behaviour
No
Llor 200944 Published article Primary 222 Adults (median
age 30.6 years)
Centor ≥ 2 points 21.2 OSOM Strep A Yes/Centor Blood agar Test accuracy No
Llor 201145 Published article Primary 276 Adults (median
age 31.7 years)
Centor ≥ 1 point 16.7 OSOM Strep A test Yes/Centor Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
Yes
McIsaac 200446 Published article Primary 787 Children
(3–17 years)
and adults
(≥ 18 years);
results reported
separately by
group
McIsaac all scores 29 TestPack Plus Strep A
test (Abbott
Laboratories)
Yes/McIsaac Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
No
Nerbrand 200247 Published article Primary 615 Mixed (children
and adults
No criteria reported
Used clinical
symptoms
21.1 TestPack Plus Strep A
test (Abbott
Laboratories)
No Blood agar Test accuracy NR
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TABLE 6 Characteristics of the included studies (continued )
Study (first author and
year of publication) Data source Setting
Study population
Index test
Comparison with
Centor/McIsaac/
FeverPAIN scores?
Throat swab
culture medium Outcomes
Test accuracy in high-risk
subpopulations with
Centor/McIsaac scores of
≥ 3 points or FeverPAIN
score of ≥ 4 pointsn
Age group as
reported
Sore throat clinical
score criteria
Strep A
prevalence (%)
Pauchard 201357 Abstract Secondary 193 Children
(3–18 years)
McIsaac > 2 points 37 Strep A Rapid Test
(Biopanda Reagents)
Yes/McIsaac NR Test accuracy NR
Penney 201648 Published article Secondary 147 Children (mean
age 8.8 years)
No criteria reported
Used clinical
symptoms
40.1 Alere TestPack +Plus
Strep A test (Abbott
Laboratories)
No Streptococcal
selective agar
Test accuracy NR
Rogo 201149 Published article Secondary 228 Children No criteria reported
Used clinical
symptoms
28.9 OSOM Strep A test No Blood agar Test accuracy NR
Rosenberg 200250 Published article Secondary 126 Mixed (children
and adults)
Centor all scores 25.4 TestPack Plus Strep A
test (Abbott
Laboratories)
Yes/Centor Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
NR
Santos 200351 Published article Secondary 49 Children
(1–12 years)
No criteria reported
Used clinical
symptoms
30 Alere TestPack +Plus
Strep A (Abbott
Laboratories)
No Blood agar Test accuracy NR
Stefaniuk 201752 Published article Primary 44 Children McIsaac/Centor all
scores
26.3 QuikRead Go Strep A
test kit (Orion
Diagnostica)
Yes/Centor Blood agar Test accuracy
Antibiotic-
prescribing
behaviour
No
96 Adults and
children
McIsaac/Centor all
scores
22.4
Thornley 201653 Published article Pharmacy 149 NR Centor > 2 points 24.2 OSOM Strep A test
(Sekisui Diagnostics)
Yes/Centor None Antibiotic-
prescribing
behaviour
NA
Valverde 201858 Abstract Secondary 580 Mixed
(aged ≥ 0 years)
NR NR or not
calculable
TestPack Plus Strep A
test
No Blood agar Test accuracy NR
Wang 201724 Published article Primary 427 Children Centor ≥ 1 point 30.2 cobas Liat Strep A
Assay (Roche
Diagnostics)
No NR Test accuracy No
Weinzierl 201854 Published article Secondary 160 Children
(median age
6.5 years)
NR 38 OSOM Strep A test No Blood agar Test accuracy NR
Alere i Strep A test
Worrall 200755 Published article Primary 533 NR Centor all scores NR or not
calculable
Clearview Exact
Strep A (Abbott
Laboratories)
Yes/Centor NA Antibiotic-
prescribing
behaviour
NA
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Study (first author and
year of publication) Data source Setting
Study population
Index test
Comparison with
Centor/McIsaac/
FeverPAIN scores?
Throat swab
culture medium Outcomes
Test accuracy in high-risk
subpopulations with
Centor/McIsaac scores of
≥ 3 points or FeverPAIN
score of ≥ 4 pointsn
Age group as
reported
Sore throat clinical
score criteria
Strep A
prevalence (%)
Manufacturer’s studies provided in responses to request by NICE
Biopanda Reagents Manufacturer’s
information
Secondary 160 Median age
6.5 years
NA 23.2 Alere i Strep A test No Blood agar Test accuracy NR
Cepheid Manufacturer’s
information
Primary 577 NR NA 25.6 Xpert Xpress Yes/Centor NA Test accuracy NR
nal von minden GmbH Manufacturer’s
information
Unknown 244 Mixed (adults
and children)
NA 34.4 NADAL Strep A test No Blood agar Test accuracy NR
Orion Diagnostica Manufacturer’s
information
Primary 271 NR NA 32.8 QuikRead Go Strep A
test kit (Orion
Diagnostica)
No Streptococcal
selective agar
Test accuracy NR
Roche Diagnostics Manufacturer’s
information
Mixed 570 Mixed
(aged ≥ 3 years)
NA 30.4 cobas Liat Strep A
Assay (Roche
Diagnostics)
No Blood agar Test accuracy NR
FDA documents
Abbott Laboratories61 FDA document Mixed 981 NR NA 20.2 Alere i Strep A 2 test No Blood agar Test accuracy NR
Becton Dickinson59 FDA document Mixed 796 Mixed
(aged ≥ 0 years)
NA 18.7 BD Veritor system No Blood agar Test accuracy NR
Cepheid62 FDA document Mixed 618 NR NA 25.6 Xpert Xpress Strep A
(Cepheid)
No NR Test accuracy NR
Quidel60 FDA document Mixed 736 NR NA 17.4 Sofia Strep A FIA
(Quidel)
No Blood agar Test accuracy NR
FIA, fluorescent immunoassay; NA, not applicable; NR, not reported.
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the included studies, participants aged < 18 years were identified as children. In fact, only two studies
met the age criterion for children (ages 5 to 14 years) as defined in the protocol and scope.50,51 Hence,
studies that included children aged < 5 years as well as ≥ 5 years were included in the present review.
More so, only two studies met the age criterion for adults (age ≥ 15 years) as defined in the protocol
and scope and, therefore, the findings of the review may be applicable to only a mixed population.39,52
All 38 studies included patients with a sore throat; however, other clinical characteristics were insufficiently
reported across most of the included studies. For instance, sore throat clinical scores (e.g. Centor/McIsaac/
FeverPAIN scores) were reported in 16 studies,6,23,35–39,44–46,50,52,53,55,57 of which two exclusively included
patients with high clinical scores (i.e. Centor ≥ 3 points, FeverPAIN ≥ 4 points).6,53 Both of these studies
were on prescribing behaviours. However, there were two test accuracy studies that included patients
with lower clinical scores (i.e. Centor scores of < 3 points) but reported test accuracy results separately
by Centor score.39,45
Recent antibiotic use prior to enrolment was considered in eight included studies, and patients without
any recent use of antibiotics prior to recruitment were eligible for inclusion in these studies.24,35,36,42,45,47,48,50
Index tests
There were more studies evaluating RADTs (76%, 29/38) than were evaluating molecular tests (18%,
7/38) or studies comparing both rapid tests and molecular tests (5%, 2/38). For instance, the Alere™
TestPack +Plus Strep A (Abbott Laboratories) was the most common antigen detection test, which was
evaluated in 13 studies (excluding unpublished studies conducted by the manufacturers).6,23,38–43,46–48,51,58
Conversely, the only molecular test evaluated in a peer-reviewed journal article was the PCR-based
cobas Liat Strep A Assay (Roche Diagnostics).24
As shown in Table 6, there were four studies providing head-to-head comparisons of index tests: BD
Veritor System (Becton Dickinson) and QuikRead Go (Orion Diagnostica);34 Alere i Strep A (Abbott
Laboratories) and BD Veritor System (Becton Dickinson);20 Alere i Strep A (Abbott Laboratories) and
Sofia Strep A fluorescent immunoassay (FIA) (Quidel);23 and Alere i Strep A (Abbott Laboratories) and
OSOM Strep A.54 Essentially, each index test was compared with throat culture as the reference
standard in order to obtain test accuracy.
The search strategy revealed test accuracy studies of OSOM Ultra Strep A (Sanofi Genzyme and
Sekisui Diagnostics).64,65 However, these studies were subsequently excluded because the EAG could
not confirm whether it is the same as the OSOM Strep A test (Genzyme and Sekisui Diagnostics),
which is listed among the scoped rapid tests. Similarly, it was unclear if Sofia Strep A+ Plus FIA
(Quidel)66 and OSOM Strep A (Sekisui Diagnostics)67 were identical to Sofia Strep A FIA (Quidel)
and OSOM Strep A (Sekisui Diagnostics), respectively; hence, studies of the former were excluded.
Comparator and reference standard
Index tests were compared with Centor, McIsaac or FeverPAIN scoring tools in 12 studies.6,35,36,38,45,46,50,52,
53,55,57,68 However, only six of these studies directly compared test accuracy between clinical scoring tools
and point-of-care tests.39,44–46,52 Only two reported test accuracy in patients with high clinical scores
(Centor ≥ 3 points, FeverPAIN ≥ 4 points).39,45
The culture medium used for the reference standard (blood agar or streptococcal selective agar) was
reported in all but five studies.24,40,56,57 Neither the manufacturers’ submissions (submitted directly to
NICE in response to a request for information) nor the FDA studies provided information on index
tests compared with clinical scoring tools.
Outcomes
Thirty-eight studies were included across all outcomes. Twenty-six published articles (full texts and
abstracts) reported test accuracy data (of which seven also reported on antibiotic-prescribing rates
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and five reported on test failure rate); there were an additional five submissions from manufacturers
and four FDA documents.
Five studies had insufficient data to construct 2 × 2 contingency tables to ascertain the accuracy of
index tests with microbiological throat culture as the reference standard.6,35,47,53,55 These studies were
further excluded from the assessment of test accuracy in Point-of-care/index tests. An attempt to verify
at least some of the discrepant results between rapid tests and microbiological culture was undertaken
in only five studies.20,23,24,37,43 Antibiotic-prescribing behaviour was reported in 12 studies.6,20,35,36,39,40,45,46,
50,52,53,55 None of the other outcomes in the scope or protocol was reported in any of the included studies.
Setting
Participants in the included studies were recruited from GP/primary care clinics/family practices,6,40,41,43–47
community pharmacies,53 paediatric clinics,42,49,54,56 paediatric emergency departments,23,48,57 hospital
outpatient departments20,51 and emergency departments.35,50 There were two multicentre studies with
mixed populations from primary and secondary care settings: Cohen et al.37 sampled patients from the
emergency department (secondary care) and urgent care clinics (primary care); and Wang et al.24
sampled patients from paediatric clinics (secondary care) and family practices (primary care).
Only one unpublished study supplied by the manufacturers confirmed the study setting (Orion Diagnostica,
primary care). The remaining unpublished studies conducted by manufacturers may have included mixed
populations from primary and secondary care settings; however, this is purely speculative as study settings
were not reported in these studies. However, these studies provide no evidence to suggest any recruitment
of inpatients.
Study design
The 26 published studies on test accuracy comprised one RCT45 and 25 cohort studies.20,23,24,34–44,46,48–52,
55–58,69 It was unclear what study design had been undertaken in any of the unpublished studies
provided by the manufacturers or the FDA.
The 12 studies that provided data on antibiotic-prescribing rates comprised three RCTs,6,45,55 one
before-and-after cohort study20 and eight one-armed cohort studies.35,36,39,40,46,50,52,53
Quality considerations of included studies
The assessment of risk of bias and applicability for the 26 included test accuracy studies20,23,24,34–46,48–52,55–58,69
using the QUADAS-2 tool are summarised in Table 7 and Figure 5. Four of the included studies compared
two index tests that are relevant to this review, so there are 30 quality assessment ratings for the index
test domains. Likewise, one study included two different culture mediums as its reference standard,
so there are 27 quality assessment ratings across the reference standard domains.
Risk of bias for test accuracy studies
In general, the methodological and reporting quality of the included studies was poor, with risk of bias
considered to be high in two or more domains for 13 studies (50%).20,34–36,38,40–43,46,49–51 No study was
considered to be at a low risk of bias in all four domains.
In 65.4% of studies (17/26),20,23,24,35,37,42,43,46,47,49,51,52,54,56–58,70 it was not clear whether patients were
consecutively included or a convenience sample had been chosen, and only 15.4% (4/26 studies)39,44,45,48
were rated as having a low risk of bias in the patient selection domain (domain 1: patient selection).
The selection process in the remaining 19.2% of studies (5/26)34,36,41,50 was rated as being at a high risk
of bias, with studies clearly reporting convenience samples, having case–control designs or having
made inappropriate exclusions from the eligible screening population.
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TABLE 7 Judgement of risk of bias and applicability of included studies
Study (first author and
year of publication)
Risk of bias Applicability concerns
Patient
selection Index test
Additional
index test
Reference
standard
Additional
reference
standard
Flow and
timing
Patient
selection Index test
Additional
index test
Reference
standard
Additional
reference
standard
Andersen 200356 Unclear High NA Unclear NA Unclear High Unclear NA Unclear NA
Azrad 201934 High Low Low Unclear NA High High Low Low Unclear NA
Berry 201820 Unclear High Low High NA Unclear High Low Low Unclear NA
Bird 201835 Unclear High NA Unclear NA High High Unclear NA Unclear NA
Bura 201736 High High NA Low NA High High Low NA Low NA
Cohen 201537 Unclear Low NA Low NA Unclear High Low NA Low NA
Dimatteo 200138 High High NA High NA High Low Unclear NA High NA
Humair 200639 Low High NA Unclear NA Low Low Low NA Low NA
Johansson 200340 Unclear High NA Unclear NA High High Unclear NA Unclear NA
Johnson 200141 High High NA High NA High High Low NA High NA
Kurtz 200042 Unclear High NA High Low Unclear High Low NA High Low
Lacroix 201823 Unclear Low High Low NA Low High Low Low Low NA
Lindbæk 200443 Unclear High NA High NA Low High Low NA High NA
Llor 200944 Low High NA Unclear NA Low High Low NA Unclear NA
Llor 201145 Low High NA Unclear NA Unclear Low Low NA Low NA
McIsaac 200446 Unclear High NA Low NA High Unclear Unclear NA Low NA
Nerbrand 200247 Unclear High NA Unclear NA Low High Low NA Low NA
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Study (first author and
year of publication)
Risk of bias Applicability concerns
Patient
selection Index test
Additional
index test
Reference
standard
Additional
reference
standard
Flow and
timing
Patient
selection Index test
Additional
index test
Reference
standard
Additional
reference
standard
Pauchard 201357 Unclear High NA Unclear NA Unclear High Unclear NA Unclear NA
Penney 201648 Low High NA Unclear NA Low High Low NA Unclear NA
Rogo 201149 Unclear High NA High NA Unclear High Low NA Unclear NA
Rosenberg 200250 High High NA Low NA Low High Low NA Low NA
Santos 200351 Unclear High NA Unclear NA High High Low NA Low NA
Stefaniuk 201752 Unclear Low NA Unclear NA Unclear High Low NA Low NA
Valverde 201858 Unclear High NA Low NA Unclear High Unclear NA Low NA
Wang 201724 Unclear Low NA Unclear NA Low High Low NA Unclear NA
Weinzierl 201854 Unclear Low High Low NA Unclear High Unclear Unclear Low NA
NA, not applicable (the study did not have this additional test).
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The key risks of bias were surrounding how the index test was undertaken (22/30 domains were
rated as being at high risk, 73.3%, 22/26 studies).20,23,35,36,38–46,48–51,55–58,69 Although all of the included
studies were on predeveloped tests that had in-built thresholds, in many cases use of the index test
required a subjective reading by a clinician (domain 2: index tests). There were further concerns that
studies often used the same swab intended for the index test to first streak the agar for biological
culture, rather than taking an additional swab sample. Using one swab for multiple purposes may
reduce the amount of the sample and underestimate the accuracy of the test.
Unclear or incomplete reporting was common in the reference standard domain (domain 3: reference
standard). In all studies, time taken to process the biological culture exceeded that of the rapid test,
with biological cultures generally reported 48 hours following sample collection. However, many
studies did not state that laboratory staff were blinded to the results of the index test or reference
standard (domain 3: reference standard, 13/27 studies, 48.1%).24,34,35,39,40,44,45,47,48,51,52,56,57 There was a
high risk of bias in 22.2% of the studies (6/27)20,38,41–43,49 because the methods of biological culture
testing did not match current UK guidelines.29
The flow of patients through the studies was rated as being at a high risk of bias in 31% of studies
(8/26, domain 4: flow and timing).34–36,38,40,41,46,51 The majority of these (62.5%, 5/8 studies)34–36,41,46,51 had
incomplete testing and made exclusions from the analysis. However, in two of these studies only some
patients received the reference standard (partial verification bias). In one study,38 only patients with
negative rapid test results received the reference standard; in the other,40 only those with positive
rapid test results were given the reference standard. The use of antibiotics was a further concern, with
one study directly reporting 61 patients taking antibiotics at the time of testing,34 and 90% (9/10) of
unclear ratings were linked to prior/current antibiotic use not being reported.20,37,42,45,49,52,54,56–58
8
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FIGURE 5 Concerns regarding bias and applicability in included studies. (a) Risk of bias; and (b) concerns regarding
applicability. a, Four studies included two index tests relevant to this review; b, one study included two reference
standards (culture methods) relevant to this review.
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Applicability of study findings for test accuracy studies
The applicability of study findings was assessed with regard to three domains: patient selection,
index test (rapid or molecular test) and reference standard (biological culture). There were significant
concerns regarding the applicability of the studies to UK practice for patient selection in 22 of the
26 studies (85%, domain 1: patient selection).20,23,24,34–37,40–44,48–52,55–58,69 In the UK, the test would be
given only following an assessment using a clinical scoring tool, such as Centor or FeverPAIN. The
rapid test would be given only to people with Centor scores of ≥ 3 points and FeverPAIN scores
of ≥ 4 points. In all 22 studies, either a clinical scoring tool was not used or, if used, patients were
included with scores lower than UK cut-off points and test accuracy data were not reported separately
by score. In addition, 17 of the 22 studies (77%)20,23,24,35,37,40,42,48–52,55–58,69 included children aged
< 5 years. Children aged < 5 years follow a different clinical pathway owing to differences in the
presentation of symptoms and difficulties around communication and sample collection.27 Concerns
regarding the applicability of the index test were rated as being low for the majority of the studies
(21/30 domains, 70%, 18 studies),20,23,24,34,36,37,39,41–45,48–52,69 with studies reporting that the tests were
carried out in accordance with manufacturer’s guidelines. The eight remaining studies35,38,40,46,54,56–58
were rated as being unclear as this was not specified (domain 2: index test). Only four studies (4/27,
14.8%)38,40,42,43 were rated as having high concern for the applicability with respect to the reference
standard (owing to deviations from UK guidelines on the undertaking of appropriate culture methods
with respect to agar type, incubation period or atmosphere; domain 3: reference standard).
Assessment of studies of prescribing behaviour and clinical outcomes
There were 12 studies that reported on antibiotic-prescribing behaviour.6,20,35,36,39,40,45,46,50,52,53,55 Of these,
three studies were RCTs6,45,55 and were quality appraised using the Cochrane risk-of-bias tool for RCTs.30
There were six studies (including one before-and-after study) that were single-arm cohorts and have
been appraised using the JBI critical appraisal checklist31 for analytical cross-sectional studies.20,36,40,50,52,71
The remaining three studies were one-armed cohort studies using predetermined guidelines to
hypothetically estimate prescribing behaviour and offer no information on what happened in the real
world or on what clinicians would do.39,46,53 These studies were not quality appraised and have been
briefly summarised later in the results (see Antibiotic-prescribing behaviours: other study designs).
Randomised controlled trials
Risk of bias of the included trials is shown in Figure 6 and Table 8. The domains regarding blinding were
removed, as we were interested in test–treat trials measuring prescribing decisions with and without
rapid tests. Therefore, clinicians could not be blinded to test results, and we considered blinding to
which exact test was used to be unnecessary in this context. In general, the methodological quality of
the RCTs was rated as being fair, with all studies having at least one domain rated as unclear. There
was unclear risk of bias in four domains across the three studies (random sequence generation,
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FIGURE 6 Concerns regarding the risk of bias of included RCTs.
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allocation concealment, incomplete outcome data and selective outcome reporting). This was owing to
insufficient information presented on which to make an assessment. The remaining applicable domains
were judged to be at a low risk of bias.
Cohort studies
Risk of bias in the included cohort studies is shown in Figure 7 and Table 9. No study was rated as
having had high methodological quality across all areas. There was low methodological quality
regarding criteria for inclusion in 83% of studies (five out of six) and details regarding the study
subjects in 33% of studies two out of six).20,35,40,50,52 These studies reported the details of the patients, but
provided no information on the details of those who are making the prescribing decisions. The outcome of
interest in these studies was prescribing behaviour. The measurement of prescribing behaviour considered
to be valid and reliable was recording in medical records; only 33% of the studies clearly reported this.20,36
A confounder in the studies was current antibiotic use; 33% (two out of six) of studies did not clearly
specify current or recent antibiotic use as an excluding factor.
Current pathway (clinical scoring tools only)
Accuracy of clinical scoring tools with culture as the reference standard
Accuracy statistics for Centor39,44,45,52 and McIsaac scores46,52,57 with microbiological culture as the
reference standard are presented in Table 10. The results show wide variations in the test accuracy of
sore throat clinical scoring tools. Specificity point estimates were reported between 0.172 and 0.648,
and sensitivity point estimates were reported between 0.735 and 0.972. This suggests that these tools
might be better at identifying people who do have Streptococcus than they are at identifying people
who do not.
Rosenberg et al.50 and Johansson et al.40 also reported accuracy statistics for sore throat symptoms
with culture as the reference standard. However, these studies provided insufficient data to construct
2 × 2 contingency tables using the recommended clinical scoring threshold (see Data extraction strategy).
The use of different clinical scoring tools, age selection criteria, clinical score inclusion criteria and
settings across the seven contributing studies precluded any pooling.
Accuracy of clinical scoring tools split by age group
Two46,52 of the six studies included a mixed population of adults and children. In the study by McIsaac
et al.,46 a threshold of > 2 points (Modified Centor/McIsaac score) produced a sensitivity estimate of
0.884 (95% CI 0.820 to 0.928) and a specificity estimate of 0.234 (95% CI 0.188 to 0.287) in children
aged 3–17 years, and a sensitivity estimate of 0.767 (95% CI 0.651 to 0.858) and a specificity estimate
of 0.439 (95% CI 0.378 to 0.501) in adults aged ≥ 18 years.
In the study by Stefaniuk et al.,52 a threshold of > 2 points (Modified Centor/McIsaac score) produced a
sensitivity estimate of 1.00 (95% CI 0.80 to 1.00) and a specificity estimate of 0.083 (95% CI 0.015 to
0.285) in children aged 1–14 years, and a sensitivity estimate of 0.739 (95% CI 0.513 to 0.889) and
TABLE 8 Judgement of risk of bias of included RCTs
Study (first author and
year of publication)
Risk of bias
Random sequence
generation
Allocation
concealment
Incomplete
outcome data
Selective outcome
reporting
Other
bias
Little 20136 Low Low Unclear Unclear Low
Llor 201145 Low Low Low Unclear Low
Worrall 200755 Unclear Unclear Low Unclear Low
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FIGURE 7 Methodological quality of included analytical cross-sectional studies. NA, not applicable.
TABLE 9 Judgement of risk of bias of included non-RCT studies
Study (first author and
year of publication)
Were the
criteria for
inclusion in the
sample clearly
defined?
Were the
study subjects
and the setting
described in
detail?
Was the
exposure
measured in
a valid and
reliable way?
Were objective,
standard
criteria used for
measurement of
the condition?
Were
confounding
factors
identified?
Were
strategies to
deal with
confounding
factors stated?
Were the
outcomes
measured in
a valid and
reliable way?
Was
statistical
analysis
appropriate?
Berry 201820 No Yes Yes No Unclear Unclear Yes Yes
Bird 201835 No Yes Yes Yes Yes Yes No Yes
Bura 201736 Unclear Yes Yes Yes Yes Yes Yes Yes
Johansson 200340 No No Yes Unclear Yes Yes No Yes
Rosenberg 200250 No Yes Yes Yes Yes Yes Unclear Yes
Stefaniuk 201752 No No Yes Yes Unclear Unclear Unclear Yes
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TABLE 10 Accuracy of clinical scores with culture as the reference standard
Study (first author and
year of publication)
Strep A
prevalence (%) Setting Clinical score
Test accuracy statistics
Culture + Culture – Total Sensitivity (95% CI) Specificity (95% CI)
Humair 200639 46.9 Primary care/
GP clinic
Centor score of ≥ 3 points 105 119 224 0.750 (0.678 to 0.822) 0.487 (0.423 to 0.551)
Centor score of < 3 points 35 113 148
Total 140 232 372
Llor 200944 21.2 Primary care/
GP clinic
Centor score of ≥ 3 points 47 104 151 0.855 (0.761 to 0.948) 0.377 (0.304 to 0.451)
Centor score of < 3 points 8 63 71
Total 55 167 222
Llor 201145 16.7 Primary care/
GP clinic
Centor score of ≥ 3 points 36 80 116 0.735 (0.587 to 0.846) 0.648 (0.581 to 0.709)
Centor score of < 3 points 13 147 160
Total 49 227 276
McIsaac 200446 29 Primary care/
GP clinic
McIsaac score of ≥ 3 points 193 375 568 0.846 (0.800 to 0.893) 0.329 (0.290 to 0.368)
McIsaac score of < 3 points 35 184 219
Total 228 559 787
Pauchard 201357 37 Hospital McIsaac score of ≥ 3 points 69 101 170 0.972 (0.893 to 0.995) 0.172 (0.112 to 0.253)
McIsaac score of ≤ 2 points 2 21 23
Total 71 122 193
Stefaniuk 201752 22.4 Primary care/
GP clinic
Centor/McIsaac score of ≥ 3 points 37 39 76 0.861 (0.714 to 0.942) 0.250 (0.145 to 0.392)
Centor/McIsaac score of ≤ 2 points 6 13 19
Total 43 52 95
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a specificity estimate of 0.414 (95% CI 0.241 to 0.609) in participants aged ≥ 15 years. As previously
discussed (see Population), this overlap across age groups potentially limits subgroup analysis. However,
none of the other six studies included patients aged < 14 years.
Accuracy of clinical scoring tools split by primary/secondary care setting
Patients were recruited from primary care settings in five39,44–46,52 of the six studies. Details of the
primary care setting studies are outlined in Table 10. In brief, these studies provided point estimates
of sensitivity of 0.74–0.86 and of specificity of 0.25–0.65. The single study from a secondary care
setting57 reported a higher point estimate for sensitivity (0.972, 95% CI 0.893 to 0.995) and a lower
point estimate for specificity (0.172, 95% CI 0.112 to 0.253), albeit with overlapping CIs with some
of the primary care setting studies, than the other five studies. This may have been a result of the
setting or other sources of heterogeneity between studies.
Accuracy of clinical scoring tools using polymerase chain reaction to resolve
discordant cases
No analysis of discordant results between sore throat clinical scores and microbiological culture was
undertaken in any of the included studies.
Point-of-care/index tests
Accuracy of point-of-care tests with culture as the reference standard
The systematic review identified 35 pieces of literature that provided evidence comparing the
performance of 18 of the named index tests with culture. These were 23 peer-reviewed papers,
three abstracts, five manufacturer responses (submitted directly to NICE in response to a request
for information) and four FDA reports. Two studies reported results that were inconsistent, which
prevented the construction of a reliable 2 × 2 contingency table, and were excluded during the data
extraction.35,47 A summary of the final 33 pieces of literature can be found in Table 11. The sources
provided by the manufacturers were not peer reviewed, and neither were three abstracts. The sources
identified from FDA reports received some scrutiny from the FDA. The remaining 21 studies were
published in peer-reviewed journals. All sensitivity and specificity estimates are presented alongside
their 95% CI. Meta-analyses were performed where appropriate, a summary of which can be found
in Figure 8.
Clearview Exact Strep A Cassette and Clearview Exact Strep A Dipstick (Abbott Laboratories)
The only evidence related to the Clearview Exact Strep A Cassette and Dipstick was provided by
Andersen et al.,56 who did not report which version of the test they used. Andersen et al.56 reported a
sensitivity of 0.68 (95% CI 0.55 to 0.81) and a specificity of 0.95 (95% CI 0.93 to 0.98) when examining
children presenting in a secondary care setting.
BD Veritor Plus System (Becton Dickinson)
Azrad et al.34 and Berry et al.20 both presented results for the BD Veritor Plus System compared with
culturing of samples in a secondary care setting. Azrad et al.34 did not report the age group, and Berry
et al.20 looked at children. The sensitivities of the test were 0.80 (95% CI 0.59 to 0.92) and 0.76
(95% CI 0.60 to 0.87), and the specificities were 0.79 (95% CI 0.67 to 0.87) and 0.94 (95% CI 0.89 to
0.97), for Azrad et al.34 and Berry et al.,20 respectively. Becton Dickinson provided data to the FDA that
estimated a sensitivity of 0.97 (95% CI 0.92 to 0.99) and a specificity of 0.96 (95% CI 0.94 to 0.97).59
Univariate models were fitted to the two studies for the BD Veritor Plus System. The models
estimated a sensitivity of 0.78 (95% CI 0.67 to 0.87) and a specificity of 0.90 (95% CI 0.86 to 0.93).
Heterogeneity of the studies could not be assessed using I2 because only two studies were present.
DOI: 10.3310/hta24310 Health Technology Assessment 2020 Vol. 24 No. 31
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fraser et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
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TABLE 11 Summary of available evidence by test performance
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Clearview Exact Strep A Cassette – Abbott Laboratories
Andersen 2003
(abstract)56
Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
Clearview Exact Strep A Dipstick – Abbott Laboratories
Andersen 2003
(abstract)56
Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
BD Veritor Plus System – Becton Dickinson
Azrad 201934 Secondary NR None 25.0 Streptococcal
selective agar
100 20 5 16 59 Sensitivity 0.80 (0.59 to 0.92)
Specificity 0.79 (0.67 to 0.87)
PPV 0.56 (0.38 to 0.72)
NPV 0.92 (0.82 to 0.97)
aBecton Dickinson
(FDA)59
NR Children
and adults
None 18.7 Blood agar 796 144 5 29 618 Sensitivity 0.97 (0.92 to 0.99)
Specificity 0.96 (0.94 to 0.97)
PPV 0.83 (0.77 to 0.88)
NPV 0.99 (0.98 to 1.00)
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Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Berry 201820 Secondary Children None 19.5 Blood agar 215 32 10 11 162 Sensitivity 0.76 (0.60 to 0.87)
Specificity 0.94 (0.89 to 0.97)
PPV 0.74 (0.56 to 0.86)
NPV 0.94 (0.89 to 0.97)
Strep A Rapid Test Cassette – Biopanda Reagents
Biopanda Reagents
(MFR)a
Primary Children
and adults
None 23.2 Blood agar 526 116 6 9 395 Sensitivity 0.95 (0.89 to 0.98)
Specificity 0.98 (0.96 to 0.99)
PPV 0.93 (0.87 to 0.96)
NPV 0.99 (0.97 to 0.99)
Strep A Rapid Test Strip – Biopanda Reagents
No data
NADAL Strep A Strip – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Cassette – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
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TABLE 11 Summary of available evidence by test performance (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
NADAL Strep A Plus Cassette – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Plus Strip – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Scan – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
OSOM Strep A Strip – Sekisui Diagnostics
Bura 201736 Primary Adults Centor score of
≥ 2 points
22.7 Blood agar 101 22 1 2 76 Sensitivity 0.96 (0.76 to 1.00)
Specificity 0.97 (0.90 to 1.00)
PPV 0.92 (0.72 to 0.99)
NPV 0.99 (0.92 to 1.00)
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Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Llor 200944 Primary Adults Centor score of
≥ 2 points
24.8 Blood agar 222 52 3 14 153 Sensitivity 0.95 (0.85 to 0.99)
Specificity 0.92 (0.86 to 0.95)
PPV 0.79 (0.69 to 0.86)
NPV 0.98 (0.94 to 0.99)
Llor 201145 Primary Adults Centor score of
≥ 2 pointsb
17.8 Blood agar 276 44 5 14 213 Sensitivity 0.90 (0.78 to 0.97)
Specificity 0.94 (0.90 to 0.97)
PPV 0.76 (0.65 to 0.84)
NPV 0.98 (0.95 to 0.99)
Rogo 201149 Secondary Children None 28.9 Blood agar 228 65 1 1 161 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.99 (0.96 to 1.00)
PPV 0.98 (0.91 to 1.00)
NPV 0.99 (0.96 to 1.00)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 54 7 9 90 Sensitivity 0.89 (0.77 to 0.95)
Specificity 0.91 (0.83 to 0.96)
PPV 0.86 (0.74 to 0.93)
NPV 0.93 (0.85 to 0.97)
QuikRead Go Strep A Kit – Orion Diagnostica
Azrad 201934 Secondary NR None 25.0 Streptococcal
selective agar
100 20 5 20 55 Sensitivity 0.80 (0.59 to 0.92)
Specificity 0.73 (0.62 to 0.83)
PPV 0.50 (0.34 to 0.66)
NPV 0.92 (0.81 to 0.97)
continued
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TABLE 11 Summary of available evidence by test performance (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Orion Diagnostica
(MFR)a
Primary Children
and adults
None 32.8 Streptococcal
selective agar
271 74 15 5 177 Sensitivity 0.83 (0.73 to 0.90)
Specificity 0.97 (0.93 to 0.99)
PPV 0.94 (0.86 to 0.97)
NPV 0.92 (0.87 to 0.95)
Stefaniuk 201752 Primary Children
and adultsb
None 45.3 Blood agar 95 39 4 8 44 Sensitivity 0.91 (0.78 to 0.97)
Specificity 0.85 (0.72 to 0.93)
PPV 0.83 (0.72 to 0.90)
NPV 0.92 (0.81 to 0.97)
Alere TestPack Plus Cassette – Abbott Laboratories
Dimatteo 200138 Secondary Adults Centor score of
≥ 1 point
NR Streptococcal
selective agar
NR NR 22 NR 361 NPV 0.94 (0.91 to 0.96)
Humair 200639 Primary Adults Centor score of
≥ 2 pointsb
37.6 Blood agar 372 128 12 11 221 Sensitivity 0.91 (0.86 to 0.95)
Specificity 0.95 (0.92 to 0.98)
PPV 0.92 (0.87 to 0.95)
NPV 0.95 (0.91 to 0.97)
Johansson 200340 Primary Children
and adults
None 31.4 NR 144 46 7 4 87 Sensitivity 0.87 (0.74 to 0.94)
Specificity 0.96 (0.89 to 0.99)
PPV 0.92 (0.80 to 0.97)
NPV 0.93 (0.85 to 0.97)
Johnson 200141 Primary Adults None NR Blood agar NR 445 NR 77 NR PPV 0.85 (0.82 to 0.88)
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Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Kurtz 200042 Secondary Children None 31.1 Blood agar 257 64 16 13 164 Sensitivity 0.80 (0.71 to 0.89)
Specificity 0.93 (0.89 to 0.97)
PPV 0.83 (0.75 to 0.92)
NPV 0.91 (0.87 to 0.95)
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 271 87 21 623 Sensitivity 0.76 (0.71 to 0.80)
Specificity 0.97 (0.95 to 0.98)
PPV 0.93 (0.89 to 0.95)
NPV 0.88 (0.85 to 0.90)
Lindbæk 200443 Primary Children
and adults
None 35.9 Streptococcal
selective agar
306 106 4 27 169 Sensitivity 0.96 (0.91 to 0.99)
Specificity 0.86 (0.80 to 0.91)
PPV 0.80 (0.72 to 0.86)
NPV 0.98 (0.94 to 0.99)
McIsaac 200446 Primary Children
and adultsb
McIsaac score of
≥ 2 points
29.0 Blood agar 787 189 39 5 554 Sensitivity 0.83 (0.77 to 0.88)
Specificity 0.99 (0.98 to 1.00)
PPV 0.97 (0.94 to 0.99)
NPV 0.93 (0.91 to 0.95)
Penney 201648 Secondary Children None 40.1 Streptococcal
selective agar
147 45 14 0 88 Sensitivity 0.76 (0.65 to 0.87)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.90 to 1.00)
NPV 0.86 (0.78 to 0.92)
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TABLE 11 Summary of available evidence by test performance (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Rosenberg 200250 Secondary Children
and adults
None 25.4 Blood agar 126 24 8 1 93 Sensitivity 0.75 (0.56 to 0.88)
Specificity 0.99 (0.93 to 1.00)
PPV 0.96 (0.78 to 1.00)
NPV 0.92 (0.85 to 0.96)
Santos 200351 Secondary Children None 30.6 Blood agar 49 11 4 2 32 Sensitivity 0.73 (0.45 to 0.91)
Specificity 0.94 (0.79 to 0.99)
PPV 0.85 (0.54 to 0.97)
NPV 0.89 (0.73 to 0.96)
Valverde 2018
(abstract)58
Secondary Children
and adults
None 40.0 Blood agar 580 181 16 27 356 Sensitivity 0.92 (0.87 to 0.95)
Specificity 0.93 (0.90 to 0.95)
PPV 0.87 (0.82 to 0.91)
NPV 0.96 (0.93 to 0.97)
bioNexia Strep A Plus Cassette – bioMérieux
No data
bioNexia Strep A Dipstick – bioMérieux
Pauchard 2013
(abstract)57
Secondary Children None 36.8 NR 193 60 11 11 111 Sensitivity 0.85 (0.74 to 0.92)
Specificity 0.91 (0.84 to 0.95)
PPV 0.85 (0.76 to 0.93)
NPV 0.91 (0.86 to 0.96)
C
LIN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
SS
R
E
V
IE
W
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
4
2
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Biosynex Strep A Cassette
No data
Sofia Strep A FIA – Quidel
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 305 53 31 613 Sensitivity 0.85 (0.81 to 0.89)
Specificity 0.95 (0.93 to 0.97)
PPV 0.91 (0.87 to 0.94)
NPV 0.92 (0.90 to 0.94)
aQuidel (FDA)60 NR NR None 17.4 Blood agar 736 116 12 24 584 Sensitivity 0.91 (0.84 to 0.95)
Specificity 0.96 (0.94 to 0.97)
PPV 0.83 (0.75 to 0.89)
NPV 0.98 (0.96 to 0.99)
Alere i Strep A – Abbott Laboratories
Berry 201820 Secondary Children None 19.5 Blood agar 215 42 0 15 158 Sensitivity 1.00 (0.90 to 1.00)
Specificity 0.91 (0.86 to 0.95)
PPV 0.74 (0.60 to 0.84)
NPV 1.00 (0.97 to 1.00)
Cohen 201537 Secondary Children
and adultsb
None 30.3 Blood agar 481 141 6 18 316 Sensitivity 0.96 (0.91 to 0.98)
Specificity 0.95 (0.91 to 0.97)
PPV 0.89 (0.82 to 0.93)
NPV 0.98 (0.96 to 0.99)
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TABLE 11 Summary of available evidence by test performance (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 60 1 0 99 Sensitivity 0.98 (0.90 to 1.00)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.93 to 1.00)
NPV 0.99 (0.94 to 1.00)
Alere i Strep A 2 – Abbott Laboratories
aAbbott Laboratories
(FDA)61
NR NR None 20.2 Blood agar 981 195 3 52 731 Sensitivity 0.98 (0.95 to 0.99)
Specificity 0.93 (0.91 to 0.95)
PPV 0.79 (0.73 to 0.84)
NPV 1.00 (0.99 to 1.00)
cobas Liat Strep A Assay – Roche Diagnostics
Roche Diagnostics
(MFR)a
NR Children
and adults
None 30.4 Blood agar 570 170 3 23 374 Sensitivity 0.98 (0.95 to 1.00)
Specificity 0.94 (0.91 to 0.96)
PPV 0.88 (0.82 to 0.92)
NPV 0.99 (0.97 to 1.00)
Wang 201724 Primary Children Centor score of
≥ 1 point
30.2 NR 427 126 3 20 278 Sensitivity 0.98 (0.93 to 0.99)
Specificity 0.93 (0.90 to 0.96)
PPV 0.86 (0.79 to 0.91)
NPV 0.99 (0.97 to 1.00)
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Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Xpert Xpress Strep A – Cepheid
Cepheid (MFR)a NR NR None 23.9 NR 577 138 0 26 413 Sensitivity 1.00 (0.97 to 1.00)
Specificity 0.94 (0.91 to 0.96)
PPV 0.84 (0.79 to 0.89)
NPV 1.00 (0.99 to 1.00)
aCepheid (FDA)62 Primary and
secondary
Children
and adults
None 25.6 NR 618 157 1 27 433 Sensitivity 0.99 (0.96 to 1.00)
Specificity 0.94 (0.91 to 0.96)
PPV 0.85 (0.79 to 0.90)
NPV 1.00 (0.99 to 1.00)
FN, false negative; FP, false positive; MFR, manufacturer; n, number of samples analysed; NR, not reported; TN, true negative; TP, true positive.
a The submission was provided by the company, and data were not included in the primary meta-analysis.
b Data were presented for subgroups of interest.
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Strep A Rapid Test Cassette (Biopanda Reagents)
The only evidence related to the Strep A Rapid Test Cassette was provided by Biopanda Reagents in
response to a request for information by NICE. Biopanda Reagents reported a sensitivity of 0.95
(95% CI 0.89 to 0.98) and a specificity of 0.98 (95% CI 0.96 to 0.99) in a population of children and
adults in a primary care setting.
NADAL Strep A Strip, NADAL Strep A Cassette, NADAL Strep A Plus Cassette, NADAL Strep A
Plus Strip and NADAL Strep A Scan (nal von minden GmbH)
The only evidence related to the NADAL Strep A Cassettes, Strips and Scan tests was provided by nal
von minden GmbH in response to a request for information by NICE and did not distinguish between
any of the NADAL varieties. It reported a sensitivity of 0.98 (95% CI 0.91 to 1.00) and a specificity of
0.98 (95% CI 0.93 to 0.99) from a study undertaken in a secondary care setting including both children
and adults.
OSOM Strep A Strip (Sekisui Diagnostics)
Five studies compared the OSOM Strep A Strip with culture.36,44,45,49,54 Bura et al.,36 Llor et al.44 and Llor
et al.45 all examined adult populations presenting at primary care centres and reported sensitivities of
0.96 (95% CI 0.76 to 1.00), 0.95 (95% CI 0.85 to 0.99) and 0.90 (95% CI 0.78 to 0.97), and specificities
of 0.97 (95% CI 0.90 to 1.00), 0.92 (95% CI 0.86 to 0.95) and 0.94 (95% CI 0.90 to 0.97), respectively.
Test/study (first author and year of publication) Sensitivity (95% Cl) Specificity (95% Cl)
BD Veritor Plus System (Beckton Dickinson)
Azrad 201934
Berry 201820
Subtotal
QuikRead Go Strep A Kit (Orion Diagnostica)
Azrad 201934
Stefaniuk 201752
Subtotal
Alere i Strep A (Abbott Laboratories)
Berry 201820
Cohen 201537
Weinzierl 201854
Subtotal
OSOM Strep A Strip (Sekisui Diagnostics)
Bura 201736
Llor 200944
Rogo 201149
Weinzierl 201854
Llor 201145
Subtotal
Alere TestPack Plus Cassette (Abbott Laboratories)
Johansson 200340
Kurtz 200042
Lacroix 201823
Lindbæk 200443
Penney 201648
Rosenberg 200250
Santos 200351
Valverde 201858
McIsaac 200446
Humair 200639
Subtotal
0.80 (0.59 to 0.93)
0.76 (0.61 to 0.88)
0.78 (0.67 to 0.87)
0.80 (0.59 to 0.93)
0.91 (0.78 to 0.97)
0.87 (0.78 to 0.95)
0.73 (0.62 to 0.83)
0.85 (0.72 to 0.93)
0.78 (0.71 to 0.85)
1.00 (0.92 to 1.00)
0.96 (0.91 to 0.98)
0.98 (0.91 to 1.00)
0.98 (0.95 to 1.00)
0.96 (0.78 to 1.00)
0.95 (0.85 to 0.99)
0.98 (0.92 to 1.00)
0.89 (0.78 to 0.95)
0.90 (0.78 to 0.97)
0.94 (0.89 to 0.98)
0.97 (0.91 to 1.00)
0.92 (0.86 to 0.95)
0.99 (0.97 to 1.00)
0.91 (0.83 to 0.96)
0.94 (0.90 to 0.97)
0.95 (0.91 to 0.98)
0.87 (0.75 to 0.95)
0.80 (0.70 to 0.88)
0.76 (0.71 to 0.80)
0.96 (0.91 to 0.99)
0.76 (0.63 to 0.86)
0.75 (0.57 to 0.89)
0.73 (0.45 to 0.92)
0.92 (0.87 to 0.95)
0.83 (0.77 to 0.88)
0.91 (0.86 to 0.95)
0.85 (0.79 to 0.90)
0.96 (0.89 to 0.99)
0.93 (0.88 to 0.96)
0.97 (0.95 to 0.98)
0.86 (0.81 to 0.91)
1.00 (0.96 to 1.00)
0.99 (0.94 to 1.00)
0.94 (0.80 to 0.99)
0.93 (0.90 to 0.95)
0.99 (0.98 to 1.00)
0.95 (0.92 to 0.98)
0.96 (0.94 to 0.98)
0.91 (0.86 to 0.95)
0.95 (0.92 to 0.97)
1.00 (0.96 to 1.00)
0.96 (0.90 to 1.00)
0.79 (0.68 to 0.87)
0.94 (0.89 to 0.97)
0.90 (0.86 to 0.93)
0.50 0.75 0.751.00 1.00
FIGURE 8 Summary of meta analyses carried out on tests with multiple studies excluding manufacturer responses and
FDA reports.
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Meanwhile Rogo et al.49 and Weinzierl et al.54 examined children in secondary care, with respective
sensitivities of 0.98 (95% CI 0.91 to 1.00) and 0.89 (95% CI 0.77 to 0.95), and specificities of 0.99
(95% CI 0.96 to 1.00) and 0.91 (95% CI 0.83 to 0.96).
Despite having five sources of data, a bivariate model failed to converge for the OSOM test. However,
univariate models did converge. These models estimated a sensitivity of 0.94 (95% CI 0.89 to 0.98)
and a specificity of 0.95 (95% CI 0.91 to 0.98). The I2 for the analysis of sensitivity was 40.65%,
suggesting some heterogeneity, whereas the I2 for the analysis of specificity was 79.14%, suggesting
high heterogeneity.
QuikRead Go Strep A Kit (Orion Diagnostica)
Azrad et al.34 and Stefaniuk et al.52 both compared the accuracy of the QuikRead Go Strep A Kit with
culture, and reported respective sensitivities of 0.80 (95% CI 0.59 to 0.92) and 0.91 (95% CI 0.78 to
0.97), and specificities of 0.73 (95% CI 0.62 to 0.83) and 0.85 (95% CI 0.72 to 0.93). Azrad et al.34
investigated both child and adult patients in a primary care setting, whereas the data from Stefaniuk
et al.52 reflected a secondary care setting but did not report the ages of the patients. Orion Diagnostica
also provided data from its own study in response to a request for information by NICE, which
estimated a sensitivity of 0.83 (95% CI 0.73 to 0.90) and a specificity of 0.97 (95% CI 0.93 to 0.99)
for children and adults in primary care.
Univariate models were fitted to the two studies that investigated the QuikRead Go test. The
resulting sensitivity was 0.87 (95% CI 0.78 to 0.95) and the specificity was 0.78 (95% CI 0.71 to 0.85).
Heterogeneity of the studies could not be assessed using I2 because only two studies were present.
Alere TestPack Plus Cassette (Abbott Laboratories)
There were 12 published studies that compared the accuracy of the Alere TestPack Plus Cassette with
culture. Two studies did not report sufficient data to estimate a complete 2 × 2 contingency table.38,41
Four of the remaining studies were conducted in a primary care setting. One of these was in an adult
population: Humair et al.39 estimated a sensitivity of 0.91 (95% CI 0.86 to 0.95) and a specificity of
0.95 (95% CI 0.92 to 0.98). The other primary care-based studies combined child and adult populations:
Lindbæk et al.43 (sensitivity 0.94, 95% CI 0.90 to 0.99; specificity 0.86, 95% CI 0.80 to 0.91), Johansson
et al.40 (sensitivity 0.87, 95% CI 0.74 to 0.94; specificity 0.96, 95% CI 0.89 to 0.99) and McIsaac et al.46
(sensitivity 0.83, 95% CI 0.77 to 0.88; specificity 0.99, 95% CI 0.98 to 1.00).
Six other studies were conducted in secondary care settings, three of which assessed children without
any restriction from a clinical tool score.42,48,51 Kurtz et al.,42 Penney et al.48 and Santos et al.51 reported
sensitivities of 0.80 (95% CI 0.71 to 0.89), 0.76 (95% CI 0.65 to 0.87) and 0.73 (95% CI 0.45 to 0.91),
respectively. Their specificities were 0.93 (95% CI 0.89 to 0.97), 1.00 (95% CI 0.95 to 1.00) and 0.94
(95% CI 0.79 to 0.99), respectively. Lacroix et al.23 also examined children in secondary care, but
restricted the study population to those with a McIsaac score of ≥ 2 points.23 The sensitivity was 0.76
(95% CI 0.71 to 0.80) and the specificity was 0.97 (95% CI 0.95 to 0.98). Two studies examined both
children and adults in secondary care: Rosenberg et al.50 estimated a sensitivity of 0.75 (95% CI 0.56 to
0.88) and a specificity of 0.99 (95% CI 0.93 to 1.00), and Valverde et al.58 estimated a sensitivity of 0.92
(95% CI 0.87 to 0.95) and a specificity of 0.93 (95% CI 0.90 to 0.95).
For the Alere TestPack Plus test, a bivariate model was fitted to meta-analyse all studies. The model
suggested that the test had a sensitivity of 0.85 (95% CI 0.79 to 0.90) and a specificity of 0.96 (95% CI
0.94 to 0.98). Univariate models were also investigated and were identical to two decimal places. The I2
for the sensitivity and specificity analyses were 82.96% and 76.14%, respectively, suggesting that high
heterogeneity is present in both of the meta-analyses.
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bioNexia Strep A Dipstick (bioMérieux)
Only one abstract presented data for bioMérieux’s bioNexia Strep A Dipstick. Pauchard et al.57
conducted a study in children in a secondary care setting, and estimated a sensitivity of 0.85 (95% CI
0.74 to 0.92) and a specificity of 0.91 (95% CI 0.84 to 0.95).
Sofia Strep A fluorescent immunoassay (Quidel)
One peer-reviewed study presented data comparing the Sofia Strep A FIA with culture. Lacroix et al.23
used the test on children in a secondary care setting, and estimated a sensitivity of 0.85 (95% CI 0.81
to 0.89) and a specificity of 0.95 (95% CI 0.93 to 0.97). Quidel also provided data from their own
study to the FDA, which estimated a sensitivity of 0.91 (95% CI 0.84 to 0.95) and a specificity of 0.96
(95% CI 0.94 to 0.97).60
Alere i Strep A (Abbott Laboratories)
Three studies compared the Alere i Strep A test with culture, all in a secondary care setting. Berry et al.20
and Weinzierl et al.54 looked only at children, and estimated respective sensitivities of 1.00 (95% CI 0.90
to 1.00) and 0.98 (95% CI 0.90 to 1.00), and specificities of 0.91 (95% CI 0.86 to 0.95) and 1.00 (95% CI
0.95 to 1.00). Cohen et al.37 examined both children and adults, and produced respective estimates of
sensitivity and specificity of 0.96 (95% CI 0.91 to 0.98) and 0.95 (95% CI 0.91 to 0.97).
When meta-analysed using univariate models, the three studies using the Alere i Strep A test yielded a
sensitivity of 0.98 (95% CI 0.95 to 1.00) and a specificity of 0.96 (95% CI 0.90 to 1.00). The sensitivity
I2 was 20.64% (low) and the specificity I2 was 87.95% (high).
Alere i Strep A 2 (Abbott Laboratories)
Only manufacturer information submitted to the FDA was available for the Alere i Strep A 2 test,
which reported a sensitivity of 0.98 (95% CI 0.95 to 0.99) and a specificity of 0.93 (95% CI 0.91 to
0.95), but did not report the age of patients or the care setting.61
cobas Liat Strep A Assay (Roche Diagnostics)
There were two sources of data comparing the cobas Liat Strep A Assay with culture. Wang et al.24
carried out the test in children in a primary care setting, and estimated a sensitivity of 0.98 (95% CI
0.93 to 0.99) and a specificity of 0.94 (95% CI 0.91 to 0.96). The manufacturer (Roche Diagnostics)
provided the other source in response to a request for information by NICE, which produced estimates
of sensitivity and specificity of 0.98 (95% CI 0.95 to 1.00) and 0.94 (95% CI 0.91 to 0.96), respectively.
Roche Diagnostics stated that the data it provided overlapped with the Wang et al.24 study. The data
supplied by Roche Diagnostics were identical to the data available from the FDA for this test.
Xpert Xpress Strep A (Cepheid)
Only manufacturer information was available for the Xpert Xpress Strep A test by Cepheid, which was
provided in response to a request for information by NICE. The data provided by the manufacturer
reported a sensitivity of 1.00 (95% CI 0.97 to 1.00) and a specificity of 0.94 (95% CI 0.91 to 0.96). This
differed slightly from the information available from the FDA, which had a sensitivity of 0.99 (95% CI
0.96 to 1.00) and a specificity of 0.94 (95% CI 0.91 to 0.96).62 Owing to the differences in sample size
and the resolution of discordant samples, we have treated these sources as two independent studies,
but it is not clear if there is overlap in patients.
Biosynex Strep A Cassette (Biosynex), Strep A Rapid Test Strip (Biopanda Reagents) and
bioNexia Strep A Plus Cassette (bioMérieux)
No data were identified for any of the following tests:
l Biosynex Strep A Cassette test (Biosynex)
l bioNexia Strep A Plus Cassette test (bioMérieux)
l Strep A Rapid Test Strip (Biopanda Reagents).
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Summary
Figures 9 and 10 present the sensitivity and specificity for all studies that had complete 2 × 2 data.
Data were available for only 18 tests, and just seven tests were used in more than one independent
study. Ignoring manufacturer and FDA sources of data, this reduces to 10 tests with published data
and five tests with more than one independent study.
Test/study (first author and year of publication) Sensitivity (95% Cl)
Alere i Strep A 2 (Abbott Laboratories)
Abbott Laboratories FDA
Clearview Exact Strep A Tests (Abbott Laboratories)
Andersen 200356
BD Veritor Plus System (Beckton Dickinson)
Azrad 201934
Beckton Dickinson FDA
Berry 201820
QuikRead Go Strep A Kit (Orion Diagnostica)
Azrad 201934
Orion Diagnostica
Stefaniuk 201752
Alere i Strep A (Abbott Laboratories)
Berry 201820
Cohen 201537
Weinzierl 201854
Strep A Rapid Test Cassette (Biopanda Reagents)
Biopanda Reagents
OSOM Strep A Strip (Sekisui Diagnostics)
Bura 201736
Llor 200944
Rogo 201149
Weinzierl 201854
Llor 201145
Xpert Xpress Strep A (Cepheid)
Cepheid FDA
Cepheid
Sofia Strep A FIA (Quidel)
Lacroix 201823
Quidel FDA
Alere TestPack Plus Cassette (Abbott Laboratories)
Johansson 200340
Kurtz 200042
Lacroix 201823
Lindbæk 200443
Penney 201648
Rosenberg 200250
Santos 200351
Valverde 201858
Mclsaac 200446
Humair 200639
NADAL Strep A tests (nal von minden GmbH)
nal von minden GmbH
bioNexia Strep A dipstick (bioMérieux)
Pauchard 201357
cobas Liat Strep A Assay (Roche Diagnostics)
Roche Diagnostics
Wang 201724
0.98 (0.96 to 1.00)
0.68 (0.54 to 0.80)
0.80 (0.59 to 0.93)
0.97 (0.92 to 0.99)
0.76 (0.61 to 0.88)
0.80 (0.59 to 0.93)
0.83 (0.74 to 0.90)
0.91 (0.78 to 0.97)
1.00 (0.92 to 1.00)
0.96 (0.91 to 0.98)
0.98 (0.91 to 1.00)
0.95 (0.90 to 0.98)
0.96 (0.78 to 1.00)
0.95 (0.85 to 0.99)
0.98 (0.92 to 1.00)
0.89 (0.78 to 0.95)
0.90 (0.78 to 0.97)
0.99 (0.97 to 1.00)
1.00 (0.97 to 1.00)
0.87 (0.75 to 0.95)
0.80 (0.70 to 0.88)
0.76 (0.71 to 0.80)
0.96 (0.91 to 0.99)
0.76 (0.63 to 0.86)
0.75 (0.57 to 0.89)
0.73 (0.45 to 0.92)
0.92 (0.87 to 0.95)
0.83 (0.77 to 0.88)
0.91 (0.86 to 0.95)
0.85 (0.81 to 0.89)
0.91 (0.84 to 0.95)
0.98 (0.92 to 1.00)
0.85 (0.74 to 0.92)
0.98 (0.95 to 1.00)
0.98 (0.93 to 1.00)
0.00 0.25 0.50 0.75 1.00
FIGURE 9 Study-level data for the studies included in the meta-analysis of test accuracy: sensitivity.
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Note that where studies provided performance data by subgroups, these were incorporated into the
relevant analyses when producing estimates to feed into the cost-effectiveness modelling. It is clear
that there is a large degree of heterogeneity between the studies, and it is difficult to attribute any
observed differences in test performance to the tests themselves. The CIs in Figures 8–10 may differ
slightly to those in Table 11, owing to differences in their method of calculation.
Test/study (first author and year of publication) Specificity (95% Cl)
Alere i Strep A 2 (Abbott Laboratories)
Abbott Laboratories FDA
Clearview Exact Strep A Tests (Abbott Laboratories)
Andersen 200356
BD Veritor Plus System (Beckton Dickinson)
Azrad 201934
Beckton Dickinson FDA
Berry 201820
QuikRead Go Strep A Kit (Orion Diagnostica)
Azrad 201934
Orion Diagnostica
Stefaniuk 201752
Alere i Strep A (Abbott Laboratories)
Berry 201820
Cohen 201537
Weinzierl 201854
Strep A Rapid Test Cassette (Biopanda Reagents)
Biopanda Reagents
OSOM Strep A Strip (Sekisui Diagnostics)
Bura 201736
Llor 200944
Rogo 201149
Weinzierl 201854
Llor 201145
Xpert Xpress Strep A (Cepheid)
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FIGURE 10 Study-level data for the studies included in the meta-analysis of test accuracy: specificity.
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It is apparent that the data sourced from the manufacturer responses (submitted directly to NICE
in response to a request for information) and the FDA submissions consistently provided higher
estimates of sensitivity and specificity than the peer-reviewed studies. This supports the view that
the manufacturer data may be judged as being at high risk of bias, and any cost-effectiveness analyses
incorporating them may be unreliable.
Head-to-head (direct) comparison between tests
Initially, we sought to identify whether or not there was evidence to support the hypothesis that the
tests might have different levels of accuracy. Owing to the large degree of interstudy variability, the
most informative studies were those that conducted multiple tests on the same patient population, of
which there were four.
Azrad et al.34 compared both the BD Veritor System (Becton Dickinson) and the QuikRead Go Strep A
Kit (Orion Diagnostica) with culture for 100 patients. The BD Veritor System had a sensitivity of 0.80
(95% CI 0.59 to 0.92) and a specificity of 0.79 (95% CI 0.67 to 0.87). The QuikRead Go test had an
identical sensitivity, of 0.80 (95% CI 0.59 to 0.92), and a slightly lower point estimate for specificity,
of 0.73, with overlapping CIs (95% CI 0.62 to 0.83).
Berry et al.20 compared both the BD Veritor System and the Alere i Strep A tests with culture. The
tests performed differently, with the BD Veritor System having a sensitivity of 0.76 (95% CI 0.60 to
0.87) and a specificity of 0.94 (95% CI 0.89 to 0.97) and Alere i Strep A having a sensitivity of 1.00
(95% CI 0.90 to 1.00) and a specificity of 0.91 (95% CI 0.86 to 0.95).
Lacroix et al.23 investigated both the Alere TestPack Plus and the Sofia Strep A FIA tests. Again, the tests
performed differently, with the Alere TestPack Plus having lower detection rates, with a sensitivity of
0.76 (95% CI 0.71 to 0.80) and a specificity of 0.97 (95% CI 0.95 to 0.98). Meanwhile, the Sofia Strep A
FIA had a sensitivity of 0.85 (95% CI 0.81 to 0.89) and a specificity of 0.95 (95% CI 0.93 to 0.97).
Finally, Weinzierl et al.54 assessed the Alere i Strep A and the OSOM Strep A Strip tests. The OSOM
Strep A Strip had a sensitivity of 0.89 (95% CI 0.77 to 0.95) and a specificity of 0.91 (95% CI 0.83 to
0.96), whereas the Alere i Strep A test had a sensitivity of 0.98 (95% CI 0.90 to 1.00) and a specificity
of 1.00 (95% CI 0.95 to 1.00).
Conclusion
There is insufficient evidence to conduct a meaningful comparison of the rapid tests or to establish
any reliable hierarchy of test performance. Although some tests may perform similarly, the existing
evidence does not allow identification of any clear groups of tests, and it is likely that there is some
variation in accuracy of the 21 tests. There is considerable heterogeneity, potentially caused by the
differences in study design and population.
Accuracy of point-of-care tests in the population at high risk of group A
Streptococcus infection as defined by sore throat clinical scores
The primary population of interest in this review is patients with high clinical scores (Centor score of
≥ 3 points, FeverPAIN score of ≥ 4 points). We report test accuracy data in that population, and for
other thresholds of clinical measuring tools, such as Centor or McIsaac, as were reported by published
studies. The majority of studies either did not place or did not report placing a restriction of the clinical
scoring tool on their patient populations.
Eight studies present results based on some restriction of Centor or McIsaac (either ≥ 1 point or 2
or 3 points), which informed test accuracy data for four tests. A summary of evidence is provided
in Table 12.
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TABLE 12 Summary of data informing test performance in studies that restricted their population by clinical throat score
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
OSOM Strep A Strip – Sekisui Diagnostics
Bura 201736 Primary Adults Centor score of
≥ 2 points
22.7 Blood agar 101 22 1 2 76 Sensitivity 0.96 (0.76 to 1.00)
Specificity 0.97 (0.90 to 1.00)
PPV 0.92 (0.72 to 0.99)
NPV 0.99 (0.92 to 1.00)
Llor 200944 Primary Adults Centor score of
≥ 2 points
24.8 Blood agar 222 52 3 14 153 Sensitivity 0.95 (0.85 to 0.99)
Specificity 0.92 (0.86 to 0.95)
PPV 0.79 (0.69 to 0.86)
NPV 0.98 (0.94 to 0.99)
Llor 201145 Primary Adults Centor score of
≥ 1 point
17.8 Blood agar 276 44 5 14 213 Sensitivity 0.90 (0.78 to 0.97)
Specificity 0.94 (0.90 to 0.97)
PPV 0.76 (0.65 to 0.84)
NPV 0.98 (0.95 to 0.99)
Llor 201145 Primary Adults Centor score of
> 2 points
31.0 Blood agar 116 33 3 3 77 Sensitivity 0.92 (0.76 to 0.98)
Specificity 0.96 (0.89 to 0.99)
PPV 0.92 (0.78 to 0.97)
NPV 0.96 (0.90 to 0.99)
Llor 201145 Primary Adults Centor score of
= 1 or 2 points
8.1 Blood agar 160 11 2 11 136 Sensitivity 0.85 (0.55 to 0.98)
Specificity 0.93 (0.87 to 0.96)
PPV 0.50 (0.35 to 0.65)
NPV 0.99 (0.95 to 1.00)
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Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Alere TestPack Plus Cassette – Abbott Laboratories
Dimatteo 200138 Secondary Adults Centor score of
≥ 1 point
NR Streptococcal
selective agar
22 361 NPV 0.94 (0.91 to 0.96)
Humair 200639 Primary Adults Centor score of
≥ 2 points
37.6 Blood agar 372 128 12 11 221 Sensitivity 0.91 (0.86 to 0.95)
Specificity 0.95 (0.92 to 0.98)
PPV 0.92 (0.87 to 0.95)
NPV 0.95 (0.91 to 0.97)
Humair 200639 Primary Adults Centor score of
= 2 points
23.6 Blood agar 148 28 7 4 109 Sensitivity 0.80 (0.63 to 0.92)
Specificity 0.96 (0.91 to 0.99)
PPV 0.88 (0.73 to 0.95)
NPV 0.94 (0.89 to 0.97)
Humair 200639 Primary Adults Centor score of
> 2 points
46.9 Blood agar 224 100 5 7 112 Sensitivity 0.95 (0.89 to 0.98)
Specificity 0.94 (0.88 to 0.98)
PPV 0.93 (0.87 to 0.97)
NPV 0.96 (0.90 to 0.98)
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 271 87 21 623 Sensitivity 0.76 (0.71 to 0.80)
Specificity 0.97 (0.95 to 0.98)
PPV 0.93 (0.89 to 0.95)
NPV 0.88 (0.85 to 0.90)
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TABLE 12 Summary of data informing test performance in studies that restricted their population by clinical throat score (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool
score restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
McIsaac 200446 Primary Children
and adultsa
McIsaac score of
≥ 2 points
29.0 Blood agar 787 189 39 5 554 Sensitivity 0.83 (0.77 to 0.88)
Specificity 0.99 (0.98 to 1.00)
PPV 0.97 (0.94 to 0.99)
NPV 0.93 (0.91 to 0.95)
Sofia Strep A FIA – Quidel
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 305 53 31 613 Sensitivity 0.85 (0.81 to 0.89)
Specificity 0.95 (0.93 to 0.97)
PPV 0.91 (0.87 to 0.94)
NPV 0.92 (0.90 to 0.94)
cobas Liat Strep A Assay – Roche Diagnostics
Wang 201724 Primary Children Centor score of
≥ 1 point
30.2 NR 427 126 3 20 278 Sensitivity 0.98 (0.93 to 0.99)
Specificity 0.93 (0.90 to 0.96)
PPV 0.86 (0.79 to 0.91)
NPV 0.99 (0.97 to 1.00)
FN, false negative; FP, false positive; NR, not reported; TN, true negative; TP, true positive.
a Data were presented for subgroups of interest.
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Only two studies presented data for populations that matched the NICE scope, that is having either a
Centor or McIsaac score of ≥ 3 points or a FeverPAIN score of ≥ 4 points.39,45 We dichotomised the
data from these studies into (1) patients meeting the scope based on throat score and (2) patients not
meeting the scope.
Humair et al.39 investigated the Alere TestPack Plus test in adults presenting in a primary care setting,
with a Centor score of ≥ 2 points. In the Centor score = 2 points and Centor score of > 2 points
subgroups, the sensitivities were 0.80 (95% CI 0.63 to 0.92) and 0.95 (95% CI 0.89 to 0.98), and
the specificities were 0.96 (95% CI 0.91 to 0.99) and 0.94 (95% CI 0.88 to 0.98), respectively. The
subgroups had 148 and 224 patients, respectively.
Llor et al.45 investigated adult patients in a primary care setting with a Centor score of ≥ 1 point when
assessing the performance of the OSOM Strep A Strip. In the population with a Centor score of 1 or
2 points, consisting of 160 patients, the OSOM Strep A Strip had a sensitivity of 0.85 (95% CI 0.55 to
0.98) and a specificity of 0.93 (95% CI 0.87 to 0.96). In the population with a Centor score of > 2 points,
with 116 patients, the test had a sensitivity of 0.92 (95% CI 0.76 to 0.98) and a specificity of 0.96
(95% CI 0.89 to 0.99).
The remaining data for studies that restricted their populations by throat score are presented in the
following sections.
OSOM Strep A Strip
Three studies compared the OSOM Strep A Strip in a restricted population. Bura et al.36 and Llor et al.44
both focused on patients with a Centor score of ≥ 2 points, and reported sensitivities of 0.96 (95% CI
0.76 to 1.00) and 0.95 (95% CI 0.85 to 0.99), and specificities of 0.97 (95% CI 0.90 to 1.00) and 0.92
(95% CI 0.86 to 0.95), respectively.
Meanwhile Llor et al.45 considered patients with a Centor score of ≥ 1 point and reported a sensitivity
of 0.90 (95% CI 0.78 to 0.97) and a specificity of 0.94 (95% CI 0.90 to 0.97).
Alere TestPack Plus Cassette
Four studies investigating the Alere TestPack Plus restricted their population by throat score. Dimatteo
et al.38 looked only at patients with a Centor score of ≥ 1 point but did not present complete 2 × 2
information and so sensitivity and specificity could not be calculated. Lacroix et al.23 and McIsaac et al.46
both examined test performance in patients with McIsaac scores of ≥ 2 points. The former estimated a
sensitivity of 0.76 (95% CI 0.71 to 0.80) and a specificity of 0.97 (95% CI 0.95 to 0.98), and the latter
estimated a sensitivity of 0.83 (95% CI 0.77 to 0.88) and a specificity of 0.99 (95% CI 0.98 to 1.00).
Humair et al.39 also considered only patients with a Centor score of ≥ 2 points, but also presented
results by score subgroup mentioned in Accuracy of point-of-care tests in the population at high risk of
group A Streptococcus infection as defined by sore throat clinical scores. In the full population, a sensitivity
of 0.91 (95% CI 0.86 to 0.95) and a specificity of 0.95 (95% CI 0.92 to 0.98) were reported.
Sofia Strep A fluorescent immunoassay
One study compared Sofia Strep A FIA with culture and restricted the population by throat score.
Lacroix et al.23 used Sofia Strep A FIA in patients with a McIsaac score of ≥ 2 points. In this population,
the test had a sensitivity of 0.85 (95% CI 0.81 to 0.89) and a specificity of 0.95 (95% CI 0.93 to 0.97).
cobas Liat Strep A Assay
One study compared cobas Liat Strep A Assay with culture in patients restricted by throat score.
Wang et al.24 used the test in patients with a Centor score of ≥ 1 point. In this population, the test had
a sensitivity of 0.98 (95% CI 0.93 to 0.99) and a specificity of 0.93 (95% CI 0.90 to 0.96).
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Conclusion
The limited evidence suggests that some tests may have a higher sensitivity in patient populations that
have a higher score according to a clinical tool, such as Centor.
Accuracy of point-of-care tests split by age group
We sought to identify whether or not there was evidence to support the hypothesis that the tests
might have different performance characteristics based on the age group on which the test is being
used. No studies were categorised into the age groups as detailed in the NICE scope, and so we
classified them into child and adult populations where possible, or a combination of children and adults.
No studies presented results specific to a ≥ 60-year-old population, although patients in this category
may have been included within an ‘adult’ population. Seven studies concentrated on exclusively adult
populations, providing accuracy data for two tests.36,38,39,41,43–45 Ten studies looked exclusively at
children, providing data for nine tests.20,23,24,42,48,49,51,54,56,57 Three studies considered both adults and
children, and presented accuracy data for them separately, allowing a within-trial comparison to be
made.37,46,52 Each of these three studies investigated a different test.
Cohen et al.37 examined both adults and children when investigating the accuracy of the Alere i Strep A
test. In children, the test had a sensitivity of 0.96 (95% CI 0.91 to 0.99) and a specificity of 0.93
(95% CI 0.89 to 0.96). In adults, the sensitivity was 0.95 (95% CI 0.74 to 1.00) and the specificity was
0.97 (95% CI 0.92 to 0.99).
McIsaac et al.46 examined the Alere TestPack Plus test in child and adult populations, presenting the
results by age category. In children, the sensitivity was 0.86 (95% CI 0.79 to 0.91) and the specificity
was 0.99 (95% CI 0.97 to 1.00). In adults, the sensitivity was 0.77 (95% CI 0.65 to 0.86) and the
specificity was 0.99 (95% CI 0.97 to 1.00).
Stefaniuk et al.52 used the QuikRead Go Strep A Kit test in both adults and children. In children, a
sensitivity of 0.80 (95% CI 0.56 to 0.94) and a specificity of 0.91 (95% CI 0.72 to 0.99) were estimated. In
adults, the test sensitivity was 1.00 (95% CI 0.86 to 0.95) and specificity was 0.79 (95% CI 0.60 to 0.92).
Further age-specific results are presented below and in Table 13.
Clearview Exact Strep A Cassette and Clearview Exact Strep A Dipstick (Abbott Laboratories)
Only data for a child population were available for the Clearview Exact Strep A Cassette and Dipstick
tests, and were provided by Andersen et al.,56 who did not distinguish between the cassette and
dipstick varieties. Andersen et al.56 reported a sensitivity of 0.68 (95% CI 0.55 to 0.81) and a specificity
of 0.95 (95% CI 0.93 to 0.98).
BD Veritor Plus System (Becton Dickinson)
The only age-specific test accuracy data for the BD Veritor Plus System were in children, and published
by Berry et al.20 The sensitivity of the test was 0.76 (95% CI 0.60 to 0.87) and the specificity was
0.94 (95% CI 0.89 to 0.97).
OSOM Strep A Strip (Sekisui Diagnostics)
Three studies presented data for the OSOM Strep A Strip in adult patients.36,44,45 Bura et al.,36 Llor
et al.44 and Llor et al.45 reported respective sensitivities of 0.96 (95% CI 0.76 to 1.00), 0.95 (95% CI 0.85
to 0.99) and 0.90 (95% CI 0.78 to 0.97), and specificities of 0.97 (95% CI 0.90 to 1.00), 0.92 (95% CI
0.86 to 0.95) and 0.94 (95% CI 0.90 to 0.97). Rogo et al.49 and Weinzierl et al.54 both studied children
only, and estimated sensitivities of 0.98 (95% CI 0.91 to 1.00) and 0.89 (95% CI 0.77 to 0.95),
and specificities of 0.99 (95% CI 0.96 to 1.00) and 0.91 (95% CI 0.83 to 0.96), respectively.
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TABLE 13 Summary of test data for age groups of interest
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Clearview Exact Strep A Cassette – Abbott Laboratories
Andersen 200356 Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
Clearview Exact Strep A Dipstick – Abbott Laboratories
Andersen 200356 Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
BD Veritor Plus System – Becton Dickinson
Berry 201820 Secondary Children None 19.5 Blood agar 215 32 10 11 162 Sensitivity 0.76 (0.60 to 0.87)
Specificity 0.94 (0.89 to 0.97)
PPV 0.74 (0.56 to 0.86)
NPV 0.94 (0.89 to 0.97)
OSOM Strep A Strip – Sekisui Diagnostics
Bura 201736 Primary Adults Centor score of
≥ 2 points
22.7 Blood agar 101 22 1 2 76 Sensitivity 0.96 (0.76 to 1.00)
Specificity 0.97 (0.90 to 1.00)
PPV 0.92 (0.72 to 0.99)
NPV 0.99 (0.92 to 1.00)
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TABLE 13 Summary of test data for age groups of interest (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Llor 200944 Primary Adults Centor score of
≥ 2 points
24.8 Blood agar 222 52 3 14 153 Sensitivity 0.95 (0.85 to 0.99)
Specificity 0.92 (0.86 to 0.95)
PPV 0.79 (0.69 to 0.86)
NPV 0.98 (0.94 to 0.99)
Llor 201145 Primary Adults Centor score of
≥ 2 pointsa
17.8 Blood agar 276 44 5 14 213 Sensitivity 0.90 (0.78 to 0.97)
Specificity 0.94 (0.90 to 0.97)
PPV 0.76 (0.65 to 0.84)
NPV 0.98 (0.95 to 0.99)
Rogo 201149 Secondary Children None 28.9 Blood agar 228 65 1 1 161 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.99 (0.96 to 1.00)
PPV 0.98 (0.91 to 1.00)
NPV 0.99 (0.96 to 1.00)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 54 7 9 90 Sensitivity 0.89 (0.77 to 0.95)
Specificity 0.91 (0.83 to 0.96)
PPV 0.86 (0.74 to 0.93)
NPV 0.93 (0.85 to 0.97)
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Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
QuikRead Go Strep A Kit – Orion Diagnostica
Stefaniuk 201752 Primary Children None 46.5 Blood agar 43 16 4 2 21 Sensitivity 0.80 (0.56 to 0.94)
Specificity 0.91 (0.72 to 0.99)
PPV 0.89 (0.68 to 0.97)
NPV 0.84 (0.68 to 0.93)
Stefaniuk 201752 Primary Adults None 44.2 Blood agar 52 23 0 6 23 Sensitivity 1.00 (0.85 to 1.00)
Specificity 0.79 (0.60 to 0.92)
PPV 0.79 (0.65 to 0.89)
NPV 1.00 (0.85 to 1.00)
Alere TestPack Plus Cassette – Abbott Laboratories
Dimatteo 200138 Secondary Adults Centor score of
≥ 1 point
NR Streptococcal
selective agar
22 361 NPV 0.94 (0.91 to 0.96)
Humair 200639 Primary Adults Centor score of
≥ 2 pointsa
37.6 Blood agar 372 128 12 11 221 Sensitivity 0.91 (0.86 to 0.95)
Specificity 0.95 (0.92 to 0.98)
PPV 0.92 (0.87 to 0.95)
NPV 0.95 (0.91 to 0.97)
Johnson 200141 Primary Adults None NR Blood agar 445 77 PPV 0.85 (0.82 to 0.88)
Kurtz 200042 Secondary Children None 31.1 Blood agar 257 64 16 13 164 Sensitivity 0.80 (0.71 to 0.89)
Specificity 0.93 (0.89 to 0.97)
PPV 0.83 (0.75 to 0.92)
NPV 0.91 (0.87 to 0.95)
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TABLE 13 Summary of test data for age groups of interest (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 271 87 21 623 Sensitivity 0.76 (0.71 to 0.80)
Specificity 0.97 (0.95 to 0.98)
PPV 0.93 (0.89 to 0.95)
NPV 0.88 (0.85 to 0.90)
McIsaac 200446 Primary Children McIsaac score of
≥ 2 points
34.1 Blood agar 454 133 22 3 296 Sensitivity 0.86 (0.79 to 0.91)
Specificity 0.99 (0.97 to 1.00)
PPV 0.98 (0.93 to 0.99)
NPV 0.93 (0.90 to 0.95)
McIsaac 200446 Primary Adults McIsaac score of
≥ 2 points
21.9 Blood agar 333 56 17 2 258 Sensitivity 0.77 (0.65 to 0.86)
Specificity 0.99 (0.97 to 1.00)
PPV 0.97 (0.88 to 0.99)
NPV 0.94 (0.91 to 0.96)
Penney 201648 Secondary Children None 40.1 Streptococcal
selective agar
147 45 14 0 88 Sensitivity 0.76 (0.65 to 0.87)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.90 to 1.00)
NPV 0.86 (0.78 to 0.92)
Santos 200351 Secondary Children None 30.6 Blood agar 49 11 4 2 32 Sensitivity 0.73 (0.45 to 0.91)
Specificity 0.94 (0.79 to 0.99)
PPV 0.85 (0.54 to 0.97)
NPV 0.89 (0.73 to 0.96)
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Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
bioNexia Strep A Dipstick – bioMérieux
Pauchard 201357 Secondary Children None 36.8 NR 193 60 11 11 111 Sensitivity 0.85 (0.74 to 0.92)
Specificity 0.91 (0.84 to 0.95)
PPV 0.85 (0.76 to 0.93)
NPV 0.91 (0.86 to 0.96)
Sofia Strep A FIA – Quidel
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 305 53 31 613 Sensitivity 0.85 (0.81 to 0.89)
Specificity 0.95 (0.93 to 0.97)
PPV 0.91 (0.87 to 0.94)
NPV 0.92 (0.90 to 0.94)
Alere i Strep A – Abbott Laboratories
Berry 201820 Secondary Children None 19.5 Blood agar 215 42 0 15 158 Sensitivity 1.00 (0.90 to 1.00)
Specificity 0.91 (0.86 to 0.95)
PPV 0.74 (0.60 to 0.84)
NPV 1.00 (0.97 to 1.00)
Cohen 201537 Secondary Children None Blood agar 355 123 5 15 212 Sensitivity 0.96 (0.91 to 0.99)
Specificity 0.93 (0.89 to 0.96)
PPV 0.89 (0.83 to 0.93)
NPV 0.98 (0.95 to 0.99)
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TABLE 13 Summary of test data for age groups of interest (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Cohen 201537 Secondary Adults None Blood agar 126 18 1 3 104 Sensitivity 0.95 (0.74 to 1.00)
Specificity 0.97 (0.92 to 0.99)
PPV 0.86 (0.66 to 0.95)
NPV 0.99 (0.94 to 1.00)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 60 1 0 99 Sensitivity 0.98 (0.90 to 1.00)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.93 to 1.00)
NPV 0.99 (0.94 to 1.00)
cobas Liat Strep A Assay – Roche Diagnostics
Wang 201724 Primary Children Centor score of
≥ 1 point
30.2 NR 427 126 3 20 278 Sensitivity 0.98 (0.93 to 0.99)
Specificity 0.93 (0.90 to 0.96)
PPV 0.86 (0.79 to 0.91)
NPV 0.99 (0.97 to 1.00)
FN, false negative; FP, false positive; NR, not reported; TN, true negative; TP, true positive.
a Data were presented for subgroups of interest.
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QuikRead Go Strep A Kit (Orion Diagnostica)
Stefaniuk et al.52 examined both adults and children. In children, a sensitivity of 0.80 (95% CI 0.56 to
0.94) and a specificity of 0.91 (95% CI 0.72 to 0.99) were estimated. In adults, the test sensitivity was
1.00 (95% CI 0.85 to 1.00) and the specificity was 0.79 (95% CI 0.60. 0.92).
Alere TestPack Plus (Abbott Laboratories)
Three studies used the Alere TestPack Plus test in adult populations.38,39,41 Dimatteo et al.38 and
Johnson et al.41 did not provide complete results, and sensitivity and specificity could not be calculated.
Humair et al.39 did provide sufficient information and the test’s sensitivity was 0.91 (95% CI 0.86 to
0.95). The specificity was 0.95 (95% CI 0.92 to 0.98).
Four studies used the test in child populations only.23,42,48,51 The lowest sensitivity was reported by
Santos et al.51 (0.73, 95% CI 0.45 to 0.91) and the highest by Kurtz et al.42 (0.80, 95% CI 0.71 to 0.89).
The sensitivities ranged from 0.93 (95% CI 0.89 to 0.97), as reported by Kurtz et al.,42 to 1.00 (95% CI
0.95 to 1.00), as reported by Penney et al.48 McIsaac et al.46 conducted the test in both groups. In children,
the sensitivity was 0.86 (95% CI 0.79 to 0.91) and the specificity was 0.99 (95% CI 0.97 to 1.00). In
adults, the sensitivity was 0.77 (95% CI 0.65 to 0.86), with a specificity of 0.99 (95% CI 0.97 to 1.00).
bioNexia Strep A Dipstick (bioMérieux)
Only data for children were available for bioMérieux’s bioNexia Strep A Dipstick. Pauchard et al.57
estimated a sensitivity of 0.85 (95% CI 0.74 to 0.92) and a specificity of 0.91 (95% CI 0.84 to 0.95).
Sofia Strep A fluorescent immunoassay (Quidel)
One study compared Sofia Strep A FIA with culture in children, with no adult data available. Lacroix et al.23
reported a sensitivity of 0.85 (95% CI 0.81 to 0.89) and a specificity of 0.95 (95% CI 0.93 to 0.97).
Alere i Strep A (Abbott Laboratories)
Two studies presented data for the Alere i Strep A test for child populations.20,54 Berry et al.20 and
Weinzierl et al.54 reported respective sensitivities of 1.00 (95% CI 0.90 to 1.00) and 0.98 (95% CI 0.90
to 1.00), and specificities of 0.91 (95% CI 0.86 to 0.95) and 1.00 (95% CI 0.95 to 1.00).
Cohen et al.37 examined both adults and children, and presented results by age group. In children, the
test had a sensitivity of 0.96 (95% CI 0.91 to 0.99) and a specificity of 0.93 (95% CI 0.89 to 0.96). In
adults, the sensitivity was 0.95 (95% CI 0.74 to 1.00) and the specificity was 0.97 (95% CI 0.92 to 0.99).
cobas Liat Strep A Assay (Roche Diagnostics)
Only data for a child population were available for the cobas Liat Strep A Assay. Wang et al.24 reported
that the test had a sensitivity of 0.98 (95% CI 0.93 to 0.99) and a specificity of 0.93 (95% CI 0.90 to 0.96).
Meta-analyses were carried out to compare the accuracy estimates of the child and adult populations
for both the OSOM Strep A Strip and the Alere TestPack Plus tests, as these were the only tests with
sufficient data.
For the TestPack Plus, in children, the sensitivity was estimated as 0.80 (95% CI 0.74 to 0.84) and the
specificity as 0.98 (95% CI 0.95 to 0.99). In adults, the sensitivity was estimated as 0.87 (95% CI 0.82
to 0.91) and the specificity as 0.98 (95% CI 0.96 to 0.99).
For OSOM, the dichotomisation of studies into the two age categories was identical to the dichotomisation
for primary and secondary care settings. Univariate models fitted to the children/secondary care data
estimated a sensitivity of 0.95 (95% CI 0.90 to 0.98) and a specificity of 0.97 (95% CI 0.95 to 0.99). Models
fitted to the adult/primary care data estimated a sensitivity of 0.93 (95% CI 0.88 to 0.97) and a specificity
of 0.94 (95% CI 0.91 to 0.97).
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Conclusion
It is unclear whether or not test accuracy varies based on the age of the population in which the test is
being used. Further evidence is required.
Accuracy of point-of-care tests split by primary/secondary care setting
We sought to identify whether or not there was evidence to support the hypothesis that the tests
might have different performance characteristics based on the setting in which the test is being used.
No studies provided a breakdown of results comparing test accuracy between primary and secondary
settings. Fourteen studies considered patients in a secondary care setting, which provided data for nine
tests. Ten studies looked at patients in primary care settings, which covered four tests. A summary of
care-setting-related data can be found in Table 14.
Clearview Exact Strep A Cassette and Clearview Exact Strep A Dipstick (Abbott Laboratories)
Only data in a hospital setting were available for the Clearview Exact Strep A Cassette and Dipstick
tests, and were provided by Andersen et al.,56 who did not distinguish between the cassette and the
dipstick varieties. Andersen et al.56 reported a sensitivity of 0.68 (95% CI 0.55 to 0.81) and a specificity
of 0.95 (95% CI 0.93 to 0.98).
BD Veritor Plus System (Becton Dickinson)
Azrad et al.34 and Berry et al.20 both presented results for the BD Veritor Plus System in a hospital
setting. The sensitivities of the test were 0.80 (95% CI 0.59 to 0.92) and 0.76 (95% CI 0.60 to 0.87),
and the specificities were 0.79 (95% CI 0.67 to 0.87) and 0.94 (95% CI 0.89 to 0.97), for Azrad et al.34
and Berry et al.,20 respectively.
NADAL Strep A Strip, NADAL Strep A Cassette, NADAL Strep A Plus Cassette, NADAL Strep A
Plus Strip and NADAL Strep A Scan (nal von minden GmbH)
Only evidence from a secondary care setting was available for the NADAL tests, which did not
distinguish between any of the varieties. The manufacturer reported a sensitivity of 0.98 (95% CI 0.91
to 1.00) and a specificity of 0.98 (95% CI 0.93 to 0.99).
Strep A Rapid Test Cassette (Biopanda Reagents)
The data provided by Biopanda Reagents for the Strep A Rapid Test were reportedly from a primary
care setting. The sensitivity was 0.95 (95% CI 0.0.89 to 0.98) and the specificity was 0.98 (95% CI
0.96 to 0.99).
OSOM Strep A Strip (Sekisui Diagnostics)
Three studies presented data for the OSOM Strep A Strip in a primary care setting.36,44,45 Bura et al.,36
Llor et al.44 and Llor et al.45 reported respective sensitivities of 0.96 (95% CI 0.76 to 1.00), 0.95 (95% CI
0.85 to 0.99) and 0.90 (95% CI 0.78 to 0.97), and specificities of 0.97 (95% CI 0.90 to 1.00), 0.92 (95% CI
0.86 to 0.95) and 0.94 (95% CI 0.90 to 0.97). Rogo et al.49 and Weinzierl et al.54 both used the test in a
hospital setting, and estimated sensitivities of 0.98 (95% CI 0.91 to 1.00) and 0.89 (95% CI 0.77 to 0.95),
and specificities of 0.99 (95% CI 0.96 to 1.00) and 0.91 (95% CI 0.83 to 0.96), respectively.49,54
QuikRead Go Strep A Kit (Orion Diagnostica)
Azrad et al.34 compared the performance of the QuikRead Go Strep A Kit with culture in a hospital
setting, and reported a sensitivity of 0.80 (95% CI 0.59 to 0.92) and a specificity of 0.73 (95% CI 0.62
to 0.83). Stefaniuk et al.52 looked at a primary care setting, and reported a sensitivity 0.91 (95% CI 0.78
to 0.97) and a specificity 0.85 (95% CI 0.72 to 0.93). The data provided by Orion Diagnostica were also
reported as being from a primary care setting, and estimated a sensitivity of 0.83 (95% CI 0.73 to 0.90)
and a specificity of 0.97 (95% CI 0.93 to 0.99).
CLINICAL EFFECTIVENESS REVIEW
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TABLE 14 Summary of test performance data by care setting
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Clearview Exact Strep A Cassette – Abbott Laboratories
Andersen 200356 Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
Clearview Exact Strep A Dipstick – Abbott Laboratories
Andersen 200356 Secondary Children None 15.0 NR 353 36 17 15 285 Sensitivity 0.68 (0.55 to 0.81)
Specificity 0.95 (0.93 to 0.98)
PPV 0.71 (0.58 to 0.83)
NPV 0.94 (0.92 to 0.97)
BD Veritor Plus System – Becton Dickinson
Azrad 201934 Secondary NR None 25.0 Streptococcal
selective agar
100 20 5 16 59 Sensitivity 0.80 (0.59 to 0.92)
Specificity 0.79 (0.67 to 0.87)
PPV 0.56 (0.38 to 0.72)
NPV 0.92 (0.82 to 0.97)
Berry 201820 Secondary Children None 19.5 Blood agar 215 32 10 11 162 Sensitivity 0.76 (0.60 to 0.87)
Specificity 0.94 (0.89 to 0.97)
PPV 0.74 (0.56 to 0.86)
NPV 0.94 (0.89 to 0.97)
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TABLE 14 Summary of test performance data by care setting (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
NADAL Strep A Strip – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Cassette – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Plus Cassette – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
NADAL Strep A Plus Strip – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
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Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
NADAL Strep A Scan – nal von minden GmbH
nal von minden GmbH
(MFR)a
Secondary Children
and adults
None 34.4 Blood agar 244 82 2 4 156 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.98 (0.93 to 0.99)
PPV 0.95 (0.88 to 0.99)
NPV 0.99 (0.95 to 1.00)
OSOM Strep A Strip – Sekisui Diagnostics
Bura 201736 Primary Adults Centor score of
≥ 2 points
22.7 Blood agar 101 22 1 2 76 Sensitivity 0.96 (0.76 to 1.00)
Specificity 0.97 (0.90 to 1.00)
PPV 0.92 (0.72 to 0.99)
NPV 0.99 (0.92 to 1.00)
Llor 200944 Primary Adults Centor score of
≥ 2 points
24.8 Blood agar 222 52 3 14 153 Sensitivity 0.95 (0.85 to 0.99)
Specificity 0.92 (0.86 to 0.95)
PPV 0.79 (0.69 to 0.86)
NPV 0.98 (0.94 to 0.99)
Llor 201145 Primary Adults Centor score of
≥ 2 pointsb
17.8 Blood agar 276 44 5 14 213 Sensitivity 0.90 (0.78 to 0.97)
Specificity 0.94 (0.90 to 0.97)
PPV 0.76 (0.65 to 0.84)
NPV 0.98 (0.95 to 0.99)
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TABLE 14 Summary of test performance data by care setting (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Rogo 201149 Secondary Children None 28.9 Blood agar 228 65 1 1 161 Sensitivity 0.98 (0.91 to 1.00)
Specificity 0.99 (0.96 to 1.00)
PPV 0.98 (0.91 to 1.00)
NPV 0.99 (0.96 to 1.00)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 54 7 9 90 Sensitivity 0.89 (0.77 to 0.95)
Specificity 0.91 (0.83 to 0.96)
PPV 0.86 (0.74 to 0.93)
NPV 0.93 (0.85 to 0.97)
QuikRead Go Strep A Kit – Orion Diagnostica
Azrad 201934 Secondary NR None 25.0 Streptococcal
selective agar
100 20 5 20 55 Sensitivity 0.80 (0.59 to 0.92)
Specificity 0.73 (0.62 to 0.83)
PPV 0.50 (0.34 to 0.66)
NPV 0.92 (0.81 to 0.97)
Stefaniuk 201752 Primary Children
and adultsb
None 45.3 Blood agar 95 39 4 8 44 Sensitivity 0.91 (0.78 to 0.97)
Specificity 0.85 (0.72 to 0.93)
PPV 0.83 (0.72 to 0.90)
NPV 0.92 (0.81 to 0.97)
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Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Alere TestPack Plus Cassette – Abbott Laboratories
Dimatteo 200138 Secondary Adults Centor score of
≥ 1 point
NR Streptococcal
selective agar
NR NR 22 NR 361 NPV 0.94 (0.91 to 0.96)
Humair 200639 Primary Adults Centor score of
≥ 2 pointsb
37.6 Blood agar 372 128 12 11 221 Sensitivity 0.91 (0.86 to 0.95)
Specificity 0.95 (0.92 to 0.98)
PPV 0.92 (0.87 to 0.95)
NPV 0.95 (0.91 to 0.97)
Johansson 200340 Primary Children
and adults
None 31.4 NR 144 46 7 4 87 Sensitivity 0.87 (0.74 to 0.94)
Specificity 0.96 (0.89 to 0.99)
PPV 0.92 (0.80 to 0.97)
NPV 0.93 (0.85 to 0.97)
Johnson 200141 Primary Adults None NR Blood agar NR 445 NR 77 NR PPV 0.85 (0.82 to 0.88)
Kurtz 200042 Secondary Children None 31.1 Blood agar 257 64 16 13 164 Sensitivity 0.80 (0.71 to 0.89)
Specificity 0.93 (0.89 to 0.97)
PPV 0.83 (0.75 to 0.92)
NPV 0.91 (0.87 to 0.95)
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 271 87 21 623 Sensitivity 0.76 (0.71 to 0.80)
Specificity 0.97 (0.95 to 0.98)
PPV 0.93 (0.89 to 0.95)
NPV 0.88 (0.85 to 0.90)
continued
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TABLE 14 Summary of test performance data by care setting (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Lindbæk 200443 Primary Children
and adults
None 35.9 Streptococcal
selective agar
306 106 4 27 169 Sensitivity 0.96 (0.91 to 0.99)
Specificity 0.86 (0.80 to 0.91)
PPV 0.80 (0.72 to 0.86)
NPV 0.98 (0.94 to 0.99)
McIsaac 200446 Primary Children
and adultsb
McIsaac score of
≥ 2 points
29.0 Blood agar 787 189 39 5 554 Sensitivity 0.83 (0.77 to 0.88)
Specificity 0.99 (0.98 to 1.00)
PPV 0.97 (0.94 to 0.99)
NPV 0.93 (0.91 to 0.95)
Penney 201648 Secondary Children None 40.1 Streptococcal
selective agar
147 45 14 0 88 Sensitivity 0.76 (0.65 to 0.87)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.90 to 1.00)
NPV 0.86 (0.78 to 0.92)
Rosenberg 200250 Secondary Children
and adults
None 25.4 Blood agar 126 24 8 1 93 Sensitivity 0.75 (0.56 to 0.88)
Specificity 0.99 (0.93 to 1.00)
PPV 0.96 (0.78 to 1.00)
NPV 0.92 (0.85 to 0.96)
Santos 200351 Secondary Children None 30.6 Blood agar 49 11 4 2 32 Sensitivity 0.73 (0.45 to 0.91)
Specificity 0.94 (0.79 to 0.99)
PPV 0.85 (0.54 to 0.97)
NPV 0.89 (0.73 to 0.96)
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Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Valverde 201858 Secondary Children
and adults
None 40.0 Blood agar 580 181 16 27 356 Sensitivity 0.92 (0.87 to 0.95)
Specificity 0.93 (0.90 to 0.95)
PPV 0.87 (0.82 to 0.91)
NPV 0.96 (0.93 to 0.97)
bioNexia Strep A Dipstick – bioMérieux
Pauchard 201357 Secondary Children None 36.8 NR 193 60 11 11 111 Sensitivity 0.85 (0.74 to 0.92)
Specificity 0.91 (0.84 to 0.95)
PPV 0.85 (0.76 to 0.93)
NPV 0.91 (0.86 to 0.96)
Sofia Strep A FIA – Quidel
Lacroix 201823 Secondary Children McIsaac score of
≥ 2 points
35.7 Blood agar 1002 305 53 31 613 Sensitivity 0.85 (0.81 to 0.89)
Specificity 0.95 (0.93 to 0.97)
PPV 0.91 (0.87 to 0.94)
NPV 0.92 (0.90 to 0.94)
Alere i Strep A – Abbott Laboratories
Berry 201820 Secondary Children None 19.5 Blood agar 215 42 0 15 158 Sensitivity 1.00 (0.90 to 1.00)
Specificity 0.91 (0.86 to 0.95)
PPV 0.74 (0.60 to 0.84)
NPV 1.00 (0.97 to 1.00)
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TABLE 14 Summary of test performance data by care setting (continued )
Study (first author and
year of publication) Care setting Age group
Clinical tool score
restriction
Strep A
infections
prevalence (%)
Reference
type N
TP
(n)
FN
(n)
FP
(n)
TN
(n) Accuracy data (95% CI)
Cohen 201537 Secondary Children
and adultsb
None 30.3 Blood agar 481 141 6 18 316 Sensitivity 0.96 (0.91 to 0.98)
Specificity 0.95 (0.91 to 0.97)
PPV 0.89 (0.82 to 0.93)
NPV 0.98 (0.96 to 0.99)
Weinzierl 201854 Secondary Children None 38.1 Blood agar 160 60 1 0 99 Sensitivity 0.98 (0.90 to 1.00)
Specificity 1.00 (0.95 to 1.00)
PPV 1.00 (0.93 to 1.00)
NPV 0.99 (0.94 to 1.00)
cobas Liat Strep A Assay – Roche Diagnostics
Wang 201724 Primary Children Centor score of
≥ 1 point
30.2 NR 427 126 3 20 278 Sensitivity 0.98 (0.93 to 0.99)
Specificity 0.93 (0.90 to 0.96)
PPV 0.86 (0.79 to 0.91)
NPV 0.99 (0.97 to 1.00)
FN, false negative; FP, false positive; NR, not reported; TN, true negative; TP, true positive.
a The submission was provided by the company, and data were not included in the primary meta-analysis.
b Data were presented for subgroups of interest.
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Alere TestPack Plus Cassette (Abbott Laboratories)
There were seven published studies that compared the performance of the Alere TestPack Plus Cassette
with culture in a secondary care setting. One study did not report sufficient data to complete a 2 × 2 table.38
Rosenberg et al.50 and Valverde et al.58 both examined a combination of children and adults, estimating
sensitivities of 0.75 (95% CI 0.56 to 0.88) and 0.92 (95% CI 0.87 to 0.95), and specificities of 0.99 (95% CI
0.93 to 1.00) and 0.93 (95% CI 0.90 to 0.95), respectively. The four remaining studies included only
children.23,42,48,51 The sensitivities ranged from 0.73 (95% CI 0.45 to 0.91)51 to 0.80 (95% CI 0.71 to 0.90)42
and the specificities ranged from 0.93 (95% CI 0.89 to 0.97)42 to 1.00 (95% CI 0.95 to 1.00).48
Five studies reported the accuracy of the Alere TestPack Plus Cassette in a primary care setting. One
did not present complete 2 × 2 data.41 One reported for adult populations: Humair et al.39 estimated a
sensitivity of 0.91 (95% CI 0.86 to 0.95) and a specificity of 0.95 (95% CI 0.92 to 0.98). Lindbæk et al.,43
Johansson et al.40 and McIsaac et al.46 combined adults and children, and reported respective sensitivities
of 0.94 (95% CI 0.90 to 0.99), 0.87 (95% CI 0.74 to 0.94) and 0.83 (95% CI 0.77 to 0.87) alongside
specificities of 0.86 (95% CI 0.80 to 0.91), 0.96 (95% CI 0.89 to 0.99) and 0.99 (95% CI 0.98 to 1.00).
bioNexia Strep A Dipstick (bioMérieux)
Only data from a hospital setting were available for bioMérieux’s bioNexia Strep A Dipstick. Pauchard
et al.57 estimated a sensitivity of 0.85 (95% CI 0.74 to 0.92) and a specificity of 0.91 (95% CI 0.84 to 0.95).
Sofia Strep A fluorescent immunoassay (Quidel)
One study compared Sofia Strep A FIA with culture in a hospital setting, with no GP data available.
Lacroix et al.23 reported a sensitivity of 0.85 (95% CI 0.81 to 0.89) and a specificity of 0.95 (95% CI
0.93 to 0.97).
Alere i Strep A (Abbott Laboratories)
Three studies compared the Alere i Strep A test with culture in a hospital setting. Berry et al.20 and
Weinzierl et al.54 looked only at children, and estimated respective sensitivities of 1.00 (95% CI 0.90 to
1.00) and 0.98 (95% CI 0.90 to 1.00), and specificities of 0.91 (95% CI 0.86 to 0.95) and 1.00 (95% CI
0.95 to 1.00). Cohen et al.37 examined both children and adults, and produced respective estimates of
sensitivity and specificity of 0.96 (95% CI 0.91 to 0.98) and 0.95 (95% CI 0.91 to 0.97).
cobas Liat Strep A Assay (Roche Diagnostics)
Only data from a GP setting were available for the cobas Liat Strep A Assay. Wang et al.24 reported that
the test had a sensitivity of 0.98 (95% CI 0.93 to 0.99) and a specificity of 0.93 (95% CI 0.90 to 0.96).
Meta-analyses were conducted to indirectly compare the accuracy estimates of the child and adult
populations for both the OSOM Strep A Strip and the Alere TestPack Plus tests, as these were the
only tests with sufficient data.
Fitted to data for the TestPack Plus test, univariate models estimated a sensitivity of 0.90 (95% CI 0.83
to 0.96) and a specificity of 0.95 (95% CI 0.88 to 0.99) in a primary setting, compared with a sensitivity
of 0.80 (95% CI 0.71 to 0.88) and a specificity of 0.97 (95% CI 0.94 to 0.99) in a secondary care setting.
The OSOM test also had sufficient studies to conduct univariate meta-analyses. However, the
dichotomisation of studies into primary and secondary care settings was identical to the age dichotomisation.
Univariate models fitted to the child/secondary care data estimated a sensitivity of 0.95 (95% CI 0.90 to
0.98) and a specificity of 0.97 (95% CI 0.95 to 0.99). Models fitted to the adult/primary care data estimated
a sensitivity of 0.93 (95% CI 0.88 to 0.97) and a specificity of 0.94 (95% CI 0.91 to 0.97).
Conclusion
Test performance may vary depending on the care setting in which the test is being used. Further
evidence is required.
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Estimates of test accuracy for cost-effectiveness modelling
Having established that a number of factors may influence test accuracy, we sought to provide
estimates for each test to be used in the cost-effectiveness modelling. This is consistent with the
findings of Leeflang et al.72 Ideally, estimates would have come from a meta-analysis of several studies
specific to the scope population, by age group and setting. However, the evidence base was not
sufficient to do this. In total, there were 21 tests × 3 age groups × 3 settings = 189 pairs of sensitivity
and specificity estimates required. However, no data were available that were specific to the elderly or
the pharmacy setting, or for three of the tests, meaning that there were just 18 × 2 × 2 = 72 potential
pairs of estimates. Each estimate came from a combination of five studies or fewer. Factoring in the
observed variation in test accuracy between studies alongside the scant evidence base, there is a
significant likelihood that the final estimates may not be representative of the tests’ true accuracy.
There is a significant risk that a test with a larger evidence base published in peer-reviewed journal
articles may be disadvantaged in comparison with a test in which there is only unpublished
manufacturer information at high risk of bias.
We prioritised information from published studies [i.e. not those in manufacturer (submitted directly
to NICE in response to a request for information) and FDA documents] in which data were available
for patients restricted by throat score as per the scope. This provided accuracy data for one pair of
estimates and relaxing the age group restriction provided another pair of estimates. It was necessary
to relax the throat score restriction to obtain further estimates. An additional 13 pairs of estimates
were obtained from studies that matched the age and care setting of the test. One further pair of
estimates was obtained by using estimates from a mixed age population for an adult population.
Relaxing the care setting and age restrictions allowed estimation of 24 pairs of test accuracy estimates
for child and adult populations. Where there were multiple options for considering relaxing either
age group or setting differences between studies and target population, factors such as sample size
and number of studies were also considered. Studies in manufacturer responses to NICE and in FDA
documents were included only if no other evidence was available for a specific test. Where these data
are used, we consider the analysis to be at extremely high risk of bias and we do not recommend that
these are sufficient to underpin any clinical decisions. The data from neither of these two sources
matched a subgroup of interest or were restricted by throat score, but relaxing the ages and care
settings provided estimates for a further 32 pairs.
A summary of the studies providing evidence for each estimate can be found in Table 15.
TABLE 15 Summary of studies providing estimates of test performance for economic modelling (colour coded for reliability)
Test
Primary care Secondary care
Children Adult Children Adult
Clearview Exact
Strep A cassette
One abstract (Andersen
et al.,56 n = 353) –
wrong setting, right
age, wrong score
restriction
One abstract
(Andersen et al.,56
n= 353) – wrong
setting, wrong age,
wrong score restriction
One abstract (Andersen
et al.,56 n= 353) – right
setting, right age, wrong
score restriction
One abstract
(Andersen et al.,56
n= 353) – right
setting, wrong age,
wrong score restriction
Clearview Exact
Strep A dipstick –
test strip
One abstract (Andersen
et al.,56 n = 353) –
wrong setting, right
age, wrong score
restriction
One abstract
(Andersen et al.,56
n= 353) – wrong
setting, wrong age,
wrong score restriction
One abstract (Andersen
et al.56) – right setting,
right age, wrong score
restriction
One abstract
(Andersen et al.,56
n= 353) – right
setting, wrong age,
wrong score restriction
BD Veritor Plus
system group A
Strep Assay –
cassette
One study (Berry
et al.,20 n = 215) –
wrong setting, right
age, wrong score
restriction
Two studies (Berry
et al.,20 n = 215; Azrad
et al.,34 n = 100) –
wrong setting, wrong
age, wrong score
restriction
One study (Berry et al.,20
n = 215) – right setting,
right age, wrong score
restriction
Two studies (Berry
et al.,20 n = 215; Azrad
et al.,34 n = 100) –
wrong setting, wrong
age, wrong score
restriction
CLINICAL EFFECTIVENESS REVIEW
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TABLE 15 Summary of studies providing estimates of test performance for economic modelling (colour coded for reliability)
(continued )
Test
Primary care Secondary care
Children Adult Children Adult
Strep A Rapid
Test – cassette
One MFR response
(Biopanda Reagents,
n = 526) – right setting,
right age, wrong score
restriction
One MFR response
(Biopanda Reagents,
n= 526) – right
setting, wrong age,
wrong score restriction
One MFR response
(Biopanda Reagents,
n= 526) – wrong setting,
right age, wrong score
restriction
One MFR response
(Biopanda Reagents,
n= 526) – wrong
setting, wrong age,
wrong score restriction
Strep A Rapid
Test – test strip
No data No data No data No data
NADAL Strep A –
test strip
One MFR response
(nal von minden GmbH,
n = 244) – wrong
setting, wrong age,
wrong score restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
One MFR response
(nal von minden GmbH,
n= 244) – right setting,
wrong age, wrong score
restriction
One MFR response
(nal von minden
GmbH, n = 244) –
right setting, wrong
age, wrong score
restriction
NADAL Strep A –
cassette
One MFR response
(nal von minden GmbH,
n = 244) – wrong
setting, wrong age,
wrong score restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
One MFR response
(nal von minden GmbH,
n= 244) – wrong setting,
wrong age, wrong score
restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
NADAL Strep A
plus – cassette
One MFR response
(nal von minden GmbH,
n = 244) – wrong
setting, wrong age,
wrong score restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
One MFR response
(nal von minden GmbH,
n= 244) – wrong setting,
wrong age, wrong score
restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
NADAL Strep A
plus – test strip
One MFR response
(nal von minden GmbH,
n = 244) – wrong
setting, wrong age,
wrong score restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
One MFR response
(nal von minden GmbH,
n= 244) – wrong setting,
wrong age, wrong score
restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
NADAL Strep A
scan test –
cassette
One MFR response
(nal von minden GmbH,
n = 244) – wrong
setting, wrong age,
wrong score restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
One MFR response
(nal von minden GmbH,
n= 244) – wrong setting,
wrong age, wrong score
restriction
One MFR response
(nal von minden
GmbH, n = 244) –
wrong setting, wrong
age, wrong score
restriction
OSOM Strep A
test – test strip
One study (Llor et al.,45
n = 116) – right setting,
wrong age, right score
restriction
One study (Llor et al.,45
n= 116) – right setting,
right age, right score
restriction
Two studies (Rogo et al.,49
n= 228; Weinzierl et al.,54
n= 160) – right setting,
right age, wrong score
restriction
Five studies
(Bura et al.,36 n = 101;
Llor et al.,44 n = 222;
Llor et al.,45 n = 276,
Rogo et al.,49 n= 228;
Weinzierl et al.,54
n= 160) – wrong
setting, wrong age,
wrong score
restriction
QuikRead Go
Strep A test kit
One study (Stefaniuk
et al.,52 n = 43) – right
setting, right age,
wrong score restriction
One study (Stefaniuk
et al.,52 n = 52) – right
setting, right age,
wrong score
restriction
Two studies (Azrad
et al.,34 n = 100; Stefaniuk
et al.,52 n = 95) – wrong
setting, wrong age, wrong
score restriction
Two studies (Azrad
et al.,34 n = 100;
Stefaniuk et al.,52
n= 95) – wrong
setting, wrong age,
wrong score
restriction
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TABLE 15 Summary of studies providing estimates of test performance for economic modelling (colour coded for reliability)
(continued )
Test
Primary care Secondary care
Children Adult Children Adult
Alere TestPack
+Plus Strep A –
cassette
One study (McIsaac
et al.,46 n = 494) – right
setting, right age,
wrong score restriction
One study (Humair
et al.,39 n = 224) –
right setting, right age,
right score restriction
Four studies (Kurtz et al.,42
n= 257; Lacroix et al.,23
n= 1002; Penney
et al.,48 n= 147; Santos
et al.,51 n= 49) – right
setting, right age, wrong
score restriction
One study and one
abstract (Rosenberg
et al.,50 n = 126;
Valverde et al.,58
n= 580) – right
setting, wrong age,
wrong score
restriction
bioNexia Strep A
plus – cassette
No data No data No data No data
bioNexia Strep A
dipstick – test
strip
One abstract (Pauchard
et al.,57 n = 193) –
wrong setting, right
age, wrong score
restriction
One abstract
(Pauchard et al.,57
n= 193) – wrong
setting, wrong age,
wrong score
restriction
One abstract (Pauchard
et al.,57 n= 193) – right
setting, right age, wrong
score restriction
One abstract
(Pauchard et al.,57
n= 193) – wrong
setting, wrong age,
wrong score
restriction
bioNexia Strep A –
cassette
No data No data No data No data
Sofia Strep A FIA One study (Lacroix
et al.,23 n = 1002) –
wrong setting, right
age, wrong score
restriction
One study (Lacroix
et al.,23 n = 1002) –
wrong setting, wrong
age, wrong score
restriction
One study (Lacroix
et al.,23 n= 1002) – right
setting, right age, wrong
score restriction
One study (Lacroix
et al.,23 n = 1002) –
right setting, wrong
age, wrong score
restriction
Alere i Strep A Three studies (Berry
et al.,20 n = 215; Cohen
et al.,37 n = 355;
Weinzierl et al.,54
n = 160) – wrong
setting, right age,
wrong score restriction
One study (Cohen
et al.,37 n = 126) –
wrong setting, right
age, wrong score
restriction
Three studies (Berry
et al.,20 n= 215; Cohen
et al.,37 n= 355; Weinzierl
et al.,54 n= 160) – right
setting, right age, wrong
score restriction
One study (Cohen
et al.,37 n = 126) –
right setting, right
age, wrong score
restriction
Alere i Strep A 2 One FDA study (Alere,
n = 981) – wrong
setting, wrong age,
wrong score restriction
One FDA study
(Alere, n = 981) –
wrong setting, wrong
age, wrong score
restriction
One FDA study (Alere,
n = 981) – wrong setting,
wrong age, wrong score
restriction
One FDA study
(Alere, n = 981) –
wrong setting, wrong
age, wrong score
restriction
cobas Liat
Strep A Assay
One study (Wang
et al.,24 n = 427) – right
setting, right age,
wrong score restriction
One study (Wang
et al.,24 n = 427) –
right setting, wrong
age, wrong score
restriction
One study (Wang et al.,24
n = 427) – wrong setting,
right age, wrong score
restriction
One study (Wang
et al.,24 n = 427) –
wrong setting, wrong
age, wrong score
restriction
Xpert Xpress
Strep A
One FDA report and
one MFR response
(Cepheid, n= 618 and
577) – wrong setting,
wrong age, wrong score
restriction
One FDA report and
one MFR response
(Cepheid, n = 618 and
577) – wrong setting,
wrong age, wrong
score restriction
One FDA report and one
MFR response (Cepheid,
n = 618 and 577) –
wrong setting, wrong age,
wrong score restriction
One FDA report and
one MFR response
(Cepheid, n = 618 and
577) – wrong setting,
wrong age, wrong
score restriction
MFR, manufacturer; n, number of patients.
Notes
‘MFR response’ refers to unpublished accuracy data from the manufacturer provided within the NICE review process.
Estimates are colour coded by number of studies, sample size of studies, source of information and
population relevance.
Dark purple shading = very unreliable, aqua shading =moderately unreliable, orange shading= somewhat unreliable.
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Accuracy of point-of-care tests using polymerase chain reaction to resolve
discordant cases
Discordant results between point-of-care tests and culture were resolved using PCR in four
studies.20,24,37,73 All discrepant results between a point-of-care test and culture (point of care positive,
culture negative and vice versa) were analysed in two of these studies.20,24
All of the 20 samples that were cobas Liat Strep A positive but culture negative were confirmed as
positive by PCR and bidirectional sequencing. All three samples that were cobas Liat Strep A negative
and reference culture positive were confirmed as positive by PCR and bidirectional sequencing.24
Wang et al.24 also examined the discrepancies between the TestPack Plus Strep A test and culture.
All discordant results, that is the 20 cases positive by the test and negative by culture and the three
cases that were test negative and culture positive, were positive according to PCR.
In evaluating the accuracy of the BD Veritor system, Berry et al.20 also identified 21 discordant results
with throat culture, including 11 positive on the index test but not culture, and 10 positive on culture
but not the index test. PCR detected strep A in 6 of the 11 results that were positive by the BD
Veritor System but negative by culture. PCR detected strep A in all of the 11 samples that were
negative by the BD Veritor system but positive by culture. In the same population, Berry et al.20 found
that 14 of the 15 results that were positive for the Alere i Strep A test and negative for culture were
found to be positive according to PCR. There were no reported occasions when the Alere i Strep A test
gave a negative result when culture gave a positive result.
Similarly, Cohen et al.37 and Lacroix et al.23 analysed only some of the discrepancies between a point-of-care
test and culture. Cohen et al.37 identified a total of 24 discordant results between the Alere i Strep A
test and culture. There were 18 positive samples on the Alere i Strep A test and not on culture, 13 of
which were confirmed as positive by PCR, whereas the other five results were PCR negative. Four
of the six cases that were positive on culture but not on Alere i Strep A were confirmed as negative
by PCR.
Lacroix et al.23 found 84 discordant results between Sofia Strep A FIA and culture (31 false positives
and 53 false negatives). Eleven of the 31 false-positive samples were missing; hence, PCR assays could
not be conducted for these samples. Eleven of those with samples present were confirmed as positive
by PCR and nine were negative by PCR. Lacroix et al.23 also found 21 results that were positive by
TestPack Plus Strep A but negative by culture, nine of which were confirmed as positive by PCR. Eight
were confirmed as PCR negative, leaving four missing samples, which precluded additional PCR assays.
Lacroix et al.23 did not provide test-specific results for the cases that were negative by rapid test and
positive by culture.
Table 16 summarises the key findings from these analyses.
Interestingly, Lindbæk et al.43 used a second culture medium (a liquid medium/broth) to resolve
discrepant results between the TestPack Plus Strep A test (Abbott Laboratories) and microbiological
culture (streptococcal selective agar). In this study, the second culture medium [colistin and oxolinic
acid (COBA) + tryptic soy agar (TSA) sheep + sulfamethoxazole and trimethoprim (SXT) + Lim broth +
first culture medium] detected strep A in 17 out of 27 (63%) patients who previously tested positive by
the Alere TestPack +Plus Strep A test but negative by the first culture medium (Columbia agar + horse
blood + COBA).
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Direct comparison of point-of-care test accuracy with clinical scores
Six studies directly compared levels of test accuracy between point-of-care tests and clinical
scores.39,44–46,52,57 The results are summarised in Table 17. Sensitivity point estimates for clinical scores
were higher for point-of-care tests than for rapid tests in two studies.46,57 However, point estimates for
sensitivity and particularly specificity of rapid tests (including TestPack Plus Strep A, OSOM Strep A
and QuikRead Go Strep A tests) were generally higher. Sensitivity (0.829 to 0.946) and specificity
(0.849 to 0.991) point estimates of point-of-care tests were consistently high when compared with
point estimates for clinical scores (sensitivity 0.735 to 0.972; specificity 0.172 to 0.648).
Test failure rate
Five studies reported on test failure rate.23,37,38,43,54 These five studies reported on three different
point-of-care tests (Alere i, Testpack Strep A Plus and Sofia FIA Strep A). For the Alere i test, the test
failure rate ranged from 0.0%54 to 2.8%.37 The TestPack Strep A Plus test failure rate ranged from 0.3%38
to 1.3%.43 The Sofia FIA strep test failure rate was reported as 4.7%.23 Differences could be a result of
environmental factors, such as staff training, as opposed to issues with the tests.
TABLE 16 Accuracy of point-of-care tests using PCR to arbitrate discordant results with culture
Study (first author
and year of publication) Index test
2 × 2 contingency tables
PCR + PCR – Total
Berry 201820 Alere i Strep A test +, culture – 14 1 15
Alere i Strep A test –, culture + 0 0 0
Total 14 1 15
Berry 201820 BD Veritor system +, culture – 6 (Berry et al.20
also report 5)
5 11
BD Veritor system –, culture + 10 0 10
Total 16 5 21
Wang 201724 cobas Liat Strep A Assay+, culture – 20 0 20
cobas Liat Strep A Assay –, culture + 3 0 3
Total 23 0 23
Cohen 201537 Alere i Strep A +, culture – 13 5 18
Alere i Strep A –, culture + 2 4 6
Total 15 9 24
Lacroix 201823 Sofia Strep A FIA+, culture – 11 9 31 (11 missing
samples)
Sofia Strep A FIA –, culture + NR NR 53
Total NR NR 84
Lacroix 201823 TestPack Plus Strep A +, culture – 9 8 21 (4 missing
samples)
TestPack Plus Strep A –, culture + NR NR 87
Total NR NR 108
NR, not reported.
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
TABLE 17 Direct comparison of point-of-care test accuracy with clinical scores
Study
(first author
and year of
publication) Clinical score
Test accuracy statistics for clinical scores Test accuracy statistics for index tests
Culture + Culture – Total
Sensitivity
(95% CI)
Specificity
(95% CI) Index test Culture + Culture – Total
Sensitivity
(95% CI)
Specificity
(95% CI)
Humair
200639
Centor score
of > 2 points
105 119 224 0.750
(0.678 to 0.822)
0.487
(0.423 to 0.551)
TestPack Plus
Strep A+
128 11 139 0.914
(0.852 to 0.953)
0.953
(0.914 to 0.947)
Centor score
of ≤ 2 points
35 113 148 TestPack Plus
Strep A–
12 221 233
Total 140 232 372 Total 140 232 372
Llor 200944 Centor score
of > 2 points
47 104 151 0.855
(0.761 to 0.948)
0.377
(0.304 to 0.451)
OSOM Strep
A+
52 14 66 0.946
(0.839 to 0.986)
0.916
(0.861 to 0.952)
Centor score
of ≤ 2 points
8 63 71 OSOM Strep
A–
3 153 156
Total 55 167 222 Total 55 167 222
Llor 201145 Centor score
of > 2 points
36 80 116 0.735
(0.587 to 0.846)
0.648
(0.581 to 0.709)
OSOM Strep
A+
44 14 58 0.898
(0.770 to 0.962)
0.938
(0.897 to 0.933)
Centor score
of ≤ 2 points
13 147 160 OSOM Strep
A–
5 213 218
Total 49 227 276 Total 49 227 276
McIsaac
200446
McIsaac score
of > 2 points
193 375 568 0.847
(0.792 to 0.889)
0.329
(0.291 to 0.370)
TestPack Plus
Strep A+
189 5 194 0.829
(0.772 to 0.874)
0.991
(0.978 to 0.997)
McIsaac score
of ≤ 2 points
35 184 219 TestPack Plus
Strep A–
39 554 593
Total 228 559 787 Total 228 559 787
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TABLE 17 Direct comparison of point-of-care test accuracy with clinical scores (continued )
Study
(first author
and year of
publication) Clinical score
Test accuracy statistics for clinical scores Test accuracy statistics for index tests
Culture + Culture – Total
Sensitivity
(95% CI)
Specificity
(95% CI) Index test Culture + Culture – Total
Sensitivity
(95% CI)
Specificity
(95% CI)
Pauchard
201357
McIsaac score
of > 2 points
69 101 170 0.972
(0.893 to 0.995)
0.172
(0.112 to 0.253)
Strep A Rapid
Test +
60 11 71 0.845
(0.735 to 0.914)
0.910
(0.841 to 0.952)
McIsaac score
of ≤ 2 points
2 21 23 Strep A rapid
Test –
11 111 122
Total 71 122 193 Total 71 122 193
Stefaniuk
201752
Centor score
of > 2 points
37 39 76 0.861
(0.714 to 0.942)
0.250
(0.145 to 0.392)
QuikRead Go
Strep A+
39 8 47 0.907
(0.770 to 0.970)
0.846
(0.719 to 0.931)
Centor score
of ≤ 2 points
6 13 19 QuikRead Go
Strep A–
4 44 48
Total 43 52 95 Total 43 52 95
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Proposed pathway (combined strategy of clinical score and point-of-care tests)
Test accuracy of combined clinical score and point-of-care test with culture as
reference standard
None of the included studies evaluated the accuracy of a combined strategy of a sore throat clinical
score (at the recommended NICE cut-off points of Centor/McIsaac score of ≥ 3 points or FeverPAIN
score of ≥ 4 points) with a point-of-care test. This would require the combination of the two methods
into a single procedure, in which positive results are produced by individuals with both a high clinical
score and a positive point-of-care test, and negative results are given either by patients with a low
clinical score or by patients with a high score but a negative point-of-care test. As shown in Table 18,
Rosenberg et al.50 provide the only available evidence that attempts to match the proposed pathway,
but not at the recommended Centor cut-off point.
Other outcomes
No information was found on the number of appointments required per episode, morbidity, mortality,
onward transmission of infection, health-related quality of life, patient satisfaction with the test or
health-care professional satisfaction with the test.
Twelve studies reported on antibiotic-prescribing behaviours. RCTs and before-and-after studies have
been described in Appendix 5 (see Tables 37 and 38 and Figure 15). The remaining eight studies that
included one-armed cohorts or hypothetical antibiotic management are briefly summarised in
Antibiotic-prescribing behaviours: other study designs.
Antibiotic-prescribing behaviours: randomised controlled trial evidence
There were three RCTs that reported on antibiotic use. All three trials found higher antibiotic prescription
rates or use in control arms with no point-of-care test than in those with a point-of-care test.
TABLE 18 Accuracy of combined Centor score of 2 or 3 points and rapid testing with culture as the reference standard
Study (first author
and year of
publication) Combined strategy
Test accuracy statistics for clinical scores
Culture + Culture – Total
Sensitivity for
patients with a
Centor score of
2 or 3 points
Specificity for
patients with a
Centor score of
2 or 3 points
Rosenberg 200250 Centor score of
2 or 3 points AND
TestPack Plus
Strep A+
12 0 12 For patients with
a Centor score
of 2 or 3 points:
0.80 (95% CI
0.52 to 0.96)
Overall: 0.88
(95% CI 0.71
to 0.96)
For patients with
a Centor score
of 2 or 3 points:
1.00 (95% CI
0.92 to 1.00)
Overall: 0.78
(95% CI 0.68
to 0.86)
Centor score of
2 or 3 points AND
TestPack Plus
Strep A–
3 44 47
Centor score of
< 2 points AND
no rapid test
1 29 30
Centor score
of 4 points or
5 points AND
no rapid test
16 21 37
Total 32 94 126
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In the UK RCT in primary care by Little et al.,6 patients (mean ages 29 and 31 years across arms, no
age range provided) in a primary health-care setting were randomly assigned to a delayed antibiotics
control arm, a clinical score arm or a RADT arm (IMI TestPack, later known as Alere i Strep A test).
In the delayed antibiotics control arm, depending on the severity of their presentation, patients were
given antibiotics, given no antibiotics or given a delayed prescription of antibiotics to collect after
3–5 days if symptoms did not improve or worsened. This control group was there to represent current
UK practice at the time. In the clinical score arm, patients were assessed using the FeverPAIN clinical
scoring tool. Patients with scores of 0 or 1 points were not offered antibiotics. Immediate antibiotics
were offered for patients with scores of ≥ 4 points; for patients with scores of 2 or 3 points, delayed
antibiotics were offered. In the RADT group, all patients also received the clinical scoring tool. Those
with scores of 0 or 1 points were not offered antibiotics or RADT, those with a score of 2 points were
offered delayed antibiotics and those with scores of ≥ 3 points were given a RADT. All those with
negative RADT results were not offered antibiotics. There were 207 patients in the delayed prescribing
arm, of whom 79% (164/207) received a delayed prescription, 10% (21/207) received no antibiotics
and 10% (21/207) received immediate antibiotics. In the clinical score arm, 41% (87/211) received
a delayed prescription, 41% (87/211) received no antibiotics and 16% (33/211) received immediate
antibiotics. In the RADT arm, there were fewer delayed prescription decisions, with only 23% (48/213)
of patients receiving a delayed prescription; 59% (126/213) of patients were offered no antibiotics and
18% (38/213) were given immediate antibiotics. Patients reported antibiotic use of 46% (75/164) in
the delayed prescription arm, 37% (60/161) in the clinical score arm and 35% (58/164) in the clinical
score plus RADT arm. The total numbers in each arm were considerably lower for antibiotic use,
indicating significant loss to follow-up, so these numbers should be interpreted with caution. Likewise,
symptom severity was worse in the control arm, so effect sizes may be overestimates. This was a
UK-based trial based in a primary health-care setting. For this reason, it is likely to be generalisable to
the UK population.
The second trial was by Llor et al.45 They included patients aged > 14 years (mean age 31.7 years)
visiting primary health-care centres across Spain. This was a cluster RCT with the centre as the unit of
randomisation. This form of randomisation can be prone to imbalancing baseline characteristics of
patients; however, the authors reported no significant differences in baseline characteristics (such as
gender, mean age and by clinical symptoms) between the participants across the intervention and
control arms. Patients were randomised to either a control arm, in which patients were assessed using
only clinical criteria (Centor), or an intervention arm, in which patients were assessed with both a
Centor score and a RADT (OSOM Strep A test). In total, 54% (291/543) of patients were prescribed
antibiotics. Antibiotics were more likely to be prescribed in the clinical score only arm, with GPs
prescribing antibiotics in 64% (168/262) of patients, compared with 44% (123/281) in the RADT arm.
There was a correlation between Centor score and antibiotic prescription rates across both groups,
with more antibiotics prescribed to those with higher scores [score of 4 points – 80% antibiotics (37/46)
in intervention arm and 96% (43/35) in the control arm compared with 16% (4/70) in intervention arm
and 33.% (20/61) in control arm]. In the subgroup of interest to the UK population (those with Centor
scores of ≥ 3 points), 74% (90/122) were given antibiotics in the intervention arm, compared with 85%
(100/119) in the control arm. Antibiotic appropriateness is also discussed in the trial. Ninety-eight per
cent (59/60) of patients with a positive RADT result were given antibiotics and 31% (69/225) of those
with a negative test result received antibiotics. The authors determined that treatment was inappropriate
(based on culture results) in 43% of patients (226/526), with 210 unnecessary prescriptions and 16
untreated cases. A total of 153 of these cases occurred in the control arm and 73 were in the RADT
arm; however, the category of inappropriate decision (overprescribing or underprescribing) is not
reported by trial arm.
The third trial was a four-armed cluster randomised trial in Canada by Worrall et al.55 The trial included
40 physicians who were asked to consecutively recruit adult patients (aged ≥ 19 years, no further
details reported). There was a control arm using usual clinical practice, an intervention arm using sore
throat decision rules (STDR) (modified Centor), an intervention arm using a rapid test (RADT) and an
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intervention arm using both STDR and RADT. In the STDR group, for clinical scores of ≤ 1 point no
antibiotics were recommended, for scores of 3 or 4 points antibiotics were recommended and for
scores of 2 points the prescribing decision lay with clinicians. In the combined STDR and RADT group,
RADTwas used only for patients with scores of 2. It is implied, although not explicitly stated, that
all those in the RADT arm received a RADT. The authors found that 47% (247/533) of patients received
antibiotics. By arm, 58% (82/141) of patients received antibiotics in the usual practice arm, compared
with 55% (94/170) with Centor score alone, 27% (32/120) with rapid antigen testing alone and 38%
(39/102) with combined rapid antigen testing and Centor score. As this was a cluster randomised trial
and each arm included only 8–10 doctors, differences could be a result of differences between doctors
rather than between strategies. In addition, they may be owing to differences in patients across arms.
The study reports on the characteristics of the physicians only; we have no baseline patient data.
Finally, the Canadian medical system differs to the UK system, so the results may not be generalisable.
There was no RCT evidence on molecular technologies and antibiotic-prescribing rates.
Antibiotic-prescribing behaviours: before-and-after studies
There was one study that was a before-and-after study assessing antibiotic-prescribing rates. The study
by Bird et al.35 analysed children (aged 6 months to 16 years) presenting to a UK paediatric emergency
department with a sore throat. The study compared baseline data from October and November 2014 with
prescribing rates in the following 2 years (August to November 2015 and September to November 2016)
following the implementation of using both a McIsaac score and a RADT. Baseline data were collected
retrospectively from a departmental audit, when it is implied that the method of diagnosis was just
clinician examination, with the aim to assess the impact of a clinical scoring system and rapid test on
prescribing rates. A rapid test could be requested only if there was a McIsaac score of ≥ 3 points.
Following implementation, antibiotic-prescribing rates fell steeply, from 79% (166/210) at baseline to 24%
(51/214) in year 1 and 28% (51/181) for the second year. However, seasonality may be a confounding factor,
with higher prescribing rates over the later autumn months (October and November) than in late summer
(August and September). Likewise, there may be some regression to the mean, as the high initial prescribing
rates may have prompted the study but may be subject to fluctuations.
There were no two-armed cohort studies analysing molecular technologies and antibiotic-prescribing rates.
Antibiotic-prescribing behaviours: other study designs
There were an additional eight studies that reported antibiotic-prescribing behaviours in single-arm
cohorts.20,36,39,40,46,50,52,53 No comparative data were possible within these study designs, only hypothetical
comparisons, so all of the results in this section should be interpreted with caution and considered less
informative than the RCT results. In these cohort studies, patients received the same intervention;
however, authors also determined hypothetical management scenarios and compared how this would
have affected antibiotic-prescribing rates. Of the eight studies, three provided hypothetical rules, which
does not help inform us on real-world behaviour. These three studies39,46,53 have been included and
briefly summarised but were not quality appraised. Five studies20,36,40,50,52 reported on either what
happened in the real world or what clinicians reported they would do. These studies suggested that
using a rapid test would decrease antibiotic use by as little as 9% up to 74%.
Two of the five single-arm cohorts reported on real-world behaviour. The first study, by Stefaniuk et al.,52
examined children and adults in a primary care setting in Poland. Forty-six per cent (44/96) of the
study group were children aged 3–14 years and 25% (24/96) were adults aged 31–35 years (overall
mean age was not provided). Ninety-eight per cent (46/47) of patients with a positive QuikRead Go
Strep A test result received antibiotics and 24% (12/49) of patients with both a negative rapid test
and a negative culture were treated with antibiotics.
The second study reporting on real-world behaviour, by Berry et al.,20 compared BD Veritor testing
with Alere i testing and a chart review to determine hypothetical impact of results on antibiotic use.
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The study took place in paediatric outpatient clinics (mean age not reported) in the USA. Prescribing
decisions were made with knowledge of the BD Veritor test results, but not of the Alere i test or culture.
The authors found that 34% (73/215) of patients were prescribed antibiotics; of these, 25 patients were
prescribed antibiotics at a clinic visit and antibiotics were later deemed to be inappropriate treatment
(on the basis of culture results). Of these, 20 out of 25 (80%) patients were negative on BD Veritor, Alere i
and culture, and five were positive with the BD Veritor only. Of the 215 who did not receive antibiotics,
13 BD Veritor-negative cases were identified by the authors as potential missed cases on the basis of PCR
and Alere i positive results, of which six received antibiotics within 6 days of the original appointment.
These analyses provide descriptive behaviour data using the BD Veritor test, but cannot be used to compare
Alere and BD Veritor for appropriateness of prescribing behaviour as decisions were made using the BD
Veritor and not the Alere i. This study using Alere i was the only study to use a molecular technology, and
no prescribing behaviours were based on it; hence, there is no evidence on molecular technologies and
antibiotic-prescribing rates.
Three of the single-arm cohort studies reported on hypothetical scenarios based around clinicians’
decisions.36,40,50 Bura et al.36 examined a cohort of adults (median age 26 years, range 18–44 years)
in primary care in Poland with Centor scores of > 2 points (this was a case–control design for test
accuracy outcomes, but cohort for prescribing behaviour). All patients and controls were given a rapid
test and culture. GPs could then choose whether or not to give antibiotic therapy. It is stated that
this choice was not influenced by the research team; however, we cannot be certain of this as they
were aware of the rapid test result. Clinicians were aware of the Centor score at the time of antibiotic
prescribing. They found that 58% (59/101) of patients received an antibiotic. All RADT-positive patients
received treatment, including two who were culture negative. In addition, 46% (35/77) of test-negative
patients received antibiotics. They determined that 40% (23/59) of cases received an unnecessary
antibiotic prescription. Unnecessary has been defined here as being culture negative. The authors also
gave hypothetical management scenarios based on different Centor scores and scenarios. Antibiotics
would be prescribed to 29% (11/38) of patients with a Centor score of 2 points, 62% (23/37) of patients
with a Centor score of 3 points and 96% (25/26) of patients with a score of 4 points. They surmised
that 23% (23/101) would have been treated using positive culture results alone and 24% (24/101) would
have been treated using a rapid test, meaning that one person was mistakenly given antibiotics. However,
54% of those given antibiotics were treated for non-strep A. From the control group, one person would
have been treated with antibiotics; additionally, other forms of streptococci were identified in 13 people
from this group.
The study by Rosenberg et al.50 was a one-armed prospective observational cohort in which all patients
were given a clinical score (Centor), rapid test and culture. The study included patients older than 3 years
[47% (59/126) aged 3–14 years, 50% (63/126) aged 15–44 years and 3% (4/126) aged ≥ 45 years]
presenting to an emergency department in Canada. The authors also report physicians’ clinical impressions
and their hypothetical management. Authors report on score alone, physician examination alone, rapid
test alone or rapid test for clinical scores of > 3 points. They found that physicians prescribed antibiotics
to 37% (46/126) of patients, after obtaining the results of the rapid test; of these, 18 had negative culture
results. They hypothesised that 20% (25/126) would have received antibiotics in the rapid test group,
compared with 29% (37/126) in the clinical score group.
The last study, by Johansson et al.,40 was a prospective observational single-armed cohort in which all
patients received both a rapid test and culture and these results were compared with hypothetical
management suggestions made by physicians. It included adult patients (aged 25–44 years, mean age
not reported) reporting to primary health-care centres in Sweden. Physicians also clinically assessed
patients, and gave hypothetical management suggestions based on their level of certainty for strep A
(absolutely positive, positive, possibly positive, possibly negative, negative and absolutely negative).
No results are clearly provided; however, 26% (24/94) of patients with a negative rapid test received
treatment, but it is unclear how many of these were culture positive.
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There were three additional studies39,46,53 that reported on hypothetical prescribing decisions based on
assumptions about doctors’ behaviour; however, no real-world decisions were reported and doctors
were not asked about behaviour.
Summary of the clinical effectiveness findings and implications for the
health economic model
Overall, the findings reveal wide variations in the sensitivity (0.679 to 1.00) and specificity (0.733 to
1.00) estimates of point-of-care tests. These estimates were 0.829 to 0.946 for sensitivity and 0.849
to 0.991 for specificity in high-risk populations, including patients with Centor/McIsaac scores of
> 2 points, which represents the population of interest. These estimates do not account for any of
the unpublished manufacturer submissions.
Clinical scoring tools (FeverPAIN and Centor) have been proposed as a method by which clinicians can
identify which patients are most likely to benefit from antibiotic use for sore throat.8 These tools were
developed to predict strep A (Centor and FeverPAIN), strep C (FeverPAIN) and strep G (FeverPAIN).
Most studies making direct comparisons between sore throat clinical scoring tools and point-of-care
tests indicated that sensitivity estimates were higher for the point-of-care tests, and that specificity
was generally comparable between the two approaches.
A methodological limitation of the clinical scoring tools concerns the varying way in which they have
been implemented across the included studies. For instance, different studies apply different clinical
score cut-off points when recruiting patients. None of these studies matched the proposed pathway of
care and treatment for patients with acute streptococcal pharyngitis, which would entail evaluating the
test accuracy of a combined strategy of sore throat clinical scores at the recommended NICE thresholds
(Centor/McIsaac score of ≥ 3 points or FeverPAIN score of ≥ 4 points) and point-of-care tests. This
limitation potentially holds important economic implications, as attempts to model this proposed
pathway may not be informed by the availability of empirical data. In addition, the over-representation
of the TestPack Plus Strep A test relative to other point-of-care tests, as well as the overlap of patients
across different age groups, potentially raises applicability concerns in the economic model.
Investigation of discordant results between the index tests and the reference standard of culture was
available for several studies using PCR or culture. This analysis indicated that using culture as the
reference standard may have resulted in underestimating sensitivity (specificity estimates derived
using PCR were too variable to draw conclusions about potential overestimation/underestimation by
culture). However, PCR can detect indolent strep A so the extent of this is unclear.
Data for test accuracy were sparse for each combination of test, population and setting. There were
very few head-to-head (direct) comparison studies between index tests. There was heterogeneity
between studies, the cause of which is unclear owing to a lack of direct comparison data of different
age groups, settings or tests within the same study.
Test accuracy point estimates in manufacturers’ submissions may be systematically higher than in the
peer-reviewed literature, and the study characteristics are often unclear. Therefore, there is a risk of
making inappropriate comparisons between tests in the economic model where one test has a range of
peer-reviewed publications and another has manufacturer data only.
With the exception of a single study using the Sofia Strep A FIA test (failure rate 4.7%),23 failure rates
for point-of-care tests were generally low (0% to 2.8%) and unlikely to hold any major implications for
the economic model, especially as the data for this outcome have not been reported in most of the
included studies.
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No evidence was found on time to antimicrobial prescribing decision, number of appointments required
per episode and onward transmission of infection.
The findings suggest that RADT may help to reduce antibiotic prescription rates in patients who
receive these tests compared with patients assessed using only a clinical scoring tool. The three RCTs
addressing this question all found that up to 30% fewer antibiotics were prescribed following the
administration of a RADT. No studies were identified that assessed the use of molecular technologies
and antibiotic prescription rates.
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Chapter 4 Cost-effectiveness
Systematic review of existing cost-effectiveness studies
Introduction
This chapter explores and reviews all published cost-effectiveness studies, including any existing
economic models of the use of different rapid antigen detection or molecular tests (as listed in the final
scope and protocol for detection of strep A in detail). Studies providing resource use, costs, utilities
and probabilities that were useful to inform economic modelling were also identified.
Methods
Search strategy
A comprehensive search of the literature for published economic evaluations (including any existing
models), cost studies and quality-of-life (utility) studies was carried out. The systematic search included
searching the following electronic databases during January 2019 (on 22, 29 and 30 January 2019),
and an updated search was conducted on all databases during March 2019 (on 7 and 13 March 2019):
l MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions
(via OvidSP)
l Excerpta Medica database (EMBASE) (via OvidSP)
l NHS Economic Evaluation Database (NHS EED) and HTA database (via CRD)
l Science Citation Index and Conference Proceedings Citation Index – Science (via the Web
of Science)
l Cost-Effectiveness Analysis (CEA) registry
l EconPapers [Research Papers in Economics (RePEc)]
l School of Health and Related Research Health Utilities Database (ScHARRHUD).
The search terms included economic and quality-of-life terms combined with either ‘sore throat’ or
‘strep A’. No date limits were applied and databases were searched from inception. The search strategy
was developed by an experienced information specialist, based on the clinical effectiveness review and
with input from a health economist. Details of the full search strategies are provided in Appendix 6.
In addition to these searches, any relevant cost-effectiveness studies identified during the clinical
effectiveness review were brought to the attention of the reviewers and assessed for eligibility
alongside the results of this review.
Assessment of eligibility
Citations and abstracts from the electronic online databases were exported into a citation software
package (EndNote X7) and duplicate records were identified and removed. Two reviewers independently
reviewed titles and abstracts to identify potentially relevant papers for inclusion. Any discrepancies were
resolved by discussion.
Inclusion criteria
Only studies meeting the following inclusion criteria were included in the review:
l study type – fully published economic evaluations (including any economic models)
l population – people aged ≥ 5 years presenting to health-care providers in a primary care
(GP surgeries, community pharmacies and walk-in centres) or secondary care (urgent care/walk-in
centres and emergency departments) setting with symptoms of an acute sore throat
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l intervention – 17 RADTs or four molecular tests (as described in Chapter 1, Comparative technical
overview of the point-of-care tests for group A Streptococcus)
l comparator – antibiotic-prescribing decisions using clinical judgement and a clinical scoring tool
such as FeverPAIN or Centor
l outcomes – cost–benefit or cost–consequences or cost-effectiveness or cost–utility studies
reporting outcomes as cost–consequence measures or clinical effectiveness measures or utility
measures [utility, EuroQol-5 Dimensions (EQ-5D) or Short Form questionnaire-6 Dimensions score
or quality-adjusted life-years (QALYs)].
Exclusion criteria
Studies meeting the following exclusion criteria were excluded from the review:
l non-English-language publications
l studies not in humans
l studies not in strep A or sore throat
l studies with the wrong test or no specified test
l studies that were not full economic evaluations (incremental costs and incremental benefits).
Studies that provided useful information for the economic model, such as resource use, costs, utilities
and probabilities, were retained but were not included in this review.
Data extraction
Data extraction was carried out by one reviewer using standardised data extraction sheets and was
then checked by a second reviewer. Data extracted included the following information:
l study details – study title, author names, source of publication, language and publication type
l baseline characteristics – population (and subgroups), intervention, comparators, outcomes, study
design, setting and location and type of economic evaluation
l methods – study perspective, time horizon, discount rate, measurement of effectiveness,
measurement and valuation of preference-based outcomes, resource use and costs, currency, price
date and conversion, model type, assumptions and analytical methods
l results – study parameters, incremental costs and outcomes and reporting of uncertainty
l discussion – study findings, limitations, generalisability and conclusions
l other – sources of funding, conflicts of interest and any comments.
Data synthesis
Information extracted from the included studies was summarised and tabulated. Findings from
individual studies were compared narratively.
Quality assessment
The quality of full economic evaluation studies that were identified was assessed using the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist by one reviewer
and cross-checked by a second reviewer. The CHEERS checklist comprises six dimensions (title and
abstract, introduction, methods, results, discussion and other); under these dimensions, a series of
questions check whether or not the criteria have been clearly reported.74 If the studies included any
model-based economic evaluations, they were further critically appraised using the framework on
quality assessment for economic modelling developed by Phillips et al.75 The framework assesses
models under the dimensions of structure, data and consistency and whether or not the criteria have
been clearly reported.
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Results
Search results
The literature search identified 6980 records through electronic database searches and other sources.
After removing duplicates, 2756 records were screened for inclusion. One article was found via our
clinical effectiveness search. Based on title and abstract sift only, 2737 records were excluded. The
remaining 19 records were included for full-text screening. A further 16 articles were excluded at
the full-text stage, as these studies did not contain a full economic evaluation or specify the right test
(see Appendix 7 for further comments).
The literature search identified three studies that had evidence pertaining to incremental costs and
outcomes: Bura et al.,36 Humair et al.39 and Little et al.76 (Figure 11).
The economic information from the first two studies has been summarised below, as there was not
enough information for a full data extraction (see Appendix 8). These two studies did not explicitly
state the following: study perspective, time horizon, type of economic evaluation, measurement of
effectiveness or analytical methods. Bura et al.36 was a prospective case–control study consisting of
101 adults (aged 18–44 years) who went to GP clinics in Poland because of sore throat lasting no
longer than 7 days. Control participants (n = 101) were volunteers from the same area, who were
matched to cases according to their age and sex. The study was conducted over 1 year. The OSOM
Strep A test (Sekisui Diagnostics) in conjunction with throat culture was compared with Centor and
throat culture to confirm presence of strep A. The costs of diagnosing and treating strep A included
symptomatic treatment, test cost (€1.39), a single culture to identify strep A, antibiotic therapy and
antimicrobial medications. Economic analysis of five strategies were compared for treating patients
with strep A in terms of cost per patient with appropriate strep A treatment ranged from €2.89
(for treat only RADT positive cases) to €6.93 [for treat only strep A + (culture-positive) cases].
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FIGURE 11 The PRISMA flow diagram for economic evaluation studies.
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The authors concluded that the use of the rapid test significantly increases the number of people
with strep A-related pharyngitis to be treated with antibiotics.
Humair et al.39 was a prospective cohort study consisting of 372 adults (aged 15–65 years) who were
treated at a GP clinic in Switzerland. The Alere TestPack +Plus Strep A (Abbott Laboratories) was
compared with throat culture. A decision tree model was used to compare antibiotic prescription for
five strategies. Information used in the decision model included antibiotic rate for appropriate use,
overuse in patients without strep A, underuse in patients with strep A, appropriate treatment for
patients with strep A and without treatment in patients without strep A. The model did not consider
quality of life, complications or adverse drug effects. Costs were in US$ in 2002 prices. Costs included
a 10-day course of penicillin, a test cost of $5.00 and $18.00 for throat culture. The authors found that
systematic throat culture had the highest rates of appropriate treatment, whereas empirical treatment
in patients with clinical scores of 3 or 4 resulted in the most antibiotic overuse. The cost per case
appropriately treated ranged from $15.30 (systematic rapid test) to $32.40 (systematic throat culture).
Sensitivity analyses were conducted to check the robustness of results. The authors concluded that the
rapid test is a valid test for diagnosis of strep A.
Little et al.76 conducted an economic analysis alongside a RCT in the UK, which included both adults and
children with acute sore throat who were seen in primary care clinics (see Appendix 8). They compared
randomised patients with targeted antibiotic use according to (1) delayed antibiotics (control group),
(2) clinical score using FeverPAIN or (3) RADT – Alere TestPack +Plus Strep A (Abbott Laboratories)
used according to clinical score. The analysis was from an NHS perspective and the time horizon was
short (14 and 28 days); hence, long-term effects were not captured. Health-related quality of life was
evaluated using the EQ-5D. QALYs were adjusted for baseline differences and were calculated using mean
EQ-5D scores obtained from the 14-day diary records. It was assumed that the health-related quality of
life changes linearly over time. The analysis included a cost-effectiveness analysis (cost per change in
symptom severity) and a cost–utility analysis (cost per QALY). Cost-effectiveness acceptability curves
(CEACs) were generated using bootstrapping with 5000 samples.
The mean symptom scores were adjusted for baseline differences. For the cost-effectiveness analysis,
the clinical score group dominated both the delayed antibiotic group and the RADT group, as it was more
clinically effective (lower symptom score) and less costly. However, the point estimate of symptom score
and the corresponding 95% CIs for clinical score and RADT groups were quite close. The CEAC showed
that if the value of a 1-point change in the symptom score was varied between £0 and £500, and it was
found that over the entire range the clinical score group was most likely to be cost-effective. In the
cost–utility analysis, the delayed group was dominated by the clinical score group for both time frames.
The incremental cost-effectiveness ratio (ICER) for the RADT group compared with clinical score group
was £74,286 for the 14-day time frame and £24,528 for the 28-day time frame.
Quality assessment
The quality of the reporting of the economic analysis of the three studies was assessed using the
25-point CHEERS checklist74 and is provided in Table 19. The Little et al.76 article was comprehensively
reported: 22 of the 25 statements (88.0%) were a ‘yes’, one statement (4.0%) was not completed and
two statements (8.0%) did not apply.
Summary
The cost-effectiveness search highlighted three studies that used the RADTs as identified in the NICE
scope and were classed as economic evaluations. Of these three studies, only one allowed a full data
extraction and was classed as a high-quality economic evaluation when checked against the CHEERS
reporting tool. In Chapter 5, we build a de novo economic model comparing the different tests
identified in the NICE scope for the various settings for patients with strep A.
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
Cost-effectiveness methods and results
Modelled population
The population of interest is people aged ≥ 5 years presenting to health-care providers in a primary
(GP surgeries and walk-in centres), secondary (urgent care/walk-in centres and emergency departments)
or pharmacy care setting with symptoms of an acute sore throat identified as most likely to benefit from
antibiotic treatment on the basis of clinical scoring algorithm (FeverPAIN score of 4 or 5 points, or a
TABLE 19 The CHEERS quality assessment checklist for economic evaluation studies
Assessment Bura et al.36 Humair et al.39 Little et al.76
Title N N Y
Abstract Y Y Y
Introduction
Background and objectives Y Y Y
Methods
Target population and subgroups Y Y Y
Setting and location Y Y Y
Study perspective N N Y
Comparators Y Y Y
Time horizon N N Y
Discount rate NA N NA
Choice of health outcomes P P Y
Measurement of effectiveness N N Y
Measurement and valuation of preference-based outcomes N N Y
Estimating resources and costs P P Y
Currency, price date and conversion N Y Y
Choice of model NA N NA
Assumptions NA N Y
Analytical methods P N Y
Results
Study parameters N N Y
Incremental costs and outcomes Y Y Y
Characterising uncertainty N P Y
Discussion
Study findings Y Y Y
Limitations Y Y Y
Generalisability N N Y
Other
Source of funding Y N Y
Conflicts of interest Y N N
N, not reported; NA, not applicable; P, partially reported; Y, yes reported.
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Centor score of 3 or 4 points). Potential subgroups identified in the NICE scope included children
(aged 5–14 years), adults (aged 15–75 years) and the elderly (aged > 75 years). However, the analyses
have been restricted to adults and children owing to a lack of evidence on test accuracy among the
elderly patient population.
Model structure
A decision tree model from the perspective of the UK NHS and Personal Social Services was developed
to estimate the costs and QALYs associated with point-of-care testing in conjunction with clinical
scoring tools, such as the Centor and FeverPAIN score for strep A, compared with clinical assessment
incorporating clinical scoring tools alone (usual care).77
The model structure, as depicted in Figures 12–14, makes use of a decision tree to model potential care
pathways associated with a suspected strep A infection/sore throat presentation under the intervention
(point-of-care testing and clinical scoring tools) and usual-care (clinical scoring tools alone) conditions.
Previous economic evaluations of management strategies for streptococcal pharyngitis have estimated
that up to 76.5 quality-adjusted life-days could be lost as a result of rare but serious complications
of the infection, such as acute rheumatic fever.78–80 Thus, for this economic model we have assumed
a 1-year time horizon in which we model only one episode of strep A per patient and we have assumed
that this time horizon is sufficient to capture the impact of rare but serious complications of the
infection on economic costs and outcomes. This differs from the stated time horizon of 14 days
originally conceived in the EAG protocol for this self-limiting illness for which the majority of cases
would be expected to resolve satisfactorily.
The model takes account of the prevalence of disease in the modelled population, the test accuracy of
clinical scoring algorithms and point-of-care tests, the proportion of patients treated with immediate
and delayed antibiotics who are given a positive or negative clinical score and/or test result (prescribing
behaviour of treating clinicians) and the probability of developing important but rare complications of the
infection (i.e. suppurative complications, such as peritonsillar abscess and quinsy,81 and non-suppurative
complications, such as acute rheumatic fever).82 Penicillin-induced rash and anaphylactic complications of
penicillin are incorporated as adverse effects of treatment.81,83
The model estimated costs in 2017/18 prices. Economic costs accrued over the modelled time horizon
are from resource use associated with simulated care pathways. They include the costs of the point-
of-care tests (including additional cost of confirmatory throat culture for a negative test result), GP
consultations, antimicrobial therapy and treatment for strep A-related complications and the unwanted
effects of penicillin. QALYs are calculated as a weighted sum of the difference between the utility
decrements associated with strep A infection and related complications and the general UK population
utility norms, weighted by the modelled time horizon in years. No discounting was applied to costs and
benefits owing to the 1-year time horizon.
The base-case analysis assumes that patients presenting with suspected strep A in the usual-care arm
receive immediate or delayed antimicrobial treatment based on clinical assessment and outcome of
clinical scoring algorithm indicating possible strep A infection. We assumed a score of ≥ 3 points on
the Centor (or FeverPAIN score of ≥ 4 points) as the threshold for commencing immediate antibiotics
(or testing for those in the intervention arm), as shown in Figure 1 and in line with recent NICE
guidance on antimicrobial prescribing for acute sore throat infections.8
We explored the impact of alternative thresholds (Centor score of ≥ 2 points and ≥ 1 point) for commencing
antibiotic treatment and on testing. These alternative thresholds have differing performance (sensitivity and
specificity) to the Centor score of ≥ 3 points; hence, they could be considered as assessing an alternative
performance of the Centor tool. For the intervention arm, we assumed that patients presenting with
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suspected strep A will be screened first using a clinical scoring tool for signs and symptoms of the infection.
Those screening positive (i.e. Centor score of ≥ 3 points or FeverPAIN score of ≥ 4 points) are offered a
point-of-care test followed by immediate antibiotics if testing indicates positive strep A infection. Those
screening negative according to a clinical scoring algorithm or test are offered delayed antibiotic prescription
with a probability of 0.49 and 0.29 in the usual-care and test arms, respectively, based on the PRImary care
Streptococcal Management (PRISM) trial data.6
Treated strep A: abscess
Complications
Centor score of ≥ 3
(true positive) Immediate antibiotics Used
No complications Treated strep A
Treated strep A: abscess
Complications
Treated strep A: rheumatic fever
Treated strep A: rheumatic fever
Strep A sore throat Used
No complications Treated strep A
Delayed antibiotics
Untreated strep A: abscess
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Untreated strep A: rheumatic fever
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Centor score of < 3
(false negative) No complications Untreated strep A
Untreated strep A: abscess
Complications
Untreated strep A: rheumatic fever
No antibiotics Not used 
No complications Untreated strep A
Centor score of ≥ 3
(false positive) Immediate antibiotics Used No complications Treated: well
Used Treated: well
No strep A sore throat
Delayed antibiotics
Not used No complications Untreated: wellCentor score of < 3
(true negative)
No antibiotics Not used No complications Untreated: well
Adults, GP
Centor and test test sheet
Centor score
FIGURE 12 Strep A model part 1.
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Over the 1-year time horizon, patients with suspected strep A infection receiving either immediate
antibiotics or delayed antibiotics can make a complete recovery or go on to develop complications
requiring a period of hospital stay. The risk of developing serious complications related to strep A is
modelled as a function of antimicrobial treatment so that those patients who are correctly diagnosed
and appropriately treated present a lower risk of serious strep A complications than do those who are
incorrectly diagnosed who receive no antimicrobial treatment. Separate models (each with the same
underlying structure depicted in Figures 12–14) are specified for adults and children in primary and
secondary care settings.
Treated strep A: abscess
Centor Complications
Treated strep A: rheumatic fever
Test +ve (true positive) Immediate antibiotics Used
No complications Treated strep A
Adults, GP
Treated strep A: abscess
Complications
Treated strep A: rheumatic fever
UsedCentor score of ≥ 3
(true positive): test 
No complications Treated strep A
Delayed antibiotics
Untreated strep A: abscess
Complications
Untreated strep A: rheumatic fever
Not used
Test -ve (false negative) No complications Untreated strep A
Untreated strep A: abscess
Complications
Untreated strep A: rheumatic fever
No antibiotics Not used 
Strep A No complications Untreated strep A
Treated strep A: abscess
Complications
Treated strep A: rheumatic fever
Used
No complications Treated strep A
Delayed antibiotics
Untreated strep A: abscess
Complications
Untreated strep A: rheumatic fever
Not used
Centor and test Centor score of < 3
(false negative): no test
No complications Untreated strep A
Untreated strep A: abscess
Complications
Untreated strep A: rheumatic fever
No antibiotics Not used 
No complications Untreated strep A
FIGURE 13 Strep A model part 2.
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Details of the methodology used to derive parameter inputs and the data sources used to inform
estimates are discussed in the following sections.
Effectiveness evidence used in the economic model
Accuracy of clinical scoring algorithms (all models)
Accuracy in the usual-care arm was based on estimates of sensitivity and specificity of the Centor score
taken from a published meta-analysis of 12 studies by Aalbers et al.84 Table 20 summarises the reported
estimates of sensitivity and specificity of the Centor score at cut-off points of ≥ 1, ≥ 2, ≥ 3 and 4 points
for positive strep A infection. The base-case model used the estimates at a cut-off point of ≥ 3 points for
a positive result and < 3 points for a negative result. At this threshold, the Centor score has a sensitivity
of 0.49 (95% CI 0.38 to 0.60) and a specificity of 0.82 (95% CI 0.72 to 0.88). Alternative thresholds on
the Centor score were explored in sensitivity analyses.84 However, we were unable to evaluate the
FeverPAIN clinical score owing to a lack of accuracy estimates in a format suitable for the economic
model (i.e. sensitivity and specificity of the FeverPAIN at a cut-off point of ≥ 4 points).
Test +ve (false positive) Immediate antibiotics Used No complications
Used Treated: well
Treated: well
Centor score of ≥ 3
(false positive):  test
Delayed antibiotics
Not used No complications Untreated: well
Test –ve (true negative)
No antibiotics Not used No complications Untreated: well
No strep A
Used Treated: well
Delayed antibiotics
Not used No complications Untreated: well
Centor score of < 3
(true negative): no test
No antibiotics Not used No complications Untreated: well
FIGURE 14 Strep A model part 3.
TABLE 20 Diagnostic accuracy of the Centor score based on meta-analysis of 12 studies reported by Aalbers et al.84
Centor threshold
(points) for positive
strep A infection Sensitivity (95% CI) Specificity (95% CI)
Number of primary
studies included in
the meta-analysis
Distributional
form in model
≥ 1 0.95 (0.91 to 0.97) 0.18 (0.12 to 0.26) 11 Normal (logit scale)
≥ 2 0.79 (0.71 to 0.86) 0.55 (0.45 to 0.65) 12 Normal (logit scale)
≥ 3 0.49 (0.38 to 0.60) 0.82 (0.72 to 0.88) 11 Normal (logit scale)
4 0.18 (0.12 to 0.27) 0.95 (0.92 to 0.97) 11 Normal (logit scale)
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Accuracy of point-of-care tests
Estimates of test accuracy for the point-of-care tests obtained from our systematic review with
and without meta-analyses are summarised in Table 21 by test, clinical setting (primary care) and
patient population (adults and children). When no studies reporting accuracy data were identified in
TABLE 21 Test accuracy of point-of-care tests used in the economic model in primary care
Test
ID Test name Manufacturer
Sensitivity
(95% CI)
Specificity
(95% CI) Distribution
Data source
(first author
and year of
publication)
Adults
1 Clearview Exact
Strep A cassette
Abbott
Laboratories
0.68 (0.54 to 0.8) 0.95 (0.92 to 0.97) Normal (logit) One abstract
(Andersen 200356)
2 Clearview Exact
Strep A dipstick –
test strip
Abbott
Laboratories
0.68 (0.54 to 0.8) 0.95 (0.92 to 0.97) Normal (logit) One abstract
(Andersen 200356)
3 BD Veritor Plus
system group A
Strep Assay –
cassette
Becton
Dickinson
0.78 (0.67 to 0.87) 0.9 (0.86 to 0.93) Normal (logit) Two studies
(Berry 201820 and
Azrad 201934)
4 Strep A Rapid
Test – cassette
Biopanda
Reagents
0.95 (0.9 to 0.98) 0.98 (0.96 to 0.99) Normal (logit) One manufacturer
response to NICE
5 Strep A Rapid
Test – test strip
Biopanda
Reagents
No data
6 NADAL Strep A –
test strip
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
7 NADAL Strep A –
cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
8 NADAL Strep A
plus – cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
9 NADAL Strep A
plus – test strip
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
10 NADAL Strep A
scan test –
cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
11 OSOM Strep A
test – test strip
Sekisui
Diagnostics
0.92 (0.76 to 0.98) 0.96 (0.89 to 0.99) Normal (logit) One study
(Llor 201145)
12 QuikRead Go
Strep A test kit
Orion
Diagnostica
1 (0.85 to 1) 0.79 (0.6 to 0.92) Normal (logit) One study
(Stefaniuk 201752)
13 Alere TestPack
+Plus Strep A –
cassette
Abbott
Laboratories
0.95 (0.89 to 0.98) 0.94 (0.88 to 0.98) Normal (logit) One study
(Humair 200639)
14 bioNexia Strep A
plus – cassette
bioMérieux No data
15 bioNexia Strep A
dipstick – test
strip
bioMérieux 0.85 (0.74 to 0.92) 0.91 (0.84 to 0.95) Normal (logit) One abstract
(Pauchard 200357)
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TABLE 21 Test accuracy of point-of-care tests used in the economic model in primary care (continued )
Test
ID Test name Manufacturer
Sensitivity
(95% CI)
Specificity
(95% CI) Distribution
Data source
(first author
and year of
publication)
16 Biosynex Strep A
– cassette
Biosynex No data
17 Sofia Strep A FIA Quidel 0.85 (0.81 to 0.89) 0.95 (0.93 to 0.97) Normal (logit) One study
(Lacroix 201823)
18 Alere i Strep A Abbott
Laboratories
0.95 (0.74 to 1) 0.97 (0.92 to 0.99) Normal (logit) One study
(Cohen 201537)
19 Alere i Strep A 2 Abbott
Laboratories
0.98 (0.96 to 1) 0.93 (0.91 to 0.95) Normal (logit) One FDA report
20 cobas Liat
Strep A Assay
Roche
Diagnostics
0.98 (0.93 to 1) 0.93 (0.9 to 0.96) Normal (logit) One study
(Wang 201724)
21 Xpert Xpress
Strep A
Cepheid 1 (0.99 to 1) 0.94 (0.92 to 0.96) Normal (logit) One manufacturer
response to NICE
and one FDA
report
Children
1 Clearview Exact
Strep A cassette
Abbott
Laboratories
0.68 (0.54 to 0.8) 0.95 (0.92 to 0.97) Normal (logit) One study
(Andersen 200356)
2 Clearview Exact
Strep A dipstick –
test strip
Abbott
Laboratories
0.68 (0.54 to 0.8) 0.95 (0.92 to 0.97) Normal (logit) One study
(Andersen 200356)
3 BD Veritor Plus
system group A
Strep Assay –
cassette
Becton
Dickinson
0.76 (0.61 to 0.88) 0.94 (0.89 to 0.97) Normal (logit) One study
(Berry 201820)
4 Strep A Rapid
Test – cassette
Biopanda
Reagents
0.95 (0.9 to 0.98) 0.98 (0.96 to 0.99) Normal (logit) One manufacturer
response to NICE
5 Strep A Rapid
Test – test strip
Biopanda
Reagents
No data
6 NADAL Strep A –
test strip
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
7 NADAL Strep A –
cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
8 NADAL Strep A
plus – cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
9 NADAL Strep A
plus – test strip
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
10 NADAL Strep A
scan test –
cassette
nal von
minden
GmbH
0.98 (0.92 to 1) 0.98 (0.94 to 0.99) Normal (logit) One manufacturer
response to NICE
11 OSOM Strep A
test – test strip
Sekisui
Diagnostics
0.94 (0.89 to 0.98) 0.95 (0.91 to 0.98) Normal (logit) One study
(Llor 201145)
12 QuikRead Go
Strep A test kit
Orion
Diagnostica
0.80 (0.56 to 0.94) 0.91 (0.72 to 0.99) Normal (logit) One study
(Stefaniuk 201752)
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our systematic review, we obtained the estimates from either the manufacturer website or the
manufacturer submissions (submitted directly to NICE in response to a request for information).
Test accuracy data were available for six (28.6%) of the 21 tests from published sources identified
in the clinical effectiveness review; a further four tests (19%) had accuracy data from both published
sources and manufacturer submissions, six tests (27.6%) had only manufacturer data and two tests
(9.5%) had FDA data. Test accuracy data were not available for the three (14.3%) remaining tests
(Biopanda Reagents’ Strep A Rapid Test strip, bioNexia Strep A cassette and bioNexia Strep A plus
cassette). Two of the three tests (bioNexia Strep A cassette and bioNexia Strep A plus cassette) were
excluded from the economic modelling of individual tests owing to a lack of test accuracy data. The
accuracy of Biopanda Reagents’ Strep A Rapid Test strip was assumed to be equal to that of the
cassette version of this test, for which accuracy estimates were available. In general, estimates of
sensitivity and specificity obtained from the published sources tended to be variable and lower
than those provided by the manufacturer. For example, sensitivity of point-of-care testing in adults
based on the published sources ranged from 0.68, for Abbott Laboratories’ Clearview Exact Strep A
cassette, to 1.00, for the QuikRead Go Strep A test kit, whereas estimates provided in the manufacturer
submission ranged from 0.95, for Biopanda Reagents’ Strep A Rapid Test cassette, to 0.98, for nal von
minden GmbH’s NADAL Strep A test. A similar trend in specificity is observed, with the manufacturers’
estimates being generally much higher than estimates based on published data. Thus, the source of test
accuracy data is likely to be an important driver of cost-effectiveness. The economic models presented
here, which are based solely on manufacturers’ test accuracy data with no peer-reviewed published
data, are likely to overestimate test accuracy and, therefore, the results of these models cannot be
reliably interpreted.
TABLE 21 Test accuracy of point-of-care tests used in the economic model in primary care (continued )
Test
ID Test name Manufacturer
Sensitivity
(95% CI)
Specificity
(95% CI) Distribution
Data source
(first author
and year of
publication)
13 Alere TestPack
+Plus Strep A –
cassette
Abbott
Laboratories
0.86 (0.79 to 0.91) 0.99 (0.97 to 1) Normal (logit) One study
(McIsaac 200446)
14 bioNexia Strep A
plus – cassette
bioMérieux No data
15 bioNexia Strep A
dipstick – test
strip
bioMérieux 0.85 (0.74 to 0.92) 0.91 (0.84 to 0.95) Normal (logit) One abstract
(Pauchard 201357)
16 Biosynex Strep A
– cassette
Biosynex No data
17 Sofia Strep A FIA Quidel 0.85 (0.81 to 0.89) 0.95 (0.93 to 0.97) Normal (logit) One study
(Lacroix 201823)
18 Alere i Strep A Abbott
Laboratories
0.98 (0.95 to 1) 0.96 (0.89 to 1) Normal (logit) Three studies
(Berry 2018,20
Cohen 201537 and
Weinzierl 201854)
19 Alere i Strep A 2 Abbott
Laboratories
0.98 (0.96 to 1) 0.93 (0.91 to 0.95) Normal (logit) One FDA report
20 cobas Liat
Strep A Assay
Roche
Diagnostics
0.98 (0.93 to 1) 0.93 (0.9 to 0.96) Normal (logit) One study
(Wang 201724)
21 Xpert Xpress
Strep A
Cepheid 1 (0.99 to 1) 0.94 (0.92 to 0.96) Normal (logit) One manufacturer
response to NICE
and one FDA
report
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Prevalence of group A streptococcal infection in the modelled population
Data on the adult prevalence of strep A in the UK were available in one study out of the 38 published
studies, abstracts and reports submitted by manufacturers to NICE included in our test accuracy
effectiveness review. The study by Little et al.6 from the review85 (with additional data from the full
HTA report76) found a prevalence rate of 34% (95% CI 31% to 38%) for pathogenic streptococcal
infection among 204 out of 597 patients aged ≥ 5 years presenting in UK primary care settings. Of these
infections, 136 (66.7%) were strep A. This gives a strep A prevalence rate of 22.7% (136/597). This study
did not consecutively recruit patients, meaning that there may be bias in the sample, which could have
affected the true prevalence rate. As there were no UK adult studies in secondary care, this estimate was
used across both primary settings and secondary settings (Table 22).
There were no clear UK estimates for prevalence in children from the systematic review; a median
value from three non-UK studies of children in primary care only was calculated.24,46,52 The median
value was 30.2%.
Treatment-related probabilities and complication rates
Treatment-related probabilities and complication rates following strep A that were used in the
economic model are presented in Table 23. The proportion of patients attending repeat consultations
for sore throat infections (used to inform calculation of treatment costs) was obtained from Little
et al.86 In this large cohort study of UK patients presenting in primary care with a sore throat, a total of
889 (14.2%) repeat consultations for new or resolved symptoms were reported among 13,288 adults
and adolescents.
In base-case models, the probability of commencing antibiotic treatment given a positive clinical score
(defined as Centor score of ≥ 3 points) in the usual-care arm or a positive clinical score and test result
in the intervention arm was set to 1 based on the prescribing behaviour of GPs reported in the PRISM
trial.6 The probability of a delayed prescription given a negative clinical score (defined as Centor score
of < 3 points in the base case) was set to 0.51 based on data suggesting that 91 out of 178 patients in
the clinical score arm of the PRISM trial with a FeverPAIN score of < 4 points were offered a delayed
prescription,6 with the assumption that a Centor score of < 3 points is equivalent to a FeverPAIN score
of < 4 points. The probability of a delayed prescription given a negative test was set to 0.273 based on
the PRISM data (48/174 patients in the clinical score plus test arm were given a delayed prescription).
The probability of antibiotic use among those receiving a delayed prescription was set to 0.46 based on
PRISM data showing reported antibiotic use among the 75 out of 164 patients in the control arm who
were offered delayed prescription.
TABLE 22 Prevalence of strep A by setting and population
Systematic review data Estimate used in model
Patient population
and clinical settings
Number
of studies
Median prevalence,
% (range)
Central
estimate SE Distribution Source
Adults
Primary and
secondary care
One6 22.6 0.226 0.051 Beta Systematic review
Children
Primary and
secondary care
Three3,46,52 30.2 (26.3–34.1) 30.2 0.015 Beta Systematic review
SE, standard error.
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Complications for treated (i.e. antibiotics given) and untreated (no antibiotics given) strep A infections
were also estimated based on another Little et al.86 study: 78 and 75 complications (quinsy, sinusitis,
otitis media and cellulitis) were reported among 5932 treated and 4974 untreated individuals,
generating a complication rate of 1.3% and 1.5%, respectively. As this study did not report rates for
rare but important non-suppurative sequalae of strep A sore throat, such as acute rheumatic fever,82
we assumed that the majority of complications were suppurative in nature, with only a tiny proportion
of patients (no more than 0.01%) going on to develop non-suppurative sequelae. The impact of this
assumption on the cost-effectiveness estimates was assessed by halving and doubling it in sensitivity
analyses. We assumed that 2% of patients who were prescribed antibiotics (100% of those prescribed
immediate antibiotics and 46% of those prescribed delayed antibiotics) will go on to develop penicillin-
induced rash and 0.1% will develop penicillin-induced anaphylaxis/sepsis based on estimates reported
in a previous economic evaluation of diagnostic and treatment strategies for adults with streptococcal
pharyngitis.78 Sensitivity analysis explored the impact of halving and doubling complications associated
with penicillin use on the base-case cost-effectiveness.
Health utility and estimation of quality-adjusted life-year gains
Table 24 presents estimates of health utilities used to inform the economic model. A mean baseline
utility of 0.863, equal to the mean utility norm for the general UK adult population,87 was assumed for
the modelled adult population treated in primary and secondary care. For the child population models,
we assume a mean utility of 0.94, equivalent to the mean UK utility norm for the aged < 25 years
population,87 the closest age group to children. Utility decrements associated with strep A and related
complications, such as development of peritonsillar abscess, rheumatic fever and anaphylactic
TABLE 23 Probabilities used in the economic model
Description of parameter Mean SEa Distribution
Source
(first author
and year of
publication)
General practice
Proportion attending repeat GP consultation following
strep A infection
0.142 0.007 Beta Little 201386
Antibiotic-prescribing probabilities
Probability of antibiotic use: Centor score of ≥ 3 points or
positive test (immediate prescription)
1 Little 20136
Probability of antibiotic use: Centor score of < 3 points
(delayed prescription, usual-care arm)
0.51 0.026 Beta Little 20136
Probability of antibiotic use: negative test (delayed prescription,
intervention arm)
0.267 0.014 Beta Little 20136
Probability of antibiotic use: delayed prescription 0.46 0.023 Beta Little 20136
Complication rates following strep A infection
Probability of complications: antibiotics (treated infection) 0.013 0.0005 Beta Little 201386
Probability of complications: no antibiotics (untreated infection) 0.015 0.0007 Beta Little 201386
Proportion of complications that are non-suppurative
(i.e. rheumatic fever)
0.0001 Analyst
assumption
Adverse effects of penicillin
Penicillin-induced rash 0.02 Beta Neuner 200378
Penicillin-induced anaphylaxis/sepsis 0.0001 Beta Neuner 200378
SE, standard error.
a SE derived assuming upper and lower bound equals to 10% of mean/central estimate.
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complications of penicillin, were obtained from previously published economic evaluations of diagnostic
and management strategies for adults with pharyngitis.78,79 The two studies78,79 reported losses of 0.15
and 0.25 in quality-adjusted life-days for treated and untreated sore throat infections, and related
complications, such as acute rheumatic fever, penicillin-induced anaphylaxis (sepsis), peritonsillar
abscess and penicillin-induced rash, were associated with the greatest health impact, with estimates
of 76.5, 9, 5 and 0.65 in quality-adjusted life-days lost, respectively. These estimates translate into
utility decrements of 0.000411 (0.15/365) and 0.000685 (0.25/365) for treated and untreated strep A
infection, respectively, 0.00178 (0.65/365) for penicillin-induced rash, 0.0037 (5/365) for peritonsillar
abscess, 0.025 (9/365) for penicillin-induced sepsis and 0.209 (76.5/365) for rheumatic fever. QALYs
were calculated at the end of each pathway in the model by subtracting from the baseline utility of
0.86 (or 0.94 for the child model) the utility decrements associated with all outcomes that occur in the
modelled pathway (assuming that utility decrements are additive) weighted by modelled time horizon in
years (i.e. 365/365 for the 1-year base-case time horizon). Disutility associated with unwanted effects
of penicillin (rash and anaphylaxis) was added to care pathways associated with treated infection
(immediate or delayed antibiotic use) weighted by the respective event probability (0.02 for penicillin-
induced rash and 0.0001 for anaphylactic reaction). For example, the total number of QALYs accrued
from uncomplicated strep A infection with complete resolution following immediate antibiotic treatment
would be equal to (0.86 – 0.000410959 – 0.00003425 – 0.00000247) × 1= 0.859552 QALYs over the
1-year time horizon considered in the base-case analysis for adults. Similarly, if this infection had resulted
in a subsequent complication (e.g. an abscess), then the total QALY estimate would be slightly lower,
at (0.86 – 0.000410959 – 0.01369863 – 0.00003425 – 0.00000247) × 1= 0.84584.
Health and social care costs
Cost of tests
Table 25 presents the unit cost for each point-of-care test and estimates of resource use in terms of
the additional GP time required to administer and process the test results. Cost data were available for
14 (66.7%) of the 21 tests considered in the NICE scope. The majority of the costs were provided by
the manufacturers (submitted directly to NICE in response to a request for information) and ranged
from £0.64 per test for Biopanda Reagents’ Strep A Rapid Test strip to £64.63 (2017/18 prices) for the
cobas Liat Strep A Assay supplied by Roche Diagnostics. Unit costs for Abbott Laboratories’ Clearview
Exact Strep A tests were obtained from the NHS supply chain catalogue at £1.92 per test for the
Clearview Strep A dipstick – test strip and £2.72 for the cassette version.88 The duration of additional
GP time for processing test results was estimated based on information provided in the manufacturer
TABLE 24 Utilities
Utility/disutility Mean SE Distribution
Source
(first author
and year of
publication)
Baseline (UK population norm, adults) 0.863 0.044 Beta Kind 199887
Baseline (UK population norm, children) 0.94 0.048 Beta Kind 199887
Utility decrement associated with untreated infection 0.000685 0.00005 Beta Neuner 200378
Utility decrement associated with treated infection 0.000411 0.00003 Beta Neuner 200378
Utility decrement associated with penicillin-induced rash 0.0017 0.0001 Beta Neuner 200378
Utility decrement associated with abscess 0.0137 0.0007 Beta Neuner 200378
Utility decrement associated with penicillin-induced
anaphylaxis (sepsis)
0.025 0.0013 Beta Neuner 200378
Utility decrement associated with rheumatic fever 0.209 0.011 Beta Neuner 200378
SE, standard error.
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submission and ranged from 5 to 12 minutes. Costs associated with additional GP time for processing
test results are included in the base-case analysis. The costs of confirmatory swab culture following
a negative test result are calculated as part of the costs associated with modelled pathways in the
intervention arm except for the Alere TestPack +Plus Strep A – cassette (Abbott Laboratories), Alere i
Strep A 2 (Abbott Laboratories), cobas Liat Strep A Assay (Roche Diagnostics) and all five NADAL
tests supplied by nal von minden GmbH. Details of costing methods are given in the next section.
TABLE 25 Test costs
Test ID Test name Cost (£)
Test process
time (minutes) Source
1 Clearview Exact Strep A cassette (Abbott
Laboratories)
2.72 5 NHS Supply chain
catalogue
(National Product
Code=HHH2552)88
2 Clearview Exact Strep A dipstick – test strip
(Abbott Laboratories)
1.92 5 Medisave UK Ltd89
3 BD Veritor Plus system group A Strep Assay –
cassette (Becton Dickinson)
Test cost not available
4 Strep A Rapid Test – cassette (Biopanda Reagents) 0.82 5 Manufacturer’s
submissiona
5 Strep A Rapid Test – test strip (Biopanda Reagents) 0.64 5 Manufacturer’s
submissiona
6 NADAL Strep A – test strip (nal von minden GmbH) 1.20 5 Manufacturer’s
submissiona
7 NADAL Strep A – cassette (nal von minden GmbH) 1.40 5 Manufacturer’s
submissiona
8 NADAL Strep A plus – cassette (nal von minden
GmbH)
1.50 5 Manufacturer’s
submissiona
9 NADAL Strep A plus – test strip (nal von minden
GmbH)
1.30 5 Manufacturer’s
submissiona
10 NADAL Strep A scan test – cassette (nal von
minden GmbH)
1.96 5 Manufacturer’s
submissiona
11 OSOM Strep A test – test strip (Sekisui Diagnostics) Test cost not available
12 QuikRead Go Strep A test kit (Orion Diagnostica) 4.34 5 Manufacturer’s
submissiona
13 Alere TestPack +Plus Strep A – cassette (Abbott
Laboratories)
2.70 5 Manufacturer’s
submissiona
14 bioNexia Strep A plus – cassette (bioMérieux) Test cost not available
15 bioNexia Strep A dipstick – test strip (bioMérieux) Test cost not available
16 Biosynex Strep A – cassette (Biosynex) Test cost not available
17 Sofia Strep A FIA (Quidel) Test cost not available
18 Alere i Strep A (Abbott Laboratories) Test cost not available
19 Alere i Strep A 2 (Abbott Laboratories) 22.94 5 Test cost not available
20 cobas Liat Strep A Assay (Roche Diagnostics) 64.63 6 Manufacturer’s
submissiona
21 Xpert Xpress Strep A (Cepheid) 4.25 12 Manufacturer’s
submissiona
a Submitted directly to NICE in response to a request for information.
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Treatment costs
Unit costs of health-care service use associated with modelled care pathways are summarised in
Table 26. As described in Model structure, the base-case models incorporate three treatment options
for patients presenting with suspected strep A infection in primary care and secondary care settings:
immediate antibiotics (option 1), delayed antibiotics with reported use (option 2) and delayed
antibiotics that have not been used or no antibiotics offered (option 3). All three options account for
TABLE 26 Treatment costs (2017/18 price year)
Treatment costs
Mean
cost (£) SE (£) Distribution Source
GP consultation (9.22 minutes) 37.4 1.91 Gamma PSSRU unit costs 201790
Antibiotic (phenoxymethylpenicillin 250 mg,
28-tablet pack)
0.91 0.046 Gamma BNF 74 (2017)91
Pain relief (paracetamol 500 mg, 32-tablet pack) 0.74 0.037 Gamma BNF 74 (2017)91
Throat culture (swab) 8.00 0.41 Gamma NHS Reference Costs 2017/1892
Penicillin-induced rash [switch to 500mg of
erythromycin (Erythrocin®; ADVANZ Pharma,
London, UK)]
10.00 0.51 Gamma BNF 74 (2017)91
Treatment costs: sepsis 1744.64 89.01 Gamma Derived from data reported in
Hex et al. (2017)93
Treatment modality costs (assumptions)
Treatment option 1 (usual-care and intervention
arms) and option 2 (usual-care arm): assume
immediate/delayed antibiotics (£0.91) at initial
consultation (£37.43); 14.2% reconsultations
during which patients get paracetamol (£5.42)
plus weighted treatment costs penicillin side
effects (£1.12 per patient)
44.89 Derived from other treatment
costs
Treatment option 2 (intervention arm):
assume that antibiotics (£0.91) given at initial
consultation (£37.43); 14.2% reconsultations
during which patients get paracetamol (£5.42),
weighted treatment costs penicillin side effects
(£1.12 per patient) and confirmatory culture (£8)
52.89 Derived from other treatment
costs
Treatment option 3 (usual-care arm): assume
paracetamol (£0.74) at initial consultation
(£37.43) and delayed antibiotic use among the
14.2% attending repeat consultation (£5.60)
43.78 Derived from other treatment
costs
Treatment option 3 (intervention arm): assume
paracetamol (£0.74) at initial consultation
(£37.43), delayed antibiotic use among the
14.2% attending repeat consultation (£5.60) and
confirmatory throat culture (£8)
51.77 Derived from other treatment
costs
Complication of strep A costs
Treatment costs: abscess 1571.28 80 Gamma NHS Reference Costs 2017/1892
[tonsillectomy, 19 years and
over (HRG code CA60A)]
Treatment costs: acute rheumatic fever 1772.44 90.43 Gamma NHS Reference Costs 2017/1892
[other acquired cardiac
conditions with a CC score of
6–8 (HRG code EB14C)]
BNF, British National Formulary; CC, complications and comorbidities; HRG, Healthcare Resource Group;
PSSRU, Personal Social Services Research Unit; SE, standard error.
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repeat GP consultations at 14.2%6 over the modelled time horizon, with a typical GP consultation
lasting 9.22 minutes at an average cost of £4.02 per minute90 and pain relief (500 mg of paracetamol)
costing £0.74 per 32-tablet pack,91 but the options differed in the way that antibiotics are prescribed.
Under options 1 and 2, patients incur a cost of antibiotics at £0.91 per treatment course
(phenoxymethylpenicillin 250 mg, 28-tablet pack)91 and costs associated with managing adverse effects
of penicillin: penicillin-induced rash [assumed to be seen by GP at additional expense (£4.02 per
minute) and switched to erythromycin 500 mg at £10 per treatment course91 weighted by 0.02, the
probability of a rash] and penicillin-induced anaphylaxis [estimated at £1744 based on data reported in
a 2017 cost of sepsis study93 (see Table 26) weighted by 0.0001, the probability of sepsis].78 No costs
associated with antibiotic use are included under option 3 (delayed antibiotics prescription given but
not used); however, we assume that 14.2% of patients attended a repeat consultation86 and will use the
delayed antibiotics prescription under this option.
Confirmatory swab culture costing £892 was added to options 2 and 3 for patients with a negative test
result (intervention only) but not to option 1, as patients with a positive test result receive immediate
antibiotics. On average, the estimated treatment costs based on these assumptions and a repeat
consultation rate of 14.2% were £44.89 (option 1: intervention and usual-care arms; option 2: usual-
care arm), £52.89 (option 2: intervention arm including confirmatory culture costs), £43.78 (option 3:
usual-care arm) and £51.77 (option 3: intervention arm including confirmatory culture costs)
(see Table 26).
The cost of sepsis was estimated to be £1744 based on data reported in a study,93 which estimated
that 93,973 adults would need treatment for sepsis in UK hospitals, at an annual total cost of
£163,949,055 (see Table 26). The cost of treating strep A-related abscess was estimated at £1571
based on the NHS reference cost for a tonsillectomy in adults aged ≥ 19 years with a Healthcare
Resource Group code of CA60A.92 The cost of treating acute rheumatic fever was estimated at
£1772.44 based on the NHS reference cost for other acquired cardiac conditions with a CC
(complications and comorbidities) score of 6–8 and a Healthcare Resource Group code EB14C.92
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was conducted to explore the impact of parameter uncertainty
on base-case cost-effectiveness of point-of-care testing for strep A infection. The PSA was implemented
via Monte Carlo simulations involving 1000 draws for all model inputs except for the acquisition costs of
the tests, which were entered as deterministic values. This enabled us to simulate 1000 replicates of the
base-case ICER (displayed on cost-effectiveness planes) and calculate the probability of cost-effectiveness
at threshold values ranging from £0 to £100,000 per QALY gained (CEACs). The sensitivity and specificity
of the clinical scoring algorithm and individual point-of-care tests were assumed to be drawn from
separate normal distributions on the logit scale, as the relatively small number of studies reporting
test-specific accuracy data precluded joint synthesis of sensitivity and specificity and estimation of
the between-study correlation (see Tables 20 and 21). Prevalence, probabilities and utility values (see
Tables 22–24) were assumed to be drawn from a beta distribution reflecting scale of measurement for
quantities constrained to lie in the interval 0–1. Costs were assigned a gamma distribution to reflect the
distribution of health-care costs, which cannot be less than 0 and are typically highly skewed to the right
due to a smaller number of individuals incurring high costs. Generally, the uncertainty surrounding input
parameters [standard errors (SEs) and CIs] was not available; therefore, we assumed a 10% of the mean
as equivalent to lower and upper 95% confidence limits and calculated the SEs assuming approximate
normal distribution.
Base-case analyses
The main base-case model was based on the adult population in a primary care setting. This model was
then adapted for adults in a secondary care setting, for children in a primary care setting and for
children in a secondary care setting.
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Adult primary care model: base-case analysis results
The base-case cost-effectiveness results for adults treated in primary care are presented in Table 27 for
14 of the 21 tests for which test accuracy and cost data were available. The rate at which incremental
QALYs accrued over the 1-year modelled time horizon was small; thus, estimates of simulated costs and
QALYs were multiplied by 1000 to aid clarity in presentation of incremental estimates in the result tables
and texts. The mean simulated costs under base-case assumptions were £49,147 per 1000 individuals
treated in primary care under usual-care practice, and ranged from £54,394 per 1000 individuals in the
test group using the NADAL Strep A – test strip (nal von minden GmbH) to £71,277 per 1000 individuals
using the cobas Liat Strep A Assay (Roche Diagnostics). The corresponding estimated mean QALYs were
859.825 per 1000 individuals under usual-care practice, and ranged between 859.821 QALYs per 1000
individuals in the intervention group using Abbott Laboratories’ Clearview Exact Strep A cassette or test
strip to 859.829 QALYs per 1000 individuals using Cepheid’s Xpert Xpress Strep A tests. In terms of
incremental cost-effectiveness, the base-case estimates suggest that usual care was cheaper and
generated marginally more QALYs than (and therefore dominated) the cassette and strip versions of
Abbott Laboratories’ Clearview Exact Strep A test. ICERs for the remaining 12 tests suggest that testing
was more costly and more effective than usual care, with ICERs ranging from £1,353,677 per QALY
gained for nal von minden GmbH’s NADAL Strep A test strip to £6,059,081 per QALY gained for Roche
Diagnostics’ cobas Liat Strep A Assay compared with usual care.
Adult primary care model: probabilistic sensitivity analyses
Table 28 presents probabilistic estimates for adults presenting in primary care. The probabilistic
estimates were very similar to the deterministic base-case results, with ICERs indicating that usual care
dominated two (the Clearview Exact Strep A cassette and the Clearview Exact Strep A dipstick – test
strip supplied by Abbott Laboratories) of the 14 tests considered in the economic modelling. Base-case
probabilistic ICERs for the remaining 11 tests ranged from £1,495,402 per QALY gained for NADAL
Strep A plus – test strip supplied by nal von minden GmbH to £6,498,666 per QALY gained for cobas
Liat Strep A Assay supplied by Roche Diagnostics. The probability for testing to be cost-effective was
zero at a cost-effectiveness threshold of £20,000 per QALY gained under the base-case assumptions
and model inputs regardless of the point-of-care test used in comparison with usual care.
Adult primary care model: exploratory sensitivity analyses
Exploratory analyses were conducted to test the robustness of the economic base-case estimates for
adults presenting in primary care with suspected strep A. The base-case ICERs are highly sensitive to
various modelling assumptions and input values. In the sections that follow, sensitivity analysis results
are presented for only those tests for which the ICER is sensitive to the alternative modelling
assumptions and parameter inputs (as indicated by changes in the direction of incremental costs or
incremental QALYs compared with usual care). See Appendix 9 for more detail.
Adult secondary care model: base-case analysis results
The primary care adult model (see Model structure) was adapted to model adult patients presenting with
suspected strep A infection in secondary care settings (urgent care/walk-in centres and emergency
departments). The modelled pathways remain the same as the adult primary care model depicted in
Figures 12–14. Sensitivity and specificity of the clinical score at the specified Centor score of ≥ 3 points
for a positive strep A infection were left unchanged as in the adult primary care model (see Table 20),
as were the modelled pathway probabilities (see Table 23) and health state utility values (see Table 24).
However, the two models differ in the way that treatment and testing costs are calculated. The secondary
care model assumes that the care pathways associated with suspected cases of strep A infections are
presenting for the first time in secondary care and have not received any treatment in primary care. The
cost of the initial GP consultation included in the adult primary care model is, therefore, excluded from
the cost. However, the model does account for patients attending a GP consultation (and the associated
costs) following hospital discharge at a rate equal to the proportion attending repeat GP consultations in
the primary care model (14.2% based on figures reported in Little et al.86). In addition, we assume that
point-of-care testing within secondary care settings can be carried out within the standard allocated time
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TABLE 27 Adult primary care model: base-case cost-effectiveness results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
cost (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£) vs.
usual care
Usual care (clinical scoring
based on Centor ≥ 3 points
plus clinical assessment)
49,147 859.82458955 0 0.0000000 –
1 Clearview Exact Strep A
cassette (Abbott Laboratories)
56,180 859.82063008 7033 –0.0039595 Dominated
2 Clearview Exact Strep A
dipstick – test strip (Abbott
Laboratories)
55,980 859.82063008 6833 –0.0039595 Dominated
3 BD Veritor Plus system group
A Strep Assay – cassette
(Becton Dickinson)
4 Strep A Rapid Test – cassette
(Biopanda Reagents)
55,442 859.82769587 6295 0.0031063 2,026,496
5 Strep A Rapid Test – test strip
(Biopanda Reagents)a
55,397 859.82769587 6250 0.0031063 2,012,006
6 NADAL Strep A – test strip
(nal von minden GmbH)
54,394 859.82846603 5248 0.0038765 1,353,677
7 NADAL Strep A – cassette
(nal von minden GmbH)
54,444 859.82846603 5298 0.0038765 1,366,577
8 NADAL Strep A plus – cassette
(nal von minden GmbH)
54,469 859.82846603 5323 0.0038765 1,373,029
9 NADAL Strep A plus – test
strip (nal von minden GmbH)
54,419 859.82846603 5273 0.0038765 1,360,126
10 NADAL Strep A scan test –
cassette (nal von minden
GmbH)
54,584 859.82846603 5438 0.0038765 1,402,700
11 OSOM Strep A test – test
strip (Sekisui Diagnostics)
12 QuikRead Go Strep A test kit
(Orion Diagnostica)
56,083 859.82810269 6936 0.0035131 1,974,319
13 Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories)
54,781 859.82751669 5634 0.0029271 1,924,717
14 bioNexia Strep A plus –
cassette (bioMérieux)
15 bioNexia Strep A dipstick –
test strip (bioMérieux)
16 Biosynex Strep A – cassette
(Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott
Laboratories)
19 Alere i Strep A 2 (Abbott
Laboratories)
59,837 859.82824206 10,691 0.0036525 2,926,915
20 cobas Liat Strep A Assay
(Roche Diagnostics)
71,277 859.82824206 22,131 0.0036525 6,059,081
21 Xpert Xpress Strep A (Cepheid) 63,323 859.82854357 14,177 0.0039540 3,585,436
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip not available; assumed that the strip has
the same test accuracy as the cassette version of the test.
Note
Missing cost-effectiveness estimates are for the tests where either test accuracy or cost data were not available.
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TABLE 28 Adult primary care model: PSA results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
costs (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£)
vs. usual care
Probability of
cost-effectiveness at
£20,000 per QALY
Usual care (clinical scoring based on Centor ≥ 3 points plus clinical
assessment)
49,295 861.0209476 0 0.0000000 1
1 Clearview Exact Strep A cassette (Abbott Laboratories) 56,387 861.0168718 7092 –0.0040758 Dominated 0
2 Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) 56,183 861.0169652 6888 –0.0039824 Dominated 0
3 BD Veritor Plus system group A Strep Assay – cassette
(Becton Dickinson)
4 Strep A Rapid Test – cassette (Biopanda Reagents) 55,636 861.0239908 6341 0.0030432 2,083,738 0
5 Strep A Rapid Test – test strip (Biopanda Reagents)a 55,590 861.0239997 6295 0.0030521 2,062,510 0
6 NADAL Strep A – test strip (nal von minden GmbH) 54,582 861.0244537 5288 0.0035061 1,508,134 0
7 NADAL Strep A – cassette (nal von minden GmbH) 54,634 861.0243797 5339 0.0034321 1,555,613 0
8 NADAL Strep A plus – cassette (nal von minden GmbH) 54,658 861.0244709 5363 0.0035233 1,522,258 0
9 NADAL Strep A plus – test strip (nal von minden GmbH) 54,607 861.0245002 5313 0.0035526 1,495,402 0
10 NADAL Strep A scan test – cassette (nal von minden GmbH) 54,775 861.0244341 5480 0.0034865 1,571,686 0
11 OSOM Strep A test – test strip (Sekisui Diagnostics)
12 QuikRead Go Strep A test kit (Orion Diagnostica) 56,273 861.0244144 6978 0.0034668 2,012,942 0
13 Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) 54,968 861.0237881 5673 0.0028405 1,997,326 0
14 bioNexia Strep A plus – cassette (bioMérieux)
15 bioNexia Strep A dipstick – test strip (bioMérieux)
16 Biosynex Strep A – cassette (Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott Laboratories)
19 Alere i Strep A 2 (Abbott Laboratories) 60,056 861.0244146 10,761 0.0034670 3,103,806 0
20 cobas Liat Strep A Assay (Roche Diagnostics) 71,565 861.0243746 22,271 0.0034270 6,498,666 0
21 Xpert Xpress Strep A (Cepheid) 63,581 861.0248804 14,286 0.0039328 3,632,549 0
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip not available; assumed that the strip has the same test accuracy as the cassette version of the test.
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for most hospital-based appointments, such that no additional time is required for administering and
processing test results.
Test accuracy estimates were obtained from our systematic review and remained broadly the same as
those used to inform the adult primary care model (see Table 21) except for three tests (OSOM Strep
A test strip, QuikRead Go Strep A test kit and the Alere TestPack +Plus Strep A – cassette). Table 29
presents test accuracy estimates used in the adult secondary care model for these three point-of-care
tests. Estimates of sensitivity changed from 0.92 in primary care to 0.94 in secondary care for the
OSOM Strep A test strip, from 1.00 in primary care to 0.87 in secondary care for the QuikRead Go
Strep A test kit and from 0.95 in primary care to 0.90 in secondary care for the Alere TestPack +Plus
Strep A – cassette. However, estimates of specificity for the three tests remain broadly unchanged
across primary and secondary care settings.
Table 30 presents the cost-effectiveness results for adults in a secondary care setting. As with the
adult primary care model, only 14 of the 21 tests that have test accuracy and costs data have been
included in this analysis. The pattern and direction of cost-effectiveness in the secondary care adult
model are similar to what has been observed in the adult primary care model, although the ICERs were
generally lower in the secondary care model.
Two tests (Abbotts Laboratories’ Clearview Exact Strep A cassette and Clearview Exact Strep A dipstick
– test trip) generated fewer QALYs than usual care and produced ICERs indicating being dominated by
usual care (i.e. were less effective and more costly). The remaining 12 tests all generated marginally
more QALYs than usual care. The ICERs ranged from £44,184 per QALY gained for NADAL Strep A –
test strip (nal von minden GmbH) to £12,700,432 per QALY gained for the QuikRead Go Strep A test kit
supplied by Orion Diagnostica.
Adult secondary care model: probabilistic sensitivity analyses
Probabilistic results for the adult secondary care model mirrored the adult primary care PSA model.
Results are shown in Table 31.
Adult secondary care model: exploratory sensitivity analyses
Exploratory analyses were conducted to test the robustness of the economic base-case estimates for
adults presenting in secondary care with suspected strep A infection. The base-case ICERs are highly
sensitive to various modelling assumptions and input values. In the sections that follow, sensitivity
analysis results are presented for only those tests for which the ICER is sensitive to the alternative
modelling assumptions and parameter inputs (as indicated by changes in the direction of incremental
costs or incremental QALYs compared with usual care). See Appendix 10 for more detail.
TABLE 29 Adult secondary care model: test accuracy of point-of-care tests used in the economic model
Test name
Sensitivity
(95% CI)
Specificity
(95% CI)
Assumed
distribution
Data source (first author
and year of publication)
OSOM Strep A test – test
strip (Sekisui Diagnostics)
0.94 (0.89 to 0.98) 0.95 (0.91 to 0.98) Normal (logit) Five studies (Bura 2017,36
Llor 2009,44 Llor 2011,45
Rogo 201149 and
Weinzierl 201854)
QuikRead Go Strep A test
kit (Orion Diagnostica)
0.87 (0.78 to 0.95) 0.78 (0.71 to 0.85) Normal (logit) Two studies (Azrad 201934
and Stefaniuk 201752)
Alere TestPack +Plus Strep
A – cassette (Abbott
Laboratories)
0.90 (0.86 to 0.94) 0.95 (0.92 to 0.96) Normal (logit) One study (Rosenberg
200250) and one abstract
(Valverde 201858)
Only tests with secondary care accuracy estimates that are different from those used to inform the adult primary care
model are presented in this table.
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TABLE 30 Adult secondary care model: base-case cost-effectiveness results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
cost (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£) vs.
usual care
Usual care (clinical scoring based
on Centor ≥ 3 points plus clinical
assessment)
49,147 859.82458955 0 0.0000000
1 Clearview Exact Strep A cassette
(Abbott Laboratories)
51,103 859.82063008 1957 –0.0039595 Dominated
2 Clearview Exact Strep A dipstick
– test strip (Abbott Laboratories)
50,903 859.82063008 1757 –0.0039595 Dominated
3 BD Veritor Plus system group A
Strep Assay – cassette (Becton
Dickinson)
4 Strep A Rapid Test – cassette
(Biopanda Reagents)
50,365 859.82769587 1219 0.0031063 392,342
5 Strep A Rapid Test – test strip
(Biopanda Reagents)a
50,320 859.82769587 1174 0.0031063 377,852
6 NADAL Strep A – test strip
(nal von minden GmbH)
49,318 859.82846603 171 0.0038765 44,184
7 NADAL Strep A – cassette
(nal von minden GmbH)
49,368 859.82846603 221 0.0038765 57,085
8 NADAL Strep A plus – cassette
(nal von minden GmbH)
49,393 859.82846603 246 0.0038765 63,537
9 NADAL Strep A plus – test strip
(nal von minden GmbH)
49,343 859.82846603 196 0.0038765 50,636
10 NADAL Strep A scan test –
cassette (nal von minden GmbH)
49,508 859.82846603 361 0.0038765 93,211
11 OSOM Strep A test – test strip
(Sekisui Diagnostics)
12 QuikRead Go Strep A test kit
(Orion Diagnostica)
51,136 859.82474622 1990 0.0001567 12,700,432
13 Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories)
49,713 859.82627789 566 0.0016883 335,358
14 bioNexia Strep A plus – cassette
(bioMérieux)
15 bioNexia Strep A dipstick – test
strip (bioMérieux)
16 Biosynex Strep A – cassette
(Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott
Laboratories)
19 Alere i Strep A 2 (Abbott
Laboratories)
54,761 859.82824206 5614 0.0036525 1,537,126
20 cobas Liat Strep A Assay
(Roche Diagnostics)
65,186 859.82824206 16,039 0.0036525 4,391,332
21 Xpert Xpress Strep A (Cepheid) 51,141 859.82854357 1994 0.0039540 504,287
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip
has the same test accuracy as the cassette version of the test.
Note
Missing cost-effectiveness estimates are for the tests where either test accuracy or cost data were not available.
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TABLE 31 Adult secondary care model: PSA results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
cost (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£)
vs. usual care
Probability of
cost-effectiveness at
£20,000 per QALY
Usual care (clinical scoring based on Centor ≥ 3 points plus clinical
assessment)
49,182 860.0288998 0 0.0000000 1
1 Clearview Exact Strep A cassette (Abbott Laboratories) 51,128 860.0249274 1947 –0.0039724 Dominated 0
2 Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) 50,924 860.024949 1743 –0.0039508 Dominated 0
3 BD Veritor Plus system group A Strep Assay – cassette (Becton
Dickinson)
4 Strep A Rapid Test – cassette (Biopanda Reagents) 50,416 860.0319673 1234 0.0030675 402,358 0
5 Strep A Rapid Test – test strip (Biopanda Reagents)a 50,370 860.0319912 1188 0.0030914 384,360 0
6 NADAL Strep A – test strip (nal von minden GmbH) 49,358 860.0323456 177 0.0034458 51,324 0
7 NADAL Strep A – cassette (nal von minden GmbH) 49,408 860.0324406 226 0.0035408 63,963 0
8 NADAL Strep A plus – cassette (nal von minden GmbH) 49,433 860.0324859 251 0.0035860 70,042 0
9 NADAL Strep A plus – test strip (nal von minden GmbH) 49,382 860.032473 201 0.0035731 56,186 0
10 NADAL Strep A scan test – cassette (nal von minden GmbH) 49,550 860.0324781 368 0.0035783 102,876 0
11 OSOM Strep A test – test strip (Sekisui Diagnostics)
12 QuikRead Go Strep A test kit (Orion Diagnostica) 51,187 860.0289465 2005 0.0000467 42,951,995 0
13 Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) 49,754 860.0306084 573 0.0017086 335,098 0
14 bioNexia Strep A plus – cassette (bioMérieux)
15 bioNexia Strep A dipstick – test strip (bioMérieux)
16 Biosynex Strep A – cassette (Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott Laboratories)
19 Alere i Strep A 2 (Abbott Laboratories) 54,870 860.0323487 5688 0.0034488 1,649,300 0
20 cobas Liat Strep A Assay (Roche Diagnostics) 65,430 860.0322608 16,248 0.0033610 4,834,450 0
21 Xpert Xpress Strep A (Cepheid) 51,204 860.0328714 2022 0.0039715 509,167 0
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip has the same test accuracy as the cassette version of the test.
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Children’s primary care model: base-case results
The primary care adult model (see Model structure) was adapted to model children presenting with
suspected strep A infection in a primary care setting. The modelled pathways remain the same as the
adult primary care model depicted in Figures 12–14. The prevalence of strep A changed from 22.6%
in the adult primary care model to 30.2%, the median prevalence in our systematic review of test
accuracy studies among children in primary care settings (see Table 22). Sensitivity and specificity of
the clinical score at the specified Centor score of ≥ 3 points for a positive strep A infection were left
unchanged (see estimates displayed in Table 20), as well as the modelled pathway probabilities (see
Table 23) and health-state utility values (see Table 24). Test accuracy estimates were obtained from our
systematic review and remained broadly the same as those used to inform the adults in primary care
model (see Table 21) except for five tests (BD Veritor Plus system group A Strep Assay – cassette
supplied by Becton Dickinson, OSOM Strep A test – test strip supplied by Sekisui Diagnostics,
QuikRead Go Strep A test kit by Orion Diagnostica and Alere TestPack +Plus Strep A – cassette and
Alere i Strep A both supplied by Abbott Laboratories). See Table 21 for further details.
Treatment costs for peritonsillar abscess and related complications of strep A infection in children
were estimated at £1420.50 (tonsillectomy, aged ≤ 18 years, with Healthcare Resource Group code
CA60B);92 this is slightly lower than the estimate used in the adult primary care model for these
complications (£1571.28 for tonsillectomy, aged ≥ 19 years, with Healthcare Resource Group code
CA60A).92 Treatment costs for penicillin-induced rash were left unchanged as in the adult models
at £10 (assuming that treatment switched to another antibiotic, e.g. 500 mg of erythromycin), and
anaphylaxis was £1744.64.93
Overall, 14 of the 21 tests were included in the child primary care model. Cost-effectiveness estimates
for these tests compared with usual care are presented in Table 32. Simulated mean costs and QALYs
were multiplied by 1000 to aid clarity in presentation because of the small number of QALYs accrued
over a 1-year time horizon. The base-case cost-effectiveness for children presenting in primary care
largely mirrored that for the adult population. However, because of the slightly higher prevalence of
strep A in children (30.2%) than in adults (22.6%), simulated costs over the 1-year time horizon were
generally higher in the children’s model than those in the adult primary care model.
The mean costs simulated under base-case assumptions were £50,185 (£49,147 in the adult primary care
model) per 1000 children treated in primary care under usual-care practice and ranged from £55,952
(£54,394 in the adult primary care model) per 1000 children for NADAL Strep A – test strip (nal von
minden GmbH) to £74,425 (£71,277 adult primary care model) per 1000 children treated in primary
care for cobas Liat Strep A Assay supplied by Roche Diagnostics. Simulated QALYs were also higher for
children treated in primary care than for adults because of the higher baseline utility in children (0.94),
compared with a utility norm of 0.863 for adults in the UK. Simulated mean QALYs were 939.7702
(859.8246 in the adult primary care model) for children treated in primary care under usual-care practice
and ranged from 939.7631 (859.8206 adult primary care model) for Abbott Laboratories’ Clearview Exact
Strep A test cassette and strip to 939.7737 (859.8285 in the adult primary care model) for the other tests.
In terms of incremental cost-effectiveness, the base-case estimates suggest that usual care was cheaper and
generated marginally more QALYs than (and therefore dominated) the QuikRead Go Strep A test kit (Orion
Diagnostica), the cassette and strip versions of the Clearview Exact Strep A test cassette supplied by Abbott
Laboratories and the Alere TestPack +Plus Strep A – cassette also supplied by Abbott Laboratories. ICERs
for the remaining 10 tests suggest that testing for children in primary care under base-case assumptions
produced ICERs ranging from £1,762,306 per QALY gained for NADAL Strep A – test strip (nal von minden
GmbH) to £7,893,857 per QALY gained for the Xpert Xpress Strep A by Cepheid compared with usual care.
Children’s primary care model: probabilistic sensitivity analyses
Probabilistic results for the children’s primary care model are shown in Table 33 and are in line with
the deterministic results for the children’s primary care model.
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TABLE 32 Children’s primary care model: base-case cost-effectiveness results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 10,000
individuals
Incremental
cost (£)
per 10,000
individuals
Incremental
QALYs
per 10,000
individuals
ICER (£) vs.
usual care
Usual care (clinical scoring based
on Centor ≥ 3 points plus clinical
assessment)
50,185 939.77019917 0 0.0000000
1 Clearview Exact Strep A cassette
(Abbott Laboratories)
57,773 939.76305927 7588 –0.0071399 Dominated
2 Clearview Exact Strep A dipstick –
test strip (Abbott Laboratories)
57,554 939.76305927 7369 –0.0071399 Dominated
3 BD Veritor Plus system group A
Strep Assay – cassette (Becton
Dickinson)
4 Strep A Rapid Test – cassette
(Biopanda Reagents)
56,899 939.77244279 6715 0.0022436 2,992,743
5 Strep A Rapid Test – test strip
(Biopanda Reagents)a
56,850 939.77244279 6665 0.0022436 2,970,792
6 NADAL Strep A – test strip (nal
von minden GmbH)
55,952 939.77347194 5768 0.0032728 1,762,306
7 NADAL Strep A – cassette (nal von
minden GmbH)
56,007 939.77347194 5822 0.0032728 1,779,026
8 NADAL Strep A plus – cassette (nal
von minden GmbH)
56,035 939.77347194 5850 0.0032728 1,787,386
9 NADAL Strep A plus – test strip
(nal von minden GmbH)
55,980 939.77347194 5795 0.0032728 1,770,666
10 NADAL Strep A scan test –
cassette (nal von minden GmbH)
56,160 939.77347194 5976 0.0032728 1,825,846
11 OSOM Strep A test – test strip
(Sekisui Diagnostics)
12 QuikRead Go Strep A test kit
(Orion Diagnostica)
58,012 939.76701428 7827 –0.0031849 Dominated
13 Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories)
56,389 939.76939575 6204 –0.0008034 Dominated
14 bioNexia Strep A plus – cassette
(bioMérieux)
15 bioNexia Strep A dipstick – test
strip (bioMérieux)
16 Biosynex Strep A – cassette
(Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott
Laboratories)
19 Alere i Strep A 2 (Abbott
Laboratories)
61,907 939.77326996 11,722 0.0030708 3,817,336
20 cobas Liat Strep A Assay
(Roche Diagnostics)
74,425 939.77326996 24,240 0.0030708 7,893,857
21 Xpert Xpress Strep A (Cepheid) 65,521 939.77368771 15,336 0.0034885 4,396,205
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip
has the same test accuracy as the cassette version of the test.
Note
Missing cost-effectiveness estimates are for the tests where either test accuracy or cost data were not available.
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TABLE 33 Children’s primary care model: PSA results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
cost (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£)
vs. usual care
Probability of
cost-effectiveness at
£20,000 per QALY
Usual care (clinical scoring based on Centor ≥ 3 points plus clinical
assessment)
50,204 940.0932608 0 0.0000000 1
1 Clearview Exact Strep A cassette (Abbott Laboratories) 57,887 940.0862286 7683 –0.0070321 Dominated 0
2 Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) 57,668 940.0862027 7464 –0.0070580 Dominated 0
3 BD Veritor Plus system group A Strep Assay – cassette (Becton
Dickinson)
4 Strep A Rapid Test – cassette (Biopanda Reagents) 57,016 940.0954301 6812 0.0021694 3,140,063 0
5 Strep A Rapid Test – test strip (Biopanda Reagents)a 56,964 940.0955022 6760 0.0022415 3,015,747 0
6 NADAL Strep A – test strip (nal von minden GmbH) 56,046 940.0960689 5841 0.0028082 2,080,115 0
7 NADAL Strep A – cassette (nal von minden GmbH) 56,101 940.0960859 5897 0.0028251 2,087,246 0
8 NADAL Strep A plus – cassette (nal von minden GmbH) 56,128 940.0961173 5924 0.0028566 2,073,823 0
9 NADAL Strep A plus – test strip (nal von minden GmbH) 56,073 940.0961534 5869 0.0028927 2,028,782 0
10 NADAL Strep A scan test – cassette (nal von minden GmbH) 56,255 940.0961639 6051 0.0029031 2,084,258 0
11 OSOM Strep A test – test strip (Sekisui Diagnostics)
12 QuikRead Go Strep A test kit (Orion Diagnostica) 58,149 940.0895996 7944 –0.0036612 Dominated 0
13 Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) 56,482 940.0924978 6278 –0.0007629 Dominated 0
14 bioNexia Strep A plus – cassette (bioMérieux)
15 bioNexia Strep A dipstick – test strip (bioMérieux)
16 Biosynex Strep A – cassette (Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott Laboratories)
19 Alere i Strep A 2 (Abbott Laboratories) 62,058 940.0960474 11,854 0.0027866 4,253,800 0
20 cobas Liat Strep A Assay (Roche Diagnostics) 74,704 940.0960301 24,500 0.0027693 8,846,880 0
21 Xpert Xpress Strep A (Cepheid) 65,741 940.096771 15,536 0.0035102 4,426,070 0
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip has the same test accuracy as the cassette version of the test.
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Children’s primary care model: exploratory sensitivity analyses
Exploratory analyses were conducted to test the robustness of economic base-case estimates for
children presenting in primary care with suspected strep A infection. The base-case ICERs are highly
sensitive to various modelling assumptions and input values. In the sections that follow, sensitivity
analysis results are presented for only those tests for which the ICER is sensitive to the alternative
modelling assumptions and parameter inputs (as indicated by changes in the direction of incremental
costs or incremental QALYs compared with usual care). See Appendix 11 for more detail.
Children in secondary care: base-case analysis results
The models for adults in secondary care (see Adult secondary care model: base-case analysis results) and
children in primary care (see Children’s primary care model: base-case results) were adapted to model
suspected strep A infection among children in secondary care settings (urgent care/walk-in centres
and emergency departments). The modelled pathways remain the same as depicted in Figures 12–14.
The prevalence rate was maintained at 30.2%, as in the children’s primary care model. Test accuracy
estimates obtained from our systematic review remained broadly the same as those used to inform
the primary care models except for six tests [BD Veritor Plus system group A Strep Assay – cassette
(Becton Dickinson), OSOM Strep A test – test strip (Sekisui Diagnostics), QuikRead Go Strep A test kit
(Orion Diagnostica), Alere TestPack +Plus Strep A – cassette (Abbott Laboratories), Alere i Strep A
(Abbott Laboratories) and Xpert Xpress Strep A (Cepheid)]. Table 34 presents test accuracy estimates
used in the children’s secondary care model for these tests.
Table 35 presents cost-effectiveness estimates for children treated in secondary care. As with the
adult primary care model, only 14 of the 21 tests that have test accuracy and costs data are included
in this analysis. The base-case estimates suggest that usual care was cheaper and generated marginally
more QALYs than (and therefore dominated) four tests [Clearview Exact Strep A cassette (Abbott
Laboratories), Clearview Exact Strep A dipstick – test strip (Abbott Laboratories), QuikRead Go Strep A
test kit (Orion Diagnostica) and Alere TestPack +Plus Strep A – cassette (Abbott Laboratories)]. ICERs
for the remaining tests suggest that testing was more costly and more effective than usual care, with
ICERs ranging from £65,122 per QALY gained for the NADAL Strep A – test strip (nal von minden
GmbH) to £5,723,279 per QALY gained for cobas Liat Strep A Assay (Roche Diagnostics) compared
with usual care.
Children’s secondary care model: probabilistic sensitivity analyses
Probabilistic results for the children’s secondary care model mirrored the children primary care PSA
model. Results are shown in Table 36.
TABLE 34 Children’s secondary care model: test accuracy of point-of-care tests used in the economic model
Test name
Sensitivity
(95% CI)
Specificity
(95% CI)
Assumed
distribution
Data source
(first author and year)
OSOM Strep A test – test
strip (Sekisui Diagnostics)
0.94 (0.89 to 0.98) 0.97 (0.95 to 0.99) Normal (logit) Two studies (Rogo 201149
and Weinzierl 201854)
QuikRead Go Strep A test
kit (Orion Diagnostica)
0.87 (0.78 to 0.95) 0.78 (0.71 to 0.85) Normal (logit) Two studies (Azrad 201934
and Stefaniuk 201752)
Alere TestPack +Plus Strep
A – cassette (Abbott
Laboratories)
0.77 (0.73 to 0.8) 0.97 (0.93 to 0.99) Normal (logit) Four studies (Kurtz 2000,42
Lacroix 2018,23 Penney
201648 and Santos 200351)
Only tests with secondary care accuracy estimates that are different from those used to inform the children’s primary
care model are presented here.
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TABLE 35 Children’s secondary care model: base-case cost-effectiveness results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 10,000
individuals
Incremental
cost (£)
per 10,000
individuals
Incremental
QALYs
per 10,000
individuals
ICER (£) vs.
usual care
Usual care (clinical scoring based
on Centor ≥ 3 points plus clinical
assessment)
50,185 939.77019917 0 0.0000000
1 Clearview Exact Strep A cassette
(Abbott Laboratories)
52,219 939.76305927 2034 –0.0071399 Dominated
2 Clearview Exact Strep A dipstick
– test strip (Abbott Laboratories)
52,000 939.76305927 1815 –0.0071399 Dominated
3 BD Veritor Plus system group A
Strep Assay – cassette
(Becton Dickinson)
4 Strep A Rapid Test – cassette
(Biopanda Reagents)
51,345 939.77244279 1160 0.0022436 517,066
5 Strep A Rapid Test – test strip
(Biopanda Reagents)a
51,296 939.77244279 1111 0.0022436 495,115
6 NADAL Strep A – test strip
(nal von minden GmbH)
50,398 939.77347194 213 0.0032728 65,122
7 NADAL Strep A – cassette
(nal von minden GmbH)
50,453 939.77347194 268 0.0032728 81,845
8 NADAL Strep A plus – cassette
(nal von minden GmbH)
50,480 939.77347194 295 0.0032728 90,205
9 NADAL Strep A plus – test strip
(nal von minden GmbH)
50,425 939.77347194 240 0.0032728 73,482
10 NADAL Strep A scan test –
cassette (nal von minden GmbH)
50,606 939.77347194 421 0.0032728 128,662
11 OSOM Strep A test – test strip
(Sekisui Diagnostics)
12 QuikRead Go Strep A test kit
(Orion Diagnostica)
52,457 939.76701428 2273 –0.0031849 Dominated
13 Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories)
50,834 939.76939575 649 –0.0008034 Dominated
14 bioNexia Strep A plus – cassette
(bioMérieux)
15 bioNexia Strep A dipstick –
test strip (bioMérieux)
16 Biosynex Strep A – cassette
(Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott
Laboratories)
19 Alere i Strep A 2 (Abbott
Laboratories)
56,353 939.77326996 6168 0.0030708 2,008,522
20 cobas Liat Strep A Assay
(Roche Diagnostics)
67,760 939.77326996 17,575 0.0030708 5,723,279
21 Xpert Xpress Strep A (Cepheid) 52,190 939.77368771 2006 0.0034885 574,900
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip
has the same test accuracy as the cassette version of the test.
Note
Missing cost-effectiveness estimates are for the tests where either test accuracy or cost data were not available.
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TABLE 36 Children’s secondary care model: PSA results
Test ID Test name
Mean cost
(£) per 1000
individuals
Mean QALYs
per 1000
individuals
Incremental
cost (£)
per 1000
individuals
Incremental
QALYs
per 1000
individuals
ICER (£)
vs. usual care
Probability of
cost-effectiveness at
£20,000 per QALY
Usual care (clinical scoring based on Centor ≥ 3 points plus clinical
assessment)
50,000 940.2967868 0 0.0000000 1
1 Clearview Exact Strep A cassette (Abbott Laboratories) 51,783 940.2897117 1783 –0.0070750 Dominated 0
2 Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) 51,563 940.2897075 1563 –0.0070792 Dominated 0
3 BD Veritor Plus system group A Strep Assay – cassette
(Becton Dickinson)
4 Strep A Rapid Test – cassette (Biopanda Reagents) 51,138 940.2989313 1138 0.0021445 530,655 0
5 Strep A Rapid Test – test strip (Biopanda Reagents)a 51,088 940.2989679 1088 0.0021812 498,896 0
6 NADAL Strep A – test strip (nal von minden GmbH) 50,217 940.2996263 217 0.0028395 76,288 0
7 NADAL Strep A – cassette (nal von minden GmbH) 50,272 940.299611 272 0.0028243 96,309 0
8 NADAL Strep A plus – cassette (nal von minden GmbH) 50,299 940.2996798 299 0.0028931 103,485 0
9 NADAL Strep A plus – test strip (nal von minden GmbH) 50,245 940.2995732 245 0.0027865 87,781 0
10 NADAL Strep A scan test – cassette (nal von minden GmbH) 50,427 940.2995398 427 0.0027531 154,933 0
11 OSOM Strep A test – test strip (Sekisui Diagnostics)
12 QuikRead Go Strep A test kit (Orion Diagnostica) 52,132 940.2930891 2132 –0.0036976 Dominated 0
13 Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) 50,652 940.2959919 652 –0.0007948 Dominated 0
14 bioNexia Strep A plus – cassette (bioMérieux)
15 bioNexia Strep A dipstick – test strip (bioMérieux)
16 Biosynex Strep A – cassette (Biosynex)
17 Sofia Strep A FIA (Quidel)
18 Alere i Strep A (Abbott Laboratories)
19 Alere i Strep A 2 (Abbott Laboratories) 56,210 940.2995831 6210 0.0027963 2,220,667 0
20 cobas Liat Strep A Assay (Roche Diagnostics) 67,693 940.2994655 17,693 0.0026787 6,605,137 0
21 Xpert Xpress Strep A (Cepheid) 52,023 940.3002769 2023 0.0034902 579,711 0
a Test accuracy data for Biopanda Reagents’ Strep A Rapid Test – test strip were not available; assumed that the strip has the same test accuracy as the cassette version of the test.
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Children’s secondary care model: exploratory sensitivity analyses
Exploratory analyses were conducted to test the robustness of economic base-case estimates for
children presenting in secondary care with suspected strep A infection. The base-case ICERs are highly
sensitive to various modelling assumptions and input values. In the sections that follow, sensitivity
analysis results are presented for only those tests for which the ICER is sensitive to the alternative
modelling assumptions and parameter inputs (as indicated by changes in the direction of incremental
costs or incremental QALYs compared with usual care). See Appendix 12 for more detail.
Additional sensitivity analyses
Appendix 13, Table 64, displays the list of the 39 deterministic sensitivity analyses conducted to explore
the impact of alternative modelling assumptions and parameter inputs on base-case ICERs. In the
majority of cases, the ICERs were robust to the implemented changes in the majority of the analyses
implemented, and the base-case cost-effectiveness conclusions remain unchanged. In particular,
assuming a shorter 14-day time horizon (sensitivity analysis 3) that is consistent with the typical
duration and resolution of symptoms of strep A sore throat infection favoured usual care but the ICERs
did not change substantially to suggest a different interpretation of the base-case cost-effectiveness.
Assuming that the treating primary care health-care professional in both the intervention arm and the
usual-care arm is a nurse or a pharmacist (sensitivity analysis 19) rather than a GP favoured testing,
only if the test cannot be carried out within the allocated consultation time. In this instance, the costs
associated with the additional clinician time taken to administer and process test results are much lower
if seen by a nurse or pharmacist than if the treating clinician is a GP. Similarly, excluding the cost of the
additional clinician time required to process test results (sensitivity analysis 22) favoured testing only
where testing cannot be done within allocated primary care consultation time.
Summary of economic modelling
We undertook a systematic search for economic evaluation studies of the use of point-of-care tests as
listed in the NICE scope for patients with suspected strep A infection. We did not identify any relevant
economic models that could be adapted. Hence, a de novo decision tree model was built to compare
point-of-care testing in conjunction with clinical scoring tools with clinical scoring tools alone for
children and adults presenting with strep A infection in primary and secondary care settings.
The model took account of the presenting prevalence of disease in the modelled population, accuracy
of clinical scoring and testing, the prescribing behaviour of treating clinicians and complications of the
infection and treatment. In the base-case analysis, costs were calculated from a UK NHS/Personal
Social Services perspective over the 1-year time horizon. The health impact of intervention was
expressed in QALYs captured through application of disutilities associated with treated and untreated
infection and related complications over the modelled time horizon.
The scope of the appraisal had called for 21 tests to be evaluated in comparison with usual-care practice;
however, difficulties in obtaining reliable test accuracy and cost data for all tests meant that we were able
to include only 14 of the 21 tests for which relevant data were available in final economic modelling.
Under the base-case model assumptions for adults presenting with suspected strep A in primary care, the
ICER suggests that usual care dominated two tests (Clearview Exact Strep A cassette and Clearview Exact
Strep A dipstick – test strip, both supplied by Abbott Laboratories). For the remaining 12 tests, testing
was marginally more effective and more costly than usual care, with ICERs ranging from £1,353,677 per
QALY gained for NADAL Strep A test strip (nal von minden GmbH) to £6,059,081 per QALY for Roche
Diagnostics’ cobas Liat Strep A Assay compared with usual care.
Probabilistic analyses based on 1000 Monte Carlo simulations of the ICER assessed parameter uncertainty
and generated probability statements about the cost-effectiveness of point-of-care testing across a range
of willingness-to-pay thresholds. Probabilistic ICERs produced results similar to the deterministic base-case
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ICERs, and suggested that testing was associated with zero probability of cost-effectiveness at
willingness-to-pay thresholds of £0 to £100,000 per QALY gained under base-case assumptions.
Similar cost-effectiveness results were obtained in the base-case models for adults presenting in
secondary care, and in primary and secondary care models for children.
Extensive exploratory deterministic sensitivity analyses of the base-case inputs and assumptions were
conducted to understand key model drivers. The findings suggest that the ICER is highly sensitive
to (1) parameter inputs and assumptions that increase the cost of testing (acquisition cost of test,
additional clinician time for administering and processing test results, and cost of confirmatory throat
culture for those testing negative) and (2) the penalty for antibiotic overprescription/unnecessary
antibiotic use (acquisition cost of antibiotic and probabilities for penicillin-induced anaphylaxis and
rash). Factoring in costs associated with additional clinician time (at £4 per minute of GP time) for
administering tests and £8 for a confirmatory throat culture given a negative test in the base case both
favour usual care, as these costs can be substantially higher than the actual cost of the test and are
applied to the intervention arm only. In contrast, the model predicts lower antibiotic use with testing
than with usual care; however, the cost of antibiotic treatment, at £0.91 per course of penicillin, the
treatment of choice for strep A infection, is considerably cheaper (than the acquisition costs for the
majority of the test kits), such that the penalty for supplying antibiotics to those who do not need it is
negligible compared with the cost of testing.
The base case incorporates serious adverse effects of penicillin, such as penicillin-induced anaphylaxis,
with associated high treatment costs and disutility; however, the modelled rate of 0.01%78 used in
the base case suggests that anaphylaxis is very rare and its impact is, therefore, minimal on the
cost-effectiveness of testing. Sensitivity analyses increasing the rate of anaphylaxis to 0.64% based on
another economic evaluation of strep A pharyngitis79 favoured testing: the ICER for Clearview Exact
Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact Strep A cassette (Abbott
Laboratories) changed from being dominated by usual care in the base case to £288,702 and £299,305
per QALY gained compared with usual care, respectively.
Cost-effectiveness estimates were also sensitive to the prevalence of strep A infection (higher prevalence
favouring usual care and lower prevalence favouring testing), the disutility for untreated infection (lower
values favoured testing and doubling the decrement associated with untreated infection favoured usual
care) and the disutility for treated strep A infection (doubling the disutility favours testing).
Points for discussion regarding the economic modelling
A number of limitations apply to the economic model:
l Although the economic model represented the clinical care pathway in the NHS, practice and
management will vary from site to site (within and across primary and secondary care settings).
l The majority of inputs for test performance came from data on populations that were not directly
relevant to the location of the tests in our modelled health-care pathway (e.g. were not specific to
patients with Centor scores of ≥ 3 points). Hence, the true performance of the tests could differ
from the current models.
l We could compare point-of-care testing for only 14 of the 21 tests listed in the NICE scope, as we
did not have test accuracy and/or cost data for the other seven point-of-care tests.
l There was not enough information on test accuracy data to model strep A infection in the pharmacy
setting or for the elderly population.
l Inputs (except for the sensitivity and specificity data from our effectiveness review) were generally
available as point estimates without associated measures of uncertainty, such as CIs and SEs,
required for probabilistic modelling. Thus, we have had to follow the common practice of assuming
± 10% around the central estimate to incorporate uncertainty in our modelling. This approach to
probabilistic analysis is itself associated with degree of uncertainty, as it may underestimate or
overestimate the true uncertainty in the evidence.
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l Our protocol had specified a time horizon of 14 days, as the evidence suggests that strep A infection
is a self-limiting illness with the majority of patients making a complete recovery within 2 weeks
of the infection.86 However, we extended the time horizon to 1 year in the base-case model to
accommodate the impact of rare complications of strep A, such as acute rheumatic fever, where we
found evidence to suggest that these complications could be associated with as many as 75 quality-
adjusted life-days lost.78–80 However, this longer time horizon required further assumptions to keep
the modelling feasible and supported by appropriate evidence. In particular, we assumed only one
episode of strep A infection (the initial index episode) per patient with no possibility of a recurrent
infection within the 1-year time horizon, which is unlikely to represent a true reflection of sore
throat infections in the community (these point-of-care tests would not be used in people with
recurrent sore throats and this was excluded from the scope of work). Extending the time horizon to
1 year may also not adequately capture all costs and consequences associated with infection. For
example, there is evidence suggesting that increased risk of death from rheumatic heart disease is
associated with complications of strep A,82,83 but this cannot be fully incorporated within the 1-year
time horizon considered in our base case.
l We did not explore the impact of a lifetime horizon on the cost-effectiveness point-of-care testing
because (1) strep A infection is a self-limiting illness (see point above) and (2) the decision tree
structure is not suitable for economic models with lifetime modelling. The model does, however,
account for rare but serious complications of the infection, such as acute rheumatic fever and
anaphylactic reactions to penicillin, both of which can have a long-lasting impact. For these, we
assume that the 1-year time horizon considered in the base case is sufficient to capture the costs
and consequences associated with such complications.
l Sensitivity analyses assuming a shorter time horizon of 2 weeks (14 days), corresponding to
the expected time for symptom resolution, did not alter the conclusions of the base-case
cost-effectiveness results.
l Although the model captures the unwanted effects of antibiotic treatment, such as penicillin-
induced rash and anaphylaxis, through incorporating appropriate costs and disutility for these
events, resistance to antimicrobial therapy was not explicitly modelled because of evidence
suggesting that strep A is highly susceptible to penicillin83,94 (the treatment of choice for strep
A infection).
l The model captures suppurative and non-suppurative complications of strep A infection and the
unwanted effects of penicillin use. The probability estimates for suppurative complications were
derived from combining data for all such complications (quinsy, sinusitis, otitis media and cellulitis)
reported in a large UK cohort study by Little et al.86 As the Little et al.86 data include figures for
non-suppurative complications of the infection, such as the acute rheumatic fever, all such
complications were included in the modelling under the assumption that majority of complications
of strep A infection were suppurative, with no more than 0.01% being non-suppurative. Sensitivity
analysis suggests that this assumption has minimal impact on the base-case cost-effectiveness
results. Other complications of the strep A infection not included in the economic modelling include
mortality outcomes and scarlet fever in the children’s models because of a lack of data informing
probability estimates for these events; hence, the costs may be underestimated and outcomes
overestimated in the models.
l Transmissions between infected and susceptible individuals are not modelled because of a lack
of evidence to inform transmission rates in dynamic disease modelling. There is also evidence to
suggest seasonality effect (e.g. an increased presentation of strep A infection during the winter
months and around Easter time), but this was not explicitly modelled. However, we carried out
exploratory analysis in which we varied the prevalence of disease, which can be taken as proxy
for seasonality effect. These exploratory analyses suggest that increasing prevalence of disease
among adults and children in primary care generally favoured usual care, but the ICERs did not
change substantially to suggest a different conclusion from the base-case cost-effectiveness
results. In contrast, lowering the prevalence favoured testing, but, again, the ICERs did not
change substantially to alter conclusions of the base-case analyses.
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l The modelling may have underestimated the costs as we did not take into account the contribution
to antimicrobial stewardship owing to the lack of evidence.
l The model has not accounted for certain high-risk populations, such as immunosuppressed patients
or pregnant women, as these patients would all be offered antibiotics.
l We have not taken into account that some of these point-of-care tests may also detect other strains
of strep infections, such as strep C and strep G, in addition to strep A.
l The modelling may have underestimated the costs as we did not take into account the different
strains of strep A that may have influenced test performance and disease characteristics, potentially
altering the profile of complications.
l We did not consider the impact that introducing routine point-of-care testing might have on patient
presentation with sore throat, which could influence the cost-effectiveness results.
l We did not place any monetary value on the impact a point-of-care test might have in including the
patient in the treatment decision-making process.
l We have not taken into account any broader societal costs, such as lost productivity or time off
work, owing to suspected strep A infection.
l Finally, modelled changes in costs and QALYs are simulations and have not been observed. Findings
should be verified through properly designed and conducted research.
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Chapter 5 Discussion
Decision problem and objectives
The overall objective was to undertake a clinical effectiveness and cost-effectiveness analysis of rapid
antigen detection and molecular tests in those with high clinical scores, compared with the use of
clinical scoring tools alone, for increasing the diagnostic confidence of suspected group A streptococcal
infection in people who present with an acute sore throat in primary and secondary care settings.
The literature informing clinical effectiveness and cost-effectiveness was systematically reviewed
and summarised. A de novo economic model was developed to assess the cost-effectiveness of rapid
antigen detection and molecular tests in conjunction with clinical scoring tools compared with clinical
scoring tools alone in England and Wales.
Summary of methods and findings
Clinical effectiveness
We searched a number of databases including MEDLINE, EMBASE, Web of Science and The Cochrane
Library. We found 3309 unique records, of which 38 were included [26 full-text articles, three
abstracts, five manufacturers’ submissions (submitted to NICE in response to a request for information)
and four FDA documents]. There were 26 studies that reported on test accuracy data. In general,
the methodological quality of the included studies was poor. In particular, in 65.4% (17/26) of studies
it was unclear whether the sample was consecutive or convenience. Convenience samples may not
provide a true representation of the prevalence of strep A. There was judged to be a high level of bias
surrounding the subjective reading of some of the point-of-care tests and through lack of adherence
to manufacturer’s guidance by using the same swab to streak the microbiological culture and then
conduct the point-of-care test. In addition, microbiological culture is unlikely to be 100% accurate and
may vary with different culture media.
Overall, the findings reveal wide variations in the point estimates for the sensitivity (67.9% to 100%)
and specificity (73.3% to 100%) of the different point-of-care tests. These estimates were 82.9% to
94.6% for sensitivity and 84.9% to 99.1% for specificity in high-risk populations, including patients with
Centor/McIsaac scores of > 2 points, representing the population of interest. These estimates do not
account for any of the unpublished manufacturer submissions.
Clinical scoring tools (FeverPAIN and Centor) have been proposed as a method by which clinicians can
identify which patients are most likely to benefit from antibiotic use for sore throat.8 These tools were
developed to predict strep A (Centor and FeverPAIN), strep C (FeverPAIN) and strep G (FeverPAIN).
Direct comparison between sore throat clinical scoring tools and point-of-care tests indicated that
specificity estimates were higher for the point-of-care tests, and that sensitivity was generally comparable
between the two approaches. Direct comparison with sore throat clinical scoring tools revealed that
point-of-care tests were generally more specific. However, one methodological limitation concerns the
varying way that clinical scoring tools have been implemented across the included studies. For instance,
different studies apply different clinical cut-off points when recruiting patients. No studies were identified
that matched the proposed pathway of care and treatment for patients with acute streptococcal pharyngitis,
which would entail evaluating the test accuracy of a combined strategy of sore throat clinical scores at the
recommended NICE thresholds (Centor/McIsaac score of ≥ 3 points or FeverPAIN score of ≥ 4 points) and
point-of-care tests. No evidence was identified for the elderly population or in a pharmacy setting. Likewise,
data for test accuracy were sparse for each combination of test, population and setting. There were very
few head-to-head (direct) comparison studies between index tests.
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It was not possible to identify which test is the most accurate owing to the lack of evidence. The large
degree of heterogeneity among results for studies using the same rapid test suggests that it is unlikely
that any single study will accurately capture a test’s true performance. The apparent accuracy of a test
may be penalised for having more studies, compared with tests with a single study, particularly those
in which the manufacturer has conducted that study. The heterogeneity introduced by the differing
characteristics of the studies further confounded attempts to produce meaningful estimates of test
performance, such as care setting, age group, throat score restriction and disease prevalence. Owing to
the potential heterogeneity, estimates for the sensitivity and specificity of each test were stratified by
age group, throat score and care setting, although a lack of evidence meant that generalisations had to
be made for the majority of estimates.
There is some RCT evidence to suggest that the use of RADTs may help to reduce antibiotic-prescribing
rates, but there was no evidence on the effect of using molecular technologies. If a test was proven to
be extremely accurate, then it is plausible that clinical staff would trust the outcomes. No evidence was
found on time to antimicrobial prescribing decision, number of appointments required per episode and
onward transmission of infection.
Cost-effectiveness
The systematic review of cost-effectiveness studies identified three studies that used the RADTs as
identified in the NICE scope and were classed as economic evaluations. Two studies had some notable
limitations and could not be fully data extracted. The one study that allowed a full data extraction was
classed as a high-quality economic evaluation when checked against the CHEERS reporting tool.
Fourteen of the 21 tests listed in the NICE scope had data on test accuracy and costs relevant to be
included in the final economic modelling. In the base-case analysis, which included adult patients seen
in primary care with suspected strep A infection, the economic model found point-of-care testing to
not be cost-effective compared with usual care for suspected strep A infection. This finding was also
seen in the other economic models, which were adapted for the different patient groups and settings
(adult patients seen in the hospital, children seen in primary care and children seen in the hospital).
Important uncertainties in the model include parameter inputs and assumptions that increase (1) the
cost of testing (acquisition cost of test, additional clinician time for administering and processing test
results, and cost of confirmatory throat culture for those testing negative) and (2) the penalty for
antibiotic overprescription/unnecessary antibiotic use (acquisition cost of antibiotic and probabilities
for penicillin-induced anaphylaxis and rash).
Strengths and limitations
We used a rigorous and exhaustive search to conduct a comprehensive systematic review (literature
search, data extraction and analysis) and locate primary studies. All relevant studies were systematically
reviewed and agreement between the two reviewers was very high.We also built a de novo decision tree
model to assess cost-effectiveness of point-of-care testing. The economic model provides a representation
of the clinical care pathway in primary and secondary care settings. The decision tree was populated with
probabilities and test accuracy values from the clinical evidence review, published studies and clinical
expert opinion.
No studies of point-of-care test use in a pharmacy setting or in the elderly population were retrieved.
In addition, no study matched the proposed pathway of care and treatment for patients with acute
streptococcal pharyngitis, which would entail evaluating the test accuracy of a combined strategy of
sore throat clinical scores at the recommended NICE thresholds (Centor/McIsaac score of ≥ 3 points
or FeverPAIN score of ≥ 4 points) and point-of-care tests in the age groups defined in the scope.
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Children aged < 5 years were not explicitly considered in this review. Although they may benefit from a
point-of-care test, following advice from health-care professionals, we understood that their diagnostic
pathway is likely to differ from older age groups, and they were considered beyond the scope of this review.
For the purpose of this review, we classified GP surgeries, health-care centres, family practices and
primary care clinics as primary care. Secondary care comprised emergency departments, private
paediatric clinics, outpatient clinics, urgent care clinics and walk-in centres. In practice, other countries
may define primary and secondary care differently; for example, paediatric clinics could be part of
primary care. However, given that it is unclear if test accuracy differs by setting, we do not know the
impact this could have on the cost-effectiveness estimates.
We included only English-language studies and studies directly matching the test name, unless we had
confirmation that a test had been taken over by another manufacturer (e.g. in the case of IMI testpack
becoming Alere). We did not include studies where it was unclear whether or not later iterations of
the test were different. During the EAG write-up of the final report, Abbott Laboratories notified NICE
that the Alere i Strep A test was no longer available. The Alere i Strep A 2 has been rebranded as the
ID NOW Strep A 2. Our previously excluded studies were rescreened by test name, and none used the
ID NOW Strep A 2 test. It is the EAG’s understanding that the information in this report relevant to
the Alere i Strep A 2 is transferable to the ID NOW Strep A 2. In addition, the Clearview Exact Strep A tests
(both cassette and dipstick) were replaced with new Clearview Exact Strep A 2 editions. The manufacturers
supplied NICE with information that there are procedural differences between previous Clearview tests and
the new A 2 editions. Therefore, the results for the Clearview Exact Strep A tests in this review may not
be generalisable to the current Clearview products on the market. Furthermore, our previously excluded
studies were rescreened by test name, and none used the Clearview Exact Strep A 2 editions.
We did not explore the effect of culture medium on test accuracy in the review. One of the included test
accuracy studies found that using different culture media was showing strep A positivity on samples that
were initially negative.42 This could indicate possible differences in accuracy of different culture media.
Test accuracy may also vary greatly based on the quality of the swabbing. It is unclear how the level of
training of clinical staff involved in these studies compares with routine care, which could limit the
generalisability of these results.
The evidence informing the test accuracy estimates was not sufficient to produce reliable or robust
estimates that we could be confident actually reflected the tests’ true performance in any particular
patient group. The main concern is that the patients’ clinical scores used in the studies of test accuracy did
not match the scores of patients anticipated to benefit from using the tests, as modelled in our economic
analysis. The health-care setting and age group were also potential variables that may affect test
performance. This concern extends to the economic modelling, which used the estimates for each test.
The studies in this review determined antibiotic appropriateness to be based on strep A positivity in the
culture. However, culture may detect strep A carriage as opposed to disease. PCR was a potential alternative
reference standard, but was less widely used, and encounters the same issue of carriage detection.
Although the economic model represented the clinical care pathway in the NHS, practice and
management will vary from site to site (within and across both primary care and secondary care
settings). There was not enough information on test accuracy data to model strep A for the pharmacy
setting or for the elderly population. Furthermore, we could compare only 14 of the 21 point-of-care
tests as listed in the NICE scope, as we did not have test accuracy and/or cost data for the other seven
point-of-care tests. The modelling may have underestimated the costs as we did not take into account
the different strains of strep A that may have influenced test performance and altered the profile
of complications, seasonality of strep A infection, resistance to antimicrobial therapy, the onward
transmission of the infection and the broader societal costs.
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Chapter 6 Conclusions
The systematic review and cost-effectiveness model identify uncertainties around the adoption ofpoint-of-care tests in primary and secondary care settings in England and Wales. The available
evidence is heterogeneous in populations studied, design, methods and analysis. Although sensitivity
and specificity estimates are promising, we have little information on the best point-of-care test to use.
Although there is potential for the point-of-care tests to be cost-effectiveness in both primary care and
secondary care settings, key parameter inputs and modelling assumptions need to be confirmed and
model findings remain uncertain.
Recommendations for future research
Further research is needed to understand the test accuracy of point-of-care tests in the proposed NHS
pathway and in comparable settings and patient groups. There was a considerable lack of evidence for
the performance of the tests based on real-world use in patients with a Centor score of ≥ 3 points or a
FeverPAIN score of ≥ 4 points. Future work that considers head-to-head test accuracy studies or RCTs
using multiple point-of-care tests in relevant patient populations and health-care settings considered
in the NICE scope would provide relevant comparator information and help to determine the value
of point-of-care testing. Results broken down by relevant subgroups, such as age and clinical score
threshold, would also be useful. Further research on the establishment of a gold reference standard
with which tests are compared would also reduce uncertainty and potential bias in reviews such as this.
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Appendix 1 Record of searches:
clinical effectiveness
Bibliographic databases
Summary of bibliographic database searches
Database Date of search
Number of records
(+ number from update search)
MEDLINE (via OvidSP) 26 November 2018
(updated 7 March 2019)
1646 (+ 33)
EMBASE (via OvidSP) 27 November 2018
(updated 12 March 2019)
2546 (+ 177)
The Cochrane Library (via Wiley Online
Library)
29 November 2018
(updated 12 March 2019)
118 (+ 1)
Science Citation Index and Conference
Proceedings Citation Index – Science
(via the Web of Science)
3 December 2018
(updated 12 March 2019)
1275 (+ 67)
DARE (via CRD) 22 January 2019
(updated 12 March 2019)
30 (+ 0)
HTA (via CRD) 22 January 2019
(updated 12 March 2019)
2 (+ 0)
Total number of records from database searches: 5617 (+ 278 from 2019 update search) = 5895.
Total number of records after deduplication: 3240 (+ 45 from 2019 update search) = 3285.
MEDLINE (via OvidSP)
Databases: Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Daily and Versions.
Date searched: 26 November 2018 (updated on 7 March 2019; see the end of this search record).
Date range searched: 1946 to 21 November 2018.
Original search: 26 November 2018
Search strategy
1. exp Pharyngitis/ (15,049)
2. pharyngit*.ti,ab,kf. (5455)
3. (nasophyryngit* or rhinopharyngit* or epipharyngit*).ti,ab,kf. (177)
4. (tonsillit* or tonsilit*).ti,ab,kf. (5589)
5. ((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*)).ti,ab,kf. (9903)
6. or/1-5 (25,137)
7. Streptococcal Infections/di, mi (13,347)
8. Streptococcus pyogenes/im, ip (5444)
9. 7 or 8 (16,609)
10. ((strep or streptococcal or group) adj2 A).ti,ab,kf. (558,959)
11. 9 and 10 (4831)
DOI: 10.3310/hta24310 Health Technology Assessment 2020 Vol. 24 No. 31
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fraser et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
139
12. (strep* adj5 (throat* or pharyn* or tonsil*)).ti,ab,kf. (3397)
13. streptoco* A.ti,ab,kf. (475)
14. (group A adj5 streptoco*).ti,ab,kf. (9481)
15. ((streptococcus or strep) adj1 (pyogenes or pyogenic)).ti,ab,kf. (7683)
16. ((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield)).ti,ab,kf. (237)
17. (s pyogenes or pyogenes s or micrococcus scarlatinae).ti,ab,kf. (2485)
18. lancefield group.ti,ab,kf. (475)
19. gabhs.ti,ab,kf. (392)
20. or/11-19 (18,796)
21. Point-of-Care Systems/ (11,122)
22. exp Reagent Kits, Diagnostic/ (19,326)
23. Antigens, Bacterial/an (7619)
24. (point-of-care or poc or poct or pocts).ti,ab,kf. (17,665)
25. ((rapid* or bedside*1 or bed-side*1 or near-patient or nearpatient or extra-laboratory or
extralaboratory or office*1) adj6 (test or tests or testing or tested or detect* or diagnos* or screen*
or kit or kits or assay* or immunoassay* or determin* or identif* or antigen*1)).ti,ab,kf. (136,637)
26. (radt or radts or rdt or rdts).ti,ab,kf. (1813)
27. (antigen*1 adj6 (test or tests or testing or tested or detect* or diagnos* or screen* or kit or kits or
assay* or immunoassay* or determin* or identif*)).ti,ab,kf. (100,724)
28. (clearview exact* or BD veritor* or strep A rapid test* or quikread go* or alere i* or cobas liat* or
genexpert* or ((alere* or testpack* or test-pack* or bionexia* or bio-nexia* or biosynex* or veritor*
or cobas* or quikread* or quik-read* or NADAL* or OSOM* or sofia* or xpert*) and (strep A or
point of care or point-of-care or POC))).ti,ab,kf. (804)
29. ((abbott or beckton dickinson or biopanda or nal von minden or sekisui or orion diagnostica or
roche or cepheid or biomerieux or quidel) and (strep A or point of care or POC or rapid test* or
rapid antigen or antigen test*)).ti,ab,kf,in. (618)
30. or/21-29 (269,698)
31. (6 or 20) and 30 (1759)
32. exp animals/ not humans/ (4,517,568)
33. 31 not 32 (1646)
34. 31 use medp,prem,mesx (114)
35. 33 or 34 (1646).
Updated search: 7 March 2019
Search strategy
Re-ran above search with the following date limits:
36. limit 35 to ed=20181126-20190307 (17)
37. limit 35 to ep=20181126-20190307 (14)
38. (2018 11* or 2018 12* or 2019*).dt,ez. (243,915)
39. 35 and 38 (13)
40. 36 or 37 or 39 (33)
Total after removing duplicates with previous search: 16.
EMBASE (via OvidSP)
Databases: EMBASE Classic and EMBASE.
Date searched: 27 November 2018 (updated on 12 March 2019; see the end of this search record).
Date range searched: 1947 to 21 November 2018.
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Original search: 27 November 2018
Search strategy
1. streptococcal pharyngitis/ or pharyngitis/ or rhinopharyngitis/ or sore throat/ or tonsillitis/ or
chronic tonsillitis/ or palatine tonsillitis/ (51,206)
2. pharyngit*.ti,ab,kw. (7851)
3. (nasophyryngit* or rhinopharyngit* or epipharyngit*).ti,ab,kw. (379)
4. (tonsillit* or tonsilit*).ti,ab,kw. (8320)
5. ((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*)).ti,ab,kw. (15,900)
6. or/1-5 (59,836)
7. Streptococcus infection/di (3821)
8. Streptococcus pyogenes/ or streptococcus group a/ or group A streptococcal infection/ (23,921)
9. 7 or 8 (26,865)
10. ((strep or streptococcal or group) adj2 A).ti,ab,kw. (792,961)
11. 9 and 10 (9617)
12. (strep* adj5 (throat* or pharyn* or tonsil*)).ti,ab,kw. (4842)
13. streptoco* A.ti,ab,kw. (636)
14. (group A adj5 streptoco*).ti,ab,kw. (12,213)
15. ((streptococcus or strep) adj1 (pyogenes or pyogenic)).ti,ab,kw. (9259)
16. ((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield)).ti,ab,kw. (388)
17. (s pyogenes or pyogenes s or micrococcus scarlatinae).ti,ab,kw. (3223)
18. lancefield group.ti,ab,kw. (567)
19. gabhs.ti,ab,kw. (504)
20. or/11-19 (24,055)
21. point of care system/ or point of care testing/ (11,966)
22. rapid test/ or diagnostic kit/ (8892)
23. antigen detection/ or bacterial antigen/an or Streptococcus antigen/ (24,501)
24. (point-of-care or poc or poct or pocts).ti,ab,kw. (25,553)
25. ((rapid* or bedside*1 or bed-side*1 or near-patient or nearpatient or extra-laboratory or
extralaboratory or office*1) adj6 (test or tests or testing or tested or detect* or diagnos* or screen*
or kit or kits or assay* or immunoassay* or determin* or identif* or antigen*1)).ti,ab,kw. (177,813)
26. (radt or radts or rdt or rdts).ti,ab,kw. (2974)
27. (antigen*1 adj6 (test or tests or testing or tested or detect* or diagnos* or screen* or kit or kits or
assay* or immunoassay* or determin* or identif*)).ti,ab,kw. (130,835)
28. (clearview exact* or BD veritor* or strep A rapid test* or quikread go* or alere i* or cobas liat* or
genexpert* or ((alere* or testpack* or test-pack* or bionexia* or bio-nexia* or biosynex* or veritor*
or cobas* or quikread* or quik-read* or NADAL* or OSOM* or sofia* or xpert*) and (strep A or
point of care or point-of-care or POC))).ti,ab,kw. (1633)
29. ((abbott or beckton dickinson or biopanda or nal von minden or sekisui or orion diagnostica or
roche or cepheid or biomerieux or quidel) and (strep A or point of care or POC or rapid test* or
rapid antigen or antigen test*)).ti,ab,kw,in. (1404)
30. or/21-29 (345,022)
31. (6 or 20) and 30 (2856)
32. (exp animal/ or nonhuman/) not exp human/ (6,749,742)
33. 31 not 32 (2546)
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Updated search: 12 March 2019
Search strategy
Re-ran above search with the following date limits:
34. limit 33 to dd=20181127-20190312 (18)
35. limit 33 to em=201811-201903 (152)
36. 34 or 35 (159)
37. limit 33 to dc=20181127-20190312 (41)
38. 36 or 37 (177)
Total after removing duplicates with other update and previous searches: 25.
The Cochrane Library (including Cochrane Database of Systematic Reviews and Cochrane
Central Register of Controlled Trials)
Date searched: 29 November 2018 (updated on 12 March 2019; see the end of this search record).
Original search: 29 November 2018
Search strategy
#1 MeSH descriptor: [Pharyngitis] explode all trees (1138)
#2 pharyngit*:ti,ab,kw (1916)
#3 (nasophyryngit* or rhinopharyngit* or epipharyngit*):ti,ab,kw (2597)
#4 (tonsillit* or tonsilit*):ti,ab,kw (826)
#5 ((sore or pain* or ache* or aching or inflam* or infect*) near/3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*)):ti,ab,kw (3198)
#6 #1 or #2 or #3 or #4 or #5 (7030)
#7 MeSH descriptor: [Streptococcal Infections] explode all trees and with qualifier(s): [diagnosis -
DI, microbiology - MI] (306)
#8 MeSH descriptor: [Streptococcus pyogenes] explode all trees and with qualifier(s): [immunology -
IM, isolation & purification - IP] (89)
#9 #7 or #8 (351)
#10 ((strep or streptococcal or group) near/2 A):ti,ab,kw (109,570)
#11 #9 and #10 (126)
#12 (strep* near/5 (throat* or pharyn* or tonsil*)):ti,ab,kw (499)
#13 streptoco* next A:ti,ab,kw (26)
#14 (group A near/5 streptoco*):ti,ab,kw (689)
#15 ((streptococcus or strep) near/1 (pyogenes or pyogenic)):ti,ab,kw (423)
#16 ((streptococcus or strep) near/1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield)):ti,ab,kw (1)
#17 (“s pyogenes” or “pyogenes s” or “micrococcus scarlatinae”):ti,ab,kw (60)
#18 “lancefield group”:ti,ab,kw (6)
#19 gabhs:ti,ab,kw (109)
#20 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 (1123)
#21 MeSH descriptor: [Point-of-Care Systems] explode all trees (424)
#22 MeSH descriptor: [Reagent Kits, Diagnostic] explode all trees (267)
#23 MeSH descriptor: [Antigens, Bacterial] explode all trees and with qualifier(s): [analysis - AN] (63)
#24 (point-of-care or poc or poct or pocts):ti,ab,kw (2560)
#25 ((rapid* or bedside*1 or bed-side*1 or near-patient or nearpatient or extra-laboratory or
extralaboratory or office*1) near/6 (test or tests or testing or tested or detect* or diagnos* or screen* or
kit or kits or assay* or immunoassay* or determin* or identif* or antigen*1)):ti,ab,kw (3506)
#26 (radt or radts or rdt or rdts):ti,ab,kw (302)
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#27 (antigen*1 near/6 (test or tests or testing or tested or detect* or diagnos* or screen* or kit or
kits or assay* or immunoassay* or determin* or identif*)):ti,ab,kw (0)
#28 (clearview next exact* or BD next veritor* or “strep A rapid” next test* or quikread next go* or
alere next i* or cobas next liat* or genexpert* or ((alere* or testpack* or test-pack* or bionexia* or
bio-nexia* or biosynex* or veritor* or cobas* or quikread* or quik-read* or NADAL* or OSOM* or
sofia* or xpert*) and (“strep A” or “point of care” or point-of-care or POC))):ti,ab,kw (114)
#29 ((abbott or “beckton dickinson” or biopanda or “nal von minden” or sekisui or “orion
diagnostica” or roche or cepheid or biomerieux or quidel) and (“strep A” or “point of care” or POC or
rapid next test* or rapid next antigen* or antigen next test*)):ti,ab,kw (47)
#30 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 (6235)
#31 (#6 or #20) and #30 (118)
Total: 118.
l Cochrane Database of Systematic Reviews – Reviews: 15.
l Cochrane Database of Systematic Reviews – Protocols: 1.
l CENTRAL: 102.
Updated search: 12 March 2019
Re-ran above search and sorted by date, with the newest first.
New since 29 November 2018:
l Cochrane Database of Systematic Reviews – Reviews: 0
l Cochrane Database of Systematic Reviews – Protocols: 0
l CENTRAL: 1.
Total after removing duplicates with other update and previous searches: 0.
Science Citation Index and Conference Proceedings (via the Web of Science)
Date searched: 3 December 2018 (updated on 12 March 2019; see the end of this search record).
Original search: 3 December 2018
Note: search record reads from bottom to top.
Search strategy
Note: search record reads from bottom to top.
Set Results History
# 23 1275 (#5 OR #14) AND #22
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 22 265,727 #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 21 487 TS=((abbott OR “beckton dickinson” OR biopanda OR “nal von minden” OR sekisui OR “orion
diagnostica” OR roche OR cepheid OR biomerieux OR quidel) AND (“strep A” OR “point* of care”
OR poc OR poct OR pocts OR “rapid test*” OR “rapid antigen” OR “antigen test*”))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
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Set Results History
# 20 849 TS=(“clearview exact*” OR “BD veritor*” OR “strep A rapid test*” OR “quikread go*” OR “alere i*”
OR “cobas liat*” OR genexpert* OR ((alere* OR testpack* OR test-pack* OR bionexia* OR bio-nexia*
OR biosynex* OR veritor* OR cobas* OR quikread* OR quik-read* OR NADAL* OR OSOM* OR
sofia* OR xpert*) AND (“strep A” OR “point* of care” OR poc OR poct OR pocts)))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 19 86,024 TS=(antigen* NEAR/5 (test OR tests OR testing OR tested OR detect* OR diagnos* OR screen* OR
kit OR kits OR assay* OR immunoassay* OR determin* OR identif*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 18 2261 TS=(radt OR radts OR rdt OR rdts)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 17 165,166 TS=((rapid* OR bedside* OR bed-side* OR near-patient OR nearpatient OR extra-laboratory OR
extralaboratory OR office*) NEAR/5 (test OR tests OR testing OR tested OR detect* OR diagnos*
OR screen* OR kit OR kits OR assay* OR immunoassay* OR determin* OR identif* OR antigen*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 16 22,883 TS=(“point* of care” OR poc OR poct OR pocts)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 15 219 TS=(diagnostic AND (reagent NEAR/0 (kit* OR strip*)))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 14 17,280 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 13 308 TS=gabhs
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 12 444 TS="lancefield group"
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 11 2042 TS=(“s pyogenes” OR “pyogenes s” OR “micrococcus scarlatinae”)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 10 59 TS=((strep*) NEAR/0 (epidemicus OR erysipelatis OR erysipelatos OR hemolyticus OR haemolyticus
OR scarlatinae OR lancefield))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 9 7107 TS=((strep*) NEAR/0 (pyogenes OR pyogenic))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 8 9638 TS=(“group A” NEAR/4 strep*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 7 1156 TS="strep* A"
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 6 2875 TS=(strep* NEAR/4 (throat* OR pharyn* OR tonsil*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 5 12,426 #1 OR #2 OR #3 OR #4
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
Set Results History
# 4 6980 TS=((sore OR pain* OR ache* OR aching OR inflam* OR infect*) NEAR/2 (pharyn* OR throat* OR
tonsil* OR nasopharyn* OR rhinopharyn* OR epipharyn*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 3 2703 TS=(tonsillit* OR tonsilit*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 2 96 TS=(nasophyryngit* OR rhinopharyngit* OR epipharyngit*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 1 4651 TS=pharyngit*
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
Updated search: 12 March 2019
Re-ran the above search with the following date limits:
Search strategy
# 23 67 (#5 OR #14) AND #22
Indexes=SCI-EXPANDED, CPCI-S Timespan=2018-2019
Total after removing duplicates with other update and previous searches: 4.
Database of Abstracts of Reviews of Effects (via Centre for Reviews and Dissemination)
and Health Technology Assessment database (via Centre for Reviews and Dissemination)
Date searched: 22 January 2019. (Not updated because no new records have been added to DARE
since 31 March 2015 or to the HTA database since 31 March 2018. The INAHTA website was checked
in March 2019 to see if a new platform for the HTA database was available.)
Original search: 22 January 2019
Search strategy
1. MeSH DESCRIPTOR Pharyngitis EXPLODE ALL TREES IN DARE,NHSEED,HTA (73)
2. (pharyngit*) (85)
3. (nasophyryngit*) OR (rhinopharyngit*) OR (epipharyngit*) (5)
4. (tonsillit* or tonsilit*) (43)
5. (((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*))) (91)
6. #1 OR #2 OR #3 OR #4 OR #5 (163)
7. MeSH DESCRIPTOR Streptococcal Infections WITH QUALIFIERS DI, MI IN DARE,
NHSEED,HTA (31)
8. MeSH DESCRIPTOR Streptococcus pyogenes WITH QUALIFIERS IM, IP IN DARE,
NHSEED,HTA (13)
9. #7 OR #8 (36)
10. ((strep or streptococcal or group) adj2 A)) (2025)
11. #9 AND #10 (17)
12. ((strep* adj5 (throat* or pharyn* or tonsil*))) (39)
13. (streptoco* adj1 A) (10)
14. ((group A adj5 streptoco*)) (27)
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15. (((streptococcus or strep or staphylococcus) adj1 (pyogenes or pyogenic))) (25)
16. (((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield))) (0)
17. ((s pyogenes or pyogenes s or micrococcus scarlatinae)) (1)
18. (lancefield group) (0)
19. (gabhs) (8)
20. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 (51)
21. #6 AND #20 (43)
22. (#21) IN DARE (30)
23. (#21) IN HTA (2)
PROSPERO (International Prospective Register of Systematic Reviews)
Date searched: 20 February 2019.
Search strategy
#1 MeSH DESCRIPTOR Pharyngitis EXPLODE ALL TREES (29)
#2 pharyngit* (48)
#3 nasophyryngit* OR rhinopharyngit* OR epipharyngit* (3)
#4 tonsillit* OR tonsilit* (35)
#5 (sore OR pain* OR ache* OR aching OR inflam* OR infect*) ADJ3 (pharyn* or throat* OR tonsil*
OR nasopharyn* OR rhinopharyn* OR epipharyn*) (105)
#6 #1 OR #2 OR #3 OR #4 OR #5 (125)
#7 strep* ADJ5 (throat* or pharyn* or tonsil*) (8)
#8 #6 OR #7 (125)
Status of review: completed or published (17).
Browsed online by information specialist: none relevant.
Trials registers
ClinicalTrials.gov
Date searched: 20 February 2019.
Search strategy
Thirty-three studies were found for:
Active, not recruiting, Completed, Suspended, Terminated, Withdrawn, Unknown status Studies | “strep
throat” OR ( strep OR streptococcus OR streptococcal OR “group a” OR gabhs ) AND ( throat OR
pharynx OR tonsils ) OR pharyngitis OR rhinopharyngitis OR epipharyngitis OR tonsillitis OR tonsilitis
OR “sore throat” | rapid OR antigen OR radt OR radts OR rdt OR rdts OR “point of care” OR poc OR
poct OR pocts OR bedside OR bed-side OR near-patient OR nearpatient OR diagnostic OR diagnosis
OR test OR tests OR testing OR kit OR kits OR clearview OR veritor OR quikread OR quik-read OR
alere OR cobas OR genexpert OR testpack OR test-pack OR bionexia OR bio-nexia OR biosynex OR
nadal OR osom OR sofia OR xpert OR abbott OR “beckton dickinson” OR biopanda OR “nal von
minden” OR sekisui OR “orion diagnostica” OR roche OR cepheid OR biomerieux OR quidel.
Downloaded to Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) and screened by an
information specialist against inclusion criteria and with reference to included studies from database
searches. No new studies were identified.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
Conferences and professional organisations
Selected with advice from several advisors [Noel McCarthy (University of Warwick, Coventry, UK) and
NICE specialist committee members].
Federation of Infection Societies conference
Date searched: 6 March 2019.
2019 November: not available yet.
2018: https://fis2018.co.uk/ (browsed abstracts > diagnostics) – 0 relevant.
2017: http://event.federationinfectionsocieties.com/ (browsed abstracts) – 0 relevant.
2016: www.journalofhospitalinfection.com/issue/S0195-6701(16)X0012-6 [searched abstracts (poster
and oral presentations and invited speaker abstracts) one term at a time. Terms used: strep or group a or
throat or pharyn or tonsil (search looked for these within words as well as whole words)] – 0 relevant.
2015: abstracts appear not to be available online.
2014: searched abstracts one term at a time. Terms used: strep or group a or throat or pharyn or
tonsil (search looked for these within words as well as whole words) – 0 relevant.
The European Congress of Clinical Microbiology and Infectious
Date searched: 5 March 2019.
URL: www.eccmid.org/.
EMBASE indexes up to 22nd European Congress of Clinical Microbiology and Infectious Diseases,
London, UK, 2012.
Older and more recent years available via the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) eLibrary: www.escmid.org/escmid_publications/escmid_elibrary/.
Searched ESCMID eLibrary on 5 March 2019 for the following terms, with no date limit.
Search strategy
strep – 25 results (three sent to reviewers).
“group a” AND streptococcus, limited to ‘Topics: Diagnostic Bacteriology & General Microbiology’ –
10 (one sent to reviewers).
“group a” AND streptococcal, limited to ‘Topics: Diagnostic Bacteriology & General Microbiology’ –
8 (one sent to reviewers).
American Society of Microbiology
American Society of Microbiology Microbes: www.asm.org/ (website restructured; past meeting
abstracts unavailable).
British Society for Antimicrobial Chemotherapy
Date searched: 6 March 2019.
URL: www.bsac.org.uk.
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British Society for Antimicrobial Chemotherapy spring meeting abstracts 2016–18 and general website
searched one term at a time. Terms used: strep or group a or throat or pharyn or tonsil (search looked
for these within words as well as whole words) – screened online; none relevant.
British Infection Association
Date searched: 6 March 2019.
URL: www.britishinfection.org/.
None relevant.
Note: British Society for Antimicrobial Chemotherapy spring conference – Thursday 21 and Friday
22 March 2019.
Public Health England Annual Conference and Public Health Research and Science Annual
Conference
Date searched: 12 March 2019.
Search strategy
2016–18: https://phe.multilearning.com/phe/#!*menu=6*browseby=3*sortby=2. Searched one term at
a time. Terms used: strep or streptococcal or streptococcus of group a or throat or pharyngitis or
pharynx or tonsillitis or tonsilitis (search looked for whole words) – screened online; none relevant.
Streptococcal biology conference
Date searched: 12 March 2019.
URL: www.grc.org/streptococcal-biology-conference/2018/.
Search strategy
Searched one term at a time. Terms used: throat or pharyn or tonsil or rapid or point or diagnos
(search looked for these within words as well as whole words) – 0 results.
Lancefield International Symposium on Streptococci and Streptococcal Diseases
Date searched: 12 March 2019.
Not indexed in EMBASE. Some abstracts indexed in Web of Science, but only up to 2009.
2017: http://lisssd2017.org/abstracts/ – website unavailable.
Not able to find a list of full abstracts for most recent 5 years online.
Microbiology Society Conference
Date searched: 12 March 2019.
2019 (abstract book for April 2019 available): https://microbiologysociety.org/event/annual-
conference/annual-conference.html.
2018: https://microbiologysociety.org/event/annual-conference/annual-conference-2018.html#tab-2.
2017: https://microbiologysociety.org/events/annual-conference.html?eventYear=2017.
2016: https://microbiologysociety.org/event/annual-conference/annual-conference-2016.html.
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2015: https://microbiologysociety.org/event/annual-conference/annual-conference-2015.html.
Searched one term at a time. Terms used: streptococcal or streptococcus of group a or throat or
pharyn or tonsil (search looked for these within words as well as whole words) – screened online;
none relevant.
Association of Clinical Biochemistry and Laboratory Medicine
Date searched: 12 March 2019.
2018 and 2019 searched.
URL: www.acb.org.uk/whatwedo/events/national_meetings.aspx.
URL: www.acb.org.uk/whatwedo/events/national_meetings/focus-2018/abstracts/posterabstracts.
Searched one term at a time. Terms used: streptococcal or streptococcus of group a or throat or
pharyn or tonsil (search looked for these within words as well as whole words) – screened online;
none relevant.
In addition, the website was searched using Google Advanced Search with www.acb.org.uk in the domain.
Search strategy
strep* OR throat OR tonsil* OR pharyn* OR “group a”
URL: www.acb.org.uk – seven results; screened online; none relevant.
Royal College of Pathologists
Date searched: 12 March 2019.
The website was searched using Google Advanced Search with www.acb.org.uk in the domain.
Search strategy
strep* OR throat OR tonsil* OR pharyn* OR “group a”.
URL: www.rcpath.org – 55 results; screened online; none relevant.
Included studies in relevant reviews
Reviews found in searches
Vachhani et al.95 focuses on manufacturers’ package inserts. The report refers to the following
systematic reviews in the background:
l Lean et al.69 cross-checked 14 articles that mention a test name within our scope, out of the
48 total included studies. All 14 have already been picked up and sifted.
l Stewart et al.96 cross-checked 58 included studies with database search results; 57 of the 58 have
already been picked up and sifted. The one remaining (Parviainen et al.97) includes tests not within
scope [ReaScan Strep A test (Reagena International Ltd, Toivala, Finland) vs. standard culture vs.
TestPack® Strep A test (Inverness Medical, Cranfield, UK)].
l Ruiz-Aragon et al.98 was not in English and older (published 2010).
Cohen et al.99 included studies scanned for test names in the scope and cross-checked against the
results of database searches.
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Some were found that we excluded owing to not having the test name in the meeting abstract, where
Cochrane reviewers contacted authors and were given more information. Sent to reviewers.
Mlejnek et al.:100
l go to characteristics of included studies: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.
CD010502.pub2/references#characteristicStudies
l and search using ctrl + f for ‘Mlejnek 2014’.
Pauchard et al.:57
l go to the same link above and search using ctrl + f for ‘Pauchard 2013’.
Pauchard et al.:101
l go to the same link above and search using ctrl + f for ‘Pauchard 2012’.
Not found in our searches:
Schwartz et al.:102
l letter.
Schwartz et al.102
Sedki et al.:103
l checked full text – not a test in our scope (Streptatest®, Dektra Pharm, Strasbourg, France).
Sedki et al.103
Also checked:
Banerjee and Ford.104
References of our included studies
Searched in March 2019 for studies.
Manufacturers’ websites
Searched in January 2019 for studies and data.
Rachel Court also checked manufacturers’ submissions for mention of studies. Forwarded relevant
details, abstracts, posters and package inserts to reviewers.
Regulatory bodies
Food and Drug Administration, Clinical Laboratory Improvement Amendments database
Targeted searches undertaken on 6 March 2019.
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Test system/manufacturer: NADAL. None found.
Test system/manufacturer: nal von minden. None found.
Test system/manufacturer: Cepheid AND Analyte Name: Streptococcus, group A. Two found, most
relevant one sent to reviewers.
Test system/manufacturer: Cobas AND Analyte Name: Streptococcus, group A. Two found; earliest one
sent to reviewers.
Test system/manufacturer: Biopanda. None found.
Test system/manufacturer: Biomerieux AND Analyte Name: Streptococcus, group A. None found.
Test system/manufacturer: Bionexia AND Analyte Name: Streptococcus, group A. None found.
Test system/manufacturer: Alere i AND Analyte Name: Streptococcus, group A One found (Alere i) –
sent to reviewers.
Test system/manufacturer: Abbott AND Analyte Name: Streptococcus, group A. One found (TestPack
Plus) – sent to reviewers.
Test system/manufacturer: Clearview AND Analyte Name: Streptococcus, group A. None found for Abbott.
Test system/manufacturer: BD Veritor AND Analyte Name: Streptococcus, group A. One found – sent
to reviewers.
Test system/manufacturer: OSOM AND Analyte Name: Streptococcus, group A. Several found, but no
details of studies in summaries/statements.
Test system/manufacturer: Orion Diagnostica AND Analyte Name: Streptococcus, group A. None found
for QuikRead Go.
Test system/manufacturer: QuikRead Go AND Analyte Name: Streptococcus, group A. None found.
Test system/manufacturer: Biosynex. None found.
Test system/manufacturer: Quidel AND Analyte Name: Streptococcus, group A. Several found; earliest
one sent to reviewers.
European commission medical devices
Checked on 6 March 2019. NB Eudamed database not yet publicly available.
Health services research agencies
International Network of Agencies for Health Technology Assessment
Date searched: 8 March 2019. HTA database also searched (see Bibliographic databases).
Google
Date searched: 27 February 2019.
Targeted search for NADAL Strep A scan using various terms. No study data found.
DOI: 10.3310/hta24310 Health Technology Assessment 2020 Vol. 24 No. 31
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Fraser et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
151

Appendix 2 Data extraction form for
primary studies
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Appendix 3 Excluded studies with reasons
Reference Reason for exclusion
Uphoff TS, Buchan BW, Ledeboer NA, Granato PA, Daly JA, Marti TN. Multicenter
evaluation of the solana group A Streptococcus assay: comparison with culture.
J Clin Microbiol 2016;54:2388–90. https://doi.org/10.1128/JCM.01268-16
Wrong test
Abd El-Ghany SM, Abdelmaksoud AA, Saber SM, Abd El Hamid DH. Group A
beta-hemolytic streptococcal pharyngitis and carriage rate among Egyptian children:
a case-control study. Ann Saudi Med 2015;35:377–82. https://doi.org/10.5144/
0256-4947.2015.377
Wrong test
Abu-Sabaah AH, Ghazi HO. Better diagnosis and treatment of throat infections
caused by group A beta-haemolytic streptococci. Br J Biomed Sci 2006;63:155–8.
https://doi.org/10.1080/09674845.2006.11732740
Wrong test
Agarwal M, Raghuwanshi SK, Asati DP. Antibiotic use in sore throat: are we judicious?
Indian J Otolaryngol Head Neck Surg 2015;67:267–70. https://doi.org/10.1007/s12070-
015-0864-1
Wrong test
Alper Z, Uncu Y, Akalin H, Ercan I, Sinirtas M, Bilgel NG. Diagnosis of acute
tonsillopharyngitis in primary care: a new approach for low-resource settings.
J Chemother 2013;25:148–55. https://doi.org/10.1179/1973947813Y.0000000071
Wrong test
Al-Tawfiq JA, Alawami AH. A multifaceted approach to decrease inappropriate
antibiotic use in a pediatric outpatient clinic. Ann Thorac Med 2017;12:51–4.
https://doi.org/10.4103/1817-1737.197779
No specific RADT mentioned
Amorim R, Filho AF, Abath A, Hatem T, Mourato F, Gomes R, Mattos S. Prevalence of
positive rapid antigen group A Streptococcus test in children and adolescents in a state
from Northeast Brazil. Cardiol Young 2017;27:s484
Wrong test
Anderson KB, Simasathien S, Watanaveeradej V, Weg AL, Ellison DW, Suwanpakdee D,
et al. Clinical and laboratory predictors of influenza infection among individuals with
influenza-like illness presenting to an urban Thai hospital over a five-year period.
PLOS ONE 2018;13:e0193050. https://doi.org/10.1371/journal.pone.0193050
Wrong test
Anderson NW, Buchan BW, Mayne D, Mortensen JE, Mackey TL, Ledeboer NA.
Multicenter clinical evaluation of the illumigene group A streptococcus DNA
amplification assay for detection of group A streptococcus from pharyngeal swabs.
J Clin Microbiol 2013;51:1474–7. https://doi.org/10.1128/JCM.00176-13
Wrong test
André M, Eriksson M, Mölstad S, Stålsbylundborg C, Jacobsson A, Odenholt I, Swedish
Study Group on Antibiotic Use. The management of infections in children in general
practice in Sweden: a repeated 1-week diagnosis-prescribing study in 5 counties
in 2000 and 2002. Scand J Infect Dis 2005;37:863–9. https://doi.org/10.1080/
00365540500335207
No specific RADT mentioned
Andrews D, Chetty Y, Cooper BS, Virk M, Glass SK, Letters A, et al. Multiplex PCR
point of care testing versus routine, laboratory-based testing in the treatment of adults
with respiratory tract infections: a quasi-randomised study assessing impact on length
of stay and antimicrobial use. BMC Infect Dis 2017;17:671. https://doi.org/10.1186/
s12879-017-2784-z
Wrong test
Anonymous. Group A streptococcal pharyngitis: diagnosis and management.
Drug Benefit Trends 2003;15:29–32
Wrong test
Aoki A, Ashizawa T, Ebata A, Nasu Y, Fujii T. Group A streptococcus pharyngitis
outbreak among university students in a judo club. J Infect Chemother 2014;20:190–3.
https://doi.org/10.1016/j.jiac.2013.10.004
Wrong test
Araujo Filho BC, Imamura R, Sennes LU, Sakae FA. Role of rapid antigen detection
test for the diagnosis of group A beta-hemolytic Streptococcus in patients with
pharyngotonsillitis. Braz J Otorhinolaryngol 2005;71:168–71
Wrong test
Araujo Filho BC, Imamura R, Sennes LU, Sakae FA. Role of rapid antigen detection
test for the diagnosis of group-A beta-hemolytic Streptococcus in patients with
pharyngotonsillitis. Braz J Otorhinolaryngol 2006;72:12–15
Wrong test
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Reference Reason for exclusion
Arbefeville S, Nelson K, Thonen-Kerr E, Ferrieri P. Prospective postimplementation
study of solana group A streptococcal nucleic acid amplification test vs conventional
throat culture. Am J Clin Pathol 2018;150:333–7. https://doi.org/10.1093/ajcp/aqy051
Wrong test
Armengol CE, Hendley JO, Schlager TA. Could repetition of the rapid antigen detection
test for group A streptococci on a second swab replace the backup throat culture?
Pediatr Res 2004;55:341A
Meeting abstract could not
be located
Armengol CE, Schlager TA, Hendley JO. Sensitivity of a rapid antigen detection test
for group A streptococci in a private pediatric office setting: answering the Red
Book’s request for validation. Pediatrics 2004;113:924–6. https://doi.org/10.1542/
peds.113.4.924
Wrong test
Atlas SJ, McDermott SM, Mannone C, Barry MJ. The role of point of care testing for
patients with acute pharyngitis. J Gen Intern Med 2005;20:759–61
Wrong test
Ayanruoh S, Waseem M, Quee F, Humphrey A, Reynolds T. Impact of rapid
streptococcal test on antibiotic use in a pediatric emergency department. Pediatr Emerg
Care 2009;25:748–50. https://doi.org/10.1097/PEC.0b013e3181bec88c
Wrong test
Balasubramanian S, Amperayani S, Dhanalakshmi K, Senthilnathan S, Chandramohan V.
Rapid antigen diagnostic testing for the diagnosis of group A beta-haemolytic
streptococci pharyngitis. Natl Med J India 2018;31:8–10. https://doi.org/10.4103/
0970-258X.243433
Wrong test
Ba-Saddik IA, Munibari AA, Alhilali AM, Ismail SM, Murshed FM, Coulter JB, et al.
Prevalence of Group A beta-haemolytic streptococcus isolated from children with
acute pharyngotonsillitis in Aden, Yemen. Trop Med Int Health 2014;19:431–9.
https://doi.org/10.1111/tmi.12264
Wrong test
Bergmark R, Bergmark B, Blander J, Fataki M, Janabi M. Burden of disease and
barriers to the diagnosis and treatment of group A beta-hemolytic streptococcal
pharyngitis for the prevention of rheumatic heart disease in Dar Es Salaam, Tanzania.
Pediatr Infect Dis J 2010;29:1135–7. https://doi.org/10.1097/inf.0b013e3181edf475
No specific RADT mentioned
Bjerrum L, Cots JM, Llor C, Molist N, Munck A. Effect of intervention promoting
a reduction in antibiotic prescribing by improvement of diagnostic procedures:
a prospective, before and after study in general practice. Eur J Clin Pharmacol
2006;62:913–18. https://doi.org/10.1007/s00228-006-0187-y
No comparison with
biological culture or clinical
scores
Brennan-Krohn T, Ozonoff A, Sandora TJ. Adherence to guidelines for testing and
treatment of children with pharyngitis: a retrospective study. BMC Pediatr 2018;18:43.
https://doi.org/10.1186/s12887-018-0988-z
No specific RADT mentioned
Briel M, Young J, Tschudi P, Hersberger KE, Hugenschmidt C, Langewitz W, Bucher HC.
Prevalence and influence of diagnostic tests for acute respiratory tract infections in
primary care. Swiss Med Wkly 2006;136:248–53
Wrong population
Brittain-Long R, Westin J, Olofsson S, Lindh M, Andersson LM. Access to a polymerase
chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics:
a randomised, controlled trial. BMC Med 2011;9:44. https://doi.org/10.1186/1741-
7015-9-44
No specific RADT mentioned
Brook I, Gober AE. Concurrent influenza A and group A beta-hemolytic streptococcal
pharyngotonsillitis. Ann Otol Rhinol Laryngol 2008;117:310–12. https://doi.org/10.1177/
000348940811700412
Wrong test
Bursle E, Robson J. Non-culture methods for detecting infection. Aust Prescr
2016;39:171–5. https://doi.org/10.18773/austprescr.2016.059
Review
Camurdan AD, Camurdan OM, Ok I, Sahin F, Ilhan MN, Beyazova U. Diagnostic
value of rapid antigen detection test for streptococcal pharyngitis in a pediatric
population. Int J Pediatr Otorhinolaryngol 2008;72:1203–6. https://doi.org/10.1016/
j.ijporl.2008.04.008
Wrong test
Cao C, Zhang F, Ji M, Pei F, Fan X, Shen H, et al. Development of a loop-mediated
isothermal amplification method for rapid detection of streptococcal pyrogenic
exotoxin B. Toxicon 2016;117:53–8. https://doi.org/10.1016/j.toxicon.2016.03.019
No specific RADT mentioned
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Reference Reason for exclusion
Cardoso DM, Gilio AE, Hsin SH, Machado BM, de Paulis M, Lotufo JP, et al. Impact of
the rapid antigen detection test in diagnosis and treatment of acute pharyngotonsillitis
in a pediatric emergency room. Rev Paul Pediatr 2013;31:4–9
No comparison with biological
culture or clinical scores
Chen FM. Culture confirmation of negative rapid strep test results. J Fam Pract
2000;49:371–2
Wrong test
Cheng C, Han B, Smoot B, Chen Y, Exner MM. Real-time PCR detection of group A
Streptococcus using the 3M integrated cycler. J Mol Diagn 2010;12:883
Wrong test
Cohen JF, Chalumeau M, Levy C, Bidet P, Benani M, Koskas M, et al. Effect of clinical
spectrum, inoculum size and physician characteristics on sensitivity of a rapid antigen
detection test for group A streptococcal pharyngitis. Eur J Clin Microbiol Infect Dis
2013;32:787–93. https://doi.org/10.1007/s10096-012-1809-1
Wrong test
Cohen JF, Chalumeau M, Levy C, Bidet P, Thollot F, Wollner A, et al. Spectrum and
inoculum size effect of a rapid antigen detection test for group A Streptococcus in
children with pharyngitis. PLOS ONE 2012;7:e39085. https://doi.org/10.1371/journal.
pone.0039085
Wrong test
Cohen JF, Cohen R, Bidet P, Elbez A, Levy C, Bossuyt PM, Chalumeau M. Efficiency of
a clinical prediction model for selective rapid testing in children with pharyngitis: a
prospective, multicenter study. PLOS ONE 2017;12:e0172871. https://doi.org/10.1371/
journal.pone.0172871
Wrong test
Cohen JF, Cohen R, Bidet P, Levy C, Deberdt P, d’Humières C, et al. Rapid-antigen
detection tests for group A streptococcal pharyngitis: revisiting false-positive results
using polymerase chain reaction testing. J Pediatr 2013;162:1282–4, 1284.e1.
https://doi.org/10.1016/j.jpeds.2013.01.050
Wrong test
Cohen R, Levy C, Ovetchkine P, Boucherat M, Weil-Olivier C, Gaudelus J, et al.
Evaluation of streptococcal clinical scores, rapid antigen detection tests and cultures
for childhood pharyngitis. Eur J Pediatr 2004;163:281–2. https://doi.org/10.1007/
s00431-004-1416-y
Wrong test
Dagnelie CF, Bartelink ML, van der Graaf Y, Goessens W, de Melker RA. Towards a
better diagnosis of throat infections (with group A beta-haemolytic Streptococcus) in
general practice. Br J Gen Pract 1998;48:959–62
Wrong test
Dale JC, Novak R, Higgens P,Wahl E. Testing for group A streptococci. Arch Pathol Lab
Med 2002;126:1467–70. https://doi.org/10.1043/0003-9985(2002)126<1467:
TFGAS>2.0.CO;2
No specific RADT mentioned
Dawson ED, Taylor AW, Smagala JA, Rowlen KL. Molecular detection of Streptococcus
pyogenes and Streptococcus dysgalactiae subsp. equisimilis. Mol Biotechnol
2009;42:117–27. https://doi.org/10.1007/s12033-009-9143-2
Wrong test
Demoré B, Tebano G, Gravoulet J, Wilcke C, Ruspini E, Birge J, et al. ‘Rapid antigen
test use for the management of group A streptococcal pharyngitis in community
pharmacies.’ Eur J Clin Microbiol Infect Dis 2018;06:06
Wrong test
Deniz R, Aktaş E, Barış A, Bayraktar B. The use of rapid antigen testing and
matrix-assisted laser desorption/ionization-time of flight mass spectrometry in
the diagnosis of group A beta-hemolytic streptococci in throat swab samples
Turk J Med Sci 2018;48:939–44. https://doi.org/10.3906/sag-1712-101
Wrong test
Dodd M, Adolphe A, Parada A, Brett M, Culbreath K, Mercier RC. Clinical impact of a
rapid streptococcal antigen test on antibiotic use in adult patients. Diagn Microbiol
Infect Dis 2018;91:339–44
Wrong test
Donato LJ, Myhre NK, Murray MA, McDonah MR, Myers JF, Maxson JA, et al.
Assessment of test performance and potential for environmental contamination
associated with a point-of-care molecular assay for group A Streptococcus in an
end user setting. J Clin Microbiol 2019;57:e01629–18
No comparison with culture
or clinical scores
Dulaney K, Hohmeier K, Fisher C, Cardosi L, Wasson M. Exploring pharmacists’
perceptions regarding influenza and streptococcal testing within a chain pharmacy.
J Am Pharm Assoc 2018;58:438–41.e1
No specific RADT mentioned.
No comparison with culture
or clinical scores
Dut R, Kocagoz S. Use of streptococcal tonsillopharyngitis diagnostic tests in children.
J Pediatric Infect Dis 2016;11:126–30
Wrong test
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Reference Reason for exclusion
Dut R, Kocagöz S. Clinical signs and diagnostic tests in acute respiratory infections.
Indian J Pediatr 2016;83:380–5. https://doi.org/10.1007/s12098-015-1943-8
No specific RADT mentioned
Edin A, Granholm S, Koskiniemi S, Allard A, Sjöstedt A, Johansson A. Development
and laboratory evaluation of a real-time PCR assay for detecting viruses and bacteria
of relevance for community-acquired pneumonia. J Mol Diagn 2015;17:315–24.
https://doi.org/10.1016/j.jmoldx.2015.01.005
No specific RADT mentioned
Edmonson MB, Farwell KR. Relationship between the clinical likelihood of group A
streptococcal pharyngitis and the sensitivity of a rapid antigen-detection test in
a pediatric practice. Pediatrics 2005;115:280–5
Wrong type of test
Edmonson MB, Weix KR. Relationship of pre-test likelihood of group A streptococcal
(GAS) pharyngitis and sensitivity of a rapid antigen detection test (RADT) in pediatric
practice. Pediatr Res 2003;53:180A
Abstract could not be located
Ehrlich JE, Demopoulos BP, Daniel KR, Ricarte MC, Glied S. Cost-effectiveness of
treatment options for prevention of rheumatic heart disease from Group A
streptococcal pharyngitis in a pediatric population. Prev Med 2002;35:250–7
Wrong test name
Ehsanipour F, Mirghorbani M, Masoumi Asl H, Harandi NV, Khanaliha K. Comparison
of clinical findings and rapid streptococcal antigen detection test in the diagnosis of
group A streptococcal (GAS) pharyngitis. Arch Clin Infect Dis 2016;11
Wrong test
Elf S, Olli J, Hirvonen S, Auvinen P, Eboigbodin KE. Molecular detection of Streptococcus
pyogenes by strand invasion based amplification assay. Mol Diagn Ther 2018;22:595–602.
https://doi.org/10.1007/s40291-018-0346-8
Wrong type of test
Elmas B, Köroğlu M, Terzi HA, Aslan FG, Menekşe E, Kösecik M, Altindiş M.
Performance of clinical features, acute phase reactants and group A streptococcus
rapid test in evaluation of the etiologic agents for tonsillopharyngitis in children.
Clin Lab 2017;63:1223–31. https://doi.org/10.7754/Clin.Lab.2017.170124
Wrong test
Engström S, Mölstad S, Lindström K, Nilsson G, Borgquist L. Excessive use of rapid
tests in respiratory tract infections in Swedish primary health care. Scand J Infect Dis
2004;36:213–18. https://doi.org/10.1080/00365540310018842
No comparison with clinical
score or throat culture
Enright K, Taheri S, Beattie T. Emergency department testing for streptococcus
in children with sore throats. Emerg Med J 2009;26:310. https://doi.org/10.1136/
emj.2008.058628
No specific RADT mentioned
Fakih MG, Berschback J, Juzych NS, Massanari RM. Compliance of resident and staff
physicians with IDSA guidelines for the diagnosis and treatment of streptococcal
pharyngitis. Infect Dis Clin Pract 2006;14:84–8
Wrong test
FDA. FDA Decision Summary: Substantial Equivalence Determination for the Sofia® Strep A
+ FIA. K141775. Silver Spring, MD: FDA; 2014. URL: www.accessdata.fda.gov/cdrh_
docs/reviews/K141775.pdf (accessed 6 March 2019)
Wrong test
FDA. FDA Decision Summary: Substantial Equivalence Determination for Cobas Liat Strep A.
K141338. Silver Spring, MD: FDA; 2015. URL: www.accessdata.fda.gov/cdrh_docs/
reviews/K141338.pdf (accessed 6 March 2019)
Data identical to those
provided by the manufacturer
in response to a request for
information by NICE
FDA. FDA Decision Summary: Substantial Equivalence Determination for TestPack Plus
Strep A. K971522. Silver Spring, MD: FDA; 1997. URL: www.accessdata.fda.gov/cdrh_
docs/pdf/K971522.pdf (accessed 6 March 2019)
Insufficient information
Felsenstein S, Faddoul D, Sposto R, Batoon K, Polanco CM, Dien Bard J. Molecular and
clinical diagnosis of group A streptococcal pharyngitis in children. J Clin Microbiol
2014;52:3884–9. https://doi.org/10.1128/JCM.01489-14
Wrong test
Fierro JL, Prasad PA, Localio AR, Grundmeier RW, Wasserman RC, Zaoutis TE,
Gerber JS. Variability in the diagnosis and treatment of group A streptococcal
pharyngitis by primary care pediatricians. Infect Control Hosp Epidemiol
2014;35(Suppl. 3):79–85. https://doi.org/10.1086/677820
No specific RADT mentioned
Fontes MJ, Bottrel FB, Fonseca MT, Lasmar LB, Diamante R, Camargos PA. Early
diagnosis of streptococcal pharyngotonsillitis: assessment by latex particle
agglutination test. J Pediatr 2007;83:465–70. https://doi.org/10.2223/JPED.1695
Wrong type of test
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Reference Reason for exclusion
Forward K. Just the berries. Diagnosing and managing group A Streptococcus
pharyngitis. Can Fam Physician 2002;48:47–8
Review
Forward KR, Haldane D, Webster D, Mills C, Brine C, Aylward D. A comparison
between the Strep A Rapid Test Device and conventional culture for the diagnosis of
streptococcal pharyngitis. Can J Infect Dis Med Microbiol 2006;17:221–3
Wrong test
Fox JW, Cohen DM, Marcon MJ, Cotton WH, Bonsu BK. Performance of rapid
streptococcal antigen testing varies by personnel. J Clin Microbiol 2006;44:3918–22
Wrong test
Fox JW, Marcon MJ, Bonsu BK. Diagnosis of streptococcal pharyngitis by detection of
Streptococcus pyogenes in posterior pharyngeal versus oral cavity specimens. J Clin
Microbiol 2006;44:2593–4
Wrong test
Gazewood J. Negative antigen test misses < 5% of strep pharyngitis. J Fam Pract
2003;52:761–2
Review
Gazzano V, Berger A, Benito Y, Freydiere AM, Tristan A, Boisset S, et al. Reassessment of
the role of rapid antigen detection tests in diagnosis of invasive group A streptococcal
infections. J Clin Microbiol 2016;54:994–9. https://doi.org/10.1128/JCM.02516-15
Wrong population
Gieseker KE, Roe MH, MacKenzie T, Todd JK. Evaluating the American Academy of
Pediatrics diagnostic standard for Streptococcus pyogenes pharyngitis: backup culture
versus repeat rapid antigen testing. Pediatrics 2003;111:e666–70
Wrong test
Gieseker KE, Mackenzie T, Roe MH, Todd JK. Comparison of two rapid Streptococcus
pyogenes diagnostic tests with a rigorous culture standard. Pediatr Infect Dis J
2002;21:922–7. https://doi.org/10.1097/00006454-200210000-00007
Wrong test
Giraldez-Garcia C, Rubio B, Gallegos-Braun JF, Imaz I, Gonzalez-Enriquez J,
Sarria-Santamera A. Diagnosis and management of acute pharyngitis in a paediatric
population: a cost-effectiveness analysis. Eur J Pediatr 2011;170:1059–67.
https://doi.org/10.1007/s00431-011-1410-0
No specific RADT mentioned
Gonsu HK, Bomki CM, Djomou F, Toukam M, Ndze VN, Lyonga EE, et al. A comparative
study of the diagnostic methods for group A streptococcal sore throat in two
reference hospitals in Yaounde, Cameroon. Pan Afr Med J 2015;20:139. https://doi.org/
10.11604/pamj.2015.20.139.4810
Wrong test
Greiver M. Practice tips. Incorporating a rapid group A streptococcus assay with the
sore throat score. Can Fam Physician 1999;45:1181–2
Review
Gröndal H, Hedin K, Strandberg EL, André M, Brorsson A. Near-patient tests and the
clinical gaze in decision-making of Swedish GPs not following current guidelines for
sore throat - a qualitative interview study. BMC Fam Pract 2015;16:81. https://doi.org/
10.1186/s12875-015-0285-y
No specific RADT mentioned
Gurol Y, Akan H, Izbirak G, Tekkanat ZT, Gunduz TS, Hayran O, Yilmaz G. The
sensitivity and the specifity of rapid antigen test in streptococcal upper respiratory
tract infections. Int J Pediatr Otorhinolaryngol 2010;74:591–3. https://doi.org/10.1016/
j.ijporl.2010.02.020
Wrong test
Haldrup S, Thomsen RW, Bro F, Skov R, Bjerrum L, Søgaard M. Microbiological point
of care testing before antibiotic prescribing in primary care: considerable variations
between practices. BMC Fam Pract 2017;18:9. https://doi.org/10.1186/s12875-016-
0576-y
No specific RADT mentioned
Hall MC, Kieke B, Gonzales R, Belongia EA. Spectrum bias of a rapid antigen detection
test for group A beta-hemolytic streptococcal pharyngitis in a pediatric population.
Pediatrics 2004;114:182–6. https://doi.org/10.1542/peds.114.1.182
Wrong test
Hammond-Collins K, Strauss B, Barnes K, Demczuk W, Domingo MC, Lamontagne MC,
et al. Group A streptococcus outbreak in a Canadian armed forces training facility.
Mil Med 2018;21:21
Wrong test
Herranz B, Rodriguez-Salinas E, Orden B. [From laboratory to clinic: usefulness of
rapid diagnostic techniques for the diagnostic techniques of Streptococcus pyogenes.]
An Pediatr Contin 2007;5:92–5
Foreign-language paper
Hinfey P, Nicholls BH, Garcia F, Ripper J, Cameron Y, Joshi S. Sensitivity of a rapid
antigen detection test for the diagnosis of group A streptococcal pharyngitis in the
emergency department. Ann Emerg Med 2010;56:S132
Wrong test
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Reference Reason for exclusion
Hoffmann K, Reichardt B, Zehetmayer S, Maier M. Evaluation of the implementation
of a rapid streptococcal antigen test in a routine primary health care setting: from
recommendations to practice. Wien Klin Wochenschr 2012;124:633–8. https://doi.org/
10.1007/s00508-012-0225-y
No specific RADT mentioned
Homme JH, Greenwood CS, Cronk LB, Nyre LM, Uhl JR, Weaver AL, Patel R. Duration
of group A streptococcus PCR positivity following antibiotic treatment of pharyngitis.
Diagn Microbiol Infect Dis 2018;90:105–8
Wrong test
Honkanen PO, Rautakorpi UM, Huovinen P, Klaukka T, Palva E, Roine R, et al.
Diagnostic tools in respiratory tract infections: use and comparison with Finnish
guidelines. Scand J Infect Dis 2002;34:827–30. https://doi.org/10.1080/
0036554021000026939
No specific RADT mentioned
Humair JP, Revaz SA, Stalder H. Antibiotic prescription in strategies using a clinical
score and a rapid streptococcal test for acute pharyngitis. J Gen Intern Med
2002;17:125
Wrong test
Igarashi H, Nago N, Kiyokawa H, Fukushi M. Abdominal pain and nausea in the
diagnosis of streptococcal pharyngitis in boys. Int J Gen Med 2017;10:311–18.
https://doi.org/10.2147/IJGM.S144310
Wrong test
Jayaratne P, Rutherford C. Detection of group A streptococci (GAS) by loop-mediated
isothermal amplification (LAMP) directly from specimens: a rapid, simple and
cost-effective alternative to culture. Can J Infect Dis Med Microbiol 2015;26:e19
Wrong test
Joachim L, Campos D, Smeesters PR. Pragmatic scoring system for pharyngitis in
low-resource settings. Pediatrics 2010;126:e608–14. https://doi.org/10.1542/
peds.2010-0569
Wrong test
Kato Y, Suzuki K, Shibai Y, Iwamoto H. Development of simultaneous detection lateral
flow immunoassay kit for GAS and ADV. Clin Chem 2015;1:S150
Wrong test
Keahey L, Bulloch B, Jacobson R, Tenenbein M, Kabani A. Diagnostic accuracy of a
rapid antigen test for GABHS performed by nurses in a pediatric ED. Am J Emerg Med
2002;20:128–30
Wrong test
Khattak MH, Khan MA, Shafiullah Orakzi UK. Incidence of acute streptococcal
pharyngitis. J Med Sci 2015;23:118–20
No specific RADT mentioned
Kivi N, Vanhanen AR, Nissinen A. Assessment of strep a point-of-care testing
performance through external quality assurance (EQA) scheme: results of a 6-year
study period (2009-2015). Clin Chem Lab Med 2016;54:eA277
No specific RADT mentioned
Klepser DG, Klepser ME, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA.
Community pharmacist-physician collaborative streptococcal pharyngitis management
program. J Am Pharm Assoc 2016;56:323–9.e1. https://doi.org/10.1016/j.japh.2015.11.013
Wrong test
Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE.
Utilization of influenza and streptococcal pharyngitis point-of-care testing in the
community pharmacy practice setting. Res Social Adm Pharm 2018;14:356–9
No specific RADT mentioned
Klepser D, Grismer SE, Klepser ME. Cost-effectiveness of pharmacist provided care
for the treatment of adult pharyngitis. J Manag Care Pharm 2011;17:241
No specific RADT mentioned
Klepser DG, Bisanz SE, Klepser ME. Cost-effectiveness of pharmacist-provided
treatment of adult pharyngitis. Am J Manag Care 2012;18:e145–54
No specific RADT mentioned
Kose E, Sirin Kose S, Akca D, Yildiz K, Elmas C, Baris M, Anil M. The effect of rapid
antigen detection test on antibiotic prescription decision of clinicians and reducing
antibiotic costs in children with acute pharyngitis. J Trop Pediatr 2016;62:308–15.
https://doi.org/10.1093/tropej/fmw014
Wrong test
Kreher NE, Hickner JM, Barry HC, Messimer SR. Do gastrointestinal symptoms
accompanying sore throat predict streptococcal pharyngitis? An UPRNet study.
Upper Peninsula Research Network. J Fam Pract 1998;46:159–64
Wrong test
Küçük O, Biçer S, Giray T, Cöl D, Erdağ GC, Gürol Y, et al. Validity of rapid antigen
detection testing in group A beta-hemolytic streptococcal tonsillopharyngitis. Indian J
Pediatr 2014;81:138–42. https://doi.org/10.1007/s12098-013-1067-y
Wrong test
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Reference Reason for exclusion
Kulkarni T, Aikawa C, Nozawa T, Murase K, Maruyama F, Nakagawa I. DNA-based
culture-independent analysis detects the presence of group A Streptococcus in throat
samples from healthy adults in Japan. BMC Microbiol 2016;16:237. https://doi.org/
10.1186/s12866-016-0858-5
Wrong type of test
Kurtz B, Kurtz M, Roe M, Todd J. Importance of inoculum size and sampling effect in
rapid antigen detection of Streptococcus pyogenes pharyngitis. Pediatr Res 1999;45:166A
Not enough information
Lasseter G, McNulty C, Hobbs FDR, Mant D, PRISM Investigators. In vitro evaluation
of five rapid antigen detection tests for group A beta-haemolytic streptococcal sore
throat infections. Health Technol Assess 2014;18(6)
Wrong population
Lasseter GM, McNulty CA, Hobbs FD, Mant D, Little P, PRImary care Streptococcal
Management (PRISM) Investigators Group. Effect of swab type on the analytical
sensitivity of five point-of-care tests for group A streptococci. Br J Biomed Sci
2011;68:91–4. https://doi.org/10.1080/09674845.2011.11978232
Wrong population
Lasseter GM, McNulty CA, Richard Hobbs FD, Mant D, Little P, PRISM Investigators.
In vitro evaluation of five rapid antigen detection tests for group A beta-haemolytic
streptococcal sore throat infections. Fam Pract 2009;26:437–44. https://doi.org/
10.1093/fampra/cmp054
Wrong population
Lathia N, Sullivan K, Tam K, Brna M, MacNeil P, Saltmarche D, Agro K. Cost-
minimization analysis of community pharmacy-based point-of-care testing for strep
throat in 5 Canadian provinces. Can Pharm J 2018;151:322–31. https://doi.org/
10.1177/1715163518790993
No specific RADT mentioned
Leydon G, McDermott L, Moore M, Williamson I, Hobbs FDR, Little P, PRISM
Investigators. A qualitative study of general practitioner, nurse practitioner and patient
views about the use of rapid Streptococcus antigen detection tests in primary care:
‘swamped with sore throats?’. Health Technol Assess 2014;18(6)
Duplicate
Leydon GM, McDermott L, Moore M, Williamson I, Hobbs FD, Lambton T, et al.
A qualitative study of GP, NP and patient views about the use of rapid streptococcal
antigen detection tests (RADTs) in primary care: ‘swamped with sore throats?’.
BMJ Open 2013;3:e002460. https://doi.org/10.1136/bmjopen-2012-002460
No specific RADT mentioned
Li Y, Kim HJ, Kong H, Ranalli TA, Olivo PD, Stenzel TT. Detection of group A
Streptococcus with a rapid, non-instrumented, isothermal molecular assay on throat
swab specimens. J Mol Diagn 2013;15:890
No specific RADT mentioned
Little P, Hobbs FD, Moore M, Mant D, Williamson I, McNulty C, et al. PRImary care
Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a
pragmatic adaptive randomised controlled trial with nested qualitative study and
cost-effectiveness study. Health Technol Assess 2014;18(6). https://doi.org/10.3310/
hta18060
Wrong population in study 1.
Wrong test in study 3
Little P, Moore M, Hobbs FDR, Mant D, McNulty C, Williamson I, et al. Randomised
controlled trial of a clinical score and rapid antigen detection test for sore throats.
Health Technol Assess 2014;18(6)
Duplicate
Llor C, Bjerrum L, Munck A, Cots JM, Hernández S, Moragas A, HAPPY AUDIT
Investigators. Access to point-of-care tests reduces the prescription of antibiotics
among antibiotic-requesting subjects with respiratory tract infections. Respir Care
2014;59:1918–23. https://doi.org/10.4187/respcare.03275
No specific RADT mentioned
Llor C, Hernández S, Sierra N, Moragas A, Hernández M, Bayona C. Association
between use of rapid antigen detection tests and adherence to antibiotics in suspected
streptococcal pharyngitis. Scand J Prim Health Care 2010;28:12–17. https://doi.org/
10.3109/02813431003669301
Wrong population and
outcome
Llor C, Moragas A, Cots JM, López-Valcárcel BG, Happy Audit Study Group. Estimated
saving of antibiotics in pharyngitis and lower respiratory tract infections if general
practitioners used rapid tests and followed guidelines. Aten Primaria 2017;49:319–25
No specific RADT mentioned
Lotufo JPB, Cardoso DM, Gilio AE, Hsin SH, Machado BM, De Paulis M, et al. Impact
of the use of rapid antigen detection test in the diagnosis and treatment of acute
pharyngitis in pediatric emergency room. Paediatr Respir Rev 2012;13(Suppl. 1):S70
No specific RADT mentioned
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Reference Reason for exclusion
Luo R, Sickler J, Vahidnia F, Lee YC, Frogner B, Thompson M. Diagnosis and
management of group A streptococcal pharyngitis in the United States, 2011–2015.
BMC Infect Dis 2019;19:193. https://doi.org/10.1186/s12879-019-3835-4
No specific RADT mentioned
Madurell J, Balague M, Gomez M, Cots JM, Llor C. Impact of rapid antigen detection
testing on antibiotic prescription in acute pharyngitis in adults. FARINGOCAT STUDY:
a multicentric randomized controlled trial. BMC Fam Pract 2010;11:25
Protocol only. No results
Makri A, Tzanakaki G, Kalimeratzi S, Iliadou H, Xiroyianni A, Kremastinou J, Voyatzi A.
Evaluation of polymerase chain reaction as rapid diagnostic tool compared to culture in
respiratory tract infections. Clin Microbiol Infect 2010;2:S513
No specific RADT mentioned
Malecki M, Mazur A, Sobolewski M, Binkowska-Bury M, Marc M, Januszewicz P.
Rapid strip tests as a decision-making tool about antibiotic treatment in children –
a prospective study. Pediatr Pol 2017;92:149–55
No comparator
Maltezou HC, Tsagris V, Antoniadou A, Galani L, Douros C, Katsarolis I, et al. Evaluation
of a rapid antigen detection test in the diagnosis of streptococcal pharyngitis in children
and its impact on antibiotic prescription. J Antimicrob Chemother 2008;62:1407–12.
https://doi.org/10.1093/jac/dkn376
Wrong test
Mayes T, Pichichero ME. Are follow-up throat cultures necessary when rapid antigen
detection tests are negative for group A streptococci? Clin Pediatr 2001;40:191–5
Wrong test
Mazur E, Bochyńska E, Juda M, Kozioł-Montewka M. Empirical validation of Polish
guidelines for the management of acute streptococcal pharyngitis in children. Int J
Pediatr Otorhinolaryngol 2014;78:102–6. https://doi.org/10.1016/j.ijporl.2013.10.064
Wrong test
Messina A, Bottaro G, Morselli I. Utility of rapid antigen detection test for group A
streptococci in a family paediatrician office setting. Acta Med Mediterr 2010;26:101–5
No outcomes by test
Michel-Lepage A, Ventelou B, Nebout A, Verger P, Pulcini C. Cross-sectional survey:
risk-averse French GPs use more rapid-antigen diagnostic tests in tonsillitis in children.
BMJ Open 2013;3:e003540. https://doi.org/10.1136/bmjopen-2013-003540
No specific RADT mentioned
Michel-Lepage A, Ventelou B, Verger P, Pulcini C. Factors associated with the use of
rapid antigen diagnostic tests in children presenting with acute pharyngitis among
French general practitioners. Eur J Clin Microbiol Infect Dis 2014;33:723–8.
https://doi.org/10.1007/s10096-013-2003-9
No specific RADT mentioned
Mirjat KA, Fatima I, Mustafa F. Prevalence of pharyngitis and tonsilitis among children.
Med For Mon 2012;23:64–7
Not enough information
Mirjat KA, ValiRam P, Fatima I. Role of rapid antigen detection test (RADT) and throat
culture in the diagnosis of streptococcal pharyngotonsillitis. Med Foru Mon 2012;23:60–3
Not enough information
Mirza A, Wludyka P, Chiu TT, Rathore MH. Throat culture is necessary after negative
rapid antigen detection tests. Clin Pediatr 2007;46:241–6
Wrong test
Miyashita N, Kawai Y, Kato T, Tanaka T, Akaike H, Teranishi H, et al. Rapid diagnostic
method for the identification of Mycoplasma pneumoniae respiratory tract infection.
J Infect Chemother 2016;22:327–30. https://doi.org/10.1016/j.jiac.2016.02.005
Wrong test
Mlejnek JR, Almulhem K, Spadafore S. Utility and cost effectiveness of throat culture
in the treatment of patients with negative rapid strep screens. Acad Emerg Med
2014;1:S51
Unclear population
Moore N. Rapid and sensitive isothermal molecular amplification of group A
Streptococcus (GAS) with Alere i Molecular Platform. J Molec Diagnos 2017;19:987
Wrong outcome
Morandi PA, Deom A, Mauris A, Rohner P. External quality control of direct antigen
tests to detect group A streptococcal antigen. Eur J Clin Microbiol Infect Dis
2003;22:670–4. https://doi.org/10.1007/s10096-003-1027-y
Wrong population
Murphy ML, Pichichero ME. Prospective identification and treatment of children with
pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal
infection (PANDAS). Arch Pediatr Adolesc Med 2002;156:356–61
Wrong test
Nakhoul GN, Hickner J. Management of adults with acute streptococcal pharyngitis:
minimal value for backup strep testing and overuse of antibiotics. J Gen Intern Med
2013;28:830–4. https://doi.org/10.1007/s11606-012-2245-8
Wrong test
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Reference Reason for exclusion
Nazgul O, Yoshihisa Y, Guli S, Toshihiro N, Mayramkan A. 2 Prevalence of group A
b-hemolytic Streptococcus among children with tonsillopharyngitis in Kyrgyzstan:
the difficulty of diagnostics and therapy. Int J Rheum Dis 2010;1:212–13
No specific RADT mentioned
NCT. Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid
Detection of Group A Streptococcus in Patients with Acute Pharyngitis. 2017.
URL: https://clinicaltrials.gov/show/nct03171350 (accessed 20 February 2019)
No study publication.
No results
NCT. Comparison of Two Rapid Antigen Detection Tests for the Detection of Group-A
Streptococcal Pharyngitis in Children. 2017. URL: https://clinicaltrials.gov/show/
nct03099018 (accessed 20 February 2019)
No outcome data
Neumark T, Brudin L, Molstad S. Use of rapid diagnostic tests and choice of antibiotics
in respiratory tract infections in primary healthcare – a 6-y follow-up study. Scand J
Infect Dis 2010;42:90–6
No specific RADT mentioned
Nissinen A, Strandén P, Myllys R, Takkinen J, Björkman Y, Leinikki P, Siitonen A.
Point-of-care testing of group A streptococcal antigen: performance evaluated by
external quality assessment. Eur J Clin Microbiol Infect Dis 2009;28:17–20.
https://doi.org/10.1007/s10096-008-0580-9
No comparison with culture
or clinical score
Noorbakhsh S, Tabatabaei A, Farhadi M, Ebrahimi TF. Immunoasssay chromatographic
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Appendix 4 The QUADAS-2 tailored
guidance notes and form
Modified QUADAS-2 and guidance notes for strep A
Risk of bias should only be classed as low for each domain if all questions could be answered with ‘yes’.
If one or more signalling question is answered with ‘no’ the risk of bias should be classed as ‘high’ and
equally if at least one question is answered with ‘unclear’ the risk of bias should be judged ‘unclear’.
Domain 1: patient selection
Test measurement ratings will differ depending on whether or not antibiotics have been
previously prescribed.
A. Risk of bias
Guidance
Was a consecutive or random sample of patients enrolled?
This question should only be answered with ‘yes’ if the study clearly states that children/adults were
recruited consecutively or randomly. Case–control or two-gate studies should be answered no.
Was a case–control design avoided?
There is increased bias in a case–control (two-gate) study compared with a cohort (one-gate) study.
Were selection criteria clearly described (age limits and Centor/FeverPAIN scores)?
All inclusion criteria should be clearly specified. Lack of clear selection criteria, or different selection
criteria, introduces bias through unclear adherence to consecutive or random sampling, and because
there is a recognised bias with the reference standard detecting strep A carriage (rather than strep A
detection), which is exacerbated if a greater proportion of less symptomatic patients are introduced.
Did the study avoid inappropriate exclusions?
Patients who meet the inclusion criteria should be given the index test. If > 5% meet the inclusion
criteria but are not given the test, this is an inappropriate exclusion. If < 5% and no reasons are
provided, this is also an inappropriate exclusion.
All patients who received the index test should have their results reported. If > 5% are not reported,
this is an inappropriate exclusion. If < 5% are reported but no reasons are provided, this is also an
inappropriate exclusion.
We would expect the whole cohort to receive a rapid test(s) (from one of our included list: Clearview
Exact, BD Veritor Plus, Strep A Rapid Test, NADAL Strep A, OSOM Strep A test, QuikRead Go Strep A
test kit, Alere TestPack +Plus Strep A, bioNexia Strep A, Biosynex, Sofia Strep A FIA) or a molecular
test (from one of our included list: Alere i, cobas Liat Strep A Assay or Xpert Xpress Strep A). Also a
comparator [Centor (modified Centor or McIsaac) or FeverPAIN] where included in the study design
and a biological culture as the reference standard. Very small numbers of exclusions (< 5%) may be
acceptable, if accompanied by reasonable explanations.
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Were patients seen in an ambulatory care setting?
Patients seen as inpatients may vary in severity and have comorbidities affecting their diagnosis.
B. Concerns regarding applicability
Guidance
Patients aged < 5 years do not meet our inclusion criteria. If more than 10% of the sample are under
5 years this should be rated as high.
In the UK the test would be given following an assessment using Centor or FeverPAIN. The rapid test
would be given only in people with Centor scores of > 2 points and FeverPAIN scores of > 1 point. If
the study does not mention these tests or no assessment test was undertaken, it should be rated high
concern. If the study included people with scores of ≤ 2 points on Centor or 1 point on FeverPAIN, this
can only be classed as low risk of bias if the test accuracy is reported separately for Centor scores of
> 2 points and FeverPAIN scores of > 1 point. If the test accuracy for low- and high-rated Centor/
FeverPAIN groups are ONLY reported together, this should be reported as a high concern for
applicability.
Domain 2: index test
The main sources of bias introduced by conducting and interpreting the index test are blinding and
defining the threshold. If the reference standard is carried out before the index test (e.g. in case
control studies) it is important to blind personnel to the results of the reference standard.
The QUADAS-2 tool requires a threshold to be prespecified in the methods to avoid adjustment of the
threshold according to the test outcome. In manufactured tests the threshold has been predetermined.
There is some subjectivity in how the RADT tests are read. If the operator claimed to follow the product
insert then the subjectivity has been reduced; however, a bias still exists. There is no subjectivity in
the molecular tests, which tell you on the screen whether or not strep A is present. In studies of test
development, the threshold must be reported and must be prespecified.
A. Risk of bias
Were the index test results interpreted without knowledge of the results of the
reference standard?
In cohort designs where the reference standard was given after or at the same time as the index test,
answer yes. This is because the reference standard is read after a longer time period than the rapid
test. If timing is unclear or the study has a case–control design then this is a yes only if blinding is
specifically mentioned or if the index test is fully automated with no human interpretation.
Was a separate swab undertaken for the index test?
Manufacturers’ specifications require separate swabs be taken for the index and reference standard.
Using one swab for multiple purposes may reduce the amount of the sample and affect the accuracy of
the test.
Was a threshold explicitly prespecified?
All manufactured rapid tests and have an inbuilt threshold; therefore, the answer should be low. If the
threshold is not prespecified then it must be rated as high risk of bias. In test development studies it
must explicitly state that the threshold has been prespecified and what the threshold is.
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Is the test reading objective?
Molecular tests provide the result on the screen so should always be answered yes (low risk of bias).
All rapid tests are subjectively read based on the internal inbuilt threshold bar the BD Veritor plus
system, NADAL Strep A scan test, QuikRead Go Strep A test and Sofia Strep A FIA, which use
analysers/readers to digitally display results. Any test where a subjective reading is taken will have a
high risk of bias and should be answered no.
B. Concerns about applicability
If the study does not specify that the test was carried out to the manufacturer’s specification the
rating should be noted as unclear. Previous versions of included tests should be rated as high.
Domain 3: reference standard
The reference standard should be throat culture. FeverPAIN or Centor are appropriate comparator
screening tests but not a reference standard.
The reference standard should be undertaken using Staphylococcus or Streptococcus agar or simple
blood agar. Cultures using a blood agar should be incubated in an anaerobic atmosphere at 35–37 °C
for 18–24 hours, with cultures read after > 18 hours. Alternatively, blood agar could be incubated
in 5–10% CO2 at 35–37 °C for 18–24 hours. Cultures using staphylococcal or streptococcal selective
agar should be incubated at 35–37 °C in aerobic conditions for 18–48 hours and read after > 24 hours.
Current guidance advises to re-examine plates at 48 hours that yield negative results at 24 hours.29
If the culture is not incubated in the correct manner then there will be a high risk of bias.
Investigators will not be blinded to the clinical scoring tool but should be blinded to the
reference standard.
A. Risk of bias
Was a separate swab taken for throat culture testing?
The American Academy of Pediatrics recommends separate swabs be taken for the index and reference
standard testing (Mitul Patel, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham,
UK, personal communication). Using one swab for multiple purposes may reduce the amount of the
sample and affect the accuracy of the test.
Is the reference standard likely to correctly classify the target condition?
If the reference standard used was throat culture and this was done appropriately then the answer
should be yes. This should be a laboratory culture on a staphylococcal, streptococcal or blood
agar plate during 48 hours. Were the culture medium, atmosphere, duration of incubation and
GAS-confirmation technique described?
Were the reference standard results interpreted without knowledge of the results
of the index test?
This can be rated as low providing the operator in the laboratory is competency assessed and follows
the standard operating procedure. This is applicable to all types of laboratory cultures.
B. Concerns about applicability
The concern of applicability of the reference standard will be ‘high’ if any measure other than a throat
culture is used. The culture should be carried out using a staphylococcal or streptococcal or simple
blood agar plate, incubated as described above and then serotyped. If any of these measures differ
then there is a high risk of bias. If it is not reported then this should be noted as unclear.
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Domain 4: flow and timing
The index test should be carried out prior to the reference standard and to antibiotic prescribing.
A. Risk of bias
Was there an appropriate interval between index test(s) and reference standard?
The swab for throat culture should be taken at the same time as the swab for the RADT and should be
processed within 48 hours. Consider the following:
l Were both index test(s) and reference standard (and comparator where included) all carried out at
the same appointment?
l Were all swabs processed within 48 hours?
If the answer to any of these is no then this is high risk of bias.
Were both index test(s) and reference standard (and comparator where included) all
carried out prior to commencement of antibiotics?
Patients should not have been treated with antibiotics prior to receiving the index test(s) and/or
reference standard.
Did all patients receive a reference standard?
All should receive both the index test and reference standard. Very small numbers of exclusions (< 5%)
may be acceptable, if accompanied by reasonable explanations.
Did all patients receive the same reference standard?
This question should be answered with ‘no’ if patients received different reference standards or if
positive cases on the index test received a different reference standard to negative subjects.
Were all patients included in the analysis?
All patients should be included in the analysis. If inconclusive or intermediate results are not considered in
the analysis the question should be answered with ‘no’. Very small numbers of exclusions (< 5%) may be
acceptable, if accompanied by reasonable explanations. If patients lost to follow-up were not included in
the analysis or > 5% of patients were lost to follow-up (even if considered in the analysis) the question
should be answered with ‘no’. (The actual proportion of patients lost to follow-up needs to be recorded for
each study.) In both cases the risk of bias should be classed as ‘high’.
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Appendix 5 Antibiotic-prescribing behaviours
TABLE 37 Randomised controlled trials on antibiotic-prescribing behaviours
Study (first
author and year
of publication) Country Index test Study details Antibiotic-prescribing behaviour
Little 20136 UK Alere TestPack
Plus (IMI TestPack)
Three-armed trial with a
delayed antibiotics arm (clinical
assessment without a tool), a
clinical tool arm and a rapid
test following clinical tool arm.
Clinicians given guidance to
follow on prescribing
Arm 1: delayed antibiotics
control arm – depending on
severity of presentation
patients were given antibiotics,
given no antibiotics or given a
delayed prescription to collect
after 3–5 days if symptoms did
not improve or worsened
Arm 2: clinical score arm –
patients assessed using
FeverPAIN. Patients with
scores of 0 or 1 were not
offered antibiotics. Immediate
antibiotics were offered for
patients with scores of ≥ 4 and
for scores of 2 or 3 delayed
antibiotics were offered
Arm 3: RADT arm – those
patients with a clinical score
of 0 or 1 were not offered
antibiotics or a RADT, those
with a score of 2 were offered
delayed antibiotics and those
with scores of ≥ 3 were given
a RADT. All those with
negative RADTs were not
offered antibiotics
Antibiotics offered immediately or
a delayed prescription to 89%
(185/207) in delayed prescription
control arm, to 59% (124/211) in
the clinical score arm and 40%
(86/213) in the clinical score plus
RADT arm
Use of antibiotics ascertained from
the patients with incomplete
responses as follows: 46% (75/164)
used antibiotics in the delayed
prescription arm compared with
37% (60/161) in the clinical score
arm and 35% (58/164) in the
clinical score plus RADT arm
Llor 201145 Spain OSOM Strep A test Two-arm cluster randomised
trial. Health-care centres
randomised to intervention
(RADT) arm or control arm
(management with clinical
criteria only)
Control arm GPs prescribed
antibiotics in 64% (168/262) of
patients compared with 44%
(123/281) in the RADT arm.
Of the 60 test-positive cases,
59 were given antibiotics (98%).
In those for whom the test was
negative, 69/225 were given
antibiotics (31%)
Across both trial arms, antibiotic
treatment was ‘inappropriate’
(as culture was negative) in 40%
(210/526) of patients, and in 3%
(16/526) of patients antibiotics
were not prescribed when culture
was positive; 153 of these cases
continued
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TABLE 37 Randomised controlled trials on antibiotic-prescribing behaviours (continued )
Study (first
author and year
of publication) Country Index test Study details Antibiotic-prescribing behaviour
were in the control arm and
73 were in the RADT arm.
Category of inappropriate
decision (overprescribing or
underprescribing) is not reported
by trial arm
Worrall 200755 Canada Clearview Exact
Strep A
Four-armed trial: control arm
using clinician’s independent
decisions as usual practice,
arm using STDR (≤ 1, no need
for antibiotics; 2, decisions
made by the clinician; 3 or 4,
antibiotics needed), arm using
a rapid test (RADT) and arm
using both STDR and RADT
(≤ 1, no need for antibiotics;
2, RADT; 3 or 4, antibiotics
needed). Clinicians were
recommended to follow the
guidance but it was not
enforced
46.7% (247/533) of patients
received antibiotics. 58% (82/141)
usual practice, 55% (94/170) with
Centor score alone compared with
27% (32/120) with rapid antigen
testing alone and 38% (39/102)
with combined rapid antigen
testing and Centor score
TABLE 38 Before-and-after study on antibiotic-prescribing behaviours
Study (first
author and year
of publication) Country Index test Study details Antibiotic-prescribing behaviour
Bird 201835 UK bioNexia Strep A Prospective cohort before-
and-after study. Baseline
antibiotic-prescribing data
were collected retrospectively
from October to November
2014 (method of diagnosis in
this phase is not reported)
and compared (following
introduction of a new
algorithm, RADT for those
with a McIsaac score of > 3)
with rates in August to
November 2015 and
September to November 2016.
Only positive RADT given
antibiotics but clinicians could
prescribe if they still had a
high level of clinical suspicion
of strep A pharyngitis
Following implementation of an
algorithm combining McIsaac
scores and bioNexia Strep A Rapid
Testing, antibiotic-prescribing
rates fell steeply from 79%
(166/210) at baseline to 24%
(51/214) in year 1 and 28.2%
(51/181) for the second year
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Primary health care (health-care
centre, GP clinic, primary care clinic)
Secondary health care (emergency
department, private paediatric clinic,
outpatient clinic, urgent care clinic, walk-in clinic)
Pharmacy 
C
h
ild
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n
A
d
u
lt
s
E
ld
er
ly
A
d
u
lt
s 
an
d
ch
ild
re
n
Alere Testpack
Strep A Plus (R)
Little 20136
(n = 1760, aged
≤ 3 years)
Clearview Strep A
Exact; test type
undefined (R)
Worrall 200755
(n = 533, aged 
≤ 19 years)
bioNexia
Strep A test; test
type undefined (R)
Bird 201835 (n = 395, aged 
6 months to 16 years) 
OSOM Strep A
test strip (R)
Llor 201145 (n = 543, aged 
14–60 years) 
FIGURE 15 Diagram of studies with comparative data (RCTs and before-and-after studies) on antibiotic-prescribing rates
by test type, setting and population. Note: lines between tests indicate head-to-head (direct) comparisons (none were
found). M, molecular test; R, rapid test.
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Appendix 6 Record of searches:
cost-effectiveness
Sore throat/group A Streptococcus with economic evaluations/
quality of life/cost and resource use
Bibliographic databases
Summary of bibliographic database searches
Database Date of search
Number of records from targeted
search results (to screen first)+
other results picked up by broader
search= total number of records
(+ update search results)
MEDLINE (via OvidSP) 22 January 2019
(updated 13 March 2019)
304 + 1728 = 2032 (+ 36)
EMBASE (via OvidSP) 22 January 2019
(updated 13 March 2019)
434 + 2673 = 3107 (+ 67)
NHS EED and HTA database (via CRD) 22 January 2019
(not updated as no new
records added)
13+ 42= 55
Science Citation Index and Conference
Proceedings Citation Index – Science
(via the Web of Science)
29 January 2019
(updated 13 March 2019)
260 + 1397 = 1657 (+ 17)
Cost-Effectiveness Analysis (CEA)
Registry
29 January 2019
(updated 13 March 2019)
3 (+ 0)
EconPapers (RePEc) 29 January 2019
(updated 13 March 2019)
6 (+ 0)
ScHARRHUD 29 January 2019
(updated 13 March 2019)
0 (+ 0)
Total number of records from database searches: (1011 + 5849 = 6860) + 120 from 2019 update
search = 6980.
Total number of records after deduplication: (522 + 2175 = 2697) + 58 from 2019 update search = 2755.
MEDLINE (via OvidSP)
Databases: Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily
and Versions.
Date searched: 22 January 2019 (updated on 13 March 2019; see at the end of this search record).
Date range searched: 1946 to 21 January 2019.
Original search: 22 January 2019
1. exp Pharyngitis/ (15,095)
2. pharyngit*.ti,ab,kf. (5487)
3. (nasophyryngit* or rhinopharyngit* or epipharyngit*).ti,ab,kf. (178)
4. (tonsillit* or tonsilit*).ti,ab,kf. (5615)
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5. ((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*)).ti,ab,kf. (9975)
6. or/1-5 (25,268)
7. Streptococcal Infections/di, mi (13,421)
8. Streptococcus pyogenes/im, ip (5463)
9. 7 or 8 (16,691)
10. ((strep or streptococcal or group) adj2 A).ti,ab,kf. (564,113)
11. 9 and 10 (4859)
12. (strep* adj5 (throat* or pharyn* or tonsil*)).ti,ab,kf. (3410)
13. streptoco* A.ti,ab,kf. (480)
14. (group A adj5 streptoco*).ti,ab,kf. (9515)
15. ((streptococcus or strep or staphylococcus) adj1 (pyogenes or pyogenic)).ti,ab,kf. (7726)
16. ((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield)).ti,ab,kf. (240)
17. (s pyogenes or pyogenes s or micrococcus scarlatinae).ti,ab,kf. (2497)
18. lancefield group.ti,ab,kf. (476)
19. gabhs.ti,ab,kf. (394)
20. or/11-19 (18,885)
21. exp Economics/ (571,394)
22. exp “Costs and Cost Analysis"/ (221,362)
23. Health Status/ (75,366)
24. exp “Quality of Life"/ (171,033)
25. exp Quality-Adjusted Life Years/ (10,672)
26. (pharmacoeconomic* or pharmaco-economic* or economic* or cost* or price or prices or pricing).ti,
ab,kf. (752,907)
27. (expenditure$ not energy).ti,ab,kf. (27,109)
28. (value adj1 money).ti,ab,kf. (32)
29. budget*.ti,ab,kf. (26,932)
30. (health state* or health status).ti,ab,kf. (57,854)
31. (qaly* or ICER or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form 36 or shortform
36 or SF-36 or SF36 or SF-6D or SF6D or SF-12 or SF12 or health utilities index or HUI).ti,ab,
kf. (224,115)
32. (markov or time trade off or TTO or standard gamble or SG or hrql or hrqol or disabilit* or
disutilit* or net benefit or contingent valuation).ti,ab,kf. (215,735)
33. (quality adj2 life).ti,ab,kf. (248,124)
34. (decision adj2 model).ti,ab,kf. (6096)
35. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).ti,ab,kf. (54,743)
36. resource*.ti,ab,kf. (294,615)
37. (well-being or wellbeing).ti,ab,kf. (77,269)
38. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or
37 (2,072,673)
39. 6 and 38 (1622)
40. 20 and 38 (714)
41. 39 and 40 (304)
42. 39 or 40 (2032
43. 42 not 41 (1728)
Updated search: 13 March 2019
Re-ran above search with following date limits:
44. limit 42 to ed=20190122-20190313 (8)
45. limit 42 to ep=20190122-20190313 (17)
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46. 2019*.dt,ez. (265,815)
47. 42 and 46 (29)
48. 44 or 45 or 47 (36)
Total after removing duplicates with previous search: 27.
EMBASE (via OvidSP)
Databases: EMBASE Classic and EMBASE.
Date range searched: 1947 to 2019 week 3.
Date searched: 22 January 2019 (updated on 13 March 2019; see at the end of this search record).
Original search: 22 January 2019
1. *streptococcal pharyngitis/ or *pharyngitis/ or *rhinopharyngitis/ or *sore throat/ or *tonsillitis/ or
*chronic tonsillitis/ or *palatine tonsillitis/ (12,255)
2. pharyngit*.ti,ab,kw. (7907)
3. (nasophyryngit* or rhinopharyngit* or epipharyngit*).ti,ab,kw. (381)
4. (tonsillit* or tonsilit*).ti,ab,kw. (8351)
5. ((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*)).ti,ab,kw. (15,999)
6. or/1-5 (32,848)
7. Streptococcus infection/di (3828)
8. Streptococcus pyogenes/ or streptococcus group a/ or group A streptococcal infection/ (24,060)
9. 7 or 8 (27,010)
10. ((strep or streptococcal or group) adj2 A).ti,ab,kw. (799,616)
11. 9 and 10 (9653)
12. (strep* adj5 (throat* or pharyn* or tonsil*)).ti,ab,kw. (4855)
13. streptoco* A.ti,ab,kw. (636)
14. (group A adj5 streptoco*).ti,ab,kw. (12,259)
15. ((streptococcus or strep or staphylococcus) adj1 (pyogenes or pyogenic)).ti,ab,kw. (9749)
16. ((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield)).ti,ab,kw. (391)
17. (s pyogenes or pyogenes s or micrococcus scarlatinae).ti,ab,kw. (3246)
18. lancefield group.ti,ab,kw. (566)
19. gabhs.ti,ab,kw. (507)
20. or/11-19 (24,568)
21. exp health economics/ (803,214)
22. exp health status/ (219,256)
23. exp “quality of life”/ (447,670)
24. exp quality adjusted life year/ (23,005)
25. (pharmacoeconomic* or pharmaco-economic* or economic* or cost* or price or prices or pricing).ti,
ab,kw. (986,866)
26. (expenditure* not energy).ti,ab,kw. (37,545)
27. (value adj2 money).ti,ab,kw. (2246)
28. budget*.ti,ab,kw. (35,940)
29. (health state* or health status).tw. (75,069)
30. (qaly* or ICER or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form 36 or shortform
36 or SF-36 or SF36 or SF-6D or SF6D or SF-12 or SF12 or health utilities index or HUI).ti,ab,
kw. (321,459)
31. (markov or time trade off or TTO or standard gamble or SG or hrql or hrqol or disabilit* or
disutilit* or net benefit or contingent valuation).ti,ab,kw. (311,593)
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32. (quality adj2 life).tw. (384,281)
33. (decision adj2 model).tw. (9229)
34. (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw. (78,125)
35. resource*.ti,ab,kw. (375,642)
36. (well-being or wellbeing).tw. (99,946)
37. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36 (2,880,444)
38. 6 and 37 (2459)
39. 20 and 37 (1082)
40. 38 and 39 (434)
41. 38 or 39 (3107)
42. 41 not 40 (2673)
Updated search: 13 March 2019
Re-ran the above search with the following date limits:
43. limit 41 to dd=20190122-20190313 (16)
44. limit 41 to em=201901-201903 (25)
45. 43 or 44 (41)
46. limit 41 to dc=20190122-20190313 (42)
47. 45 or 46 (67)
Total after removing duplicates with other update and previous searches: 25.
NHS Economic Evaluation Database and Health Technology Assessment database
(via Centre for Reviews and Dissemination)
Searched on 22 January 2019. (Not updated because no new records have been added to NHS EED
since 31 March 2015 or to the HTA database since 31 March 2018. The INAHTA website was checked
in March 2019 to see if a new platform for the HTA database was available.)
Original search: 22 January 2019
1. MeSH DESCRIPTOR Pharyngitis EXPLODE ALL TREES IN DARE,NHSEED,HTA (73)
2. (pharyngit*) (85)
3. (nasophyryngit*) OR (rhinopharyngit*) OR (epipharyngit*) (5)
4. (tonsillit* or tonsilit*) (43)
5. (((sore or pain* or ache* or aching or inflam* or infect*) adj3 (pharyn* or throat* or tonsil* or
nasopharyn* or rhinopharyn* or epipharyn*))) (91)
6. #1 OR #2 OR #3 OR #4 OR #5 (163)
7. MeSH DESCRIPTOR Streptococcal Infections WITH QUALIFIERS DI, MI IN DARE,
NHSEED,HTA (31)
8. MeSH DESCRIPTOR Streptococcus pyogenes WITH QUALIFIERS IM, IP IN DARE,
NHSEED,HTA (13)
9. #7 OR #8 (36)
10. (((strep or streptococcal or group) adj2 A)) (2025)
11. #9 AND #10 (17)
12. ((strep* adj5 (throat* or pharyn* or tonsil*))) (39)
13. (streptoco* adj1 A) (10)
14. ((group A adj5 streptoco*)) (27)
15. (((streptococcus or strep or staphylococcus) adj1 (pyogenes or pyogenic))) (25)
16. (((streptococcus or strep) adj1 (epidemicus or erysipelatis or erysipelatos or hemolyticus or
haemolyticus or scarlatinae or lancefield))) (0)
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17. ((s pyogenes or pyogenes s or micrococcus scarlatinae)) (1)
18. (lancefield group) (0)
19. (gabhs) (8)
20. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 (51)
21. #6 AND #20 (43)
22. (#21) IN NHSEED, HTA (13)
23. #6 OR #20 (171)
24. (#23) IN NHSEED, HTA (55)
25. (#24 NOT #22) IN NHSEED, HTA (42)
Science Citation Index and Conference Proceedings Citation Index – Science
(via the Web of Science)
Date of search: 29 January 2019 (updated on 13 March 2019; see at the end of this search record).
Original search: 29 January 2019
Note: search record reads from bottom to top.
# 20 1397 #19 not #18
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 19 1657 #17 OR #16
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 18 260 #17 AND #16
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 17 709 #15 AND #14
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 16 1208 #15 AND #5
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 15 3,164,661 TS=(“quality of life” or qol or hrql or hrqol or (“quality adjusted life” NEAR/0 year*) or qaly* or icer
or cost* or economic* or pharmacoeconomic* or pharmaco-economic* or price or prices or pricing
or (expenditure* not energy) or (value NEAR/1 money) or budget* or euro-qol or utilit* or
disutilit* or (net NEAR/0 benefit*) or (contingent NEAR/0 valuation*) or euroqol or “euro qol” or
eq5d or eq-5d or “short-form 36” or “shortform 36” or sf-36 or sf36 or sf-6d or sf6d or sf-12 or
sf12 or “health utilities index” or hui or (time NEAR/0 trade*) or tto or “standard gamble” or sg or
markov or (decision NEAR/1 model*) or (visual NEAR/0 analog*) or “discrete choice” or ((health*
NEAR/0 year*) NEAR/0 equivalen*) or (health NEAR/0 stat*) or (willing* NEAR/1 pay) or
resource* or wellbeing or well-being)
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 14 17,381 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 13 308 TS=gabhs
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 12 445 TS="lancefield group”
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 11 2059 TS=(“s pyogenes” OR “pyogenes s” OR “micrococcus scarlatinae”)
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
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# 10 60 TS=((strep*) NEAR/0 (epidemicus OR erysipelatis OR erysipelatos OR hemolyticus OR
haemolyticus OR scarlatinae OR lancefield))
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 9 7163 TS=((strep*) NEAR/0 (pyogenes OR pyogenic))
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 8 9682 TS=(“group A” NEAR/4 strep*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 7 1165 TS="strep* A”
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 6 2877 TS=(strep* NEAR/4 (throat* OR pharyn* OR tonsil*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 5 12,508 #1 OR #2 OR #3 OR #4
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 4 7034 TS=((sore OR pain* OR ache* OR aching OR inflam* OR infect*) NEAR/2 (pharyn* OR throat* OR
tonsil* OR nasopharyn* OR rhinopharyn* OR epipharyn*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 3 2716 TS=(tonsillit* OR tonsilit*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 2 96 TS=(nasophyryngit* OR rhinopharyngit* OR epipharyngit*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
# 1 4667 TS=pharyngit*
Indexes=SCI-EXPANDED, CPCI-S Timespan=1900-2019
Updated search: 13 March 2019
Re-ran the above search with the following date limits.
# 19 17 #17 or #16 Indexes=SCI-EXPANDED, CPCI-S Timespan=2019-2019
Total after removing duplicates with other update and previous searches: 6.
Cost-Effectiveness Analysis (CEA) Registry
Searched on 29 January 2019 (updated on 13 March 2019; see at the end of this search record).
Original search: 29 January 2019
Single-term searches, deduplicated and screened online. Results (number selected):
pharyngitis 6 (3)
pharynx 4 (0)
nasopharyngitis 0 (0)
nasopharynx 0 (0)
rhinopharyngitis 0 (0)
rhinopharynx 0 (0)
epipharyngitis 0 (0)
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epipharynx 0 (0)
tonsillitis 0 (0)
tonsilitis 0 (0)
tonsil 3 (1, already got from search on pharyngitis above)
throat 6 (2, both already got from search on pharyngitis above)
streptococcus 22 (2, both already got from search on pharyngitis above)
streptococcal 7 (2, both already got from search on pharyngitis above)
strep 30 (3, both already got from search on pharyngitis above)
Potentially relevant results downloaded to EndNote: 3.
Updated search: 13 March 2019
Re-ran the above searches on 13 March 2019. No further records added.
EconPapers (RePEc)
Date searched: 30 January 2019 (updated on 13 March 2019; see at the end of this search record).
Original search: 30 January 2019; advanced search
#1
((pharyn* | nasopharyn* | rhinopharyn* | epipharyn* | tonsil* | throat) + (strep* | “lancefield group” |
pyogenes | micrococcus)) 6
#2
((sore | pain* | ache* | aching | inflam* | infect*) + (throat | pharyn* | tonsil* | nasopharyn* |
rhinopharyn* | epipharyn*)) 31
#3
pharyngitis | nasopharyngitis | rhinopharyngitis | epipharyngitis | tonsilitis | tonsillitis 28
Above three searches combined with OR (|):
#4
((pharyn* | nasopharyn* | rhinopharyn* | epipharyn* | tonsil* | throat) + (strep* | “lancefield group” |
pyogenes | micrococcus)) | ((sore | pain* | ache* | aching | inflam* | infect*) + (throat | pharyn* |
tonsil* | nasopharyn* | rhinopharyn* | epipharyn*)) | (pharyngitis | nasopharyngitis | rhinopharyngitis |
epipharyngitis | tonsilitis | tonsillitis) 52
Deduplicated and screened online, selecting all potentially relevant.
Potentially relevant results downloaded to EndNote: 6.
Updated search: 13 March 2019
Re-ran above combination search on 13 March 2019. One further record added, but this was not
relevant.
School of Health and Related Research Health Utilities Database
Searched on 30 January 2019 (updated on 13 March 2019; see at the end of this search record).
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Original search: 30 January 2019
Single-term searches, deduplicated and screened online. Results (number selected):
pharynx* 0 (0)
nasopharyn* 0 (0)
rhinopharyn* 0 (0)
epipharyn* 0 (0)
tonsil* 0 (0)
throat* 1 (0)
strep* 0 (0)
gapbs 0 (0)
pyogene* 0 (0)
Potentially relevant results downloaded to EndNote: 0.
Updated search: 13 March 2019
Re-ran above searches on 13 March 2019. No further records added.
Other sources
In addition to these searches, any relevant cost-effectiveness studies identified during the clinical
effectiveness review were brought to the attention of the reviewers.
Search engine
Google: searched 22 March 2019.
Search strategy
(HTA OR “health technology assessment”) AND (pharyngitis OR strep OR streptococcus OR
streptococcal).
Checked first 20 records.
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
190
Appendix 7 Excluded studies after full-text
papers received for group A Streptococcus
economics search
Study (first author and
year of publication) Title Reason for exclusion
Banerjee 2018104 Rapid tests for the diagnosis of group A
streptococcal infection: a review of
diagnostic test accuracy, clinical utility,
safety, and cost-effectiveness
The review provides information on two
cost-effectiveness studies. One study has
been included76 and the other study was
excluded as it is not an economic
evaluationa and the test is outside the
NICE scope105
Benjamin 2000106 The costs of testing for streptococcal
pharyngitis in the office laboratory
Letter to editor commenting on Tsevat
and Kotagal107
Not an economic evaluationa
Boyler 2002108 A cost-effectiveness analysis of
recommended strategies for acute
pharyngitis
Abstract
Test outside NICE scope
Ehrlich 2002109 Cost-effectiveness of treatment options
for prevention of rheumatic heart disease
from group A streptococcal pharyngitis in
a pediatric population
No specific test stated
Giraldez-Garcia 2011110 Diagnosis and management of acute
pharyngitis in a paediatric population:
a cost-effectiveness analysis
No specific test stated
Klepser 2011111 Cost-effectiveness of pharmacist provided
care for the treatment of adult pharyngitis
Abstract
No specific test stated
Klepser 201280 Cost-effectiveness of pharmacist provided
care for the treatment of adult pharyngitis
No specific test stated
Komaroff 1983112 A cost-effectiveness analysis of alternate
strategies for management of sore throat
Abstract
No specific test stated
Lathia 2018113 Cost-minimization analysis of community
pharmacy-based point-of-care testing for
strep throat in 5 Canadian provinces
No specific test stated
Maizia 2012114 Diagnostic strategies for acute tonsillitis in
France: a cost-effectiveness study
Not in English (in French)
No specific test stated
Malecki 2017115 Rapid strip tests as a decision-making tool
about antibiotic treatment in children –
a prospective study
Not an economic evaluationa
No comparator
Meier 1990116 Effects of a rapid antigen test for group A
streptococcal pharyngitis on physician
prescribing and antibiotic costs
No specific test stated
Mlejnek 2014100 Utility and cost effectiveness of throat
culture in the treatment of patients with
negative rapid strep screens
No specific test stated
Neuner 200378 Diagnosis and management of adults with
pharyngitis. A cost-effectiveness analysis
Test outside NICE scope
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Study (first author and
year of publication) Title Reason for exclusion
Polisena 2009117 Point of care testing for streptococcal
sore throat: a review of diagnostic
accuracy, cost-effectiveness, and
guidelines
The review provides information on
one cost-effectiveness study that was
excluded as it did not mention a
specific test79
Tsevat 1999107 Management of sore throats in children:
a cost-effectiveness analysis
No specific test stated
Van Howe 200679 Diagnosis and management of pharyngitis
in a pediatric population based on
cost-effectiveness and projected
health outcomes
No specific test stated
a Not looking at incremental costs and incremental benefits.
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Appendix 8 Data extraction for
cost-effectiveness studies
TABLE 39 Data extraction for cost-effectiveness studies: Little et al.76
Study details subheading Description of study details
Study details
Study title PRImary care Streptococcal Management (PRISM) study: in vitro study,
diagnostic cohorts and a pragmatic adaptive RCT with nested qualitative
study and cost-effectiveness study
First author Paul Little (Programme Director of Programme Grants for Applied
Research, Editor-in-Chief for the Programme Grants for Applied Research
journal and member of the NIHR Journals Library Board)
Co-authors Richard Hobbs, Michael Moore, David Mant, Ian Williamson, Cliodna
McNulty, Gemma Lasseter, MY Edith Cheng, Geraldine Leydon, Lisa
McDermott, David Turner, Rafael Pinedo-Villanueva, James Raftery
[previously a member of the NIHR Journals Library Editorial Group
(2012–14), current member of NIHR HTA and EME Editorial Board,
previously Director of the Wessex Institute and Head of NIHR Evaluation,
Trials and Studies Coordinating Centre], Paul Glasziou and Mark Mullee on
behalf of the PRISM investigators
Source of publication Health Technology Assessment 2014, Volume 18, Issue 6
Language English language
Publication type Original article
Inclusion criteria/study eligibility/PICOS
Population (and subgroups) Patients aged ≥ 3 years, who had acute sore throat
Intervention(s) RADTs used with clinical score (FeverPAIN)
All patients received the clinical scoring tool. Those with a score of 0 or 1
were not offered antibiotics or a RADT, those with a score of 2 were
offered delayed antibiotics and those with scores of ≥ 3 were given a RADT.
All those with negative RADTs were not offered antibiotics
Comparator(s) Delayed antibiotics (control group) or clinical score only
In the control group, depending on the severity of their presentation
patients were given antibiotics, given no antibiotics or given a delayed
prescription to collect after 3–5 days if symptoms did not improve or
worsened
In the clinical score group, patients were assessed using the FeverPAIN
clinical scoring tool. Patients with scores of 0 or 1 were not offered
antibiotics. Immediate antibiotics were offered to patients for scores of
≥ 4 and for scores of 2 or 3 delayed antibiotics were offered
Outcome(s) Point change in symptom severity score (primary outcome measure in trial)
and QALYs based on EQ-5D
The symptom severity score is a two-item score (sore throat, difficulty
swallowing); each symptom was scored 0= no problem to 6= as bad as it
can be. A higher score indicates worse symptoms
continued
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TABLE 39 Data extraction for cost-effectiveness studies: Little et al.76 (continued )
Study details subheading Description of study details
Study design Economic analysis alongside a clinical trial
Setting and location GP clinics in south and central England
Type of economic evaluation Cost-effectiveness and cost–utility analysis
Methods
Study perspective NHS perspective
Time horizon 14 days and 28 days (1 month) after randomisation
Discount rate Not applicable
Measurement of effectiveness EQ-5D measure completed at baseline and 14 days after recruitment and
recorded in a patient-completed diary
Measurement and valuation of
preference-based outcomes
EQ-5D values were scored using the standard UK tariff
Resource use and costs Resource use data were obtained from GP case notes and from study
clinicians. Data included GP and nurse practitioner visits; antibiotics;
practice visits for complications of infections and antibiotic complications;
and hospital admissions related to infections. Costs included test costs, staff
time, medications, complications and hospital admissions. Unit costs were
obtained from the Unit Costs of Health and Social Care, NHS Reference
Costs and NHS drug tariff
The costs associated with the clinical score plus the test comprised the
additional time required to provide the intervention as well as the cost of
the RADT (£3.25 per test; £65 for 20 tests)
Currency, price date and conversion Costs are in 2010/11 prices in Great British pounds
Model type None, as it was based on trial data
Assumptions EQ-5D results for the end of the 28-day follow-up period were not
available; therefore, the values obtained at the end of the 14-day period
were assumed to persist to the end of the study period; that is, the last
value obtained was carried forward for 14 days
Analytical methods Incremental costs and outcomes presented
Results
Study parameters Means and 95% CIs were generated for use cost variables. Mean values
(with 95% CI) for outcome variables (both symptom score and QALYs) were
estimated using regression equations controlling for baseline characteristics
(fever and baseline symptoms)
Incremental costs and outcomes Cost-effectiveness analysis
l Mean cost in each group was £44 (clinical score; n = 167), £49 (RADT;
n = 163) and £51 (delayed prescribing; n = 168)
l Mean point estimate in severity score was 2.83 (clinical score), 2.84
(RADT) and 3.15 (delayed prescribing)
l Overall results showed that the clinical score group dominated the other
two groups, being more clinically effective (having a lower symptom
score) and less costly
Cost–utility analysis (complete-case analysis, n = 257)
l Mean cost in each group was £46 (clinical score), £49 (RADT) and £50
(delayed prescribing)
l Mean QALYs at 28 days were 0.0174 (clinical score), 0.0175 (RADT) and
0.0171 (delayed prescribing)
l As the QALY gain is marginally higher in the test group than in the
clinical score group, the RADT generates additional QALYs at £24,528
per QALY. Delayed prescribing was dominated
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TABLE 39 Data extraction for cost-effectiveness studies: Little et al.76 (continued )
Study details subheading Description of study details
Characterising uncertainty Bootstrapping using 5000 samples was used to generate CEACs.
Bootstrapping was also used to generate scatterplots on the cost-
effectiveness plane
At a value of £30,000 per QALY, the probabilities that the three groups
were cost-effective were 28%, 38% and 35%, for the delayed prescribing,
clinical score and RADT groups, respectively, for the 28-day QALY gain
Discussion
Study findings The clinical scoring tool (FeverPAIN) was effective in helping to reduce
symptoms, and the costs in all three groups were similar. The cost–utility
analysis was less clear, as QALY differences were very small, generating
wide CIs. The CEACs for the cost–utility study indicate that clinical score is
most likely to be cost-effective over all values; however, they also indicate
considerable uncertainty
Limitations l 14-day diary had EQ-5D data for only two time points (0 and 14 days)
l The smaller QALY data set may not be representative of the larger group
of individuals in the cost-effectiveness study
l Time frame was short; hence, longer-term impacts were not known
Generalisability The generalisability of the analysis may be limited to the unit costs used in
the analysis
Other
Source of funding The study was funded by the NIHR HTA programme
Conflicts of interest None declared
Comments None
Authors conclusion
Using a clinical score appears to be an efficient use of health-care resources compared with either delayed antibiotic
prescribing or the use of a RADT combined with a clinical score
Reviewer’s conclusion
The authors used appropriate economic methods for the study
EME, Efficacy and Mechanism Evaluation; NIHR, National Institute for Health Research; PICOS, participants,
interventions, comparisons, outcomes and study design.
Note
Name of first reviewer: Hema Mistry. Name of second reviewer: Felix Achana.
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Appendix 9 Adult primary care model:
exploratory sensitivity analyses
Adult primary care model: prevalence of group A Streptococcus and clinical
score threshold for starting antibiotics (usual-care arm) and testing
(intervention arm)
In the base case, a cut-off score of 3 points on the Centor scale was used as the threshold for starting
antibiotic treatment, with scores of ≥ 3 points indicating positive strep A infection. Changing this
threshold to a score of ≥ 2 points had minimal impact on the base-case cost-effectiveness estimates.
However, a threshold of ≥ 1 point for initiating point-of-care testing in primary care (equivalent to a
test-all approach) favoured testing and changed the QALY difference from incremental QALY loss
(–0.00396 per 1000 individuals) to incremental QALY gain (0.00346 per 1000 individuals) for
Clearview Exact Strep A test cassette (Abbott Laboratories) and Clearview Exact Strep A dipstick –
test strip (Abbott Laboratories) compared with usual care (Table 40). The corresponding ICERs changed
from these two tests being dominated in the base case to £7,071,480 and £6,875,048 per QALY gained
for the cassette and dipstick versions, respectively, when compared with usual care.
The cost-effectiveness estimates were also sensitive to the prevalence of strep A among adults
presenting in primary care. Increasing the prevalence rate from 22.6% (base-case model) to 35.9%
(upper estimate from studies included in systematic review of test accuracy studies) generally favoured
usual care (results not shown here); however, decreasing the prevalence to 10% (the value used in the
Neuner et al. study78) favoured the intervention arm (i.e. testing). In the majority of cases, the ICERs
did not change substantially to influence interpretation of cost-effectiveness, but the ICERs for
Clearview Exact Strep A dipstick – test strip and Clearview Exact Strep A test – cassette (Abbott
Laboratories) changed from being dominated (less effective and more costly) to being more effective
and more costly at a 10% prevalence rate (see Table 40).
TABLE 40 Adult primary care model: deterministic sensitivity analyses – Centor threshold for starting antibiotic therapy
and prevalence of strep A
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 2 – changed Centor threshold for starting antibiotics from ≥ 3 to ≥ 1 points
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £24,462 0.00346 £7,071,480
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £23,783 0.00346 £6,875,048
Sensitivity analysis 5 – changed strep A prevalence from 22.6% (base case) to 10% (Neuner et al.78)
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £6092 0.00131 £4,638,696
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £5923 0.00131 £4,510,168
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Adult primary care model: complication rates in treated and untreated
group A streptococcal infection
The ICERs for only Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview
Exact Strep A dipstick – cassette (Abbott Laboratories) were sensitive to modelled rates of complications
(peritonsillar abscess, quinsy and cellulitis as the probabilities used in the model represented all of these
complications as shown Table 41). In the base-case analysis, strep A-related complications rates were set
to 1.5% for untreated infection and 1.3% for treated strep A infection based on UK primary care data
published by Little et al.86 Halving and doubling the complications rates in the untreated group did not
influence ICERs substantially but doubling complications in the treated infection to 2.6% favoured testing.
The ICER for the Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact
Strep A cassette (Abbott Laboratories) changed from being dominated in the base case by usual care to
£3,935,182 and £4,062,173 per QALY gained compared with usual care, respectively (see Table 41).
Adult primary care model: side effects of penicillin
Cost-effectiveness estimates were most sensitive to modelled rates of penicillin-induced anaphylaxis.
In the base case, penicillin-induced anaphylaxis was set to 0.01% probability (see Table 23) and a utility
decrement of 9 quality-adjusted life-days lost (see Table 24) based on figures reported in the Neuner
et al. study,78 with £1744 in treatment costs (Hex et al.93), reflecting the rare but serious nature of
this event. Changing the rate of penicillin-induced anaphylaxis from 0.01% to 0.64% as reported in
Van Howe and Kusnier79 favoured testing: the ICER for Clearview Exact Strep A dipstick – test strip
(Abbott Laboratories) and Clearview Exact Strep A cassette (Abbott Laboratories) changed from being
dominated by usual care in the base case to £3,935,182 and £4,062,173 per QALY gained compared
with usual care. When the rate of mild penicillin rash was doubled from 2% to 4%, the ICER for
Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact Strep A
cassette (Abbott Laboratories) changed from being dominated by usual care in the base case to
£288,702 and £299,305 per QALY gained compared with usual care, respectively (Table 42).
Adult primary care model: assume testing within standard general practice
consultation time
The base-case analysis assumes that the typical general practice consultation duration of 9.22 minutes
on average90 is not sufficient to administer and process tests concurrently with usual consultation
activities. Consequently, 5–12 minutes (depending on test) of additional clinician time was added when
TABLE 41 Adult primary care model: deterministic sensitivity analyses – complications following strep A infection
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 10 – doubled complications in treated strep A to 2.6%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £6399 0.00158 £4,062,173
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £6199 0.00158 £3,935,182
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calculating test costs to account for longer consultation during testing in primary care. Excluding the
additional cost of clinician time favoured testing but the ICERs for only the five NADAL tests fell
below £100,000 per QALY gained compared with usual care (Table 43).
TABLE 42 Adult primary care model: deterministic sensitivity analyses – exploring the impact of complications of penicillin
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 16 – doubled rates of mild penicillin reaction (rash) to 4%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £6399 0.00107 £4,062,173
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £6199 0.00107 £3,935,182
Sensitivity analysis 17 – changed rates of anaphylaxis from 0.01% (Neuner et al.78) to 0.64% (Van Howe and Kusnier79)
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £5647 0.01887 £299,305
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £5447 0.01887 £288,702
TABLE 43 Adult primary care model: deterministic sensitivity analyses – exploring the impact of excluding additional
clinician time to administer and process test results
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 22 – assume testing within standard GP time
NADAL Strep A –
test strip (nal von
minden GmbH)
£5248 0.00388 £1,353,677 £171 0.00388 £44,184
NADAL Strep A –
cassette (nal von
minden GmbH)
£5298 0.00388 £1,366,577 £221 0.00388 £57,085
NADAL Strep A
plus – cassette (nal
von minden GmbH)
£5323 0.00388 £1,373,029 £246 0.00388 £63,537
NADAL Strep A
plus – test strip (nal
von minden GmbH)
£5272 0.00388 £1,360,126 £196 0.00388 £50,636
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£5438 0.00388 £1,402,700 £361 0.00388 £93,211
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Adult primary care model: utility decrement, group A Streptococcus sore
throat and related complications
The base-case estimates were sensitive to changes in disutility associated with strep A sore throat
and related complications. Decreasing the utility decrement associated with untreated strep A by half
favoured testing, and doubling it favoured usual care (Table 44). All other testing scenarios involving
doubling the utility decrements for treated strep A infection and penicillin-induced rash produced
ICERs favourable to testing (key result changes are presented in Table 44).
TABLE 44 Adult primary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 27 – halved the utility decrement, untreated strep A
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £7033 0.00667 £1,054,577
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £6833 0.00667 £1,024,581
Sensitivity analysis 28 – doubled utility decrement, untreated strep A
Strep A Rapid Test –
cassette (Biopanda
Reagents)
£6295 0.00311 £2,026,496 £6295 –0.0002 Dominated
Strep A Rapid Test –
test strip (Biopanda
Reagents)
£6250 0.00311 £2,012,006 £6250 –0.0002 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£5634 0.00293 £1,924,717 £5634 –0.0004 Dominated
Sensitivity analysis 30 – doubled utility decrement, treated strep A
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £7033 0.00879 £799,685
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £6833 0.00879 £776,939
Sensitivity analysis 36 – doubled utility decrement, penicillin-induced rash
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7033 –0.00396 Dominated £7033 0.00107 £6,554,023
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£6833 –0.00396 Dominated £6833 0.00107 £6,367,600
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Appendix 10 Adult secondary care model:
exploratory sensitivity analyses
Adults in secondary care: Centor threshold for starting antibiotics
and testing
In the base-case secondary care model, a Centor score of ≥ 3 points was used as an indication for
starting antibiotic treatment in the usual-care arm and to initiate testing using a point-of-care test
in the intervention arm. Changing this threshold to a Centor score of ≥ 2 points favoured testing
and produced ICERs for the NADAL’s tests ranging between £30,230 and £69,690 per QALY gained
compared with usual care (Table 45). Using a threshold of ≥ 1 point also favoured testing. The ICER
for Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact Strep A
cassette (Abbott Laboratories) changed from being dominated by usual care to £1,890,627 and
£2,087,056 per QALY gained in comparison with usual care, respectively (see Table 45). The ICERs
for NADAL’s tests reduced further to between £22,220 and £56,190 per QALY gained in comparison
with usual care. ICERs for the other tests remained well above £100,000 per QALY gained in these
scenario analyses.
Adults in secondary care: prevalence of group A Streptococcus
Changing the prevalence of strep A infection in secondary care from 22.6% base-case value to 35.9%
(upper value reported in studies included in the test accuracy systematic review) was less favourable
to testing, with usual care dominating QuikRead Go Strep A test kit (Orion Diagnostica) and Alere
TestPack +Plus Strep A – cassette (Abbott Laboratories) in comparison with base-case results (Table 46).
In contrast, a lower prevalence of disease was more favourable to testing, with ICERs for Clearview
Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact Strep A cassette (Abbott
Laboratories) changing from being dominated by usual care to £1,248,775 and £1,377,303 per QALY
gained, respectively, in comparison with usual care (see Table 46). ICERs for NADAL’s tests decreased
to between £20,628 and £53,506 per QALY gained in comparison with usual care. ICERs for all other
tests did not change substantially to suggest change in the direction of cost-effectiveness in comparison
with usual care.
Adults in secondary care: complication rates
In the base-case analysis, strep A-related complications rates were set to 1.5% for untreated infection and
1.3% for treated infection based on UK primary care data published by Little et al.86 Halving complications
in the treated group to 0.65% and doubling the rate in the untreated group to 3% were less favourable to
testing, with usual care dominating QuikRead Go Strep A test kit (Orion Diagnostica) and Alere TestPack
+Plus Strep A – cassette (Abbott Laboratories). In contrast, doubling the complications rates in the treated
group to 2.6% and halving the rate in the untreated group to 0.75% favoured testing. The ICER for the
Clearview Exact Strep A dipstick – test strip (Abbott Laboratories) and Clearview Exact Strep A cassette
(Abbott) changed from being dominated by usual care in the base case to £712,813 and £839,805 per
QALY gained, respectively (Table 47). ICERs for the NADAL tests ranged between £31,184 and £83,041
per QALY gained in the scenarios that favoured testing. ICERs for all other tests were much lower in
comparison with the base-case estimates but still remained well above £100,000 per QALY gained in
comparison with usual care.
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TABLE 45 Adult secondary care model: deterministic sensitivity analyses – Centor threshold for starting antibiotics
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 1 – changed Centor threshold from ≥ 3 (base case) to ≥ 2 points
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £307 0.01015 £30,230
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £412 0.01015 £40,614
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £465 0.01015 £45,807
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £359 0.01015 £35,422
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £707 0.01015 £69,690
Sensitivity analysis 2 – changed Centor threshold from ≥ 3 (base case) to ≥ 1 points
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £7220 0.00346 £2,087,056
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £6540 0.00346 £1,890,627
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £422 0.019 £22,220
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £592 0.019 £31,159
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £677 0.019 £35,629
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £507 0.019 £26,690
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £1068 0.019 £56,190
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TABLE 46 Adult secondary care model: deterministic sensitivity analyses – prevalence of strep A
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 4 – changed strep A prevalence from 22.6% to 35.9%
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £246 0.00282 £87,196
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £275 0.00282 £97,522
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £2120 –0.00241 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £711 –0.00055 Dominated
Sensitivity analysis 5 – changed strep A prevalence from 22.6% to 10%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1809 0.00131 £1,377,303
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1640 0.00131 £1,248,775
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £101 0.00488 £20,628
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £143 0.00488 £29,280
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £164 0.00488 £33,606
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £122 0.00488 £24,954
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £261 0.00488 £53,506
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TABLE 47 Adult secondary care model: deterministic sensitivity analyses – complications following strep A sore throat
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 9 – halved complications in treated infection to 0.65%
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £191 0.0037 £51,597
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £241 0.0037 £65,100
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £266 0.0037 £71,853
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £216 0.0037 £58,350
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £2119 –0.00097 Dominated
Sensitivity analysis 10 – doubled complications in treated infection to 2.6%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1323 0.00158 £839,805
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1123 0.00158 £712,813
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £132 0.00422 £31,184
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £182 0.00422 £43,028
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £207 0.00422 £48,948
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £157 0.00422 £37,104
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £322 0.00422 £76,191
Sensitivity analysis 11 – halved complications in untreated infection to 0.75%
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £148 0.00408 £36,415
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £198 0.00408 £48,684
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Adults in secondary care: adverse effects of penicillin
Cost-effectiveness estimates were most sensitive to the adverse effects of penicillin. Halving the mild/
uncomplicated side effects of penicillin (rash) to 1.0% favoured usual care, and doubling it favoured
testing (Table 48). The Clearview Exact Strep A cassette (Abbott Laboratories) and Clearview Exact
Strep A dipstick – test strip (Abbott Laboratories) are no longer dominated by usual care under this
scenario. ICERs for the NADAL tests ranged between £8913 and £32,557 per QALY gained compared
with usual care. In the base case, penicillin-induced anaphylaxis was set to 0.01% probability (see
Table 23) and a utility decrement of 9 quality-adjusted life-days lost (see Table 24) based on figures
reported in Neuner et al.,78 with £1744 in treatment costs (Hex et al.93). Changing the rate of penicillin-
induced rash from 0.01% to 0.64% as reported in Van Howe and Kusnier79 favoured testing with Alere
TestPack +Plus Strep A – cassette (Abbott Laboratories) and all five NADAL tests, dominating usual
care (see Table 48). ICERs for the remaining 12 tests ranged from £18 per QALY gained for Strep A
Rapid Test – test strip (Biopanda Reagents) to £57,598 per QALY gained for QuikRead Go Strep A
test kit (Orion Diagnostica).
TABLE 47 Adult secondary care model: deterministic sensitivity analyses – complications following strep A sore
throat (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £223 0.00408 £54,820
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £173 0.00408 £42,551
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £338 0.00408 £83,041
Sensitivity analysis 12 – doubled complications in untreated infection to 3%
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £217 0.00348 £62,404
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £267 0.00348 £76,786
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £292 0.00348 £83,978
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £242 0.00348 £69,596
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £2287 –0.00244 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £795 –0.00031 Dominated
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TABLE 48 Adult secondary care model: deterministic sensitivity analyses – adverse effect of penicillin
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 15 – halved probability of mild penicillin reaction (rash) to 1%
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £2034 –0.00169 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £618 –0.00046 Dominated
Sensitivity analysis 16 – doubled rates of mild penicillin reaction (rash) to 4%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1836 0.00107 £1,711,314
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1636 0.00107 £1,524,891
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £72 0.00804 £8913
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £122 0.00804 £15,136
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £147 0.00804 £18,246
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £97 0.00804 £12,024
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £262 0.00804 £32,557
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £463 0.00599 £77,328
Sensitivity analysis 17 – changed penicillin-induced anaphylaxis from 0.01% (Neuner et al.78) to 0.64% (Van Howe
and Kusnier79)
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £571 0.01887 £30,270
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £371 0.01887 £19,668
Strep A Rapid Test –
cassette (Biopanda
Reagents)
£1219 0.00311 £392,342 £45 0.02243 £2024
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Note that, of the tests with ICERs in the region of £30,000 per QALY, only the Alere TestPack Plus
and QuikRead Go tests used test accuracy data from published peer-reviewed studies. See Table 15 for
more information.
Adults in secondary care: cost of testing in secondary care
In the base case, the cost of confirmatory throat culture following a negative test result was applied to
6 of the 14 tests considered in the analyses [Clearview Exact Strep A cassette (Abbott Laboratories),
Clearview Exact Strep A dipstick – test strip (Abbott Laboratories), Strep A Rapid Test – cassette
(Biopanda Reagents), Strep A Rapid Test – test strip (Biopanda Reagents), QuikRead Go Strep A test
kit (Orion Diagnostica) and Xpert Xpress Strep A (Cepheid)]. Excluding confirmatory throat culture
favoured testing. The ICER for Strep A Rapid Test – cassette and test strip supplied by Biopanda
Reagents reduced from £392,342 and £377,852 to £26,452 and £11,963 per QALY gained compared
with usual care, respectively (Table 49).
TABLE 48 Adult secondary care model: deterministic sensitivity analyses – adverse effect of penicillin (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Strep A Rapid Test –
test strip (Biopanda
Reagents)
£1174 0.00311 £377,852 £0 0.02243 £18
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 –£975 0.02275 Dominant
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 –£925 0.02275 Dominant
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 –£900 0.02275 Dominant
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 –£950 0.02275 Dominant
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 –£785 0.02275 Dominant
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £973 0.0169 £57,598
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 –£618 0.0212 Dominant
Xpert Xpress Strep A
(Cepheid)
£1994 0.00395 £504,287 £903 0.02192 £41,202
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Adults in secondary care: utility decrement, group A Streptococcus sore
throat and related complications
The base-case estimates were sensitive to changes in disutility associated with strep A-related
complications (Table 50). Decreasing the utility decrement associated with treated infection and
the utility decrement for penicillin-induced rash by a half, doubling the decrement associated with
untreated infection and doubling the decrement for abscess each favoured usual care, producing ICERs
that suggested that usual care dominated testing (see Table 50 for specific tests) in comparison with
the base-case assumptions. Halving the utility decrement for untreated infection and doubling the
decrements for treated infection and penicillin-induced rash all favoured testing. The Clearview Exact
Strep A cassette (Abbott Laboratories) and Clearview Exact Strep A dipstick – test strip (Abbott
Laboratories) were no longer dominated by usual care when the utility decrement associated with
penicillin-induced rash was doubled, and the NADAL tests produced ICERs ranging from £21,309 to
£44,953 per QALY gained compared with usual care.
TABLE 49 Adult secondary care model: deterministic sensitivity analyses – excluding cost of confirmatory throat culture
given negative test result
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 20 – assume no swab culture in those with a negative test result
Strep A Rapid Test –
cassette (Biopanda
Reagents)
£1219 0.00311 £392,342 £82 0.00311 £26,452
Strep A Rapid Test –
test strip (Biopanda
Reagents)
£1174 0.00311 £377,852 £37 0.00311 £11,963
TABLE 50 Adult secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 27 – halved utility decrement, untreated infection
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1957 0.00667 £293,426
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1757 0.00667 £263,430
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £171 0.00454 £37,720
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £221 0.00454 £48,734
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TABLE 50 Adult secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £246 0.00454 £54,242
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £196 0.00454 £43,228
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £361 0.00454 £79,575
Sensitivity analysis 28 – doubled utility decrement, untreated infection
Strep A Rapid Test –
cassette (Biopanda
Reagents)
£1219 0.00311 £392,342 £1219 –0.00022 Dominated
Strep A Rapid Test –
test strip (Biopanda
Reagents)
£1174 0.00311 £377,852 £1174 –0.00022 Dominated
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £171 0.00255 £67,224
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £221 0.00255 £86,852
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £246 0.00255 £96,668
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £196 0.00255 £77,040
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £1990 –0.00848 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £566 –0.00495 Dominated
Sensitivity analysis 29 – halved utility decrement, treated infection
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £171 0.00348 £49,248
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £221 0.00348 £63,627
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £246 0.00348 £70,818
continued
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TABLE 50 Adult secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £196 0.00348 £56,439
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £1990 –0.00243 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £566 –0.0003 Dominated
Sensitivity analysis 30 – doubled utility decrement, treated infection
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1957 0.00879 £222,505
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1757 0.00879 £199,759
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £171 0.00467 £36,648
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £221 0.00467 £47,349
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £246 0.00467 £52,700
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £196 0.00467 £42,000
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £361 0.00467 £77,313
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £566 0.00567 £99,787
Sensitivity analysis 32 – doubled utility decrement, abscess
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £1990 –0.00019 Dominated
Sensitivity analysis 35 – halved utility decrement, penicillin-induced rash
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£1990 0.00016 £12,700,432 £1990 –0.00169 Dominated
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £566 –0.00046 Dominated
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TABLE 50 Adult secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 36 – doubled utility decrement, penicillin-induced rash
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£1957 –0.00396 Dominated £1957 0.00107 £1,823,596
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1757 –0.00396 Dominated £1757 0.00107 £1,637,173
NADAL Strep A –
test strip (nal von
minden GmbH)
£171 0.00388 £44,184 £171 0.00804 £21,309
NADAL Strep A –
cassette (nal von
minden GmbH)
£221 0.00388 £57,085 £221 0.00804 £27,531
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£246 0.00388 £63,537 £246 0.00804 £30,642
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£196 0.00388 £50,636 £196 0.00804 £24,420
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£361 0.00388 £93,211 £361 0.00804 £44,953
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£566 0.00169 £335,358 £566 0.00599 £94,521
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Appendix 11 Children’s primary care
model: exploratory sensitivity analyses
Children’s primary care model: Centor threshold for starting antibiotics
and testing
In the base-case children’s primary care model, a Centor score of ≥ 3 points was used as the cut-off
score for starting antibiotic treatment in the usual-care arm and to initiate testing in the intervention
arm. Lowering the threshold to a Centor score of ≥ 1 point favoured testing. The ICER for the QuikRead
Go Strep A test kit (Orion Diagnostica) and the Alere TestPack +Plus Strep A – cassette (Abbott
Laboratories) changed from being dominated in the base case to £2,163,678 and £7,367,395 per QALY
gained, respectively, compared with usual care (Table 51). Lowering the threshold to a Centor score
of ≥ 2 points favoured testing, with the ICER for Alere TestPack +Plus Strep A – cassette (Abbott
Laboratories) changing from being dominated in the base case to £5,525,377 per QALY gained compared
with usual care. ICERs for the other tests remain unchanged in comparison with base-case ICERs.
Children’s primary care model: prevalence of group A Streptococcus
Changing the prevalence of strep A infection among children presenting in primary care from 30.2%
(base-case value) to 40.1% (upper value reported in studies included in the test accuracy systematic
review) had minimal impact on base-case cost-effectiveness results. Changing the prevalence rate
to 10% favoured testing but only the ICERs for Clearview Exact Strep A test – cassette (Abbott
Laboratories), Clearview Exact Strep A dipstick – test strip (Abbott Laboratories), QuikRead Go Strep A
test kit (Orion Diagnostica) and Alere TestPack +Plus Strep A – cassette (Abbott Laboratories)
changed from being dominated in the base case to values between £1,319,975 per QALY gained for
Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) and £4,635,543 per QALY gained for
Clearview Exact Strep A cassette (Abbott Laboratories) compared with usual care (Table 52).
TABLE 51 Children’s primary care model: deterministic sensitivity analyses – Centor threshold for starting antibiotic
therapy
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 1 – changed Centor threshold for starting antibiotics from ≥ 3 to ≥ 2 points
Alere TestPack
+Plus Strep A –
cassette (Abbott
Laboratories)
£6204 –0.0008 Dominated £12,460 0.00226 £5,525,377
Sensitivity analysis 2 – changed Centor threshold for starting antibiotics from ≥ 3 to ≥ 1 points
QuikRead Go
Strep A test kit
(Orion
Diagnostica)
£7827 –0.00318 Dominated £25,379 0.00344 £7,367,395
Alere TestPack
+Plus Strep A –
cassette (Abbott
Laboratories)
£6204 –0.0008 Dominated £19,273 0.00891 £2,163,678
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Children’s primary care model: complication rates in treated and untreated
group A streptococcal infection
In the base-case analysis, strep A-related complication rates were set to 1.5% for untreated infection
and 1.3% for treated strep A infection based on UK primary care data published by Little et al.86
Doubling the complications rate in the treated group to 2.6% favoured testing and changed the ICERs
for Clearview Exact Strep A cassette (Abbott Laboratories), Clearview Exact Strep A dipstick – test
strip (Abbott Laboratories), QuikRead Go Strep A test kit (Orion Diagnostica) and Alere TestPack
+Plus Strep A – cassette (Abbott Laboratories) from being dominated to values between £2,412,772
per QALY gained for Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) and £26,635,474
per QALY gained for Clearview Exact Strep A cassette (Abbott Laboratories) compared with usual care
(Table 53). Decreasing complications in the untreated group to 0.75% favoured testing and changed the
ICER for Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) from being dominated in the
base-case analysis to £5,652,302 per QALY gained compared with usual care. The ICERs for all other
tests were much lower in comparison with the base-case estimates but remained well above £100,000
per QALY gained in comparison with usual care.
Children’s primary care model: side effects of penicillin
Changing the rate of penicillin-induced rash from 0.01% to 0.64%, as reported in Van Howe and
Kusnier,79 favoured testing: the ICERs for Clearview Exact Strep A dipstick – test strip (Abbott
Laboratories), Clearview Exact Strep A cassette (Abbott Laboratories), QuikRead Go Strep A test kit
(Orion Diagnostica) and Alere TestPack +Plus Strep A – cassette (Abbott Laboratories) changed from
being dominated by usual care in the base case, ranging from £264,313 to £404,873 per QALY gained
compared with usual care (Table 54).
Note that, of the tests with ICERs in the region of £30,000 per QALY, only the Alere TestPack Plus
used test accuracy data from published peer-reviewed studies. See Table 15 for more information.
TABLE 52 Children’s primary care model: deterministic sensitivity analyses – prevalence of strep A
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 5 – changed strep A prevalence from 30.2% to 10% (Neuner et al.78)
Clearview
Exact Strep A
cassette (Abbott
Laboratories)
£7588 –0.00714 Dominated £6088 0.00131 £4,635,543
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£7369 –0.00714 Dominated £5919 0.00131 £4,507,015
QuikRead Go
Strep A test
kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £6328 0.00247 £2,564,058
Alere TestPack
+Plus Strep A –
cassette (Abbott
Laboratories)
£6204 –0.0008 Dominated £4707 0.00357 £1,319,975
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TABLE 53 Children’s primary care model: deterministic sensitivity analyses – complications following strep A infection
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 10 – doubled complications in treated strep A infection to 2.6%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7588 –0.00714 Dominated £6822 0.00026 £26,635,474
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£7369 –0.00714 Dominated £6603 0.00026 £25,780,890
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £7348 0.00144 £5,111,532
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.0008 Dominated £5869 0.00243 £2,412,772
Sensitivity analysis 11 – halved complications in untreated strep A infection to 0.075%
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.0008 Dominated £6010 0.00106 £5,652,302
TABLE 54 Children’s primary care model: deterministic sensitivity analyses – complications of penicillin
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 16 – doubled rates of mild penicillin reaction (rash) to 4%
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £7724 0.00113 £6,823,310
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.00080 Dominated £6100 0.00355 £1,718,859
Sensitivity analysis 17 – changed rates of anaphylaxis from 0.01% (Neuner et al.78) to 0.64% (Van Howe and Kusnier79)
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7588 –0.00714 Dominated £6211 0.01554 £399,674
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£7369 –0.00714 Dominated £5992 0.01554 £385,589
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £6638 0.01640 £404,873
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.00080 Dominated £5005 0.01894 £264,313
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Children’s primary care model: utility decrement, group A Streptococcus sore
throat and related complications
As in the adult primary and secondary care models, decreasing the utility decrement associated with
untreated strep A by half, doubling the utility treatment for treated strep A and doubling the utility
decrement for penicillin-induced rash all favoured testing, and doubling the decrement associated with
untreated infection favoured usual care (Table 55).
TABLE 55 Children’s primary care model: deterministic sensitivity analyses – utility decrements associated with
strep A-related complications
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 27 – halved the utility decrement, untreated strep A
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7588 –0.00714 Dominated £7588 0.00706 £1,074,366
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£7369 –0.00714 Dominated £7369 0.00706 £1,043,375
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £7827 0.00569 £1,375,142
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.00080 Dominated £6204 0.00541 £1,146,652
Sensitivity analysis 28 – doubled utility decrement, untreated strep A
Strep A Rapid
Test – cassette
(Biopanda Reagents)
£6715 0.00224 £2,992,743 £6715 –0.00219 Dominated
Strep A Rapid
Test – test strip
(Biopanda Reagents)
£6665 0.00224 £2,970,792 £6665 –0.00219 Dominated
Sensitivity analysis 30 – doubled utility decrement, treated strep A
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£7588 –0.00714 Dominated £7588 0.00990 £766,212
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£7369 –0.00714 Dominated £7369 0.00990 £744,109
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £7827 0.00747 £1,048,198
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.00080 Dominated £6204 0.00665 £932,465
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Children’s primary care model: lower and upper estimates of the accuracy
for the clinical score and test
Changing the test accuracy data from the central estimate of test sensitivity and specificity to the lower
confidence limit for all tests and the Centor score favoured testing, but the ICER for only Alere TestPack
+Plus Strep A – cassette (Abbott Laboratories) changed from being dominated by usual care under the
base-case assumption to £13,737,541 per QALY gained compared with usual care (Table 56). The upper
limits of test sensitivity and specificity favoured testing (results not presented) but none of the ICERs
changed substantially to suggest different interpretation of base-case cost-effectiveness results.
TABLE 55 Children’s primary care model: deterministic sensitivity analyses – utility decrements associated with
strep A-related complications (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 36 – doubled utility decrement, penicillin-induced rash
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£7827 –0.00318 Dominated £7827 0.00113 £6,914,611
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£6204 –0.0008 Dominated £6204 0.00355 £1,748,223
TABLE 56 Children’s primary care model: deterministic sensitivity analyses – lower limits of CIs for test accuracy data
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 39 – lower confidence limits of test accuracy
Alere TestPack
+Plus Strep A –
cassette (Abbott
Laboratories)
£6204 –0.0008 Dominated £6987 0.00051 £13,737,541
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Appendix 12 Children’s secondary care
model: exploratory sensitivity analyses
Children’s secondary care model: Centor threshold for starting antibiotics
and testing
In the base-case model for children treated in secondary care, a threshold of a Centor score of ≥ 3 points
plus clinical assessment was used as the basis for immediate antibiotic treatment in the usual-care arm
and to initiate testing in the intervention arm. Changing this threshold to a Centor score of ≥ 2 points
had minimal impact on the base-case cost-effectiveness of all tests included in the analysis [except the
Alere TestPack +Plus Strep A – cassette (Abbott Laboratories)]. Using a threshold of a Centor score
of ≥ 1 point favoured testing and changed the ICERs for the Alere TestPack +Plus Strep A – cassette
(Abbott Laboratories) and the QuikRead Go Strep A test kit (Orion Diagnostica) from being dominated in
the base case to £205,449 per QALY gained and £2,303,715 per QALY gained compared with usual care,
respectively (Table 57).
Children’s secondary care model: prevalence of group A Streptococcus
Changing the prevalence of strep A infection among children presenting in secondary care from 30.2%24
to 40.1%48 (upper value reported in studies included in the test accuracy systematic review) had minimal
TABLE 57 Children’s secondary care model: deterministic sensitivity analyses – Centor threshold for starting antibiotics
and testing
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 1 – changed Centor threshold for starting antibiotics from ≥ 3 (base case) to ≥ 2 points
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £371 0.00879 £42,226
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £482 0.00879 £54,800
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £537 0.00879 £61,086
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £426 0.00879 £48,513
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £791 0.00879 £90,007
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £1241 0.00226 £550,135
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impact on the base-case ICERs in the children’s secondary care model. In contrast (Table 58), a lower
prevalence of disease at 10% was more favourable to testing, with ICERs ranging from £20,575 per
QALY gained for NADAL Strep A – test strip (nal von minden GmbH) to £1,374,151 per QALY gained for
the Clearview Exact Strep A cassette (Abbott Laboratories) compared with usual care. ICERs for all
other tests did not change substantially to change the direction of the base-case cost-effectiveness
estimates.
Children’s secondary care model: complication rates
Halving complications in the treated group to 0.65%, the ICER was favourable to testing for the Alere
TestPack +Plus Strep A – cassette (Abbott Laboratories) in comparison with ICERs produced under
base-case assumptions. Doubling the complications rate in the treated group to 2.6% favoured testing;
the ICER for the Clearview Exact Strep A dipstick – test strip (Abbott Laboratories), Clearview Exact
Strep A cassette (Abbott Laboratories), Alere TestPack +Plus Strep A – cassette (Abbott Laboratories)
and QuikRead Go Strep A test kit (Orion Diagnostica) changed from being dominated by usual care to
between £1,247,882 [Alere TestPack +Plus Strep A – cassette (Abbott Laboratories)] and £4,949,827
[Clearview Exact Strep A cassette (Abbott Laboratories)] per QALY gained compared with usual care
(Table 59). ICERs for all other tests were much lower in comparison with the base-case estimates but
still remained well above £100,000 per QALY gained in comparison with usual care.
TABLE 57 Children’s secondary care model: deterministic sensitivity analyses – Centor threshold for starting antibiotics
and testing (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 2 – changed Centor threshold for starting antibiotics from ≥ 3 (base case) to ≥ 1 points
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £495 0.01670 £29,604
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £666 0.01670 £39,891
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £752 0.01670 £45,035
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £580 0.01670 £34,748
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £1148 0.01670 £68,697
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £7936 0.00344 £2,303,715
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £1830 0.00891 £205,449
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TABLE 58 Children’s secondary care model: deterministic sensitivity analyses – prevalence of strep A infection among
children presenting in secondary care
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 5 – changed strep A prevalence from 22.6% to 10%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£2034 –0.00714 Dominated £1805 0.00131 £1,374,151
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1815 –0.00714 Dominated £1636 0.00131 £1,245,623
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £100 0.00488 £20,575
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £143 0.00488 £29,227
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £164 0.00488 £33,553
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £121 0.00488 £24,901
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £261 0.00488 £53,453
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £2045 0.00247 £828,590
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £424 0.00357 £118,942
TABLE 59 Children’s secondary care model: deterministic sensitivity analyses – complications of strep A infection
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 10 – doubled complications in treated infection to 2.6%
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£2034 –0.00714 Dominated £1268 0.00026 £4,949,827
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1815 –0.00714 Dominated £1049 0.00026 £4,095,204
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Children’s secondary care model: adverse effects of penicillin
Cost-effectiveness estimates were most sensitive to the adverse effects of penicillin. Halving the
mild/uncomplicated side effects of penicillin (rash) to 1.0% favoured usual care (results not shown
here), and doubling it favoured testing (Table 60). Changing the rate of penicillin-induced anaphylaxis
from 0.01% to 0.64% favoured testing and generated ICERs with the Alere TestPack +Plus Strep A –
cassette (Abbott Laboratories) and the NADAL tests all dominating usual care. The Clearview Exact
Strep A dipstick – test strip and cassette supplied by Abbott Laboratories produced ICERs of £28,181
and £42,266 per QALY gained, and the Strep A Rapid Test – test strip and cassette supplied by
Biopanda Reagents produced £1643 and £4105 per QALY gained compared with usual care (see
Table 60). The Xpert Xpress Strep A (Cepheid) and QuikRead Go Strep A test kit (Orion Diagnostica)
produced ICERs of £51,637 and £66,111 per QALY gained, respectively. ICERs for the Alere i Strep A 2
(Abbott Laboratories) and cobas Liat Strep A Assay (Roche Diagnostics) remained above £100,000 per
QALY gained compared with usual care (not displayed in Table 60).
Note that, of the tests with ICERs in the region of £30,000 per QALY, only the Alere TestPack Plus
used test accuracy data from published peer-reviewed studies. See Table 15 for more information.
TABLE 59 Children’s secondary care model: deterministic sensitivity analyses – complications of strep A infection
(continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £165 0.00374 £44,246
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £220 0.00374 £58,899
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £247 0.00374 £66,225
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £193 0.00374 £51,574
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £373 0.00374 £99,924
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £1794 0.00144 £1,247,882
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £314 0.00243 £129,172
Sensitivity analysis 11 – halved complications in untreated infection to 0.75%
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £456 0.00106 £428,791
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TABLE 60 Children’s secondary care model: deterministic sensitivity analyses – adverse effects of penicillin
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 16 – doubled rates of mild penicillin reaction (rash) to 4%
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £123 0.00705 £17,378
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £177 0.00705 £25,134
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £205 0.00705 £29,013
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £150 0.00705 £21,256
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £331 0.00705 £46,855
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £2169 0.00113 £1,916,392
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £545 0.00355 £153,598
Sensitivity analysis 17 – changed penicillin-induced anaphylaxis from 0.01% (Neuner et al.78) to 0.64% (Van Howe
and Kusnier79)
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£2034 –0.00714 Dominated £657 0.01554 £42,266
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1815 –0.00714 Dominated £438 0.01554 £28,181
Strep A Rapid
Test – cassette
(Biopanda Reagents)
£1160 0.00224 £517,066 £82 0.02000 £4105
Strep A Rapid
Test – test strip
(Biopanda Reagents)
£1111 0.00224 £495,115 £33 0.02000 £1643
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 –£828 0.02043 Dominant
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 –£773 0.02043 Dominant
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 –£746 0.02043 Dominant
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Children’s secondary care model: cost of testing in secondary care
Excluding confirmatory throat culture costs following a negative test result favoured testing and
generated ICERs ranging from £29,702 per QALY gained for Strep A Rapid Test – test strip (Biopanda
Reagents) to £51,653 per QALY gained for the Strep A Rapid Test – cassette (Biopanda Reagents)
compared with usual care (Table 61).
Children’s secondary care model: utility decrement and group A
Streptococcus-related complications
The base-case estimates were sensitive to changes in disutility associated with strep A-related
complications (Table 62). Scenarios that favoured testing include decreasing the utility decrement of
untreated infection by half, doubling the decrement of treated infection and doubling the decrement
TABLE 60 Children’s secondary care model: deterministic sensitivity analyses – adverse effects of penicillin (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 –£801 0.02043 Dominant
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 –£620 0.02043 Dominant
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £1084 0.0164 £66,111
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated –£549 0.01894 Dominant
Xpert Xpress Strep A
(Cepheid)
£2006 0.00349 £574,900 £1019 0.01974 £51,637
TABLE 61 Children’s secondary care model: deterministic sensitivity analyses – excluding costs of confirmatory culture
given negative test result
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 20 – assume no swab culture in those with a negative test result
Strep A Rapid Test –
cassette (Biopanda
Reagents)
£1160 0.00224 £517,066 £116 0.00224 £51,653
Strep A Rapid Test-
test strip (Biopanda
Reagents)
£1111 0.00224 £495,115 £67 0.00224 £29,702
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TABLE 62 Children’s secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat
and related complications
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 27 – halved utility decrement, untreated infection
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£2034 –0.00714 Dominated £2034 0.00706 £287,940
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1815 –0.00714 Dominated £1815 0.00706 £256,947
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £213 0.00416 £51,228
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £268 0.00416 £64,383
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £295 0.00416 £70,959
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £240 0.00416 £57,804
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £2273 0.00569 £399,281
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £649 0.00541 £120,004
Sensitivity analysis 28 – doubled utility decrement, untreated infection
Strep A Rapid
Test – cassette
(Biopanda Reagents)
£1160 0.00224 £517,066 £1160 –0.00219 Dominated
Strep A Rapid
Test – test strip
(Biopanda Reagents)
£1111 0.00224 £495,115 £1111 –0.00219 Dominated
Sensitivity analysis 30 – doubled utility decrement, treated infection
Clearview Exact
Strep A cassette
(Abbott Laboratories)
£2034 –0.00714 Dominated £2034 0.00990 £205,352
Clearview Exact
Strep A dipstick –
test strip (Abbott
Laboratories)
£1815 –0.00714 Dominated £1815 0.00990 £183,248
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £213 0.00434 £49,131
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £268 0.00434 £61,748
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associated with mild penicillin reaction. The ICER for the Clearview Exact Strep A cassette and test
strip supplied by Abbott Laboratories were no longer dominated by usual care, and ICERs for NADAL’s
tests remained under £100,000 per QALY gained compared with usual care. In contrast, doubling the
utility decrement of untreated infection was less favourable to testing and resulted in Strep A Rapid
Test – cassette (Biopanda Reagents) and Strep A Rapid Test – test strip (Biopanda Reagents) being
dominated by usual care (see Table 62).
TABLE 62 Children’s secondary care model: deterministic sensitivity analyses – utility decrement, strep A sore throat and
related complications (continued )
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £295 0.00434 £68,055
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £240 0.00434 £55,438
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £421 0.00434 £97,068
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £2273 0.00747 £304,351
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £649 0.00665 £97,588
Sensitivity analysis 36 – doubled utility decrement, penicillin-induced rash
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £213 0.00705 £30,212
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £268 0.00705 £37,970
NADAL Strep A plus
– cassette (nal von
minden GmbH)
£295 0.00327 £90,205 £295 0.00705 £41,848
NADAL Strep A plus
– test strip (nal von
minden GmbH)
£240 0.00327 £73,482 £240 0.00705 £34,090
NADAL Strep A scan
test – cassette (nal
von minden GmbH)
£421 0.00327 £128,662 £421 0.00705 £59,689
QuikRead Go Strep A
test kit (Orion
Diagnostica)
£2273 –0.00318 Dominated £2273 0.00113 £2,007,701
Alere TestPack +Plus
Strep A – cassette
(Abbott Laboratories)
£649 –0.0008 Dominated £649 0.00355 £182,962
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Children’s secondary care model: lower and upper estimates of the
accuracy for the clinical score and test
Changing the test accuracy data from the central estimate of test sensitivity and specificity to the lower
confidence limit for all tests and the Centor score favoured testing, but only the ICER for Alere TestPack
+Plus Strep A – cassette (Abbott Laboratories) changed from being dominated by usual care under base-
case assumption to £1,356,265 per QALY gained compared with usual care, whereas ICERs for NADAL’s
tests remained under £100,000 per QALY gained compared with usual care (Table 63). The upper limits
of test sensitivity and specificity favoured testing (results not presented) but none of the ICERs changed
substantially to suggest a different interpretation of base-case cost-effectiveness results.
TABLE 63 Children’s secondary care model: deterministic sensitivity analyses – lower limits of CIs for test accuracy data
Test
Base case Sensitivity analysis
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Incremental
costs per 1000
individuals
Incremental
QALYs per 1000
individuals ICER
Sensitivity analysis 39 – lower confidence limits of test accuracy
NADAL Strep A –
test strip (nal von
minden GmbH)
£213 0.00327 £65,122 £208 0.00378 £54,933
NADAL Strep A –
cassette (nal von
minden GmbH)
£268 0.00327 £81,845 £270 0.00378 £71,352
NADAL Strep A
plus – cassette (nal
von minden GmbH)
£295 0.00327 £90,205 £301 0.00378 £79,562
NADAL Strep A
plus – test strip
(nal von minden
GmbH)
£240 0.00327 £73,482 £239 0.00378 £63,143
Alere TestPack
+Plus Strep A –
cassette (Abbott
Laboratories)
£649 –0.0008 Dominated £690 0.00051 £1,356,265
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Appendix 13 Additional sensitivity analyses
TABLE 64 List of additional sensitivity analyses
Sensitivity
analysis Description of sensitivity analysis
Updated input
parameter
0 Base case
1 Changed Centor threshold score for starting antibiotics from ≥ 3 (base case)
to ≥ 2 points
2
2 Changed Centor threshold score for starting antibiotics from ≥ 3 (base case)
to ≥ 1 points
1
3 Changed time horizon to 14 days 14
4 Changed strep A prevalence (adults) from 22.6% to 35.9% (upper value reported in
studies included in the test accuracy systematic review)
0.359
5 Changed strep A prevalence (adults) from 22.6% to 10% (Neuner et al.78) 0.1
6 Delayed prescription rate set to 27.3% in both arms (RADT group, Little et al.6) 0.273
7 Delayed prescription rate set to 51% in both arms (clinical score group, Little et al.6) 0.51
8 Doubled proportion who use delayed antibiotics to 92% 0.92
9 Halved probability of strep A complications when given antibiotics from 0.013
(Little et al.6) to 0.0065 (analyst assumption)
0.0065
10 Doubled probability of strep A complications when given antibiotics from 0.013
(Little et al.6) to 0.026 (analyst assumption)
0.026
11 Halved probability of strep A complications when given no antibiotics from 0.015
(Little et al.6) to 0.0075 (analyst assumption)
0.0075
12 Doubled probability of strep A complications when given no antibiotics from 0.015
(Little et al.6) to 0.03 (analyst assumption)
0.03
13 Halved probability of rheumatic fever to 0.00005 0.00005
14 Increased probability of rheumatic fever 10-fold to 0.001 0.001
15 Halved mild penicillin reaction (rash) to 0.01 0.01
16 Doubled mild penicillin reaction (rash) to 0.04 0.04
17 Changed probability of anaphylaxis from 0.0001 (Neuner et al.78) to 0.0064
(Van Howe and Kusnier79)
0.0064
18 Changed cost of antibiotics from £0.74 (BNF,91 15 capsules of amoxicillin 500 mg) to
£6.11 (NG51 costing report118)
6.11
19 Assume that patient is seen by practice nurse (£62/hour, PSSRU,90 section 10.1)
instead of doctor
1.03
20 Assume no swab culture in those with a negative test result 0
21 Double the cost of alternative antibiotic in those with penicillin-induced rash to £20 20
22 Assume testing within standard GP time Yes
23 Doubled cost of anaphylaxis to £3489.28 £3489.28
24 Doubled cost of abscess to £3142.56 £3142.56
25 Doubled cost of acute rheumatic fever to £3544.88 £3544.88
26 Changed baseline utility from 0.863 (UK norm) to 0.6305 (PRISM study, table 176) 0.6305
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TABLE 64 List of additional sensitivity analyses (continued )
Sensitivity
analysis Description of sensitivity analysis
Updated input
parameter
27 Halved utility decrement, untreated strep A 0.125
28 Doubled utility decrement, untreated strep A 0.5
29 Halved utility decrement, treated strep A 0.075
30 Doubled utility decrement, treated strep A 0.3
31 Halved utility decrement, strep A-related abscess 2.5
32 Doubled utility decrement, strep A-related abscess 10
33 Halved utility decrement, acute rheumatic fever 38.25
34 Doubled utility decrement, acute rheumatic fever 153
35 Halved utility decrement, penicillin-induced rash 0.3125
36 Doubled utility decrement, penicillin-induced rash 1.25
37 Halved utility decrement, strep A-related sepsis 4.5
38 Doubled utility decrement, strep A-related sepsis 18
39 Lower confidence limits of test accuracy
40 Upper confidence limits of test accuracy
BNF, British National Formulary; PSSRU, Personal Social Services Research Unit.
Note
Bold and shaded rows indicate the sensitivity analysis number, description of sensitivity analysis, location in the model
Microsoft Excel workbook where the changes were made and the updated model input used in the sensitivity analysis.
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Appendix 14 Summary of manufacturers’
information
Biopanda Reagents
1. Checklist of confidential information.
2. Product insert: Strep A Rapid Test RAPG-STRA-001.
3. Declaration of conformity DOCSTRA1826.
4. Response to request for information.
Cepheid
1. Package insert: Xpert Xpress Strep A XPRSTREPA-CE-10.
2. CE declaration of conformity.
3. The GeneXpert System. CE-IVD test menu 2.
4. The GeneXpert System. CE-IVD test menu.
5. Ferrieri et al.85
6. Matthys et al.119
7. Response to request for information.
8. Xpert Xpress Strep A brochure CEIVD 3106-01.A.
9. Xpert Xpress Strep A datasheet CEIVD 3105-01.
nal von minden GmbH
1. Gazzano et al.120
NADAL Strep A
1. EC-declaration of conformity for product number 221002A – signed 30 January 2017.
2. EC-declaration of conformity for product number 221002A – signed 9 February 2017.
3. EC-declaration of conformity for product number 222008 – signed 28 July 2017.
4. Instructions for use for NADAL Strep A Test (test strip), reference 221001A, version 2.2, 11
August 2017.
5. Instructions for use for NADAL Strep A Test (test cassette), reference 222001A, version 2.3, 24
October 2017.
6. Checklist of confidential information. For test strip.
7. Checklist of confidential information. For cassette.
8. Response to request for information NADAL Strep A cassette.
9. Response to request for information NADAL Strep A test strip.
NADAL Strep A plus
1. EC-declaration of conformity. Product number 221050N-50.
2. Instructions for use for NADAL Strep A plus Test (test strip) 221050N-50.
3. Instructions for use for NADAL Strep A plus Test (test cassette) 222007.
4. Instructions for use for NADAL Strep A plus Test (test cassette) 222008.
5. Checklist of confidential information. For test strip.
6. Checklist of confidential information. For test cassette.
7. Response to request for information NADAL Strep A+ cassette.
8. Response to request for information NADAL Strep A+ test strip.
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NADAL Strep A Scan
1. EC-declaration of conformity. Product number 222049NBUL-20.
2. Instructions for use for NADAL Strep A scan test (test cassette) 222049NBUL-20.
3. Checklist of confidential information. For NADAL Strep A scan (cassette).
4. Response to request for information NADAL Strep A scan (cassette).
Orion Diagnostica
1. Shallcross and Davies.121
2. Checklist of confidential information. 10122018.
3. Clinical impact of rapid POC test for acute sore throat poster ECCMID 2016. URL: www.
oriondiagnostica.com/globalassets/documents-and-materials/quikread-go/quikread-go-strep-a/
9031_clinical_impact_of_rapid_poc_tests_for_accute_sore_throat_eccmid_2016_a3_web.pdf
(accessed 17 April 2019).
4. Response to request for information.
5. Declaration of conformity for QuikRead Go Strep A System and QuikRead Go Strep A cat.
no 135883.
6. Instructions for use QuikRead Go Strep A. 136262-3.
7. Poster ESPID 2013.
8. QuikRead Go Strep A – an evaluation of performance in comparison with Alere TestPack+Plus
with OBC, by Oulun Työterveys laboratory.
9. Evaluation of QuikRead Go Strep A test regarding the detection level of Streptococcus pyogenes,
by Pia Karlsson at Microbiology laboratory of Medicinsk Diagnostik, Jönköping, Sweden.
10. Stefaniuk et al.52
11. The report from Scandinavian evaluation of laboratory equipment for primary health care (SKUP)
on QuikRead Go Strep A.
Roche Diagnostics
1. Declaration of conformity DOC-2017-38.
2. cobas Strep A – nucleic acid test for use on the cobas Liat system – package insert.
3. Response to request for information.
4. Checklist of confidential information.
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